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Melanoma, a potentially lethal form of skin cancer, is widely thought to be 
immunogenic in nature.  While numerous studies have examined T cell-mediated 
immune responses to melanoma and their therapeutic potential, there has been 
less focus on B cell-mediated immune responses and the tumor-reactive antibodies 
they produce.  The aim of this work was three-fold: (1) to develop a methodology 
to detect antibodies secreted by human B cells that recognize melanoma cell 
surface proteins; (2) to evaluate the mature B cell repertoire of individuals with 
melanoma for antibody subclass composition and the presence and prevalence of 
anti-tumor antibodies; and (3) to study patient-derived antibodies and two 
engineered antibodies recognizing melanoma cells for their propensity to activate 
immune effector cells and their capacity to kill or restrict the growth of tumor 
cells.   
As part of this thesis, a novel tumor cell-based ELISA was developed for the 
detection of tumor-reactive antibodies.  Utilizing this new assay, the presence and 
prevalence of melanoma-reactive IgG antibodies derived from ex vivo cultured 
peripheral blood B cells from a cohort of 21 patients with melanoma (Stage I, n=1; 
Stage II, n=8; Stage III, n=6; Stage IV, n=6) were compared to those from healthy 
volunteers (n=10).  While B cells from melanoma patients secreted IgG antibody 
concentrations comparable to those from healthy volunteer B cell cultures, a 
significantly increased reactivity of antibodies derived from patients to primary 
and metastatic melanoma cells was measured compared to healthy volunteers 
(P<0.001).  Interestingly, there was a significant reduction in antibody responses 
to melanoma with advancing disease stage that was not found to be solely due to a 
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reduction in the B cell memory compartment size.  Comparing IgG antibody 
subclass distribution among cutaneous tumors, patient lymph nodes and 
peripheral blood B cells all isolated from individuals with metastatic disease, 
elevated proportions of IgG4 subclass antibodies were observed in cutaneous 
tumors which present a novel finding of this thesis.  These findings point to 
differentially polarized humoral immune responses in cutaneous tumor 
microenvironments. 
Lastly, an antibody derived from a patient was then selected and preliminary 
evaluations of reactivity and specificity to a range of melanoma cell lines and 
primary human melanocytes were conducted.  Using a live cell imaging 
cytotoxicity assay, this patient-derived melanoma-specific antibody was observed 
to kill melanoma cells via antibody-mediated cellular cytotoxicity.  Additionally, 
two engineered monoclonal antibodies recognizing a melanoma associated antigen 
were found to partially restrict tumor cell migration and adhesion and to kill 
melanoma cells via antibody-dependent cellular cytotoxicity or phagocytosis.   
In summary, examining the humoral immune response to melanoma and the 
effector function of antibodies targeting melanoma cells provides insight into the 
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1.1    Antibodies 
The study of antibodies commenced in the 1890s with the seminal work of Emil 
von Behring and Shibasaburo Kitasato.  Behring and Kitasato discovered that a 
non-cellular component of the blood of animals immune to tetanus toxoid and 
diphtheria could mount short anti-toxic activity in unimmunized individuals.  This 
was the first evidence of an immune mediator in serum that could neutralize 
infections.  Building upon this work, Paul Ehrlich in the beginning of the 20th 
century theorized that cells “grew additional side chains” (antibodies) that could 
bind to specific toxins and these side chains could break off and circulate through 
the body.  Ehrlich postulated that these “side chains” could specifically seek out 
targeted cells without harming normal cells and postulated they were “magic 
bullets” to cure diseases.   The scientific community to the present date has 
focused on elucidating the source, structure, function, and therapeutic utility of 
antibodies.   The emergence of antibodies as an important class of drugs since the 
1990s has shown some realization of Ehrlich’s notion of antibodies as “magic 
bullets” for the treatment of many diseases, including cancer. 
 
1.1.1 The Role of Antibodies in the Adaptive Immune Response 
The immune system can mount a rapid response to foreign pathogens by the 
engagement of the innate immune system comprised of soluble factors such as 
complement proteins and cellular components including natural killer (NK) cells, 
macrophages/monocytes, eosinophils, basophils, neutrophils, mast cells and 
dendritic cells.  These components of the innate immune system can recognize 
pathogens by pattern-recognition receptors and other surface molecules to 
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mediate the destruction of invading pathogens by proteolysis, phagocytosis, and 
the secretion of cytokines and/or chemokines leading to inflammation and the 
recruitment of other phagocytic cells such as neutrophils.  While slower to 
develop, the adaptive arm of the immune system can also mount an immune 
response to pathogens but with increased antigenic specificity and memory 
compared to innate immune responses, taking effect within 4 to 7 days (Janeway, 
Travers et al. 2005).  The adaptive immune response is mediated by two major 
types of lymphocytes: B and T cells.  B cells can regulate adaptive immune 
responses in multiple ways such as by the secretion of meditators that drive T cell 
responses or by the production of antibodies specific for foreign antigens which 
could mount a humoral immune response (Lund and Randall 2010).  These 
antibodies, once bound to a pathogen, can result in pathogen neutralization or can 
interact with cellular and non-cellular components of the innate immune system 
resulting in pathogen destruction.  T cells specific for foreign antigens are capable 
of cell-mediated immunity either by direct killing via the perforin/granzyme 
pathways and death ligands of cells displaying foreign antigens (cluster of 
differentiation [CD]8+ T cells), or through the enhancement of antibody 
production, CD8+ T cell, NK cell or macrophage cytotoxic function (CD4+ T cells) 
against pathogen coated or infected cells. 
Humoral immune responses, a primary focus of this thesis, are mediated by 
antibodies.  Antibodies or immunoglobulin (Ig) are proteins produced by B cells in 
response to the presence of pathogens or foreign antigens.  Antibodies can be 
membrane bound on the surface of B cells as an antigen receptor (B cell receptor 
or BCR) or secreted as soluble proteins, with each B cell producing antibodies with 
specificity for a single epitope of an antigen.  B cells mature in the bone marrow, 
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and then continually circulate from the blood into peripheral lymphoid tissues 
such as the spleen, lymph nodes and mucosal lymphoid tissues.  Once activated by 
an antigen in either a T cell dependent or independent manner, B cells can then 
undergo further expansion and clonal differentiation for the selection of high 
affinity antibodies following  further rounds of mutation (somatic hypermutation) 
(Rajewsky 1996; Janeway, Travers et al. 2005).  The activation of B cells to 
produce antibodies mostly occurs in a T cell dependent manner where CD4+ 
activated helper T cells can activate B cells that have encountered the same 
antigen.  This activation of B cells by CD4+ T cells occurs through the interaction of 
C40 ligand on the surface of activated T cells and the CD40 protein on the B cell 
surface.  In response to co-stimulatory molecules such as engagement of the CD40 
receptor on B cells and by CD40 ligand (CD154) and the secretion of various 
cytokines, B cells will maintain antigen specificity but undergo class switching 
from IgM and IgD to IgA, IgG or IgE resulting in structural changes to the region of 
the molecule that interact with different immune effector molecules creating a 
tailored immune response.  
Following activation by antigen in germinal centers, B cells can develop into 
memory B cells or plasma cells, regulated by antigen-dependent triggering of BCR, 
cytokines and direct interactions between T and B cells by molecules such as CD40 
and CD27 (Agematsu, Nagumo et al. 1998).  Some cells will become terminally 
differentiated plasma cells capable of secreting high levels of antibodies in an 
antigen-independent manner and other cells will become long lived memory B 
cells (Slifka, Antia et al. 1998).  The conventional lineage of different B cell 
populations in the human body can be distinguished by the expression of different 
cell surface molecules such as CD molecules (Table 1.1), with CD27 being a widely 
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used marker to identify memory B cells (Klein, Rajewsky et al. 1998; Sato, Tuscano 
et al. 1998; Edwards and Cambridge 2006; Sanz, Wei et al. 2008; Manjarrez-
Orduno, Quach et al. 2009).  Memory B cells, generally producing antibodies with 
high affinity to antigen, can quickly mount a secondary immune response 
maintaining immunological memory following activation by antigen or antigen-
independent polyclonal stimuli such as CpG deoxyribonucleic acid (DNA) to 
proliferate as antibody secreting cells (Bernasconi, Traggiai et al. 2002).   
 
Table 1.1  Cell Surface Molecules Used to Identify Selected Conventional B 
cell Subpopulations in Humans 
 
† Plasma cells can be found in both the bone marrow and peripheral compartments. 
Modified from Sato, Tuscano et al. 1998; Janeaway, Travers et al., 2005; Edwards and 








There have been five major antibody classes or isotypes described in humans: IgM, 
IgD, IgG, IgA, and IgE, with each antibody class having distinct distribution in the 
body and roles in mediating immune responses.  The first antibody class produced 
in a humoral immune response is IgM.  IgM can be produced from B cells prior to 
class switching and tends to have low affinity to antigen compared to the class 
switched antibody classes, IgG/A/E.  IgM can be expressed as a monomer on the 
surface of B cells or as a pentameter in soluble form with poor tissue diffusion due 
to its large size.  IgM is found in the blood and lymphatic system and its effector 
functions are thought to primarily lie in the activation of the complement pathway.  
IgD is the second lowest antibody class expressed in the blood, >1% compared to 
the other antibody classes, and its function is the least understood.  IgD is 
expressed on the surface of B cells as they exit the bone marrow and enter 
peripheral lymphoid tissues.  Recent insight into the function of IgD has suggested 
that it may have pro-inflammatory and antimicrobial functions upon crosslinking 
on basophils (Chen, Xu et al. 2009).  IgG is the most abundant antibody class in the 
body, it is secreted as a monomer primarily in the blood, and its primary function 
is to protect against bacterial and viral infections predominantly through the 
activation of complement pathways and opsonization of pathogens for engulfment 
by phagocytes.  There have been four subclasses described for IgG: IgG1, IgG2, IgG3 
and IgG4.  IgA is found in mucosal membranes and secretions and also in the blood 
and it is thought to play a key role in mucosal immunity primarily through the 
neutralization of pathogens.  IgA can be found as a monomer or in dimers and two 
subclasses have been described for this antibody class: IgA1 and IgA2.   IgE is the 
least abundant antibody in the blood and it is found primarily in lungs, skin and 
mucous membranes as a monomer.  IgE is involved in allergic reactions and 
immune responses to parasitic infections.  IgE has high affinity to receptors on 
-7- 
 
immune cells, such as mast cells, and upon antigen binding, it can trigger these 
immune cells to release inflammatory mediators to induce allergic inflammation.  
Antibodies have multiple mechanisms to engage an immune response against 
invading pathogens and foreign molecules.  These mechanisms include the 
neutralization of pathogens preventing entrance into cells and replication, 
opsonization of extracellular bacteria, and activation of the complement system.   
Antibodies play a crucial role in directing phagocytic cells to pathogens and other 
foreign substances resulting in their ingestion, degradation and ultimate removal 
from the body.  The aggregation or multimerization of antibodies in the presence 
of multivalent antigens can induce the crosslinking of antibody receptors on 
immune cells, resulting in high avidity binding and immune cell activation, 
whereas monomeric immunoglobulin engaged with monomeric antigens, or in the 
absence of antigen, has low affinity to antibody receptors on immune cells and 
cannot crosslink and activate immune cells.  Antibodies in the presence of antigen 
play an important role in the adaptive immune responses because they are able to 
specifically target the destruction of foreign pathogens through the engagement of 
innate immune effector cells and complement proteins.   
Humans can have a large repertoire of antibodies, with as many as 1011 antibodies 
per person (Janeway, Travers et al. 2005).  Central to the maintenance of this large 
antibody repertoire is the role of circulating memory B cells able to mount a 
secondary antibody response to pathogens (Lanzavecchia, Bernasconi et al. 2006).  
The persistence of this cell pool, affinity to antigens, and the diversity of antigen 
specificity and effector mechanisms of antibodies collectively play a vital role in 




1.1.2 Antibody Structure and Fc Effector Function 
Antibodies are large molecules: as monomers they range from 150 to 190 kDa in 
size.  An antibody is composed of two identical heavy chains and two identical light 
chains (Figure 1.1).  Antibody structure is relatively similar among the five Ig 
classes; however, they differ in three ways: (1) number of heavy chain domains, 
(2) distribution and number of carbohydrate groups, and (3) the number and 
location of disulfide bonds linking different domains.  Heavy chains are comprised 
of one variable domain (VH) and multiple constant domains (CH), three for IgA, IgD, 
and IgG (CH1, CH2 and CH3) and four for IgE and IgM (CH1, CH2, CH3, and CH4).  Light 
chains are also composed of one variable domain (VL) but in contrast to the heavy 
chain only have a single constant domain (CL) for all antibody classes. 
Antibodies have two distinct binding regions: the fragment antigen binding (Fab) 
region and the fragment crystallizable (Fc) region (Figure 1.1).  The Fab and Fc 
binding regions of antibodies each have a separate functional role.  Antigen 
binding sites are located in the variable domains of the Fab region.  Each variable 
domain (VH and VL) contains three polypeptide loops termed complementarily 
determining regions (CDRs) which are the key determinants of the specificity and 
affinity of antigen binding.  These CDRs are supported by four polypeptides in each 
VH and VL called framework regions, which form a structural scaffold for CDR 
presentation.  While variable regions in the Fab region contain binding sites to 
antigens, the constant domains in the Fc regions primarily determine the effector 
functions of antibodies through their interaction with soluble proteins and Fc 





Figure 1.1  IgG structure.  IgG molecules are composed of identical heavy and light 
protein chains which are linked by disulfide bonds (orange lines).  Heavy chains consist 
of three constant domains (CH1, CH2, and CH3) and one variable domain (VH).  Light 
chains also contain one variable domain (VL) but only one constant domain (CL).   
Antigen binding sites are located in the VH and VL domains of the Fab region.  Effector 
function is mediated by the binding of the heavy chains in the Fc region, CH2 and CH3, 
to various components of the immune system.  
 
The Fc structure of IgG and its affinity for different FcRs can confer different 
biological activities and regulate antibody distribution.  For example, the 
concentration of IgG in circulation is regulated by the neonatal Fc receptor (FcRn) 
(Roopenian and Akilesh 2007).  Fc regions of antibodies of the IgG class can also 
mediate immune effector functions by opsonization, complement activation, and 
the activation of immune cells following Fab binding.  The ability of IgG to mount a 
cellular immune response is regulated through Fc receptors specific for the IgG Fc 
fragment (FcγR) expressed on immune cells such as monocytes/macrophages, 
neutrophils, dendritic cells, and NK cells (Janeway, Travers et al. 2005; 
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Nimmerjahn and Ravetch 2008).  For IgG, there are three activating receptors,  
FcγRI (CD64), FcγRIIA (CD32) and FcγRIII (CD16); and one inhibitory receptor 
FcγRIIB (CD32) (Nimmerjahn and Ravetch 2008), with each receptor having 
differential expression on immune effector cells (Table 1.2).  Upon aggregation by 
multivalent antibody-antigen complexes FcγRs present on immune cells can 
modulate biological activity.  Each of the four IgG subclasses has a different Fc 
structure resulting in differential specificity and affinities for these FcγRs on 
immune cells (Table 1.2), contributing to the different biological activities 
attributed to each subclass (Bruhns, Iannascoli et al. 2009).   
IgE is known to be recognized by two Fc epsilon receptors (FcεRs) expressed on 
immune cells: the low affinity receptor (CD23 or FcεRII) and the high affinity 
receptor (FcεRI) (Gould, Sutton et al. 2003).  CD23 is expressed on hematopoietic 
cells such as B cells, macrophages, monocytes, and eosinophils.  The higher affinity 
IgE Fc receptor, FcεRI, is expressed on mast cells and basophils as tetramers and 
on antigen-presenting cells such as dendritic cells and monocytes/macrophages as 
trimers in much lower amounts (Kraft and Kinet 2007).  The affinity of IgE to FcεRI 
is 1010 M-1, at least a hundred fold higher than the affinity of IgG for any FcγR or 
IgA for Fc receptor alpha I (FcαRI) (Table 1.2), and this high affinity of IgE to this 
receptor may result in the engagement of immune cells such as mast cells and 
basophils capable of producing a potent immune response including the release of 
inflammatory mediators and cytokines (Gould and Sutton 2008). 
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Table 1.2  Selected Properties of Fc Receptors on Innate Immune Cells 
Relevant for the Function of Therapeutic Monoclonal Antibodies 


























FcεRII (CD23) IgE 107-108 M-1 Monocytes ADCP 




IgG IgG1=6.5 x 107 M-1 
IgG2=No binding 
IgG3=6.1 x 107 M-1 















IgG †IgG1=5.2 x 106 M-1 
IgG2=4.5 x 105 M-1      
IgG3=9.1 x 105 M-1      









†IgG1=3.5 x 106 M-1      
IgG2=1.0 x 105 M-1      
IgG3=1.7 x 105 M-1      
IgG4=2.0 x 105 M-1      
FcγRIIB 
(CD32) 
IgG  IgG1=1.2 x 105 M-1 
IgG2=0.2 x 105 M-1 
IgG3=1.7 x 105 M-1 







Inhibition of stimulation 
 
 




IgG  ††IgG1=1.2 x 106 M-1     
IgG2=0.3 x 105 M-1      
IgG3=7.7 x 106 M-1      
IgG4=2.0 x 105 M-1      
††IgG1=2.0 x 106 M-1     
IgG2=0.7 x 105 M-1      
IgG3=9.8 x 106 M-1      














*Affinity measurements were reported from: Janeway, Travers et al.  2005 for FcαRI; Gould, Sutton 
et al. 2003 for FcεR and FcεRI; and Bruhns, Iannascoli et al. 2009 for the IgG subclasses.  
† R131/H131 polymorphic variants, respectively.   
†† F158/V158 polymorphic variants, respectively.   
ADCC= antibody dependent cellular cytotoxicity; ADCP=antibody dependent cellular phagocytosis 
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Antibody classes and their subclasses have different biological activity mediated 
through their Fc regions which are crucial in modulating a variety of cell-mediated 
immunological responses such as phagocytosis and cellular cytotoxicity regulated 
through the FcRs on immune cells.  These Fc-mediated mechanisms result in the 
engagement of a variety of immune cells to mount a response against antibody 
bound target antigens.  Harnessing the Fc-FcR interactions is a worthwhile 
strategy in the development of antibody therapeutics (Woof 2012).  This is 
because antibodies are not only highly specific molecules with favorable 
pharmacokinetics properties, able to block certain receptor-ligand interactions 
and trigger Fab-directed signaling even upon engagement with target antigen, but 
they can also engage immune effector cells to specifically target the destruction of 
unwanted substances in the body (Table 1.2).   
 
1.1.3 Therapeutic Mechanisms of Action of Monoclonal Antibodies 
Because of the specificity of antibodies to their antigens, antibodies have become 
an important class of drugs used to target specific cells or neutralize and eliminate 
soluble proteins such as cytokines.  Antibodies have been engineered to fight 
infection, inflammation and cancer (Reichert 2011).  There are potentially multiple 
mechanisms of action of antibody therapeutics (Table 1.3) including blockade of 
relevant receptors, inhibition of growth factors, inhibition of signaling, virus 
neutralization, specific delivery of toxins or radioisotopes to tumor cells,  and the 
activation of the immune system to kill targeted cells by mechanisms such as 
complement dependent cytotoxicity (CDC) and antibody dependent cytotoxicity 
and phagocytosis (ADCC and ADCP) (Carter 2006).  Alternative strategies have 
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been employed to enhance these mechanisms of action, including the engineering 
of antibodies or antibody fragments with specificity to more than one antigen to 
recruit immune cells to the target (bi-specific antibodies), the engineering of 
differentially glycosylated Fc regions to enhance bioavailability, or the use of 
peptides to produce anti-idiotypic antibodies in patients to produce human 
antibodies with Fab regions that mimic antigenic epitopes (Riemer and Jensen-
Jarolim 2007; Chames and Baty 2009; Jefferis 2009). 
All marketed antibodies are of the IgG class (Reichert 2012) due to favorable 
pharmacokinetic properties; however, different antibody subclasses have been 
employed therapeutically, such IgG1, IgG2 and IgG4 depending of the desired role 
of Fc-mediated mechanisms of action.   Antibodies of the IgG1 subclass generally 
have higher affinity to FcγRs and it is largely thought that this subclass can 
mediate the most potent effector functions (Bruggemann, Williams et al. 1987; 
Bruhns, Iannascoli et al. 2009).  In contrast to the other IgG subclasses, the IgG4 
antibody subclass is generally thought to have overall weak affinity to FcγRs and 
weak effector functions and has been employed therapeutically when antibody Fc-
mediator effector functions are not desirable (Bruggemann, Williams et al. 1987; 
Bruhns, Iannascoli et al. 2009).  There has been some exploration of the use of 
antibodies of alternate Ig classes such as IgA and IgE (reviewed further in Section 
1.3.3.1) in cancer immunotherapy to enhance Fc-mediated effector functions by 
the engagement of alternate FcRs on immune cells such as FcαRI, FcεRI, and CD23 




Table 1.3  Mechanisms of Action of Marketed Monoclonal Antibodies in 




Mechanisms of action 
Oncology  
CD20 IgG1 Rituximab (Mabthera®) ADCC, direct induction of apoptosis, and 
CDC 
IgG1 Ofatumumab (Arzerra®) ADCC and CDC 
IgG1 90Y-labelled Ibritumomab/ 
tiuxetan (Zevalin®) 





ADCC, direct induction of apoptosis and 
delivery of radioisotope 
CD30 IgG1 Brentuximab vedotin (Adcetris®) Delivery of toxin 
CD33 IgG4 Gemtuzumab/ ozogamicin 
(Mylotarg®)* 
Delivery of toxin 
CD52 IgG1 Alemtuzumab (Campath®) Direct induction of apoptosis and CDC 
EGFR IgG1 Cetuximab (Erbitux®) Inhibition of EGFR signaling and ADCC 
IgG2 Panitumumab (Vectibix®) Inhibition of EGFR signaling and ADCC 
HER2 IgG1 Trastuzumab (Herceptin®) Inhibition of HER2 signaling and ADCC 
IgG1 Pertuzumab (Perjeta®) Inhibition of HER2 signaling and ADCC 
VEGF IgG1 Bevacizumab (Avastin®) Inhibition of VEGF signaling 
CTLA-4 IgG1 Ipilimumab (Yervoy®) Inhibition of CTLA-4 signaling 
Inflammation  
BAFF IgG1 Belimumab (Benlysta®)  Inhibition of B cell activator 





Ustekinumab (Stelara®) Receptor blockade 
IL-1B IgG1 Canakinumab (Ilaris®)  Receptor blockade 
IL-6R IgG1 Tocilizumab (Actemra®) Receptor blockade 







Certolizumab pegol (Cimzia®); 





Natalizumab (Tysabri®) Blockade of immune cell adhesion 
 Infectious disease  
RSV IgG1 Palivizumab (Synagis®)  Pathogen neutralization 




Abciximab (ReoPro®)  Inhibitor of platelet aggregation  
 Transplantation  
CD25 IgG1 Basiliximab (Simulect®)  Inhibition of T cell proliferation and B 
cell activation 
Hematological disorders  
C5 IgG2 Eculizumab (Soliris®) Complement blockade 
* Withdrawn from use.  BAFF= B cell activating factor; CTLA-4= cytotoxic lymphocyte antigen 4; 
C5= complement component 5; EGFR= epidermal growth factor receptor; gp=glycoprotein, HER2= 
human epidermal growth factor receptor 2; IL=interleukin; RANKL= receptor activator of nuclear 
factor kappa-B; RSV=respiratory syncytial virus; TNF= tumor necrosis factor; VEGF= vascular 
endothelial growth factor.  Table adapted from Reichert 2012. 
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Monoclonal antibodies can specifically target the destruction of cancer cells which 
over-express certain tumor associated antigens (TAAs) such as Her2/neu or EGFR 
in breast and colorectal cancer, respectively.  Antibodies with specificity to these 
cell surface TAAs, once bound to cancer cells, can directly inhibit antigen function 
through their Fab regions and/or can engage FcRs on immune effector cells 
through their Fc regions thereby recruiting the immune system to specifically kill 
these cancer cells (Hudis 2007; Nimmerjahn and Ravetch 2007; Nimmerjahn and 
Ravetch 2008).  Antibodies can also be conjugated to other drugs such as 
immunotoxins, radioisotopes or enzymes  followed by a prodrug in the case of 
antibody-directed enzyme prodrug therapy, to specifically deliver these agents to 
targeted cancer cells (Mayer, Francis et al. 2006; Junutula, Flagella et al. 2010; 
FitzGerald, Wayne et al. 2011).   
As cancer therapeutics, the binding of antibodies to cell surface TAAs can result in 
the recruitment of immune effector cells and the crosslinking of activating FcRs on 
these immune cells to mediate ADCC and ADCP (Figure 1.2).  The engagement of 
FcγRs on immune cells by IgG tumor-specific antibodies to mediate ADCC of tumor 
cells has emerged as an important mechanism of action for some monoclonal 
antibodies (Clynes, Takechi et al. 1998; Carter 2006).  The importance of the Fc-
mediated mechanisms of action of antibody therapeutics to engage human host 
immunity has also become clear by recent studies evaluating the correlations 
between a patient’s polymorphisms in FcγRs and the clinical efficacy of antibodies 
(Cartron, Dacheux et al. 2002; Zhang, Gordon et al. 2007; Musolino, Naldi et al. 
2008).  Fc-mediated functions of antibodies are gaining interest in light of more 
recent insight into their important contribution to the mechanisms of action of 





Figure 1.2  Fc-mediated cellular mechanisms of action of antibodies directed 
against tumor associated antigens.  Antibodies targeting TAAs can interact with 
FcRs expressed on the surface of innate immune cells, resulting in the targeted 
destruction of antibody coated tumor cells.  This antibody Fc-mediated tumor cell killing 
can be a result of ADCC or ADCP.  Tumor cell ADCC can be mediated by NK cells, 
neutrophils, monocytes and eosinophils by the release of cytotoxic granules such as 
granzymes, perforins, along with the release of inflammatory mediators such as TNFα 
and IFN-γ resulting in tumor cell apoptosis.  Antibodies recognizing TAA can also 
mediate ADCP through interactions of FcRs on phagocytes such as macrophages and 




1.1.4 Monoclonal Antibodies for the Treatment of Cancer 
Monoclonal antibodies have emerged as an important class of drugs in oncology 
over the last twenty years, with 13 monoclonal antibodies having been approved 
for use in oncology (Weiner, Surana et al. 2010; Lipson and Drake 2011; Reichert 
2011).   Approved monoclonal antibodies are currently used to treat a variety of 
hematological malignancies such as leukemia and lymphoma along with more 
recently developed antibodies that are available for the treatment of some solid 
tumors such breast, lung, colorectal cancers and most recently melanoma (Weiner, 
Surana et al. 2010; Lipson and Drake 2011).  These approved antibodies target 
TAAs which include hematopoietic differentiation antigens (CD20, CD30, CD33, 
and CD52), human epidermal growth factor receptor (HER) 2 (HER2; erbB2/neu; 
Her2/neu) or HER1 (human epidermal growth factor receptor [EGFR]), vascular 
endothelial growth factor (VEGF), which contributes to angiogenesis in the tumor 
vasculature, and cytotoxic lymphocyte antigen 4 (CTLA-4) which regulates T cell 
responses (Table 1.4).   Currently, antibody therapeutics for the treatment of 
cancer encompasses the targeting of only 8 antigens (Table 1.4); however, there 
are several monoclonal antibodies being evaluated in clinical studies that target 
new groups of TAAs.  Examples of such antibodies (Table 1.5) include those 
against glycoproteins and carbohydrates expressed by solid tumors, stromal and 
extracellular matrix (ECM) antigens, and new anti-angiogenic targets (Reichert 

























































therapeutic mAbs  
Examples of antigen expressing 
tumor types  
Glycoproteins EpCAM IGN101 and 
Adecatumuab 
Epithelial tumors (breast, colon and 
lung) 
CEA Labetuzumab Breast, colon and lung tumor 
gpA33 HuA33 Colorectal carcinoma 
Mucins Pemtumomab and 
Oregovomab 
Breast, colon, lung and ovarian 
tumors 
PSMA J591 Prostrate carcinoma 
CAIX Girentuximab Renal cell carcinoma 
TAG-72 Minretumomab Breast, colon and lung tumors 
FRα MOv18 and 
Farletuzumab 
Ovarian tumors 
Carbohydrates Lewis Y  Hu3S193 and 
IgN311 






EGFR  Nimotuzumab and 
806  
Glioma, lung, breast, colon, and head 
and neck tumors  
HER3  MM-121  Breast, colon, lung, ovarian and 
prostate, tumors  
HGFR  Rilotumumab, 
Onartuzumab and 
SCH 900105  
Breast, colorectal, ovarian and lung 
tumors  
IGF1R  AVE1642, IMC-A12, 
MK-0646, R1507 
and CP 751871  
Glioma, lung, breast, head and neck, 
prostate and thyroid cancer  
EPHA3  KB004 and IIIA4  Lung, kidney and colon tumors, 
melanoma, glioma and 
hematological malignancies  
TRAILR1  Mapatumumab 
(HGS-ETR1)  
Colon, lung and pancreas tumors 
and hematological malignancies  
TRAILR2  HGS-ETR2 and 
CS-1008  
Colon, lung and pancreas tumors 




FAP Sibrotuzumab and 
F19 
Colon, breast, lung, pancreas, and 
head and neck tumors 
Tenascin 81C6 Glioma, breast and prostate tumors 
Targets of anti-
angiogenic mAbs 
VEGFR  IM-2C6 and CDP791  Epithelium-derived solid tumors  
Integrin 
αVβ3  
Etaracizumab  Tumor vasculature  
Integrin 
α5β1  
Volociximab  Tumor vasculature  
CAIX= carbonic anhydrase IX; CEA= carcinoembryonic antigen; EpCAM= epithelial cell adhesion 
molecule; EPHA3= ephrin receptor A3; FAP= fibroblast activation protein; gpA33= glycoprotein 
A33; FRα= folate receptor alpha; HGFR= hepatocyte growth factor receptor; IGF1R= insulin-like 
growth factor 1 receptor; mAbs= monoclonal antibodies; PSMA= prostate-specific membrane 
antigen; RANKL= receptor activator of nuclear factor-κB ligand; TAG-72= tumor-associated 
glycoprotein 72; TRAILR= tumor necrosis factor-related apoptosis-inducing ligand receptor; 
VEGFR= VEGF receptor.  Table reproduced in part from Scott, Wolchok et al. 2012. 
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Antibodies can afford some advantages over small molecule drugs for the 
treatment of cancer and other diseases such as their potential for low toxicity, 
improved pharmacokinetics, and target specificity (Weiner and Borghaei 2006).  
However, antibodies as cancer therapeutics can also have limitations such as poor 
tumor penetration, poor oral bioavailability, and are expensive to manufacture.   
The first FDA approved antibodies in the US were for the treatment of 
hematological malignances, and monoclonal antibodies have also met considerable 
success in the treatment of solid tumors in combination with chemotherapy with 
the approval of Trastuzumab and other EGFR antibodies, such as Cexitumab and 
Panitumumab, for the treatment of breast and colorectal cancer, respectively 
(Romond, Perez et al. 2005; Jonker, O'Callaghan et al. 2007).  More recently, the 
monoclonal antibody Ipilimumab has demonstrated a meaningful achievement in 
the treatment of metastatic melanoma, and it is the first antibody therapy that 
functions by an immunomodulatory mechanism (reviewed further in Section 
1.2.1).  While these antibodies have laid the foundations for antibody-based 
therapies for the treatment of solid tumors, future successes may lie in optimizing 
antibody Fc structure to enhance anti-tumor responses in the tumor 
microenvironments along with further understanding of the interaction of the host 





1.1.5 Monoclonal Antibody Production 
Monoclonal antibodies were coined “magic bullets” by Paul Ehlrich in the early 
20th century, soon after their discovery.  The immediate clinical application of 
antibodies as passive immunotherapies was hindered due to limitations around 
their production.  Technological improvements in the engineering of antibodies 
over the last forty years have enabled the emergence of monoclonal antibodies as a 
relevant class of drug with demonstrated clinical utility in the treatment of many 
diseases. 
 
1.1.5.1   Historical Perspectives on the Production of Antibody Therapeutics 
In 1975, the development of hybridoma technology by Kohler and Milstein allowed 
for the production of monoclonal antibodies from laboratory generated cell lines, 
which was a crucial step in the development monoclonal antibodies as 
therapeutics.  Hybridoma technology, which fuses splenocytes from immunized 
mice with murine myeloma cells, resulted in the production of a hybridoma cell 
line capable of producing antibodies of a desired specificity (Kohler and Milstein 
1975).  This work was a major breakthrough in the scientific community, 
permitting the production of antibodies in unlimited amounts to serve as valuable 
research tools; although without any further manipulation, these antibodies had 
limited clinical therapeutic utility being of murine origin.  The murine antibodies 
produced by hybridoma were immunogenic in humans, resulting in the production 
of human anti-murine antibodies, fast clearance, and had poor ability to engage 
human immune effector responses (Shawler, Bartholomew et al. 1985; Ober, Radu 
et al. 2001). 
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Following the invention of hybridoma technology, there have been numerous 
efforts leading to the successful production of more human/fully human 
antibodies over the last forty years (Figure 1.3).  The advancement of strategies to 
engineer fully human antibodies has resulted in the reduced concerns of 
immunogenicity along with the potentially greater efficacy of fully human 
antibodies which have superior pharmacokinetic properties compared to mouse 
antibodies because of FcRn binding (Ober, Radu et al. 2001).  Additionally, 
antibodies with fully human Fc regions may optimally engage human Fc receptors 
on immune cells to mediate cellular mechanisms of action against tumor cells such 
as ADCC and ADCP.  As a first step towards the creation of fully human antibodies, 
recombinant DNA technologies were employed to join murine variable regions to 
human constant regions in order to produce chimeric antibodies (Sahagan, Dorai 
et al. 1986).  Further genetic engineering of these chimeric antibodies resulted in 
the production of humanized antibodies containing only murine CDRs (Carter, 
Presta et al. 1992).  And more recently, techniques have emerged to produce fully 
human monoclonal antibodies using either in vivo or in vitro approaches, which 
have included phage display technologies and the creation of transgenic mice with 





Figure 1.3  Timeline of the progress of monoclonal antibody production.  
Following the concept of antibodies as “magic bullets” there have been many efforts to 
manufacture mAbs as drugs for the treatment of diseases such as infection, 
inflammation and cancer.  The first marketed antibody approved by the US FDA was a 
fully murine antibody, Muromonab, produced using hybridoma technology.  Due to 
production of human anti-mouse antibodies following the administration of mouse 
mAbs in humans, efforts over the next 20 years focused on producing more fully 
human mAbs.  These first efforts resulted in the production of chimeric murine-human 
antibodies containing murine variable regions and human constant regions, followed by 
humanized antibodies containing only murine CDRs.  Next, the production of fully 
human mAbs was achieved either by the application of antibody phage display 
technology, or the use of transgenic mice with human immunoglobulin genes.  Also of 




The generation of fully human therapeutic antibodies against a desired antigen has 
been achieved in vitro by the use of antibody phage display technology.  This 
technology utilizes large sized libraries of heavy and light chain encoding genes 
which are cloned and then displayed on the surface of cells such as bacteriophages 
to pan for reactivity against a particular antigen (McCafferty, Griffiths et al. 1990; 
Barbas 1995).  Following the selection of antibody fragments with desired 
specificity, these Fab or single-chain fragments of the variable region (scFv) can 
then be cloned into full sized human IgG antibodies.  This approach can be applied 
to generate monoclonal antibodies against TAAs through the use of 
complementary deoxyribonucleic acid (cDNA) libraries generated from mice 
following immunization (Chester, Begent et al. 1994) or through the use of 
synthetic or human  cDNA combinatorial libraries (Mao, Gao et al. 1999).  One 
advantage of this approach is that it can be independent from the mammalian 
immune system and possibly could avoid issues such as immune tolerance and 
epitope dominance and can lead to the generation of high number of antibody 
fragments with specificity to a given antigen.  Also, because the variable region 
genes are already cloned, this approach does not necessarily require laborious 
techniques such as humanization.  In some cases, disadvantages of the production 
of antibodies by phage display can include the need to convert antibody fragments 
to the whole IgG format, the random pairing of heavy and light chains, and that 
some antibodies can have low affinity to antigen and thus require affinity 
maturation and lead optimization, processes that can take months.  However, new 
technologies are emerging to circumvent these limitations, such as the 
construction of novel libraries with unique combinations of Ig sequence from 
human donor and synthetic diversity (Hoet, Cohen et al. 2005) or the coupling in 
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vitro of somatic hypermutation with mammalian cell display resulting in the 
immediate generation of affinity matured antibodies (Bowers, Horlick et al. 2011). 
An in vivo approach to generate fully human therapeutic antibodies has been the 
creation of transgenic mice expressing human immunoglobulin genes.  Transgenic 
mice such as the Xenomouse® have entirely human immunoglobulin loci in their 
germ lines and are deficient in the production of mouse Ig (Jakobovits, Amado et 
al. 2007).  Because these transgenic animals are capable of producing antigen-
specific B cell responses and undergoing mammalian immune processes key to 
generating antibody diversity such as somatic hypermutation, the resulting 
antibodies are often of high affinity (Green, Hardy et al. 1994; Lonberg, Taylor et al. 
1994).  These mice can rapidly generate fully human antibodies following 
immunization with target antigen, unlike antibody phage display which may 
require lead optimization and conversion into IgG format (Lonberg 2008).  There 
could be limitations to this approach with regards to the generation of antibodies 
against highly conserved antigens which may not be produced due to mechanisms 
of tolerance and also antibodies produced by these transgenic mice may be against 
dominant antigenic epitopes rather than those that inhibit antigen function 
(Chames, Van Regenmortel et al. 2009). 
The production of fully human antibodies either by transgenic mice with human 
antibody genes or phage display technologies has been successfully translated into 
clinical use in the last ten years (Figure 1.3).  The first marketed antibody 
therapeutic with a fully human IgG structure was Adalimumab, approved for the 
treatment of rheumatoid arthritis in 2002, which was produced using antibody 
phage display technology (Lonberg 2008).  The first fully human monoclonal 
antibody created from transgenic mice was Panitumumab, approved for the 
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treatment of colorectal cancer in 2007 (Jakobovits, Amado et al. 2007).  Both the 
use of Xenomouse® and antibody phage display represent technologies capable of 
generating fully human antibodies, but have limitations in that they can require 
the use of proprietary animals such as the Xenomouse® or of bacterial cells to 
express mammalian proteins which involve the lengthy process of in vitro 
antibody affinity maturation and further engineering into IgG format.   
The above strategies employing immunization or surface display approaches to 
create fully human antibodies require the use of known antigens either for 
immunization (transgenic mice) or for selection of specific variable regions 
(antibody phage display).  Recently, there has been some renewed interest in the 
identification and generation of fully human antibodies by the immortalization of 
patient B cells, a strategy which presents the unique potential to select naturally 
affinity-matured antibodies with matched heavy and light chains, without the 
requirement of a known antigen or the more lengthy process of in vitro 
maturation.  Human B cell immortalization presents an additional methodology to 
produce human antibodies which could lead to the discovery of novel antibodies, 




1.1.5.2 Strategies to Discover Human Antibodies from Patient B cells 
An alternate strategy for the generation of novel antibodies to those previously 
described such as hybridoma and phage display, is the immortalization of human B 
cells following exposure to pathogens.  The key advantages of this approach are 
that it does not require antigen for the production of antibodies, or necessarily 
require the use of additional host cell lines to express antibodies for antibody 
characterization, and results in the immediate production of human antibodies.  
This approach also has the potential to reveal antibodies of novel specificity by 
studying natural human antibody responses following the exposure to foreign 
pathogens.  The immortalization of human B cells into antibody-secreting cell lines 
has been primarily achieved by the co-incubation with Epstein-Barr virus (EBV), a 
lymphotrophic herpes virus that infects human B cells resulting in B cell 
proliferation (Miller and Lipman 1973).  EBV has been demonstrated to 
‘immortalize’ human B cells in culture to create lymphoblast cell lines (Steinitz, 
Klein et al. 1977) and this method has been widely used.   Unfortunately, the 
realization of this approach to generate fully human monoclonal antibodies has 
been limited by the historically low efficiency rates of B cells, with reported rates 
of EBV transformation being as low 3% of B cells (Sugden and Mark 1977).  
Additionally, B cells cultured ex vivo have historically not survived for long periods 
in culture or secreted acceptable amounts of antibodies for adequate study.  These 
difficulties have hindered the widespread application of this technique in the past 
to study the breadth of natural antibody responses from human B cells and to 




There have been more recent improvements to the culturing of human B cells such 
as the addition of polyclonal B cell activators to enhance EBV transformation 
efficiencies or the genetic programing of B cells.  In 2004, Traggiai and colleagues 
found that the addition of a polyclonal B cell activator, a CpG oligonucleotide (CpG 
ODN 2006, CpG ODN or CpG 2006), which is a toll-like receptor (TLR) 9 agonist 
(Figure 1.4), resulted in the improved efficiency rates of memory B cell 
transformation ranging from 30 to 100% (Traggiai, Becker et al. 2004).  This 
methodology preferentially activates and expands memory B cells and the 
production of Igs in culture through the activation of TLR9 receptors, which are 
more highly expressed on memory B cells compared to naïve B cells and do not 
require BCR triggering for activation in culture (Bernasconi, Traggiai et al. 2002; 
Bernasconi, Onai et al. 2003).  A second example of a recent improvement to the 
culturing of human B cells is the retroviral introduction of genes into B cells, which 
increases cell proliferation in culture.  Kwakkenbos and colleagues found that the 
introduction of genes for B cell lymphoma-6  and xL proteins which have been 
implicated in the inhibition of terminal B cell differentiation in vitro and blocking 
of apoptosis, respectively,  along with the co-culture of CD40 ligand and IL-21, 
increased the in vitro expansion of B cells (Kwakkenbos, Diehl et al. 2010).  This 
technique resulted in the simultaneous expression of BCR and secretion of 
antibodies which allowed for the screening of B cells with desired antigen 
specificity (Kwakkenbos, Diehl et al. 2010).  These approaches have been 
successfully applied to discover novel neutralizing antibodies from patients 




Figure 1.4  Generation of antibody-secreting cell lines from humans.  Following 
the isolation of B cells from patients, antibody-secreting B cell cultures can be rapidly 
generated through the co-culture of B cells with EBV and the TLR9 agonist, CpG 2006, 
along with irradiated autologous PBMCs.  Antibodies secreted from these patient-
derived B cell lines can then be further studied to elucidate immunological memory 
responses, such as those following infection with a virus. 
 
Improvements in the culturing of human B cells have resulted in the generation of 
neutralizing monoclonal antibodies in infectious diseases.  Traggiai and colleagues 
identified 35 neutralizing monoclonal antibodies to the SARS corona-virus from 
one infected individual, illustrating their technique was a rapid and efficient 
approach to the discovery of monoclonal antibodies against a virus (Traggiai, 
Becker et al. 2004).  Others have applied and slightly modified these techniques to 
identify antibodies against cytomegalovirus (Funaro, Gribaudo et al. 2008).  And 
Kwakkenbos and colleagues demonstrated that their genetic reprograming 
techniques could produce monoclonal antibodies capable of neutralizing the 
respiratory syncytial virus.  Importantly, antibody repertoires from patient 
memory B cells following exposure to a virus provide new understanding of 
antibody responses to infectious diseases such as influenza (Wrammert, Smith et 
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al. 2008; Li, Chiu et al. 2012) and Human Immunodeficiency virus (HIV) (Scheid, 
Mouquet et al. 2009) and can inform the design of efficacious vaccines by 
identifying antigenic epitopes.  In light of these recent advancements in the 
transformation of human B cells, the study of antibody repertoires following the 
development of infectious diseases in individuals provides an alternate strategy in 
the discovery of fully human monoclonal antibodies, and deserves further 
consideration in more disease settings. 
Harnessing the antibody repertoire of individuals with cancer through the 
transformation and immortalization of patient B cells could provide an alternate 
strategy in the discovery of antibodies against cell surface TAAs.  Naturally 
occurring antibody responses to cancer antigens have been described in the 
serum, circulating memory B cells, and tumor-infiltrating B cells of individuals 
with melanoma (reviewed in Section 1.3.1) and other cancers such as breast and 
lung cancers (Coronella-Wood and Hersh 2003; Kotlan, Simsa et al. 2005; 
Mizukami, Hanagiri et al. 2005).  Most of these studies have centered on humoral 
immune responses to melanoma because it is widely thought to be a prototypic 
immunogenic cancer.  Yet prior to the work done in this thesis, there are no 
reports of applying these reported improvements for ex vivo B cell activation to 
evaluate antibodies produced in individuals in response to cancer antigens.1  It is 
hypothesized here that application of the B cell activator described by Traggiai et 
al., namely CpG 2006, to the EBV immortalization of human B cells from melanoma 
patients could yield an efficient route to identify and generate fully human 
antibodies against TAAs.   
                                                         
1 Results described in this thesis evaluating these methods have been previously published 
elsewhere (Gilbert, Karagiannis et al. 2011).   
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Historically, there have been several attempts to derive melanoma-reactive 
antibodies from EBV transformed patient-derived peripheral blood and tumor-
resident B cells.  These efforts have yielded a few antibodies of the IgM and IgG 
class (Kirkwood and Robinson 1990; Punt, Barbuto et al. 1994).  A major technical 
obstacle of these studies was reported to be loss of antibody production from long 
term B cell cultures (Kirkwood and Robinson 1990; Yeilding, Gerstner et al. 1992), 
providing justification of applying improved methodologies to increase human B 
cell transformation in vitro in order to allow for a more comprehensive study of 
the antibody repertoires in melanoma patients.  Studying the antibody response of 
individuals with melanoma could possibly afford multiple advantages in the 
discovery of novel antibodies: antigens do not need to be known a priori; high 
affinity matured human antibodies can be identified; clinically relevant clones can 
be selected by studying patients’ antibody responses against melanoma cells; and 
human B cell cultures could provide an immediate source of antibodies with which 
to perform early in vitro characterizations.   
Important to the attainment of tumor-specific antibodies from the B cells of cancer 
patients is the development of in vitro screening assays to identify antibodies with 
reactivity to TAAs.  This poses a challenge in that few cell surface antigens have 
been described for melanoma and are readily commercially available in 
recombinant form.  For these reasons, the identification of melanoma-reactive 
antibodies from patient B cells has primarily been done against tumor cell lines 
which are readily available (Chen, Güre et al. 1998; Carter, Smith et al. 2004) and 
do not require the identification or production of TAAs.   Since cancer is widely 
thought to be heterogeneous and cell lines may differentially express antigens, the 
evaluation of multiple cell lines would be crucial in this screening approach.  While 
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it could be assumed that cell lines may have altered protein expression after 
several generations in culture, some studies have shown antigens in cell lines 
correspond to antigen expression on freshly isolated tumors making them a 
suitable starting point (Degiovanni, Hainaut et al. 1990; Wistuba, David Bryant et 
al. 1999).   Furthermore, the identification of tumor-reactive antibodies from 
patients has been performed using cell lines with techniques such as 
hemadorsption assays, immunohistochemistry (IHC), immunocytochemistry (ICC) 
using cytospins, immunoblots, enzyme-linked immunoabsorbant assay (ELISA), 
and fluorometric microvolume assay technology (Carey, Takahashi et al. 1976; 
Yeilding, Gerstner et al. 1992; Punt, Barbuto et al. 1994; Miraglia, Swartzman et al. 
1999; Carter, Smith et al. 2004).  Therefore, essential to performing a 
comprehensive screening of antibodies from many individuals would be the 
generation of an inexpensive, medium-throughput cell-based assay for screening 
using available resources to aide in the discovery of novel antibodies against TAAs 
present in patients with cancer.  The design of such an assay was a primary goal of 
this thesis, to permit for the identification and characterization of melanoma-
reactive antibodies secreted from the B cells of individuals with melanoma.    
 
 
1.2    Melanoma 
Malignant melanoma is one of the most lethal forms of skin cancer; while it 
accounts for less than 5% of skin cancer cases it is responsible the majority of skin 
cancer related deaths, and incidence rates are sharply rising world-wide compared 
to other cancers (Lens and Dawes 2004; ACS 2012).  Melanoma arises from the 
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unregulated growth of melanocytes, pigmented cells found primarily in the skin 
and other epithelial surfaces such as the eye.  Melanocytes originate from highly 
motile neural crest progenitors and melanoma can be a highly invasive cancer.  If 
diagnosed early, and localized in the skin, 98% of these individuals can be cured by 
surgical resection (ACS 2012).  However once metastatic, patient prognosis 
becomes increasingly poor with disease progression, and patients diagnosed with 
Stage IV melanoma have reported median survival rates of  6 to 10 months and 5-
year survival rates between 5 and 22% (Cummins, Cummins et al. 2006; Hodi, 
O'Day et al. 2010; ACS 2012; CRUK 2012).  Historically, melanoma in its advanced 
stages has been proven highly resistant to treatments such as chemotherapy 
(Soengas and Lowe 2003). 
Melanoma is widely accepted to be the prototypic immunogenic tumor, and this 
notion has been supported by reports of  partial or complete regression of 
melanoma lesions, reported cases of spontaneous remissions in patients, along 
with evidence of tumor-specific T and B cell responses (Stockert, Jäger et al. 1998; 
Lee, Yee et al. 1999; Kalialis, Drzewiecki et al. 2009).  This could be viewed as a 
paradox when considering that malignant melanoma has historically been highly 
resistant to treatment in its advanced stages, even with the use of therapies aimed 
at enhancing host immunity.  The immunogenic nature of melanoma coupled with 
the low survival rates of patients with malignant disease exemplify the complexity 
of the relationship between the host immune system and cancer, discussed further 
in Section 1.3.   Examination of the immune response in melanoma provides 
opportunities to elucidate immunomodulatory mechanisms and the potential to 




1.2.1 Therapy for Metastatic Melanoma 
Until recently, only a few therapies were approved for the treatment of malignant 
melanoma by the US FDA (Table 1.6), and these therapies have had limited clinical 
results.  Dacarbazine, a chemotherapeutic agent, has been used as a standard 
therapy in melanoma for decades; however, it has only shown short-lived clinical 
responses without evidence for improvement of patient survival (Hill, Krementz et 
al. 1984).  The second type of therapy used in melanoma has been immunotherapy, 
through the use of the immune activating cytokines high dose interleukin (IL)-2 or 
interferon (IFN) α2b.  IL-2 is a cytokine that increases the proliferation of NK, B 
and T cells and upon administration to patients it can result in the expansion of 
these lymphocytes thus increasing their effector function against tumor cells 
(Waldmann 2006).  The administration of high doses of IL-2 has met with some 
success in the clinic, but unfortunately it has been limited to some subgroups of 
patients and it is associated with high rates of toxicity (Atkins, Lotze et al. 1999).  
Another immunotherapy that has been used to treat high risk melanoma is 
IFNα2b, a highly pleiotropic cytokine thought to have anti-proliferative, apoptotic, 
and anti-angiogenic properties along with the promotion of a host anti-tumor 
response brought on by the stimulation of cytotoxic cells such NK cells, and the 
enhancement of dendritic cell presentation to prime tumor-specific T cells 
(Kirkwood, Tarhini et al. 2008; Diamond, Kinder et al. 2011).  It has been 
hypothesized that the use of this cytokine can induce  T helper cell subset 1 (Th1) 
responses against the tumor in micrometastases thought to associated with less 
established immune tolerance (Tarhini and Kirkwood 2009).  Clinical studies 
administering high doses of IFNα2b have demonstrated a reduction in the 
reoccurrence of melanoma, however a clear impact of IFNα2b on overall patient 
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survival rates has not been demonstrated (Wheatley, Ives et al. 2003).  IFNα2b and 
IL-2 have both demonstrated clinical utility for the treatment of some patient 
groups since their FDA approval in 1995 and 1998, respectively.  However, the 
overall lack of effective therapies to treat larger groups of patients remained and 
resulted in the generation of considerable scientific interest in the discovery and 
development of new therapeutics aimed at improving patient outcomes. 
 
Table 1.6  US FDA Approved Drugs for the Treatment of Malignant Melanoma  
Drug 
(brand name) 
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2011 
† A pegylated version of IFNα2b was approved in 2011 with enhanced efficacy and half-life. 
 
 
The recent approval of two new drugs in 2011 by the US FDA has brought much 
promise in the treatment of metastatic melanoma.  The first drug, Vemurafenib 
(PLX4032 or Zelboraf®) is a small molecule kinase inhibitor which selectively 
targets a mutant form of the BRAF protein, namely BRAF V600E, which has been 
detected in 66% of patients with malignant melanoma (Davies, Bignell et al. 2002).  
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This inhibitor can selectively block the mitogen-activated protein kinase (MAPK) 
pathway, thereby reducing the proliferation of melanoma cells carrying this BRAF 
mutation.  Application of this agent has shown complete or partial tumor 
regression in a Phase I trial (Flaherty, Puzanov et al. 2010).   In a Phase II trial, 
Vemurafenib demonstrated a 50% response rate and median survival rate of 16 
months for those individuals with Stage IV melanoma carrying this BRAF V600E 
mutation (Sosman, Kim et al. 2012).  Patients with the BRAF V600E mutation in a 
Phase III trial were observed to have response rates of 48% for Vemurafenib and 
5% for Dacarbazine, with survival rates of 84% and 64% for Vemurafenib and 
Dacarbazine, respectively, in the 6 months following treatment (Chapman, 
Hauschild et al. 2011).  These clinical data demonstrate the ability of 
Vermaurafenib to increase the rate of survival and patient responses following 
treatment. 
The second promising drug with recent approval for the treatment of melanoma is 
Ipilimumab, a monoclonal antibody targeting the high affinity receptor CTLA-4 
expressed on T cells.  Upon binding to its ligand, CD80 or CD86, CTLA-4 can 
transmit an inhibitory signal to T cells, and it is hypothesized that the blockade of 
this receptor may result in the enhancement of T cell-mediated anti-tumor 
immunity (O'Day, Hamid et al. 2007).  The mechanism of action of this antibody is 
discussed further in Section 1.2.2.  In a Phase III study, metastatic melanoma 
patients had  survival rates of approximately 10-11 months when treated with 
Ipilimumab with or without the gp100 peptide, compared to a survival of rate of  
6.4 months for those receiving the peptide vaccine alone (Hodi, O'Day et al. 2010).  
Further follow up for 177 patients treated with Ipilimumab has shown that median 
survival rates ranged from 13-16 months and complete response rates ranged 
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from 6 to 17% for three clinical trials, highlighting the promise of  this 
immunotherapy to sustain tumor regressions (Prieto, Yang et al. 2012).  The 
success of the monoclonal antibody Ipilimumab has been a significant 
breakthrough for the treatment of malignant melanoma, particularly for those 
patients diagnosed with metastatic melanoma that do not carry the BRAF V600E 
mutation and potentially for those patients who relapse following treatment with 
Vemurafenib.  This treatment thus represents a new class of promising cancer 
immunotherapies aimed at blocking immune inhibitory pathways which can boost 
the host immune response to cancer.     
While Ipilimumab and Vemurafenib are associated with some complete responses 
and show encouraging results with respect to the prolonged survival of patients, 
the need for further therapeutic options in melanoma remains, and many on-going 
efforts are focused on exploring similar or other novel immunotherapeutic 
approaches. 
 
1.2.2 Immunotherapeutic Approaches for the Treatment of Melanoma 
Melanoma is widely thought to be highly immunogenic in nature, supported with 
clinical observations of spontaneous regression (Bulkley, Cohen et al. 1975; 
Kalialis, Drzewiecki et al. 2009), the presence of tumor-infiltrating lymphocytes 
(Clemente, Mihm et al. 1996; Erdag, Schaefer et al. 2012), and clinical responses to 
immune stimulation such as the polyclonal activating exogenous cytokines IL-2, 
IFNα2b (Kirkwood, Tarhini et al. 2008).  Many therapeutic approaches are aimed 
at enhancing or modulating these host immune responses by actively (vaccines or 
mimitopes) or passively (monoclonal antibodies or adoptive cell therapy 
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approaches) engaging the immune system to produce an anti-tumor response, or 
in the case of adoptive cell therapies to provide the patient with more potent anti-
tumor immune effector cells. 
An active immunotherapeutic approach to the treatment of melanoma has been in 
the development of vaccines.  Melanoma vaccines are based on immunizing 
patients against their own cancers using plasmid DNA or viral vectors, peptides, 
proteins, tumor cell lysates, and whole cells, including autologous cells.  Melanoma 
vaccines can result in induction of host T cell or humoral immune response against 
cancer cells.  Much work has been done on the development of vaccines for 
melanoma, however the results of these vaccines have not yet reached profound 
benefits for large groups of patients (Rosenberg, Yang et al. 2004; Latzka, Gaier et 
al. 2011; Lacy, Karagiannis et al. 2012).  A limitation of active immunotherapies 
may be the inability to induce a potent enough response in patients to overcome 
local immune suppression found in metastatic cancers.  However, this potentially 
can be overcome with the development of novel delivery systems such as 
electroporation for DNA vaccines (Rice, Ottensmeier et al. 2008), or by the 
enhancement of host lymphocyte responses against the vaccine by the co-
administration of immune cell activating cytokines such as IL-2 
(Schwartzentruber, Lawson et al. 2011), or through dendritic cell vaccine 
approaches (Nestle, Alijagic et al. 1998).  
Cell-based immunotherapies such as dendritic cell vaccines or adoptive T cell 
therapies have shown some promise for the treatment of melanoma.  The ex vivo  
activation of autologous dendritic cells with peptides or tumor cell lysates to 
trigger host tumor-specific T cell responses has shown some responses in patients 
(Nestle, Alijagic et al. 1998).  While the widespread application of dendritic cell 
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vaccines has not been fully realized for melanoma, their evaluation has provided 
insights into elucidating the powerful role of dendritic cells for active 
immunotherapeutic approaches, and has paved the way for clinical use of a 
dendritic cell vaccine for prostate cancer in 2010 (Cheever and Higano 2011).   
Adoptive cell therapy approaches, mostly focused on activating T cells, have also 
warranted much attention. The ex vivo  expansion and activation of autologous 
tumor-infiltrating lymphocytes (TILs) has led to patient response rates as high as 
50% and tumor regressions in clinical studies comprised of small groups of 
patients (Dudley, Wunderlich et al. 2005; Besser, Shapira-Frommer et al. 2010).  
While these studies highlight the merit of this strategy to enhance the host 
lymphocyte responses to melanoma, practical drawbacks to adoptive cell therapies 
include the labor intensity, risk of infection, expense of autologous TIL or dendritic 
cell expansion, and the personalized nature of these treatments, making their 
widespread use challenging. 
Monoclonal antibodies represent a passive immunotherapeutic approach for the 
treatment of melanoma.  As mentioned above, monoclonal antibodies can function 
in multiple ways, including the activation of immune effector cells to mount an 
anti-tumor response, blockade of receptor-ligand interactions involved in tumor 
cell proliferation and mobility, and the blockade of immune checkpoints such as 
those modulating host immune responses (Carter 2006; Pardoll 2012).  As 
described previously, the first monoclonal antibody for use in the treatment of 
melanoma, Ipilimumab, has been recently approved.  This monoclonal antibody 
functions by blocking the binding of CTLA-4 expressed on activated T cells to its 
ligands CD80/CD86 expressed on antigen presenting cells.  This results in reversal 
of inhibitory signals which limit T cell proliferation in response to antigen and 
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CD80/CD86 stimulation (O'Day, Hamid et al. 2007).  Ipilimumab represents the 
first marketed monoclonal antibody that functions by overcoming host tolerance 
to cancer (Lipson and Drake 2011). 
Other emerging immunomodulatory monoclonal antibodies have shown some 
clinical promise for the treatment of melanoma, such as those targeting the 
programmed death 1 (PD-1) receptor.  This inhibitory receptor, a tyrosine-based 
inhibitor motif (ITIM) receptor, is a member of the CTLA-4 protein family and is 
expressed by activated T cells.  Antibodies blocking the binding of PD-1 to its 
ligand, which is expressed on dendritic cells and activated T and B cells, have been 
shown to increase the T cell anti-tumor responses in  melanoma patients 
(Brahmer, Drake et al. 2010; Topalian, Hodi et al. 2012).   Antibodies targeting the 
PD-1 receptor may result in a more specific regulation of tumor escape than CTLA-
4 blockade since a ligand for PD-1 receptor is also expressed on melanoma cells 
and the blockade of this receptor in tumors may prevent the inhibition of the 
regulatory response of tumor cells on T cells (Iwai, Ishida et al. 2002; Hino, 
Kabashima et al. 2010). 
Monoclonal antibodies against TAAs residing on the cell surface may also provide 
effective therapeutic options for melanoma.  Antibodies such as Rituximab and 
Trastuzumab for treatment of lymphoma and breast cancer, respectively, target 
antigens over-expressed on the surface of cancer cells, and their demonstrated 
clinical efficacy along with other antibody therapeutics support the merits of the 
passive administration of monoclonal antibodies against TAAs.  Administration of 
antibodies against antigens over-expressed in melanoma may result in Fab-
mediated non-immunological mechanisms of action against melanoma cells 
and/or may result in the engagement of the innate immune system to specifically 
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target melanoma cells by mechanism such as CDC and ADCC/ADCP.  Examples of 
such antibodies include those targeting over-expressed molecules implicated in 
cell adhesion and the metastatic potential of cells such as tyrosinase-related 
protein (TYRP) 1,  melanoma cell adhesion molecule, and the high molecular 
weight melanoma associated antigen (HMW-MAA) (Chang, Campoli et al. 2004; 
Patel, Balderes et al. 2007; Staquicini, Tandle et al. 2008).  Thus antibodies against 
melanoma TAAs may provide a combination of non-immunological mechanisms 
such as the blockade of signaling pathways involved in cell proliferation, tumor cell 
adhesion and invasion along with engagement of the innate immune system by Fc-
mediated effector functions, resulting in the generation of potent passive 
immunotherapies specifically directed at melanoma cells. 
Antibodies targeting the HMW-MAA are of great potential interest for the 
treatment of melanoma and constitute a partial focus of this thesis.  This antigen 
represents an ideal antibody target because it resides on the cell surface and has 
been described to have restricted distribution in normal tissues and have high 
expression in melanomas (Campoli, Chang et al. 2004).  Antibodies against 
multiple regions of the antigen were discovered over 30 years ago following the 
immunization of mice with melanoma cells and generation of hybridoma cell lines 
(Wilson, Imai et al. 1981), and a multitude of antibodies have been produced 
against this highly immunogenic antigen (Herlyn, Steplewski et al. 1983).  
Antibodies against HMW-MAA (HMW-MAA antibodies) have revealed key aspects 
of the function of this TAA (reviewed in the next section) in metastatic processes 
and have been shown to inhibit the proliferation, migration, spreading, and 
invasion of melanoma cells (Harper and Reisfeld 1983; de Vries, Keizer et al. 1986; 
Iida, Meijne et al. 1995).  Preclinical studies of this molecule, such as those using 
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mouse xenograft models of melanoma, demonstrated that the administration of 
murine antibodies targeting HMW-MAA resulted in a significant reduction of 
tumor growth (Hafner, Breiteneder et al. 2005).  Most of the preclinical studies of 
HMW-MAA antibodies have utilized murine antibodies, however human scFv’s 
have been generated using phage display technology (Desai, Wang et al. 1998) and, 
more recently, scFv-Fc fusion molecules were used to construct recombinantly 
engineered IgG1 antibodies which have demonstrated some anti-tumor activity 
(Wang, Katayama et al. 2011).  However, to-date full-length antibodies with human 
Fc regions, while having been constructed, have not been assessed for their ability 
to mediate Fc-mediated immune effector functions in relevant preclinical models.  
The evaluation of antibodies against HMW-MAA with human Fc regions would be 
important for the assessment of clinically-relevant antibody candidates for their 
ability to engage innate immune effector cells as a way of improving their potential 
clinical utility. 
 
1.2.3 Melanoma Antigens Recognized by the Immune System 
Melanoma antigens are instrumental for the detection, treatment, and monitoring 
of patients with melanoma.   Knowledge of antigen expression is crucial to the 
design of effective immunotherapies.  Many melanoma antigens have been 
identified over the last 20 years by examining T cells and serum antibodies and 
using SEREX (serological analysis of recombinant DNA expression libraries) 
platforms (Jager, Stockert et al. 2000; Geuijen, Bijl et al. 2005; Zippelius, Gati et al. 
2007).  The expression of melanoma antigens has been found to be heterogeneous 
and identified antigens can broadly be placed in categories such as cancer testis 
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antigens, differentiation antigens, amplified gene products, and mutation derived 
proteins (Barrow, Browning et al. 2006).  The identification and possible roles of 
cancer testis antigens, differentiation antigens, and another antigen of interest, the 
HMW-MAA, will next be discussed. 
In melanoma and some other cancers, cancer testis antigens such as the New York 
esophageal squamous cell carcinoma 1 (NY-ESO-1) antigen and those of the 
melanoma associated antigen (MAGE) gene family have been found to be 
overexpressed on cancer cells and have restricted expression on adult testicular 
germ cells and the placenta and little expression on normal tissues (De Plaen, 
Traversari et al. 1994; Caballero and Chen 2009).  Studies of cancer testis antigen 
expression have shown the higher expression of such antigens in metastatic 
melanoma compared to primary lesions (Barrow, Browning et al. 2006).  Both 
humoral and T cell mediated immune responses have been observed against 
cancer testis antigens such as MAGE-1 and MAGE-3 and NY-ESO-1, with NY-ESO-1 
thought to be the most immunogenic antigen based on observations of coordinated 
antigen-specific CD8+ T cell and antibody responses against this antigen 
(Caballero and Chen 2009).  To-date the functions of these antigens and their role 
in tumorgenesis are poorly understood. 
Differentiation antigens such as gp100, melan-A, tyrosinase proteins (TYRP-1 and 
TYRP-2) are involved in the pathway of melanin production and are expressed in 
both melanocytes and melanoma cells.  These antigens are strongly expressed in a 
majority of both primary and metastatic melanomas and are commonly used as 
markers for the detection of melanoma (Barrow, Browning et al. 2006).   The 
concordant loss of expression of differentiation antigens in melanoma has been 
found in some individuals to be associated with progressing disease (Trefzer, 
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Hofmann et al. 2006).  However, the mechanisms of immune evasion behind the 
loss of these antigens are not understood.  Notably, it has been found that the 
treatment with Vemurafenib enhances the expression of these antigens on cells, 
possibly implicating the MAPK pathway in the expression of these antigens and in 
immune evasion (Boni, Cogdill et al. 2010). 
 
1.2.3.1 HMW-MAA  
One example of an over-expressed protein in melanoma of special interest for this 
thesis is HMW-MAA, otherwise named chondroitin sulfate proteoglycan 4 (CSPG4), 
or melanoma chondroitin sulfate proteoglycan (MCSP).  The antigen was identified 
30 years ago by a monoclonal antibody due to its high expression on melanoma 
cells and immunogenicity (Wilson, Imai et al. 1981).  HMW-MAA is a highly 
glycosylated transmembrane proteoglycan comprised of a 280 kDa N-linked 
glycoprotein component (core glycoprotein) and a 450 kDa chondroitin sulfate 
proteoglycan component expressed on the cell membrane (Figure 1.5).  The core 
protein consists of 2322 amino acids and is comprised of a large extracellular 
domain, hydrophobic transmembrane region and short cytoplasmic tail (Campoli, 
Chang et al. 2004; Price, Colvin Wanshura et al. 2011).  HMW-MAA has restricted 
distribution on normal tissues and has been found to be expressed in a high 
proportion (>80%) of melanomas (Campoli, Chang et al. 2004).  The expression of 
this antigen has also been described in other cancers including triple negative 
breast cancer, mesotheliomas, squamous cell carcinomas of the head and neck, and 
glioblastomas, supporting the targeting of this antigen for cancer immunotherapy 
(Price, Colvin Wanshura et al. 2011; Rivera, Ferrone et al. 2012).  Additionally, 
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HMW-MAA may also hold some importance in the diagnosis of melanoma, having 
utility in the diagnosis of micrometastases in the sentinel lymph nodes of patients 
(Goto, Ferrone et al. 2008).    
HMW-MAA is thought to play a critical role in linking multiple oncogenic pathways 
that mediate the progression of malignancy (Price, Colvin Wanshura et al. 2011).  
HMW-MAA has been described to contribute to the metastatic potential of HMW-
MAA expressing cells by modulating or enhancing signaling pathways involved in 
cell adhesion, proliferation, and invasion (Price, Colvin Wanshura et al. 2011).  The 
antigen is thought to be critical to the growth of melanoma tumors through the 
modulation of integrin function, heterodimeric receptors important in mediating 
cell-cell and cell-ECM interaction, and growth factor receptor regulated signaling 
pathways (Hynes 1992; Price, Colvin Wanshura et al. 2011).  HMW-MAA has been 
shown to activate integrin-regulated focal adhesion kinase (FAK) signaling and 
receptor tyrosine kinase signaling through the MAPK cascade, signaling cascades 
which ultimately promote tumor progression (Yang, Price et al. 2004).  The 
antigen has also been implicated in enhancement of α4β1-integrin-mediated 
melanoma cell spreading along with the regulation of matrix metalloproteinases 
(MMP)-dependent cell invasion into type I collagen (Iida, Skubitz et al. 1992; Iida, 
Pei et al. 2001).  The mechanisms by which this protein can contribute to 
metastatic processes are beginning to become more fully understood, as is the 




Figure 1.5  Structure of HWM-MAA.  Schematic representation of HMW-MAA, a 
transmembrane proteoglycan comprised of a cytoplasmic C-terminal domain, 
transmembrane region, and an extracellular domain.  The large extracellular domain 
consists of three subdomains (ECD): (ECD1) globular N-terminal subdomain consisting 
of laminin G-like regions (LG) and disulfide bonds; (ECD2) 15 chondroitin sulfate 
proteoglycan repeats known to bind to soluble growth factors and a chondroitin sulfate 
glycosaminogylcan chain responsible for binding to integrin and MMPs; and (ECD3) 
the globular subdomain located next the plasma membrane containing lectin binding 
sites and proteolytic cleavage sites by MMPs.  The short cytoplasmic C-terminal 
domain contains tyrosine residues (T) that serve as phosphoacceptor sites for protein 
kinase Cα and extracellular signal-regulated kinase (ERK) 1,2 and also a proline-rich 
region (PR) may facilitate protein-protein interactions.  The C-terminus contains a PDZ 




There have been a number of preclinical and clinical evaluations of 
immunotherapeutic strategies aimed at inhibiting the function of HMW-MAA in 
melanoma.  These strategies have included active immunotherapeutic approaches 
such as the use of peptides mimicking the structure of HMW-MAA epitope 
(mimotopes or peptide vaccines) (Riemer, Hantusch et al. 2005; Wagner, Hafner et 
al. 2005; Luo, Ko et al. 2006) or mouse anti-idiotypic antibodies bearing the 
internal image of HMW-MAA acting as an immunogen for the induction of humoral 
immunity.  This later strategy has been associated with statistically signification 
prolongation of patient survival in some clinical studies (Mittelman, Chen et al. 
1990; Mittelman, Chen et al. 1992).  In the preclinical setting, there have been 
numerous studies of evaluating passive immunotherapeutic approaches using 
monoclonal antibodies targeting different regions of this protein, and antibodies 
such as the 225.28S clone have demonstrated direct functions in the blockade of 
adhesion, migration and anchorage-dependent growth (reviewed in detail in 
Section 1.2.2).   Antibodies targeting HMW-MAA have also been conjugated to 
immunotoxins and to alpha and beta emitting radioisotopes.  In preclinical models, 
these antibody conjugates have shown cytotoxic effects on melanoma cells (Imai, 
Nakanishi et al. 1983; Ghose, Ferrone et al. 1991; Liewendahl and Pyrhönen 1993).  
These studies all highlight the potential of immunotherapeutic strategies to target 
this melanoma antigen. 
Understanding the expression, antigenicity, and functions of melanoma antigens is 
essential to the diagnosis, prognosis, and treatment of melanoma.  Antibodies 
against melanoma antigens could serve as potential therapeutic agents and also 
possibly as key diagnostic tools, although no prognostic markers are currently 
recommended for clinical use in melanoma (Rothberg, Bracken et al. 2009).  
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Central to the design of effective immunotherapeutic strategies to treat melanoma 
is the attainment of a better understanding of how the host recognizes and 
responds to these melanoma antigens.  Such an understanding is expected to allow 
for the more rational selection of antigen targets for both passive and active 
immunotherapeutic approaches for the treatment of melanoma. 
 
 
1.3  Immune Responses to Cancer 
The immune system plays a dual role in cancer, producing an anti-tumor response 
on one hand, but also aiding the escape of tumors from eradiation by host immune 
responses on the other (Dunn, Bruce et al. 2002).  A current paradigm in cancer 
immunology is cancer immunoediting which hypothesizes that there are three 
phases in the host response to cancer: (1) elimination, (2) equilibrium, and (3) 
evasion resulting in the change of the host response to cancer from that of immune 
surveillance to immune escape (Dunn, Bruce et al. 2002; Schreiber, Old et al. 
2011).  In the initial immune response to cancer, it is thought that innate and 
adaptive immune systems mount anti-tumor responses to eliminate cancer cells.  If 
not successful, it is thought that cancer cells then remain in a state of equilibrium 
with the immune system suppressing further malignancy.  However, this state is 
thought to be temporary and eventually leads to immune editing where the 
continuous pressure on the immune response against tumor cells results in the 
selection of cells with low immunogenicity leading to the escape of tumor cells 
from the host anti-tumor immune response (Schreiber, Old et al. 2011).  This 
concept of immunoediting has been supported by clinical observations in 
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melanoma patients such as the example of the downregulation of NY-ES0-1 
expression in relapsed patients following NY-ESO-1 vaccine treatment (Nicholaou, 
Chen et al. 2011). 
Central to immune surveillance is the ability of immune effector cells, such as 
lymphocytes, to mount a cytotoxic response against tumor cells (Dunn, Bruce et al. 
2002).  Antigen-specific lymphocyte responses have been described in melanoma 
with an emphasis on T cells (Lee, Yee et al. 1999; Vence, Palucka et al. 2007), 
supported by successful clinical case scenarios using immunotherapeutic 
strategies to enhance T cell anti-tumor responses including dendritic cell vaccines, 
adoptive T cell therapies, and monoclonal antibodies targeting CTLA-4 
(Schadendorf, Ugurel et al. 2006; Dudley, Yang et al. 2008; Kirkwood, Tarhini et al. 
2008; Besser, Shapira-Frommer et al. 2010; Hodi, O'Day et al. 2010).  There has 
been much emphasis on the role of T cells in melanoma, while the roles of B cells 
and their subsets in melanoma and the breadth of humoral immune responses are 
less understood. 
  
1.3.1  Humoral Responses to Melanoma 
It has been reported that B cells constitute a major subset of immune cell 
infiltrates in primary and metastatic melanoma along with T cells and other 
immune effector cells such as macrophages (Clemente, Mihm et al. 1996; Erdag, 
Schaefer et al. 2012); however, the antigen-specific B cell response in the tumor 
microenvironment is not well understood and insights into antibody responses to 
melanoma have primarily been inferred from serological studies (Stockert, Jäger et 
al. 1998; Trefzer, Hofmann et al. 2006). 
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Reports of tumor-reactive antibodies in the sera of melanoma patients date back 
over forty years (Lewis, Ikonopisov et al. 1969; Muna, Marcus et al. 1969) and have 
provided evidence of a humoral response to melanoma.  One extensive study 
performed by Stockert and colleagues examined the presence of antibodies against 
NY-ESO-1, MAGE-1, MAGE-3, and synovial sarcoma X (SSX2 or HOM-MEL-40) 
cancer testis antigens along with the differentiation antigens melan-A and 
tyrosinase proteins in the sera of 127 metastatic melanoma patients (Stockert, 
Jäger et al. 1998).  From this study it was found that twelve patients had reactivity 
to NY-ESO-1, two patients had reactivity to MAGE-3, and one patient had 
antibodies reactive to both MAGE-1 and SSX2 and no antibodies to the above 
differentiation antigens were detected (Stockert, Jäger et al. 1998).  These results 
highlight the presence of humoral immune responses to some cancer testis 
antigens in a proportion of metastatic melanomas; however, while the study 
examined a large group of patients, it was restricted to a number of recombinant 
melanoma antigens.  Other groups have examined the reactivity of serum 
antibodies to identify novel biomarkers for melanoma by screening against 
autologous cells.  One such study led to the identification of bullous pemphigoid 
antigen 1 in melanoma, which was found in significantly higher amounts in 
patients with metastatic disease compared to healthy volunteers (Shimbo, 
Tanemura et al. 2010).   These studies all provide evidence of the antigen-specific 
B cell response to selected melanoma antigens. 
Serological studies have provided some meaningful insights into the anti-tumor 
antibody responses to melanoma; however, the breadth of these responses and 
changes in the anti-melanoma antibody repertoire of patients with disease 
progression are not fully understood.  Serological studies have been limited to 
-51- 
 
temporal responses primarily in metastatic patients and do not allow for the 
evaluation of the full antibody repertoire and assessments of antibody responses 
occurring in early disease stages.  Examining the antibody repertoire of patients’ 
memory B cells could enhance the findings of these serological studies by 
examining immunologic memory, rather than the temporal responses to 
melanoma, along with potentially providing insights into the presence and 
prevalence of an anti-melanoma memory B cell compartment in patients. 
Several groups have examined patient peripheral blood B lymphocytes (PBBL) and 
tumor-infiltrating B lymphocytes (TIL-B) in the quest to discover melanoma-
reactive antibodies (Yamaguchi, Furukawa et al. 1987; Kirkwood and Robinson 
1990; Yeilding, Gerstner et al. 1992; Punt, Barbuto et al. 1994).  From these 
studies, a few antibodies of the immunoglobulin classes IgM and IgG have been 
identified from patients PBBL and TIL-B that have reactivity to melanoma cells 
(Kirkwood and Robinson 1990; Yeilding, Gerstner et al. 1992; Punt, Barbuto et al. 
1994).  These antibodies have been shown to have reactivity to autologous and 
allogeneic tumor cells of similar histology and some were found to not react with 
human fibroblasts (Punt, Barbuto et al. 1994).  However, the prevalence of such 
antibodies and their functional capacity to engage the immune system to mount an 
anti-tumor response against melanoma cells have not been fully evaluated, likely 
due to past limitations in the production of antibodies from patient memory B cells 
(described in Section 1.1.5.2). 
Understanding the nature and significance of the anti-melanoma humoral immune 
response thus warrants further attention and may provide the basis for future 
strategies aimed at heightening this antibody response in the context of cancer 
immunotherapy.  B cells and other immune cells have been proposed to have dual 
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roles in cancer: on the one hand they can have anti-tumor effects, but on the other 
hand, following perturbations in immune tolerance, these cells or subsets of these 
cells can also contribute to mechanisms of immune escape by tumors. 
 
1.3.2  Mechanisms of Immune Evasion in Tumors 
Despite being reported as a highly immunogenic cancer, melanoma is thought to 
employ multiple mechanisms which can result in the evasion of innate and 
adaptive immune responses.  Metastatic melanoma cells may mediate tumor 
escape by the secretion of immunosuppressive factors such as the cytokine IL-10, 
which can inhibit the production of a number of cytokines by different immune cell 
types potentially resulting in a range of anti-tumor effects such as the impairment 
of tumor antigen presentation, induction of regulatory T cells (Tregs), and the 
impairment of macrophage and NK cell functions (Gerlini, Tun-Kyi et al. 2004; 
Rabinovich, Gabrilovich et al. 2007; Couper, Blount et al. 2008; Emmerich, Mumm 
et al. 2012).  Additionally, tumor cells may secrete pro-angiogenic factors such as 
VEGF which support tumor growth through the promotion of endothelial cell 
growth and migration from pre-existing vasculature to the tumor (Claffey, Brown 
et al. 1996; Hicklin and Ellis 2005).  Melanoma cells have also been found to 
express antibody inhibitory receptors such as FcγRIIB which may function as a 
decoy, possibly rendering the Fc portion of otherwise cytotoxic antibodies 
incapable of mounting an immune response against the tumor (Cassard, Cohen-
Solal et al. 2008).  Additionally, the expression of PD-1 ligand by tumor cells may 
protect melanoma cells from effector T cell responses in the tumors (Dong, Strome 
et al. 2002; Iwai, Ishida et al. 2002).  These are just a few mechanisms of tumor 
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induced immune suppression, and many more have been described including 
those that further impact the functions of immune effector cells, such as NK cells, 
within the tumor, along with the recruitment of myeloid-derived suppressor cells 
that can modulate T cell effector functions (Poschke, Mougiakakos et al. 2011; 
Kerkar and Restifo 2012; Pietra, Manzini et al. 2012). 
Leukocytes, such as lymphocytes and macrophages, can be found in high densities 
in melanoma tumors and have also been implicated in immune suppression which 
may lead to tumor progression.   High numbers of Tregs in patients have been 
found in the blood and tumor microenvironments, and these cells are thought to 
be immmuosuppressive and have been correlated with poor prognoses 
(Nicholaou, Ebert et al. 2009; Wang, Ma et al. 2012).  Tregs can also potentially 
directly suppress B cell responses in secondary lymphoid tissues and inhibit 
mature antibody responses (Lim, Hillsamer et al. 2005).  The upregulation of  PD-1 
on melanoma antigen-specific CD8+ T cells from  TILs compared to normal tissue 
and peripheral blood leukocytes has been hypothesized to contribute to the 
impairment of  effector antigen-specific effector T cell responses (Ahmadzadeh, 
Johnson et al. 2009).  Additionally, macrophages infiltrating tumors are thought to 
become polarized to M2 or “alternately activated” macrophages, induced by 
signals in the tumor microenvironment such as the cytokines IL-4, IL-13, and IL-10 
(Mantovani, Sozzani et al. 2002).  These alternatively activated macrophages are 
thought to have altered functions in that they secrete different cytokines and 
chemokines, have decreased expression of FcγRs, and increased expression of 
FcεRII (Mantovani, Sozzani et al. 2002).  The polarization of macrophages in the 
tumor can impair the anti-tumor functions of these macrophages by suppressing 
adaptive immune responses, facilitating matrix remodeling, and promoting 
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angiogenesis, leading to the promotion of tumor growth and the metastatic 
processes (Sica, Schioppa et al. 2006). 
Some B cell populations have also been described to promote tumor development 
and metastatic processes.  Certain subsets of B cells, such as B-1, have been 
suggested to contribute to metastatic processes through the expression of 
glycoproteins involved in cell adhesion, such as the melanoma cell adhesion 
molecule in mouse models of melanoma (Staquicini, Tandle et al. 2008).   The 
presence of antibodies in premalignant tissue in mouse models has also been 
suggested to contribute to tumor progression and development through Fc-
mediated recruitment and activation of leukocytes which contribute to a chronic 
inflammatory environment (Tan and Coussens 2007; Andreu, Johansson et al. 
2010).  Additionally, regulatory B cells (Bregs) have been suggested to be tumor 
promoting by the secretion of the inflammatory cytokine TNF-α in mouse models 
of cancer (Schioppa, Moore et al. 2011).  The roles of B cells in tumor progression 
are starting to emerge; most likely the relationship between B cells and tumor 
progression is complex and variable among B cell subsets.   The understanding of 
the complex nature of B and T cell responses to tumors, especially those of a 
regulatory nature, can provide insights into novel therapeutic approaches for the 
treatment of cancer, and the clinical utility of this notion has recently been 






1.3.3 Th2 Responses in Cancer and Activation of Alternative Humoral 
Immunity 
A dysregulation of immune cells has been noted in metastatic melanoma and many 
other cancers and a bias towards T helper cell subset 2 (Th2) inflammation has 
been suggested in both the periphery and local tumor microenvironments (Sheu, 
Lin et al. 2001; Nevala, Vachon et al. 2009).  Th2 cells are a subset of CD4+ T helper 
cells that promote humoral immunity, producing cytokines such as IL-4, IL-5, IL-6, 
IL-10 and IL-13.  Th2 immune responses are also thought to play a role against 
parasitic infections and are known to be active in the context of immune responses 
to allergens.  These Th2 cytokines are important in regulating humoral immune 
responses; for example, the cytokines IL-4 and IL-13 stimulate class switching and 
production of IgE and IgG4 antibodies, with both antibodies being important 
mediators of allergic immune responses (Gascan, Gauchat et al. 1991; Punnonen, 
Aversa et al. 1993).   IL-10 has also been shown to regulate humoral immune 
responses by enhancing the production of antibodies of the IgG4 subclass 
compared to IgE and to direct a  “modified Th2 response” which sometimes occurs 
when IgG4 antibodies are found in the absence of IgE (Jeannin, Lecoanet et al. 
1998; Platts-Mills, Vaughan et al. 2001) . 
It is hypothesized here that modulation of humoral immunity by local and possibly 
systemic production of Th2 modulatory cytokines such as IL-4 and IL-10 may 
occur in metastatic melanoma, which may favor the production of the IgG4 
antibody subclass.  IgG4 is generally perceived to have weakened effector 
functions in relation to the other IgG subclasses (Bruggemann, Williams et al. 
1987; Aalberse, Stapel et al. 2009).  IgG4 is thought to have low immune effector 
functions due to its low affinity to Fc receptors, poor ability to bind complement, 
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and its unique ability to interact with other immunoglobulins and engage in Fab 
arm exchange, leading to antigen bi-specificity of antibodies (van der Zee, van 
Swieten et al. 1986; van der Neut Kolfschoten, Schuurman et al. 2007; Bruhns, 
Iannascoli et al. 2009).  A polarization of antibody subclasses towards IgG4 
production, induced by the Th2 cytokine environment in tumors, could possibly 
represent a mechanism of impaired humoral immunity through the enhanced 
production of this antibody subclass, which compared to the other IgG subclasses 
has relatively weak effector functions.   
There has been recent recognition of a group of inflammatory conditions known as 
IgG4-related diseases such as autoimmune pancreatitis; however, the role of IgG4 
in the pathogenesis of these diseases in not clearly understood (Stone, Zen et al. 
2012).  Furthermore, the association of IgG4 and melanoma has not been 
described beyond one report dating back 35 years noting alterations in IgG4 
proportions in the serum of some malignant melanoma patients (Daveau, Pavie-
Fischer et al. 1977).  No other associations have thus far been reported in the 
literature pertaining to alterations of IgG4 levels in sera and other cancers, 
although more recently one report has described the infiltration of IgG4+ plasma 
cells in extrahepatic cholangiocarcinoma (Harada, Shimoda et al. 2012).   Thus, 
exploration of the alteration and modulation of antibody subclass in malignancy 
merits further attention and may represent a mechanism of tumor escape from the 
host humoral immune response by the preferential production of IgG4 antibodies 
against TAAs.  Studies of the distribution of antibodies of the IgG subclasses in the 
periphery and metastatic tumor microenvironment could provide further insight 




1.3.3.1 Preclinical Evaluations of Tumor-specific Antibodies of the IgE Class 
A newly emerging immunotherapeutic approach to harnessing the Th2 responses 
in cancer is the application of antibodies of the IgE antibody class for passive 
immunotherapy (Jensen-Jarolim, Achatz et al. 2008; Karagiannis, Josephs et al. 
2012).  Therapeutic antibodies of the IgE class may have some potential benefits in 
their clinical application over antibodies of the IgG class and their use in cancer 
immunotherapy has been supported by a number of preclinical studies 
(Karagiannis, Josephs et al. 2012).  Therapeutic antibodies of the IgE class may 
confer several advantages over their IgG counterparts in the treatment of solid 
tumors, including a hundred-fold higher affinity to Fc receptors compared to IgG; 
lack of IgE inhibitory Fc receptors in tissues and circulation; desirable 
pharmacokinetic properties such as fast clearance from circulation; the tissue 
residence of IgE effector cells in tumor lesions such as in melanoma; and the 
interaction of therapeutic IgE antibodies with FcεRs on macrophages, eosinophils, 
and mast cells to activate these tissue-resident effector cells against tumors 
(Karagiannis, Josephs et al. 2012).   
Through its Fc region, IgE can recruit and activate Th2 immune effector cells 
expressing FcεRs resulting in potent inflammatory responses including release of 
inflammatory mediators and ADCC.  It has been hypothesized that Fcε-mediated 
effector functions could be harnessed against tumor cells using tumor-specific IgE 
antibodies resulting in potent allergic responses in tumors (Figure 
1.6)(Karagiannis, Josephs et al. 2012).  Tumor antigen-specific IgE antibodies have 
been suggested to have anti-tumor functions via the engagement of FcεRs on 
monocytes/macrophages in a number of in vitro and in vivo investigations 
(Karagiannis, Wang et al. 2003; Karagiannis, Bracher et al. 2007; Karagiannis, 
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Bracher et al. 2008; Karagiannis, Singer et al. 2009).  A tumor-specific IgE 
therapeutic holds particular interest in melanoma with reports of high densities of 
FcεR bearing immune cells in the solid tumor, such as macrophages and mast cells 
(Duncan, Richards et al. 1998; Tth, Tth-Jakatics et al. 2000; Erdag, Schaefer et al. 
2012).  Thus, the immunotherapeutic use of the IgE antibody class may yield a new 
class of promising agents with potential to mount a specific and potent anti-tumor 
immune response within the context of Th2-driven immune responses already 
present in cancers such as melanoma, and the concept of tumor-specific IgE 




Figure 1.6  Mediation of ADCC or ADCP by IgE antibodies targeting tumor 
associated antigens.  Antibodies of the IgE class targeting TAAs can mediate cellular 
mechanisms of action resulting in the destruction of tumor cells through the interaction 
with FcεRs present on immune effector cells.  IgE, bound to TAAs on cancer cells in a 
multimeric fashion can interact with the FcεRI expressed on immune cells such as 
mast cells, basophils, eosinophils and monocytes resulting in multimerization, 
crosslinking and activation resulting in the release of inflammatory mediators such as 
leukotrines and histamines.  IgE, bound to TAAs on cancer cells in a multimeric fashion 
can also interact with the FcεRII (CD23) to mediate the phagocytosis of tumor cells 








Preclinical studies have demonstrated the use of the IgE antibody class against 
TAAs to harness an allergic response against cancer cells to mediate tumor cell 
cytotoxicity.  Engineered IgG and IgE antibodies (MOv18 IgG and IgE) directed at 
FRα were both observed to inhibit tumor cell growth in a mouse severe combined 
immunodeficiency (SCID) xenograft model of ovarian carcinoma in the presence of 
human immune effector cells (Gould, Mackay et al. 1999).  Following these 
findings, later studies revealed the important role of monocytic cells as effector 
cells in these models and the ability of a tumor-specific IgE antibody to mediate 
ADCC through FcεRs on monocytes and other FcεR bearing immune cells such as 
eosinophils (Karagiannis, Wang et al. 2003; Karagiannis, Bracher et al. 2007; 
Karagiannis, Bracher et al. 2008).  Further efforts to evaluate tumor-specific IgE 
antibodies resulted in the construction of an IgE homologue of Trastuzumab.  This 
antibody was also shown to mediate ADCC in the presence of breast cancer cells 
and monocytes and to trigger the degranulation of mast cells following antibody 
crosslinking (Karagiannis, Singer et al. 2009).  Interestingly, these studies revealed 
the different functions of Trastuzumab IgE, which was found to primarily mediate 
ADCC, compared to Trastuzumab (IgG1) which was found to primarily mediate 
ADCP in functional flow cytometry assays designed to simultaneously measure 
ADCC and ADCP (Karagiannis, Singer et al. 2009).  Others have also tested the 
efficacy of tumor-specific IgE antibodies in mouse models of breast and ovarian 
cancer, demonstrating the prolonged survival or restriction of tumor growth in 
transgenic FcεRI mice following the administration IgE antibodies targeting 
Her2/neu and mucin 1 (Daniels, Leuchter et al. 2012; Teo, Utz et al. 2012).  In 
summary, these preclinical data support the efficacy of antibodies of the IgE class 
to mediate cytotoxicity against cancer cells through the engagement and activation 
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of FcεRs and present an alternative strategy to IgG-based immunotherapeutic 
approaches. 
IgE is implicated in mediating allergic reactions and the administration of a tumor-
specific IgE antibody in patients comes with the primary concern of the possible 
induction of undesirable allergic responses.  While a tumor-specific IgE antibody 
could mediate its therapeutic effect through the crosslinking of IgE molecules upon 
binding to tumor cell surface antigens and FcεRI expressing cells, such crosslinking 
would be undesirable in the blood because, in certain circumstances, it could lead 
to possible type 1 allergic hypersensitivity which could range from a mild irritation 
to anaphylactic shock.  Such concerns have been explored using human ex vivo  
allergy models which showed that the induction of possible type 1 hypersensitivity 
in blood required large concentrations of circulating soluble antigens or tumor 
cells, concentrations not normally found in patients with metastatic disease 
(Rudman, Josephs et al. 2011).  Using these ex vivo allergy models, Rudman and 
colleagues also demonstrated a lack of basophil activation in the blood of patients 
with ovarian cancer following incubation with a tumor-specific IgE antibody, even 
in the presence of soluble antigen and in the presence of autoantibodies to this 
antigen (Rudman, Josephs et al. 2011).  These ex vivo findings suggest that there 
may be a relatively low risk of type 1 hypersensitivity following the systemic 
administration of IgE to patients, even in the presence of a monomeric soluble 
tumor antigen and circulating tumor cells in levels greater than physiologically 
found in patients.  Importantly, the Fc-mediated mechanism of action of IgE 
antibodies depends on the crosslinking of antibodies, and it is desirable that such 
crosslinking occurs only in solid tumors in the presence of multivalent antigens 
presented on tumor cells.  
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The preclinical efficacy of IgE antibodies targeting tumor antigens in breast and 
ovarian carcinomas taken together with the infiltration of IgE effector cells such as 
macrophages and mast cells in melanoma tumors support the design and 
development of IgE immunotherapies against melanoma cell surface antigens.  The 
engineering of IgE antibodies targeting cell surface melanoma antigens such as 
HMW-MAA may combine the direct Fab-mediated functions of an antibody, which 
could be to block melanoma cell adhesion and invasion along with the potent Fc-
mediated mechanisms of action of IgE, with the aim of harnessing the Th2 
responses in melanoma tumors.   
 
 
1.4  Hypotheses and Aims 
Given the importance of understanding the complexity of the immune response to 
melanoma in the design of effective immunotherapies, this thesis aims to firstly 
characterize key elements of the humoral immune responses to melanoma.   This 
entails the characterization of the antibody response to melanoma residing in the 
periphery along with the local tumor environment.  Additionally, the function of 
antibodies directed at melanoma cells, including antibodies of the IgE class, are 
evaluated using in vitro models to examine potentially novel immunotherapies that 
specifically target melanoma cells.  
The first part of this thesis investigates an approach to discover antibodies from 
cancer patients through the application of techniques to activate B cells to secrete 
high levels of  antibodies (Traggiai, Becker et al. 2004), a technique which has yet 
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to be applied to the cancer field.  Central to this is the establishment of ex vivo 
antibody-secreting B cell cultures from patients and healthy volunteers, and the 
design and development of screening tools to identify tumor-specific antibodies 
from these B cell culture supernatants (Chapter 3). 
The second part of this thesis examines humoral immune responses in melanoma 
(Chapter 4) by characterizing the anti-melanoma antibody compartment from 
peripheral blood B cells from a patient cohort, utilizing the methods designed in 
Chapter 3.  These studies provide insight into the extent of the humoral immune 
response to melanoma cells existing in patient circulating memory B cells.  This 
work expands upon previous serological studies by assessing the reactivity of 
antibodies from the human memory B cell antibody repertoire, characterizing long 
term antibody responses to melanoma.   While a decrease in the memory B cell 
phenotype has been more recently described in patients with Stage IV melanoma 
(Carpenter, Mick et al. 2009), any changes in the anti-melanoma antibody 
compartment have not been characterized with progressing disease, and it is 
hypothesized here that, following the immunoediting paradigm, the humoral 
immune responses to melanoma are modulated with disease progression. 
Additionally, modulations of antibody responses to melanoma are evaluated from 
a unique perspective.  Immunosuppressive cytokines such as IL-10 have been 
widely described in the melanoma tumor microenvironment, and the presence of 
IL-10 has been demonstrated to increase the production of IgG4 (Jeannin, Lecoanet 
et al. 1998; Satoguina, Weyand et al. 2005).  Taken together, it was investigated 
whether IL-10 or other Th2 cytokines could impair humoral immunity in the 
periphery and tumor microenvironment by the polarization of antibody subclass 
production towards the weakened IgG4 subclass (Chapter 4). 
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The last part of this thesis evaluates the function of antibodies targeting melanoma 
cell surface antigens (Chapter 5).  First, a novel monoclonal melanoma-specific 
antibody derived from a patient is characterized, and the ability of this patient-
derived antibody to engage immune effector cells is evaluated using in vitro 
models.  Next, engineered antibodies of the IgG and IgE class targeting HMW-MAA 
are evaluated using in vitro models for their ability to restrict the adhesion and 
invasion of melanoma cells.  Additionally, the immune effector functions of these 
HMW-MAA antibodies are evaluated in assays examining ADCC and ADCP using 
primary monocytes, since it is hypothesized that different antibody classes can 
each have potent but different Fc effector mechanisms against tumor cells.  
Comparing the function of a melanoma-specific IgE antibody to its IgG counterpart 
may provide further support for future clinical application of IgE, a novel class of 






Chapter 2: Materials and Methods2 
  
                                                         




2.1   Human Subjects 
After obtaining informed consent, peripheral blood was isolated from healthy 
volunteers and from patients with melanoma.  Patient melanoma tumor specimens 
were also provided following informed consent from patients prior to the surgical 
removal of tumor.  Patients were staged and classified according to the American 
Joint Committee on Cancer Melanoma Staging and Classification criteria (Balch, 
Gershenwald et al. 2009).  Human studies were all conducted in accordance with 
the Helsinki Declaration and approved by the Guy’s Research Ethics Committee,  St 




2.2   Tissue Culture  
2.2.1 General Reagents 
The tables following list the source of cell lines (Table 2.1) and the reagents used 
to culture these cells (Table 2.2). 
Table 2.1  Mammalian Cell Lines 
Cell line  Type of cell line Supplier Code number 
A-2058 
Metastatic human melanoma 
derived from a lymph node 
ATCC CRL-11147 
A-375 
Metastatic human melanoma 
derived from skin 
ATCC CRL-1619 
B95-8 
Marmoset cell line infected 
with human EBV 
ATCC VR-1492 
Fibroblasts 
Human skin fibroblasts 






Metastatic human melanoma 













Metastatic human melanoma 
derived from skin 
ATCC HTB-68 
SK-MEL-28 
Metastatic human melanoma 
derived from skin 
ATCC HTB-72 
U-937 
Human monocytic-like cells 




Human primary melanoma 
derived from skin 
ATCC CRL1675 
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Table 2.2  Tissue Culture Reagents 
Name               Supplier Code number 
Dermal Cell Basal Medium ATCC PCS-200-030 
Dimethyl sulfoxide (DMSO) Sigma 472301 
Dulbecco’s Modified Eagle’s Medium (DMEM) Gibco 41966-029 
Eagle’s Minimum Essential Medium (MEM) with 
Earle’s Salts 
PAA E15-825 
Fetal calf serum (FCS) Gibco 10106-169 
Low Serum Growth Supplement Invitrogen S-003-10 
McCoy's 5a Medium Modified Invitrogen 36600021 
Medium 106 Invitrogen M106500 
Melanocyte Growth Kit ATCC PCS-200-041 
Phosphate buffered saline 1x pH 7.2 (PBS), sterile Gibco 20012 
Penicillin (100 U/mL) and streptomycin (100 
µg/mL) (PenStrep) 
PAA P11-010 
RPMI 1640 Gibco 21875-0 








2.2.2 Cell Line Maintenance 
Tissue culture was performed under sterile conditions in a Nuaire™ laminar flow 
hood using aseptic technique.  Cells were grown in a humidified atmosphere at 
37˚C in 5% CO2 in the Nuaire™ CO2 Air-Jacketed Incubator.  Cell culture medium 
was supplemented with 10% FCS and 1% PenStrep, referred to as standard 
additives unless otherwise specified.  Cell lines were maintained for a maximum of 
30 passages.  Adherent cell lines were passaged once they reached 80-90% 
confluence.  To passage adherent cells, medium was removed and the cell 
monolayer was washed with PBS and then a minimal amount of 0.05% Trypsin-
EDTA was used to cover the monolayer.  Cells were then placed in incubator for 
the minimal time required for cell detachment (typically 2-10 minutes) which was 
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monitored by light microscopy.  Detached cells were promptly placed in excess of 
the culture medium they were grown in and centrifuged (Hettich Rotina 420R 
Centrifuge, used for all experiments unless otherwise specified) at 200 x g for 5 
minutes at room temperature.  Cell supernatants were then discarded and cells 
were split at an optimal ratio and placed in a new tissue culture flask.  Culture 
medium for non-adherent cell lines was replaced by centrifugation of cell culture 
flask contents for 5 minutes at 200 x g at room temperature.  Supernatant was then 
discarded and replaced with fresh medium.  Non-adherent cell lines were passaged 
once cell concentrations were above recommended cell density.  Cells were stored 
in liquid nitrogen in 1mL aliquots of 10 x 106 cells in 0.9 mL of freezing media 
(90% FCS and 10% cell-specific culture media) plus 0.1 mL of DMSO (final 
concentration 10%).  Prior to being placed in liquid nitrogen, cells were placed in a 
cryopreservation freezing container in a -80˚C freezer where the cells were cooled 
at a rate of -1˚C/minute.   
The specific maintenance for each cell line used in the experiments described 
herein is listed below. 
A-2058 Cell Line:  The adherent human malignant melanoma cell line A-2058 was 
used for in vitro screening assays.  A-2058 cells were maintained in DMEM with 
standard additives and medium was replaced three times per week.  Cells were 
passaged as detailed above and split at a ratio of 1:6 to 1:12. 
A-375 Cell Line:  The adherent human malignant melanoma cell line A-375 was 
used for in vitro screening assays along with studies of cell migration, adhesion, 
cytotoxicity, ADCP and ADCC.  A-375 cells were maintained in DMEM with 
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standard additives and medium was replaced three times per week.  Cells were 
passaged as detailed above and split at a ratio of 1:3 to 1:8. 
B95-8 Cell Line:  The EBV infected marmoset lymphoblastoid cell line B95-8 was 
used as a source of EBV (Miller and Lipman 1973).  A detailed description of the 
methodology used to produce EBV from these cells is described in Section 2.2.3.  
B95-8 cells were maintained in RPMI 1640 medium at a density of 1-2 x 106 cells 
per mL. 
Fibroblast:  Human dermal fibroblasts isolated from a healthy volunteer were a 
gift from Dr. Christian Hundhausen, KCL.  Primary fibroblasts were isolated from 
adult human skin by separating the dermis from the epidermis after an overnight 
incubation with Dispase (1 mg/mL concentration) at 4°C.  The dermis was then cut 
into 1 mm2 pieces using a scalpel.  The dermis was next incubated in 0.1% 
Collagenase I diluted in RPMI 1640 medium and then placed in a 50 mL conical 
tube at 37°C on a shaker for a minimum of 2 hours with intermittent mixing.  Next, 
the solution was filtered using a cell strainer with a 100 µm pore size, the filtrate 
was washed two times with PBS, resuspended in Medium 106 and supplemented 
with Low Serum Growth Supplement.  Cells were maintained using the above 
media and were split once 80-90% confluence was reached. 
G-361 Cell Line:  The adherent human malignant melanoma cell line G-361 was 
used for in vitro screening assays.  G-361 cells were maintained in McCoy's 5a 
Medium modified with standard additives and medium was replaced three times 




Melanocytes:  Primary neonatal human epidermal melanocytes were used for in 
vitro screening assays as a control.  Cells were grown in Dermal Cell Basal Medium 
with the addition of a Melanocyte Growth Kit containing L-glutamine, recombinant 
human insulin, ascorbic acid, epinephrine, calcium chloride, and a proprietary 
supplement containing FCS and other factors.  Medium was replaced twice per 
week and cells were split a ratio of 1:2 to 1:4. 
SK-BR-3 Cell Line:  The adherent human breast cancer cell line SK-BR-3 was used 
for the development of an in vitro screening assay.  SK-BR-3 cells were maintained 
in DMEM with standard additives.  Medium was replenished three times per week 
and cells were split at a ratio of 1:2. 
SK-MEL-2 Cell Line:  The adherent human malignant melanoma cell line SK-MEL-
2 was used for in vitro screening assays.  SK-MEL-2 cells were maintained in MEM 
with standard additives and medium was replenished three times per week.  Cells 
were split at a ratio to 1:3 to 1:6. 
SK-MEL-28 Cell Line:  The adherent human malignant melanoma cell line SK-
MEL-28 was used in in vitro screening assays.  SK-MEL-28 cells were maintained in 
MEM with standard additives and medium was replenished three times per week.  
Cells were split at a ratio to 1:3 to 1:6. 
U-937 Cell Line:  The human monocyte-like cell line U-937 was used to establish 
and perform in vitro screening assays and as effector cells in some cytotoxicity 
assays.  U-937 cells were maintained in RPMI media with standard additives.  A 
cell density of 2 x105 to 2 x106 cells per mL was maintained and the medium was 
replaced every 3 to 4 days. 
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WM-115 Cell line:  The adherent human melanoma cell line WM-115 was used for 
in vitro screening assays.  WM-115 cells were maintained in MEM with standard 
additives.  Media was replenished three times a week and split at a ratio to 1:3 to 
1:6.   
 
2.2.3 Preparation of EBV from B95.8 Cells 
This section documents the methods used to produce EBV, a double-stranded DNA 
virus belonging to the herpes virus family, for B cell immortalization and 
transformation experiments.  EBV can persist in the nuclei of infected B cells 
resulting in the lytic replication of virons and in vitro it has been found to 
transform B cells into proliferating lymphoblastoid cell lines by the secretion of 
EBV-encoded latent proteins and RNA (Kuppers 2003).  The EBV producing 
lymphoblastoid marmoset cell line B95-8 sheds EBV (of human origin) into cell 
culture supernatants (Miller and Lipman 1973).   
B95-8 cells were grown until confluent and then starved of nutrients for 7-10 days.   
Next the contents of the tissue culture flask, including cells and supernatant, were 
frozen at -20˚C overnight. The virus was then harvested from the starved cells by 
first centrifuging the thawed contents of the flask for ten minutes at 400 x g.  Next, 
the supernatant was removed and centrifuged again for another ten minutes at 
700 x g.  After centrifugation, the supernatant was removed, filtered using a 0.45 




2.3    Primary Cell Isolation  
2.3.1 General Reagents 
The reagents used to isolate primary human cells are listed in the table below. 
Table 2.3  Reagents Used for Primary Cell Isolation 




CpG ODN Operon Custom order 
EDTA 0.5 M pH 8.0, ultrapure Gibco 15575-020 
FCS Gibco 10106-159 
Filcoll-Paque PLUS™ GE Healthcare 17-1440-03 
GentleMACS C tubes Miltyeni Biotec 130-093-237 
PenStrep PAA P11-010 
PBS, sterile Gibco 20012 












2.3.2 Isolation of Peripheral Blood Mononuclear Cells (PBMCs)   
PBMCs were isolated from blood by density gradient centrifugation.  Equal 
volumes of blood and PBS + 2% FCS were gently mixed at a maximum volume of 
15 mL and slowly pipetted on top of 15 mL of Ficoll-Paque PLUS™ density medium 
in a 50 mL conical vial.  The tube was centrifuged for 20 minutes at 1200 x g with 
no brake at room temperature.  After centrifugation, PBMCs were removed from 




2.3.3 Isolation of B cells from Peripheral Blood 
B cells were isolated from whole blood by performing negative selection using the 
RosetteSep® B cell enrichment cocktail containing monoclonal antibodies to the 
following human cell surface antigens: Glycophorin A, CD2, CD3, CD16, CD36, 
CD56, and CD66b.  For each blood sample, 50µL of RosetteSep® B cell enrichment 
cocktail was added to 1 mL of blood and this solution was mixed gently and 
incubated for 20 minutes at room temperature.  The sample was next diluted in an 
equal volume of PBS + 2% FCS and mixed gently.  The diluted sample, at a 
maximum volume of 15 mL, was slowly pipetted on top of 15 mL of Ficoll-Paque 
PLUS™ density medium in a 50 mL conical vial so that any mixing was minimized.  
The tube was centrifuged for 20 minutes at 1200 x g at room temperature with no 
brake.  After centrifugation, enriched cells were removed from the density medium 
and plasma interface.   
 
2.3.4 Isolation of Monocytes from Peripheral Blood  
Human monocytes were isolated by negative selection using the RosetteSep® 
monocyte cell enrichment cocktail containing tetrameric antibody complexes to 
the following human cell surface antigens: Glycophorin A, CD2, CD3, CD8, CD19, 
CD56, and CD66b.  Monocytes were isolated in the same manner as B cells as 






2.3.5 Isolation of Cells from Tumor Specimens 
Melanoma tumor specimens from skin or lymph nodes were processed on the 
same day as surgery.  Specimens were rinsed with PBS/2% PenStrep, cut into 
approximately 2 mm2 pieces, and placed into RPMI 1640 media containing 1% 
PenStrep, 10% FCS, 30% EBV supernatant, and 2.5 ng/mL of the TLR9 agonist CpG 
ODN in a Nuaire™ CO2 Air-Jacketed Incubator set at 37˚C and 5% CO2 overnight.  
The following day, the contents were strained over a filter with a pore size of 100 
µm.  After filtering, the collected liquid was centrifuged at 300 x g for 8 minutes at 
room temperature and the cell pellet was resuspended in RPMI 1640 media and 
returned to 37˚C incubator.  The tissue remaining on the filter was then removed 
and dissociated using the gentleMACS™ dissociator (Miltyeni Biotec) using RPMI 
1640 media/10 % FCS, gentleMACS™ C tubes and the “m imp tumor 01.01” 
gentleMACS™ program.  The contents of the tube were filtered using a 100 µm 
filter and transferred to a 50 mL conical vial, centrifuged for 8 minutes at 300 g 
and the cell pellet was resuspended in RPMI 1640 media and added to cells 




2.4   Human Primary B cell Cultures 
2.4.1 General Reagents 
The culture of human B cells was performed using the materials and reagents 
listed below. 
Table 2.4  General Reagents and Materials Used for Establishing B cell 
Cultures 
Name Supplier Code number 
CpG ODN Operon Special order 
EBV -- See Section 2.2.3 
Tissue culture 96 well round bottom Plates Nunc 163320 
RPMI 1640 Medium Gibco 21875-0 
 
 
2.4.2 Peripheral Blood B cell Cultures 
Immediately after isolation from blood, B cells were added onto 96 well round 
bottom plates at densities of 100 to 1000 cells per well.  Each culture well 
contained 40 µL of RPMI media, 60 µL of EBV supernatant and 2.5 ng/mL of the 
TLR 9 agonist CpG ODN.  Using the Gammacell 10000 Elite vs. 2.09 cell irradiator, 
autologous PBMCs were irradiated at a dose of 3010 cGy.  Irradiated PBMCs at a 
concentration of 3 x 105 cells in 100 µL of RPMI 1640 medium were added to the B 
cell cultures as feeder cells.   Thus B cells were cultured in media containing 2.5 





2.4.3 Tumor-derived B cell Cultures 
Mixed populations of cells isolated from tumors (see Section 2.3.5) were plated in 
96 well round bottom plates at approximate densities of 5 x105- 5 x106 cells per 
well in RPMI 1640/30% EBV supernatant/2.5 ng/mL CpG ODN.  Cells were 
maintained in the Nuaire™ CO2 Air-Jacketed Incubator set at 37˚C and 5% CO2.   
 
 
2.5   Immunocytochemical Methods 
2.5.1 General Reagents 
The specific binding of antibodies to cells was qualitatively detected using ICC 
methods with the reagents listed below. 
Table 2.5  General Reagents Used for Immunocytochemical Analyses 
Name, chemical formula, formula weight Supplier Code number 
Antibody Diluent Dako S3022 
Acetone, CH3COCH3, 58.08 Sigma 320110 
3,3' Diaminobenzidine (DAB) chromogenic 
substrate for horseradish peroxidase (HRP) 
Dako K3466 
Ethanol BDH Prolabo 20821.330 
Formaldehyde solution, CH2O, 30.03 Sigma F1268 
Human AB serum Sigma H4522 
1 M Hydrochloric acid (HCl), HCl, 36.46 Sigma H1758 
Mayer’s Haematoxylin Merck 1.09249 
Neutral mounting medium (DPX) BDH 360294H 








The specific binding of antibodies to cells was qualitatively detected using ICC 
methods with the antibodies listed below. 











HMW-MAA /LHM2 Human - Mouse Invitrogen 41-2000 
IgG Mouse Peroxidase Rabbit Dako P0268 
 
 
2.5.3 Preparation of Cytospins 
Cytospins for ICC analyses were prepared by washing cells of interest in PBS/10% 
FCS.  Cells were then diluted to a concentration of 2x105 cells in 100 µL PBS and 
added to a microscope slide.  Using the Shandon Cytospin® 4 Cytocentrifuge 
(Thermo Scientific) cells were spun for 5 minutes at approximately 50 x g, then 
removed from the centrifuge and left to dry overnight.  On the following day, cells 
were fixed with cold (-20˚C) acetone for 10 minutes and left to air dry for 30 
minutes.  Cytospins were either used immediately or placed in a slide box at -80˚C 
covered in foil until day of use. 
 
2.5.4 Detection of Tumor-specific Antibodies by Immunocytochemistry 
For ICC analyses, cells on cytospins were circled using a hydrophobic barrier pen.  
Next, 250 µL of antibody diluted in antibody diluent was added per cytospin and 
incubated overnight at 4˚C.  Cytospins were then washed in TBS three times with a 
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5 minute incubation of wash buffer between washing steps.  Secondary antibody 
labeled with HRP was diluted 1:100 and 250 µL was added to each cytospin and 
incubated for 45 minutes at room temperature.  Cytospins were then washed as 
described above.  Next DAB chromogenic substrate for HRP was added to each 
cytospin.  Color was allowed to develop for 1 to 5 minutes and the reaction was 
stopped by washing with TBS as previously described.  Slides were washed in tap 
water and cells were counterstained by immersion in Mayer’s Haematoxylin for 
approximately 1 minute.   Slides were washed again in tap water and excess stain 
was removed by briefly dipping the slides into 0.5%HCl/70% ethanol, and then 
slides were washed once more in tap water until the nuclei were blue.  Slides were 
dehydrated in a series of graded ethanol concentrations (50, 70, 90 and 100%) for 
3 second intervals each and then placed in xylene for 1 minute.  Slides were then 
mounted with glass cover slips using DPX. 
 
 
2.6   Flow Cytometry 
The detection of cell surface or intracellular protein expression was performed 
using flow cytometry.  Using fluorescently labeled antibodies, the expression of 
desired antigens could be detected on cells of interest.  Flow cytometry 
experiments were conducted with either a FACSAria or a FACSCanto (BD 
Biosciences) instrument operated with FACSDIVA™ software (BD Biosciences) and 
data were analyzed using Flow Jo (Tree Star, Ashland, OR) software unless 
otherwise specified.  The general reagents (Table 2.7) and antibodies (Table 2.8) 
used in flow cytometric assays are listed below. 
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2.6.1 General Reagents 
Flow cytometric analyses were conducted using the reagents listed below. 
Table 2.7  General Reagents Used for Flow Cytometry 
Name Supplier Code number 
BD Cytofix™ BD Biosciences 55465 
Normal goat serum (NGS) Sigma G9023 
IntraStain Fixation and Permeabilization Kit 
for Flow Cytometry 
DAKO K2311 




Flow cytometric analyses were performed using the antibodies listed below. 
Table 2.8  Antibodies Used for Flow Cytometry 
























Her2/neu  -- Human Genentech Herceptin™  




225.28S -- Human KCL Gift 
IgA + IgG + 
IgM* 






IgG heavy + 
light Chain* 












 * F(ab’)2 fragments 
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2.6.3 Cell Surface Staining 
Antibodies bound to cell surface antigens were also detected on live cells by flow 
cytometry.  Adherent cells were detached using StemPro® Accutase® cell 
dissociation solution.  For the detection of tumor specific antibodies, live tumor 
cells were incubated with isotype control antibody or cell culture supernatants 
containing antibodies secreted by ex vivo activated B cells for 30 minutes at 4˚C.   
Cells were then washed with fluorescence-activated cell sorting (FACS) buffer, 
PBS/2% NGS, and incubated with fluorescently labeled secondary antibodies 
against the human Ig Fc portion of the antibody for 30 minutes at 4˚C.  Expression 
of cell surface antigens on melanoma cell lines was evaluated as described above 
using antibodies recognizing known cell surfaces antigens such as the HMW-MAA.   
 
2.6.3.1 Phenotypic Analysis of Memory B cell Compartments 
Phenotypic analyses of the memory B cell compartments from healthy volunteer 
blood and also from the blood of patients with Stage I-IV melanoma were 
performed with antibodies which stained for a mature B cells (CD22) and memory 
B cell (CD27) markers (Klein, Rajewsky et al. 1998; Sato, Tuscano et al. 1998).  B 
cells were freshly isolated using the Rosette Sep® B cell enrichment cocktail, 
suspended in FACS buffer, and then incubated with fluorescently labeled 
antibodies to CD22 and CD27 for 30 minutes at 4˚C.  Cells were washed as 





The portion of memory B cells was estimated with the following formula:  
               
                                      
                     
 
 
All analyses were performed by calculating the percentage of CD22 positive and 
also CD22 and CD27 double positive cells (CD22+CD27+) relative to isotype 
antibody controls (Figure 2.1). 
 
 
Figure 2.1  Phenotypic analysis of memory B cell populations from human 
peripheral blood cells.  Freshly isolated peripheral blood B cells were stained with 
anti-human CD27 and CD22 antibodies and memory B cell subsets were evaluated.  
Gates were set using non-specific anti-murine CD22 and CD27 antibodies as isotype 







2.6.4 Intracellular Staining 
For the intracellular staining of human primary B cells, B cells were isolated from 
the peripheral blood of patients (n=3), cultured ex vivo for 18 days, removed from 
culture wells (n=360), pooled, and washed in appropriate culture media.  Staining 
was performed using the IntraStain Fixation and Permeabilization Kit according to 
the manufacturer's instructions.  B cells were first fixed for 15 minutes, washed in 
buffer, and centrifuged for 5 minutes at 500 x g at room temperature.  After 
removal of the wash supernatant from tubes, cells were permeabilized, the desired 
fluorescently labeled antibody was added to tubes, and cells were incubated in the 
dark for 15 minutes.  B cells were then washed in buffer as described previously, 




2.7   ELISA 
Measurement of immunoglobulin concentration and reactivity to antigens on the 
surface of cells was performed by ELISA.  The general reagents (Table 2.9) and 
antibodies (Table 2.10) used for ELISAs are listed below. 
 
2.7.1 General Reagents 
Table 2.9  General Reagents Used for ELISA 
Name Supplier Code number 
BupH™ carbonate-bicarbonate Buffer, 0.2M pH 
9.4 
Pierce 0028382 
Formaldehyde solution Sigma F1268 
Hank’s Buffered Salt Solution (HBSS), calcium and 
magnesium Free 
Sigma 14170-088 
1 M HCl Sigma H1758 
Marvel dried skim milk 
Premier 
International 
Foods (UK) Ltd 
-- 
Maxisorp™ 96 well plates Nunc 442404 
σ-Phenylenediamine dihydrochloride (OPD) 
Tablet 
Sigma P6912 
PBS 1x pH 7.2, non-sterile Severn Biotech 20-7400-10 
RPMI 1640 Gibco 21875-0 
Stable Peroxidase Substrate Buffer 10x Pierce 34062 
Tissue culture 96 well flat bottom plates Corning BC015 





Table 2.10  Antibodies Used for ELISA 
Specificity Clone Conjugate 
Host 
species 
Supplier Code number 
IgG Standard -- -- Human Sigma I450 
IgG -- -- Goat AbD Serotec 204001 











IgG1 2C11 -- Mouse AbD Serotec 5218-9850 
IgG2 G18-21 -- Mouse BD Pharmigen 555873 
IgG3 HP6050 -- Mouse AbD Serotec MCA516G 











  * F(ab’)2  fragment 
 
2.7.3 Total IgG ELISA 
IgG concentrations in B cell culture supernatants were determined by ELISA using 
the following method.  First, the capture antibody, a goat anti-human IgG, was 
diluted in carbonate-bicarbonate buffer to a final concentration of 1 µg/mL.  Next 
100 µL of this coating solution was added to each well on a Maxisorp™ 96 well 
plate and incubated overnight at 4˚C.  After overnight incubation, the coating 
solution was removed from the wells and 200 µL of blocking buffer, 2% Skim 
Milk/PBS + 0.5% Tween®20 (PBS-T), was added to each well.  Plates were 
incubated for 2 hours and then wells were washed twice with 250 µL of PBS-T.  
Next, the IgG standard was diluted to 400 ng/mL in 50% RPMI 1640 media (same 
as cell culture media) and 50% PBS-T/1% Skim Milk (assay buffer) and serially 
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diluted 1:2 in the well plate down to 0.78 ng/mL in duplicate so that each well had 
a final volume of 50 µL.  The remaining wells were given 25 µL of assay buffer and 
25 µL of supernatants or diluted supernatants derived from B cell cultures.  
Standards and samples were incubated for 2 hours before wells were washed four 
times with 250 µL of PBS-T.  Next the secondary antibody, goat anti-human IgG-
HRP, was diluted 1:1000 in assay buffer and 50 µL of this solution was added to 
each well.   After a two hour incubation period, wells were washed four times with 
250 µL PBS-T.  Next 50 µL of substrate, which was prepared by diluting 5 mg of 
OPD into 10 mL 1x Stable Peroxidase Substrate Buffer, was added to each well.  
The substrate was incubated for 15 minutes and the reaction was stopped by the 
addition of 50 µL of 1 M HCl to each well.   The absorbance of each well was 
determined using the Flurostar Omega (BMG Labtech) Spectrophotometer using 
an absorbance of 492 nm and a reference wavelength subtraction of 650 nm.  The 
standard curve fitting was performed using GraphPad Prism© software with a 4-
parameter curve fit with no weighting using a minimum of 6 points on the 
standard curve (Findlay and Dillard 2007).   
 
2.7.4 Subclass IgG ELISA 
The composition of IgG subclasses (IgG1,2,3 and 4) in cell culture supernatants 
was determined by an ELISA which was developed for this purpose and modified 
from a method by Pinna et al. (Pinna, Corti et al. 2009).  Wells on Maxisorp™ 96 
well plates were coated with either mouse anti-human IgG1, IgG2, IgG3 or IgG4 
antibodies in a carbonate-bi-carbonate buffer at a concentration of 1 µg/mL.  After 
an overnight incubation at 4°C, coating solution was removed from the wells and 
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200 µL of 2% Skim Milk in PBS-T were added to each well.  Plates were incubated 
for 2 hours and then wells were washed three times with 300 µL of PBS-T.  
Immunoglobulin values for each subclass were quantified using Certified 
Reference Material 470 (Schauer, Stemberg et al. 2003) as the assay standard.  The 
IgG subclass standard was diluted to a concentration of 1280 ng/mL for each 
subclass in standard buffer: 50% RPMI media and 50% PBS-T/1% Skim Milk 
(assay buffer) and serially diluted 1:2 in standard buffer down to 5 ng/mL in 
duplicates, so that each well had a final volume of 50 µL.  The remaining wells were 
given 25 µL of assay buffer and 25 µL of supernatants or diluted supernatants from 
B cell cultures.  Standards and samples were incubated for 3 hours at 37˚C before 
wells were washed four times with 300 µL of PBS-T.  Next, the secondary antibody 
goat anti-human IgG F(ab')2 fragment (heavy and light chain specific), was diluted 
either 1:1000 (IgG1 and IgG2) or 1:5000 (IgG3 and IgG4) in assay buffer and 50 µL 
of this solution was added to each well.   After 3 hour incubation at 37˚C, wells 
were washed four times with 300 µL of PBS-T.  Next 50 µL of substrate, which was 
prepared by diluting 5 mg of OPD into 10 mL of 1x Stable Peroxidase Substrate 
Buffer, was added to each well.  The substrate was incubated for 15 minutes before 
the reaction was stopped by the addition of 50 µL of 1 M HCl to each well.   The 
absorbance of each well was determined using the Flurostar Omega (BMG 
Labtech) Spectrophotometer using an absorbance of 492 nm and a reference 
wavelength subtraction of 650 nm.  The standard curve fitting was performed 
using GraphPad Prism© software with a 4-parameter curve fit using a minimum of 




2.7.5 Novel Cell-based ELISA 
A cell-based ELISA was developed to detect the binding of antibodies to cell 
surface antigens (Figure 2.2).  Adherent cells of interest were first plated onto flat 
bottom tissue culture 96 well plates at a density of 3 x105 cells in 200 µL of normal 
media and placed in a 37˚C incubator.  Once cells were 80-100% confluent in all 
wells, the media were removed and wells were lightly fixed in 50 µL of 0.5% 
formaldehyde/HBSS, calcium and magnesium free, overnight or until the solution 
evaporated.  Plates were then either wrapped in foil and placed in a freezer set to 
˗80˚C or used immediately.   
On the day of the assay, plates were thawed for 30 minutes if stored in the freezer 
and wells were washed 3 times with 250 µL of PBS and then blocked with 5% Skim 
Milk/PBS for 90 minutes.  Wells were again washed 3 times with 250 µL of PBS.  
After washing, 50 µL of 1% Skim Milk/PBS were added to each well.  Samples of 
interest were added to each well in 50 µL volumes and incubated for 90 minutes.  
For cell culture supernatant screening, positive and negative controls were added 
to each plate in triplicate along with samples.  The negative control was a human 
IgG1 antibody and the positive control was Trastuzumab (Herceptin™), a human 
anti-Her2/neu antibody which has been shown to bind to melanoma cells (Stove, 
Stove et al. 2003) & (Figure 3.16).  Both positive and negative control antibodies 
were tested at a concentration of 500 ng/mL.  Plates were incubated for 90 
minutes and wells were washed four times with 250 µL of PBS-T.  The detection of 
IgG was performed with an anti-human IgG, F(ab’)2 antibody fragment, specific for 
Fcγ.  This antibody fragment was diluted 1:500 in %1 Skim Milk/PBS-T buffer and 
50 µL were added to each well.  After 45 minute incubation, plates were washed 
four times in PBS-T.  Next, 5 mg of OPD was diluted in 10 mL of 1X substrate buffer 
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and 50 µL volumes of this substrate solution were added to each well.  After 15 
minutes the enzymatic reaction was stopped by the addition of 50 µL of I M HCl to 
each well.   Using the Flurostar Omega plate reader, the absorbance of each well 
was read at 492nm with reference wavelength subtraction of 650 nm.  
Corresponding B cell cultures with the highest absorbance relative to the positive 
and negative controls in this assay were selected for further expansion in ex vivo 
cultures (described further in Section 2.8.2). 
 
 
Figure 2.2  Schematic of cell-based ELISA used to detect antibodies against cell 
antigens.  Depiction of the steps used to detect the binding of antibodies to cell 





2.8   Assessment of Antibody Reactivity to Tumor Cells 
2.8.1 Criteria for Evaluating Antibody Responses to Melanoma 
IgG antibodies secreted in human ex vivo B cell cultures derived from both patients 
and health volunteers were assessed for reactivity against cells of interest using 
the cell-based ELISA described previously (see Section 2.7.5).   The reactivity of the 
supernatant from each B cell culture to tumor cells or melanocytes relative to a 
negative control antibody, non-specific human IgG, was evaluated.  In order to 
compare anti-tumor antibody responses to metastatic and primary melanoma cells 
between patients and healthy volunteers and among patient groups, absorbance 
values were normalized against a negative control using the following formula: 
            
                                     
                                    
 
 
This calculation was also used to normalize ELISA results across multiple 
melanoma cell lines and primary melanocytes in order to evaluate the tumor 
specificity of antibodies.   
 
2.8.2 Selection of Clones 
To compare the percentage of positive melanoma-reactive cultures across patients, 
absorbance values were also normalized against the positive control.  Others have 
considered tumor-reactive antibody cultures with absorbance values above 
negative controls + 3 standard deviations as positive cultures (Punt, Barbuto et al. 
1994; Zhang, Lake et al. 1995; Zhang, Casiano et al. 2003).  However, this approach 
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used more stringent criteria through the use of Trastuzumab as a positive control 
antibody as a means to identify cultures reactive to melanoma cells (refer to the 
Appendix for a comparison of these two approaches).  For these evaluations, the 
mean positive antibody control absorbance was assigned a relative absorbance of 
1 for each plate and B cell cultures were converted from absorbance units to 
relative absorbance units.  Next, culture wells with relative absorbance values 
greater than 0.75 to melanoma cells but not to melanocytes were then labeled 
positive cultures.   
Following the selection of promising clones from positive cultures, i.e. wells with 
high reactivity to melanoma cells and not melanocytes, monoclonal cultures were 
derived following the cloning of cells by serial dilution of B cells in 96 well plates 
(Figure 2.3).  This conservative approach was chosen over other single cell cloning 
approaches such as single cell sorting by FACS and limiting dilution because of the 
maintenance of antibody clones at higher densities should the cell plating 





Figure 2.3  Derivation of monoclonal cultures by serial dilution.  Following the 
selection of melanoma-reactive antibody cultures, B cell clones from a chosen culture 
were plated at a density of 1 x 103 cells in well A1 on 96 well round bottom plates.  The 
rest of the plate wells were filled with 200 µL of RMPI warmed to 37˚C.  First, well A1 
was thoroughly mixed and 100 µL were removed from this well and serially diluted (1:2) 
from column A from row 1 down to row 8.  Next using a multichannel pipette, all of the 
wells in column A were thoroughly mixed and then 100 µL were serially diluted (1:2) 
across the plate from column A to column H.  After waiting 2 to 3 hours for cells to 
settle to the plate bottoms, wells were then checked by light microscopy to identify 
cultures with single cells.  All wells then received previously frozen irradiated 
autologous PBMCs at plated at density of 1 x 105 cells in 100 µL of RMPI at 37˚C.  All 
culture wells were maintained and identified single cell cultures were monitored for 
clonal expansion by light microscopy and re-tested for reactivity to melanoma cells by 







2.8.3 Limiting Dilution Assay (LDA) 
The frequency of B cells producing melanoma-reactive IgG antibodies was 
estimated using LDAs.  B cells were isolated from patients and plated at multiple 
densities (125, 500, 1,000, 1,500, 2,500, and 10,000 B cells/well) and cultured as 
described in Section 2.4.2.  After 18 days in culture, the reactivity of B cell culture 
supernatants to melanoma cell lines and to normal melanocytes was evaluated 
using the cell-based ELISA.  The percentage of B cell cultures that were non-
reactive or negative for reactivity (with absorbance values <75% of the positive 
control) against the chosen cell line was then calculated.  The frequency of 
melanoma-reactive IgG B cells was next estimated according to Poisson 
distribution when 37% of the wells were negative for reactivity to melanoma cells.  
Linear regression analysis was performed to extrapolate the point at which the 
regression line crossed the Y axis=37%.  These calculations were done in line with 
the work of Pinna et al. who estimated the frequency of influenza-specific 
antibodies from ex vivo cell cultures (Pinna, Corti et al. 2009).   It is important to 
note that LDAs performed herein are not against one specific antigen but rather 
are against cells.  This means that the LDAs estimate reactivity of antibodies in 
cultures against various antigens on cells such as melanocytes, primary melanoma 
and metastatic melanoma.  Due to nature of the methodology, it is possible that 
reactive/positive cultures may have arisen from more than one B cell clone.  Thus 
the frequency of reactive antibodies to multiple antigens on various human cell 
types rather than the frequency of antibodies specific to a single antigen was 




2.9    Cell Adhesion and Migration Assays 
The ability of antibodies targeting HMW-MAA to restrict tumor cell adhesion and 
migration was evaluated using the general reagents (Table 2.11) and antibodies 
(Table 2.12) listed below. 
 
2.9.1 General Reagents 




96 Well flat bottom plate Corning BC015 
Bovine serum albumin (BSA), tissue culture grade Sigma A9418 
Cell stain CHEMICON 90144 
Cotton swabs CHEMICON 10202 
Crystal violet Sigma HT90132 
DMEM Gibco 41966-029 
Ethanol BDH Prolabo 20821.330 
Extraction buffer CHEMICON 90145 
Fibronectin Sigma F2006 
PBS, sterile  Gibco 20012 
Sterile 24 well plates with collagen-coated Insert, 


















Antibodies were engineered 
by Tihomir Dodev, KCL from a 








Antibodies were engineered 
by Tihomir Dodev, KCL from a 
published sequence b 
a Neri, Natali et al. 1996; b Gould, Mackay et al. 1996 
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2.9.3 Cell Adhesion Assay 
Inhibition of melanoma cell adhesion by monoclonal antibodies was measured in 
vitro using a cell adhesion assay (Wang, Osada et al. 2010).  Prior to starting the 
assay, A-375 melanoma cells were allowed to reach 80% confluence in culture and 
then grown in serum-free DMEM media for 24 hours.  On the day of the assay, a 96 
well plate was coated with fibronectin at a concentration of 6 µg/mL, with the 
exception of one row of wells which was left uncoated.  These uncoated wells were 
given 100 µL of 1% BSA to serve as a negative control of adhesion for the assay.  At 
the same time, serum starved A-375 cells at a concentration of 2 x106 cells/mL 
were incubated with PBS alone or with a buffer containing the following 
antibodies: IgG or IgE class antibodies against HMW-MAA and MOv18 IgG or IgE 
antibodies recognizing the tumor associated antigen FRα (Gould, Mackay et al. 
1999); these MOv18 antibodies which do not react with A-375 melanoma cells and 
therefore served as negative isotype control antibodies.  Antibodies were used at a 
concentration of 0.25 mg/mL in PBS and allowed to interact with A-375 melanoma 
cells for 20 minutes at room temperature prior to the addition on the fibronectin 
or BSA coated wells.   
After one hour incubation at 37˚C with fibronectin or 1% BSA, the 96 well coated 
plate was washed with room temperature PBS.  Washing was performed by gently 
adding 200 µL of PBS to the side of the well using a multichannel pipette.  
Immediately following washing, 2 x 105 cells incubated with appropriate 
antibodies as described above were seeded into the fibronectin or BSA coated 96 
plate wells and plates were placed in an incubator set at 37˚C, 5% CO2 for 30 
minutes.  After 30 minutes, wells were washed with 200 µL of PBS five times to 
remove any non-adherent cells.  Wells were then given 50 µL of 70% ethanol to fix 
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any adherent cells.  Next, ethanol was removed from wells and cells were stained 
with 50 µL 0.1% crystal violet diluted in water for 30 minutes.  Wells were then 
washed twice in tap water and resuspended in 50 µL of PBS and the absorbance of 
each well at 540 nm was read using the Flurostar Omega plate reader.  Results 
were expressed as percent inhibition of adhesion relative to the PBS-treated 
control. 
 
2.9.4 Collagen-based Cell Migration Assay 
The ability of anti-HMW-MAA IgG and IgE antibodies to inhibit the migration of A-
375 melanoma cells across a collagen layer in vitro was evaluated using the QCM™ 
24-Well Collagen-Based Cell Invasion Assay (Chemicon, Catalog number ECM 551).  
This collagen layer was comprised of approximately 85% type I collagen and 15% 
type III collagen.   A-375 cells were grown until 80% confluent and then placed in 
serum free DMEM medium for 24 hours prior to the assay.  On the first day of the 
assay, reagents were first brought to room temperature and media warmed to 
37˚C.  Next, collagen coated invasion chambers (inserts) were rehydrated with 300 
µL of pre-warmed serum-free media for 15 to 30 minutes.  After rehydration, 
media was carefully removed from each insert.  A-375 cells at a concentration of 1 
x 106 cell/mL were incubated at room temperature with antibodies at 0.25 mg/mL 
or PBS for 20 minutes and then 250 µL of this prepared suspension was added to 
the appropriate inserts.  Next, 500 µL of media with 10% FBS per well were added 
to the lower chambers on the 24-well plate, except for negative control wells; each 
of the latter wells received 500 µL of media without FBS.  Plates were covered and 
incubated at 37˚C, 5% CO2 for 24 hours. 
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On the second day of the assay, cells/media were carefully removed from the top 
side of the insert by pipetting out the remaining cell solution.  The invasion 
chamber was then inserted into a clean well on a 24 well plate containing 400 µL 
of cell stain solution and incubated for 20 minutes so that migrated cells could be 
identified.  The invasion chamber was next dipped into a beaker of tap water and 
rinsed several times.  While the chamber was still moist, a cotton swab was used to 
gently remove the non-invading cells from the interior of the chamber with careful 
attention made not to puncture the membrane and to remove cells from the inside 
perimeter.  This step was then repeated with another clean cotton swab.  The 
stained chamber was then transferred to a clean well containing 200 µL of 
extraction buffer for 15 minutes, and the stained cells were extracted from the 
underside of the chamber by gently tilting the chamber back and forth several 
times throughout the incubation.   Chambers without cells were also processed as 
described above and used as blanks to calculate assay background. The chambers 
were removed from the plates and 100 µL of the dye mixture was transferred to a 
96 well plate.  Absorbance was next read at 560 nm using the Flurostar Omega 
plate reader.  Results were expressed as percent inhibition of migration relative to 








2.10 Cytotoxicity Assays 
Cytotoxicity assays were employed to measure the ability of patient-derived and 
engineered monoclonal antibodies to mediate cellular cytotoxicity against tumor 
cells.  The general reagents (Table 2.13) and antibodies (Table 2.14) used in these 
assays are listed in the following tables. 
 
2.10.1   General Reagents 






Carboxyfluorescein diacetate,succinimidyl ester 
(CFSE) 
Sigma 21888 
CellTracker™ blue dye (7-Amino-4-
Chloromethylcoumarin) 
Molecular Probes C2110 
4',6-diamidino-2-phenylindole (DAPI) Invitrogen D1306 
DMEM Gibco 21063029 
LIVE/DEAD Viability/Cytotoxicity Kit for 
Mammalian Cells containing Calcein AM and 
Ethidium homodimer-1 
Molecular Probes L3224 
Neuraminidase, Type X Sigma N-2133 
6 well tissue culture plates Corning 3516 
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2.10.2   Antibodies 
Table 2.14  Antibodies Used in Cytotoxicity Assays 
Specificity Clone Conjugate 
Host 
species 
Supplier Code number 










-- Chimeric KCL 
Antibodies were 
engineered by 
Tihomir Dodev from 
a published 






-- Chimeric KCL 
Antibodies were 
engineered by 
Tihomir Dodev from 
a published 
sequence b 
a Neri, Natali et al. 1996; b Gould, Mackay et al. 1996 
 
 
2.10.3 Live/Dead Cell Imaging Assays 
The tumor-killing potential of patient derived monoclonal antibodies was assessed 
using a three-color fluorescent live cell imaging cytotoxicity assay.   A-375 
melanoma cells were plated overnight at a density of 2x105 cells per well on 6 well 
culture plates.   Using the components of a LIVE/DEAD® Viability/Cytotoxicity kit, 
immediately prior to cytotoxicity assays tumor cells were labeled with 2µM of 
Calcein AM, a green fluorescent dye which labels viable cells but is quenched upon 
loss of cell viability (Lichtenfels, Biddison et al. 1994).  A-375 cells were incubated 
with Calcein AM for 30 minutes in RPMI 1640 media free of phenol red and FCS.  
Cells were then washed in RPMI 1640 supplemented with 10% FCS and 1% 
PenStrep, and resuspended in media containing 4 µM Ethidium homodimer-1.  
Ethidium homodimer-1 incorporates into the DNA of dead cells which have lost 
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their membrane integrity and served as a label for cell death in this assay (King 
2000).   U-937 monocytic cells expressing Fcγ receptors were used as immune 
effector cells at a ratio of 3:1 (effectors: tumor cells) (Bracher, Gould et al. 2007).  
Immune effector cells were incubated with antibodies for 30 minutes, stained with 
the CellTracker™ blue dye, washed and added to the Calcein AM-labeled tumor 
cells in culture wells containing Ethidium homodimer-1.  Samples were incubated 
and images were captured every 5 minutes for a period of two hours in a 
humidified temperature-controlled chamber using a Zeiss Axiovert (20x objective) 
microscope and AxioVision software system (Carl Zeiss, Jena, Germany).  Following 
incubation, fluorescent intensities of Calcein AM-positive live tumor cells, as well 
as incorporation of Ethidium Homodimer-1 into cells were measured (Table 2.15) 
and cell death was assessed with NIS-Elements BR 3 software (Nikon).  The 
movement of effector cells in the cultures was tracked and analyzed using Imaris 
software (Bitplane, Zurich, Switzerland).  
 








Calcein AM Green 495 515 
CellTracker™ blue dye Blue 353 466 
CFSE Green 494 521 
DAPI Blue 358 461 





2.10.4 ADCC and ADCP Assays 
The ability of antibodies to induce tumor cell death by cell-mediated cytotoxicity 
(ADCC) and/or phagocytosis (ADCP) was evaluated using a three-color flow 
cytometric method (Bracher, Gould et al. 2007).  Assays were performed as 
described by Bracher et al. with the exception of the labels used for tumor and 
dead cells along with the use of freshly isolated human monocytes from patients 
and healthy volunteers rather than cell lines.  The day before the assay A-375 cells 
were incubated with 5.0 µM CFSE in PBS for 10 minutes at 37˚C.  Cells were then 
washed in DMEM containing 10% FCS and returned to normal cell culture 
conditions for this cell line overnight.  
On the day of the assay, primary monocytes were washed in PBS/2% FCS, 1 mM 
EDTA (monocyte isolation buffer) and incubated with neuraminidase at 
concentration of 0.3 units per 2×107 cells in 1 ml PBS plus 2% human AB 
serum/DMEM which ensured retained expression and availability of FcεRI 
receptors on the surface of human monocytes as previously reported (Reischl, 
Corvaia et al. 1996; Karagiannis, Wang et al. 2003).  After 30 minute incubation, 
monocytes were washed once with monocyte isolation buffer.  Next, CFSE-labeled 
tumor cells were washed in FACS buffer and mixed with freshly isolated (within 
one hour of cell isolation) human monocytes (see Section 2.3.4) at an effector to 
target ratio (E:T) of 3:1.  Antibodies were diluted to 10 µg/mL in PBS and this or 
PBS alone was added to tumor and effector cell mixtures and incubated for 3 hours 
at 37˚C and 5% CO2.  Cells were than washed in sterile FACS buffer and human 
monocytes were next incubated for 30 minutes at 4˚C with an anti-CD89-PE 
antibody, which targets the IgA Fc receptor (FcαRI) expressed on monocytes. 
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Following monocyte labeling and the washing of cells once in FACS buffer, dead 
cells were then stained with 5 µg/mL of DAPI (emission max=452 range=410-600 
nm) replacing the use of propidium iodide (emission max=650; range 600-
750nm)(Bracher, Gould et al. 2007).  This modification allowed reduced spectral 
overlap between DAPI (emission max=452 range=410-600 nm) and CSFE labeled 
cells (emission max=520nm; range 480-650) in the flow cytometer and represents 
an improvement from a previously published method.   Cells were then washed 
and mixed thoroughly to interrupt cell-cell contact, and samples were resuspended 
in 300 µL of FACS buffer and analyzed on a FACS Canto (BD Biosciences) flow 
cytometer using FACSDIVA™ software (BD Biosciences) for data acquisition and 
analysis. 
ADCP was measured by calculating the number of cells positive for both tumor 
cells (CFSE, read in FITC channel) and effector cells (PE) (see Figure 2.4 left, 
quadrant 2 [Q2]) relative to controls not treated with antibodies.  ADCC was 
calculated from the number of dead tumor cells (see Figure 2.4 right, P1 gate) 
stained with DAPI (Pacific Blue) along with the total loss of tumor cells in the assay 
(see Figure 2.4, quadrants 2 and 3) to account for lysed cells; both numbers were 




Figure 2.4  Quantification of ADCP and/or ADCC by flow cytometry.  Antibody 
mediated phagocytosis was calculated from dot plots (left) with melanoma cells stained 
in green (FITC, x-axis) and monocytes in red (PE, y-axis).  Phagocytosis was 
estimated from cells that were double positive for FITC and PE dyes (Q2).  Cytotoxicity 
was calculated from dot plots (right) where the number of dead melanoma cells was 
estimated by FITC and Pacific Blue double positive cells (P1) along with loss of total 
melanoma cells (right) from Q2 and Q3 compared to cells treated with no antibody.  
See below for exact calculations.   
 
The following formulas were used to calculate antibody mediated tumor cell death: 
         
    
            
     
(Q2 + Q3)= Number of FITC stained tumor cells in assay 
(Control Q2 +Q3)= Mean number of FITC stained tumor cells from tubes (n=3) 
given no antibody  
X= (control Q2 + Q3)-(Q2+Q3) 
P1= Number of cells stained with DAPI  
 
 
      
  
            




2.11 Statistical Methods 
All statistical analyses were performed using GraphPad Prism software (version 
5.03, GraphPad, San Diego, CA). 
 
2.11.1  Assessments of Anti-tumor Antibodies Produced from Peripheral 
Blood B cells 
Descriptive statistics were generated to examine the distribution of melanoma-
reactive B cell cultures from each patient including the mean, 95% CI and 
maximum reactivity to melanoma cells.  A two-sided Student’s t test was used to 
compare the mean reactivity of antibody cultures derived from melanoma 
patients, with those values derived from healthy volunteers against primary or 
metastatic melanoma cell lines.  A two-sided Student’s t test was also used to 
compare antibody responses between patients with non-metastatic and metastatic 
disease.  A one-way analysis of variance (ANOVA) was used to compare antibody 
reactivity to a metastatic melanoma cell line among B cell cultures derived from 
patients with Stage II, III and IV disease using a Tukey’s post hoc comparison test.  
 
2.11.2 Analysis of Peripheral Blood Memory B cell Compartment  
The Mann-Whitney U test was used to compare the peripheral blood memory B 
cell compartment between healthy volunteers and metastatic melanoma patients 




2.11.3  Analysis of the Proportional Production of IgG Subclasses from 
Peripheral Blood and Tumor-resident B cells 
The proportion of IgG1-4 subclasses secreted in ex vivo B cell cultures was 
compared between healthy volunteers and patients with metastatic melanoma 
using a two-sided Student’s t test. 
 
2.11.4  Cell Adhesion and Migration Assays 
A two-sided Student’s t test was used to compare the inhibition of tumor cell 
migration and adhesion with the addition of tumor-specific monoclonal antibodies 
compared to non-specific antibody isotype controls. 
 
2.11.5  Cell-mediated Cytotoxicity Assays 
A two-sided Student’s t test was used to compare antibody-mediated tumor cell 
killing between tumor-specific and non-specific monoclonal antibodies derived 
from the same patient.  A two-sided Student’s t test was also employed to compare 
the movement of immune monocytic effector cells, pre-incubated with patient-
derived antibodies, in contact with tumor cells with the movement of immune cells 
not in contact with tumor cells.  For ADCC/ADCP assays, a two-sided Student’s t 
test was also employed to compare anti-HMW-MAA IgG and IgE mediated 
phagocytosis and cytotoxicity to either isotype control antibodies or no antibody 




Chapter 3: A Novel Approach for Identifying Anti-
melanoma Antibodies from Clinical Specimens3 
  
                                                         
3 Sections 3.2 & 3.3 and Figures 3.1-3.3, 3.6-3.8, 3.13-3.16, and 3.21 are produced in part or full 
from Gilbert, Karagiannis et al. 2011. 
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3.1   Introduction and Aims 
Monoclonal antibodies have emerged as a key therapeutic modality in the 
treatment of many cancers (Pillay, Gan et al. 2011).  The recent approval of the 
first monoclonal antibody for melanoma, Ipilimumab, has shown promising clinical 
results including it being the first melanoma drug to significantly prolong survival 
(Hodi, O'Day et al. 2010; Prieto, Yang et al. 2012).  The achievement of such 
profound clinical success of Ipilimumab is in part due to the extensive 
understanding of the nature of T cell responses in melanoma, which highlights the 
merits of understanding and potentially harnessing the host immune responses to 
cancer in order to develop efficacious therapeutics, including monoclonal 
antibodies that can activate the immune system.  While there has been much focus 
on T cell-mediated immune responses in melanoma, limited knowledge exists on 
the role B cells may play in melanoma and the nature and potency of the 
antibodies they produce.   
There has been some focus on the identification of novel antibodies against TAAs 
from the in vivo study of humoral immune responses to cancer cells in both mice 
and individuals with cancer.  Melanoma and some other cancers are thought to be 
immunogenic, with demonstrated serological antibody responses to TAAs (Sahin, 
Türeci et al. 1995; Old and Chen 1998; Stockert, Jäger et al. 1998).  Approaches to 
discovering such novel antibodies have included the generation of antibodies by 
the immunization of mice with human tumor cells/cell lysates/antigens to 
generate hybridoma cell lines or in some cases phage libraries; the immunization 
of  patients with genetically modified autologous tumor cells with enhanced 
immunogenicity; and the isolation of antibodies from B cells located in the 
peripheral blood or tumors from individuals with cancer (Kirkwood and Robinson 
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1990; Chester, Begent et al. 1994; Cai and Garen 1995).  These approaches can all 
lead to the identification of novel antibodies against known or unknown antigens; 
however, some approaches require rather time-consuming processes, such as the 
immunization of animals and generation of hybridoma cells lines, the creation of 
phage display libraries and the selection of clones, or in vitro affinity maturation, 
and these processes are often followed by the engineering of scFv into full-length 
humanized or human antibodies.  Studying the humoral immune response of 
individuals with cancer harbors the potential to rapidly identify novel human 
affinity-matured antibodies, with potentially high specificity to TAAs.  Potential 
benefits of this approach to discovering antibodies from patients include the 
identification of antibodies against clinically relevant tumor antigens with 
naturally matched heavy and light chains and the elimination of the requirement 
for in vitro affinity maturation to antigen.  Additionally, the fully human sequences 
of patient antibodies are also expected to be associated with reduced concerns of 
immunogenicity when administered in humans, compared to engineered 
antibodies which often contain murine variable regions. 
While identifying tumor-specific antibodies from patients themselves may allow 
for the selection of relevant antibodies generated by the host in response to 
malignancy, in reality the approach poses several technical challenges.  Primarily, a 
major concern lies with the production of sufficient amounts of antibodies from B 
cell cultures derived from patients.  To create long term primary cell cultures, B 
cells can be ‘immortalized’ with EBV, a lymphotrophic herpes virus, which has 
historically been used to establish antibody producing B cell lines from melanoma 
patients (Watson, Burns et al. 1983; Kirkwood and Robinson 1990).  However, B 
cell transformation with EBV alone has been limited by low cloning efficiency, 
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reported to be as low as 3% (Sugden and Mark 1977).   Past efforts to produce 
antibody-secreting B cell cultures from patients with melanoma using EBV 
transformation cite the loss of antibody production from these EBV transformed B 
cells as a major technical obstacle in the identification of antibodies against 
melanoma-specific antigens from patient B cells (Kirkwood and Robinson 1990; 
Yeilding, Gerstner et al. 1992).   
The creation of antibody-secreting B cell lines from melanoma patients pre-date 
more recent improvements to activate B cells in culture.  One such major 
improvement to the culturing of patient B cells has been reported by Traggiai et al., 
who demonstrated that the addition of CpG 2006, a TLR9 agonist and polyclonal 
activator of memory B cells, to EBV transformed B cells increased the cloning 
efficiency rate of memory B cells to 30-100% (Traggiai, Becker et al. 2004).  The 
addition of CpG 2006 resulted in a major improvement to the historically low 
cloning efficiency rates of human B cells.  The technique presented by Traggiai and 
colleagues has permitted novel insights into humoral memory responses to 
infectious disease by examining the antibody repertoire of an individual following 
infection with SARS coronavirus.  This advancement in ex vivo culturing and 
activation of B cells has yet to be applied to the field of cancer and if it is possible to 
achieve this, a greater understanding of humoral immune responses to cancer can 
be gained.  Thus, applying this technique to individuals with melanoma could allow 
for closer examination of host B cell responses to melanoma as well as for the 
identification of novel melanoma-specific antibodies.  The aim of the work 
described within this chapter is to apply the methodology set forth by Traggiai and 




Crucial to performing a comprehensive screening of the specificity of antibodies 
produced by individuals’ B cells is the construction of an inexpensive medium-
throughput assay as a means to identify melanoma-specific antibodies from B cell 
culture supernatants.  Screening antibodies against whole cells, rather than 
recombinant antigens or antigenic peptides, provides a number of advantages. 
Firstly, antibody reactivity can be assessed against the multitude of antigens 
expressed on tumor cells, thus permitting an assessment of the broad anti-tumor 
mature B cell responses to melanoma.  Secondly, using whole cells rather than a 
few pre-defined recombinant antigens may allow for the identification of 
antibodies against novel antigens.  Thirdly, while melanoma cells are readily 
available, very few cell surface antigens in melanoma have been identified and are 
available commercially in recombinant forms at the present time.  Finally, antigens 
on the surface of melanoma cells are expected to be expressed in their native and 
active conformation and this may not always be the case for antigens expressed in 
recombinant forms.  For these reasons, a cell-based screening methodology was 
devised and verified to serve as a crucial tool in the identification of novel 
melanoma-reactive antibodies.  
Applying new methods to activate B cells ex vivo will allow for evaluation of the 
humoral memory responses to melanoma to complement serological studies 
(Chapter 4), and such evaluations may reveal novel antibodies against tumor 
associated antigens (Chapter 5).  Instrumental to these evaluations is the 
development of a screening methodology to identify melanoma-reactive 
antibodies; this, along with the evaluation of the feasibility of identifying 
monoclonal antibodies from melanoma patient ex vivo B cell cultures, remains a 
primary focus of this chapter. 
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The objectives of this chapter are threefold:  
1. To establish ex vivo human B cell cultures from healthy individuals and from 
patients with cancer capable of secreting large amounts of IgG antibodies for 
further evaluations.   
2. To develop a robust and medium-throughput methodology to detect antibodies 
from human B cell culture supernatants that react to tumor cells.   
3. To apply the above newly developed screening methodology to perform initial 





3.2   Establishment of Antibody-secreting Cultures from Human B cells 
As a first step in the evaluation of antibodies from clinical specimens and their 
reactivity to melanoma cells, the isolation and expansion of B cells in culture was 
assessed in order to demonstrate that B cell cultures could be established from 
healthy individuals and from patients with cancer.  Additionally, the quantities of 
IgG antibodies secreted by these B cells were measured to ascertain that these B 
cells were capable of producing sufficient quantities of IgG to further study the 
reactivity of these antibodies to cell surface antigens. 
 
3.2.1 Expansion of Human B cells ex vivo from Peripheral Blood 
With the aim of establishing antibody-secreting human ex vivo cell cultures, B cells 
were isolated from the peripheral blood unfractionated PBMCs of human 
volunteers using negative selection.  Following negative selection (detailed 
previously in Chapter 2, Section 2.3.3), mature B cells (CD22+ cells) were isolated 
in high purity (>90%).  Low populations of both CD3+ T cells (Figure 3.1, left) and 
CD14+ monocytic cells (Figure 3.1, right) were measured to be present following B 
cell isolation, with a representative example shown to be comprised of 0.3% CD3+ 
T cells and 2.1% CD14+monocytic cells.  The measurement of low levels (<5%) of 
the two most abundant immune cell populations in PBMCs (i.e. T cells and 
monocytic cells), demonstrate that negative selection was an adequate method to 
isolate relatively pure and large populations of mature B cells from volunteer 
peripheral blood and would provide sufficient amounts of B cells from humans for 




Figure 3.1  Purity of human B cells for primary cell culture.  Human B cells were 
isolated from blood by negative selection using RosetteSep® and a Ficoll density 
gradient.  Purity of B cell isolation was measured by comparing the amount of mature B 
cells (CD22+ cells) to other leukocytes such as T cells (CD3+, left) and monocytes 
(CD14+, right) using flow cytometry.  Representative dot plots are shown. 
 
While other methods of primary cell isolation, such as immunomagnetic or FACS 
cell sorting, may yield higher purities of B cells, negative selection using the 
Rosette Sep® was chosen due to efficiency in speed, minimal requirement for 
equipment, and minimal manipulation of cells.  An important criterion in choosing 
this isolation methodology was the selection of a technique with least amount of 
handling of primary cells in order to obtain good cell viability in ex vivo cultures.  
By employing negative cell selection using Rosette Sep®, cells can remain within 
the sterility of a cell culture hood in a 50 mL conical tube, whereas other 
techniques require the transfer of cells to different instruments where cells 
undergo further manipulation such as binding to magnetic beads or flowing 
through a cytometric sorter.  The introduction of extra steps or use of 
instrumentation not kept in a sterile environment during the isolation of primary 
cells can pose a challenge in the recovery and culture of primary cells due to the 
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introduction of possible contaminants which can reduce the viability of primary 
cell cultures for longer periods of maintenance (>1 month).  In summary, the 
chosen approach to isolate human B cells was selected since it resulted in highly 
pure populations of mature B cells with minimal cell manipulation for establishing 
longer-term ex vivo B cell cultures. 
Next, the expansion of ex vivo peripheral blood B cells in culture was monitored.  B 
cell colonies were observed to form in the first 10 days and were viable for more 
than 8 weeks in culture (Figure 3.2).  While B cells were initially cultured with 
feeder cells, EBV, and a TLR9 agonist, B cell colonies were observed to expand 
following subcloning without the addition of feeder cells, additional nutrients, or 
growth factors beyond those contained in the normal media.  This antigen-
independent sustained growth may be attributed to the differentiation of B cells 
into plasma blast and plasma cells driven by the addition of a TLR9 agonist which 
selectively results in the expansion of memory B cells (Bernasconi, Traggiai et al. 
2002).  The driving of B cells toward plasma blast and plasma cell phenotypes 
resulting in the secretion of high levels of antibodies could also impact cell 
proliferation and the long term division of these cells and their culture 
maintenance over longer periods of time.  The expansion of B cells in ex vivo 
cultures was observed to be maintained over 8 weeks, which, for the purposes of 
this work, was sufficient time to allow for the identification of melanoma-reactive 





     Day 1              Day 10          Week 8 
Figure 3.2  Expansion of human B cells in culture seen by light microscopy.  
Transformed and activated B cells were plated with autologous PBMCs after isolation 
(left), clonal formation was observed after 10 days (middle) and cells proliferated for 8 
weeks or longer in culture (right) (40x magnification). 
 
Cultured B cells were next evaluated to confirm the ex vivo expansion of switched 
memory B cells in culture.  It is thought that TLR9 agonists preferentially expand 
memory B cells in culture because the upregulation of TLR9 receptors requires the 
triggering of B cell receptors and such receptors are present on memory B cells 
and not on naïve B cells (Bernasconi, Onai et al. 2003).  In order to verify that the 
expanded B cells were memory B cells, expression of class switched antibodies 
such as those of the IgG class, indicative of the presence of memory B cells, was 
examined in patient cultures.  B cells from 3 different melanoma patients 
comprised of 180 different B cell cultures (n=60 cultures per patient) were studied 
for intracellular and extracellular IgG expression after 18 days in culture by flow 
cytometry (method detailed in Chapter 2, Sections 2.6.3 and 2.6.4).  Approximately 
80% of the cultured B cells studied from these patients were found to be positive 
for IgG antibodies by intracellular and extracellular flow cytometric analysis 
(Figure 3.3, left).  Additionally, to assess the presence of B cells producing other 
antibody classes, the reactivity of a F(ab’)2 (specific for heavy and light chains on 
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IgG, IgA, and IgM) was tested using B cells from the same patients.  Approximately 
88% of the cells were measured to be positive for these three antibody classes 
(Figure 3.3, right).  One could estimate that 8% of the ex vivo cultured B cells 
expressed IgM and/or IgA antibodies, a small proportion of expanded B cells.  In 
summary, IgG-positive B cells were found to expand in high percentages in ex vivo 
patient B cell cultures. 
 
 
Figure 3.3  B cell expression of IgG in melanoma patient B cell cultures.  
Proportion of IgG positive (left, 80%) and IgA/IgG/IgM positive (right, 88%) B cells from 
the pooled B cell cultures (n=180) derived from melanoma patient peripheral blood 
(n=3).  B cells were cultured for 18 days and IgG positive cells were identified (left) by 
intra and extracellular flow cytometric staining with a goat anti-human FITC-conjugated 
antibody F(ab’)2 fragment (solid black line) relative to a goat IgG-FITC F(ab’)2 fragment 
which served as isotype control (shaded grey).  IgA/IgG/IgM positive B cells were also 
identified (right) using a FITC labeled F(ab’)2 fragment (solid black line) that reacts with 
IgA, IgG and IgM positive cells were also calculated relative to a goat IgG- FITC F(ab’)2 
fragment isotype control (shaded grey). 
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The production of IgG from memory B cells is desirable over the IgM 
immunoglobulin classes since antibodies from these cells have been affinity 
matured and are expected to yield antibodies with high specificity to their antigen, 
thereby possessing greater potential clinical utility.  Additionally, IgG is the 
dominant class of antibody used therapeutically for cancer due to its well 
described favorable pharmacokinetics, immunomodulatory properties, antigen 
specificity, and low incidence of off target toxicities (Weiner, Surana et al. 2010).  
The high expression of IgG positive B cells from these results support this 
approach to culturing B cells from cancer patients as a way to expand IgG+ 
memory B cells from individuals with melanoma.  Next, it was determined whether 
the expanded memory B cells were capable of secreting IgG antibodies in sufficient 
quantities for further study of the humoral memory responses in patients and for 
examination of their reactivity and specificity to melanoma cells. 
 
3.2.2 Production of IgG Antibodies from Human B cell Cultures 
In order to confirm that it was possible to derive B cell cultures from healthy 
volunteers and patients with cancer, and to study the tumor reactivity of the 
antibodies they produce, the ex vivo culture and activation of patient B cells were 
performed similarly to those described by Traggiai and colleagues (detailed in 
Chapter 2, Section 2.4.2).  After culturing B cells ex vivo for 18 days, the 
concentration of IgG in culture supernatants was measured by ELISA (see Chapter 
2, Section 2.73).  IgG concentrations were found to range from 20-45 µg/mL from 
B cell culture supernatants (Figure 3.4).  These concentrations were comparable to 
the antibody amounts obtained by Traggiai et al. who found that B cells isolated 
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from one 35 year old patient infected with SARS coronavirus secreted IgG 
antibodies in the range of 3-20 µg/mL (Traggiai, Becker et al. 2004).  Additionally, 
the production of antibodies from cells seeded at low concentrations was 
evaluated in order to assess the feasibility of establishing monoclonal cultures.  
Cultures seeded at very low cell densities, such as 1 or 2 cells per well, were found 
to secrete measurable antibody concentrations after 10 days in culture (Figure 
3.5).  In summary, prior to developing techniques to evaluate patient antibody 
responses to melanoma, it was crucial to verify that sufficient amounts of 
antibodies could be produced ex vivo. 
 
 
Figure 3.4  IgG production from B cell cultures derived from one patient.  The 
amount of IgG produced from peripheral blood B cell cultures (n=10 wells) established 
from one patient and arising from 500 B cells per well was measured by ELISA after 18 
days. Media with no B cells (n=3 wells) were used as the negative control in the ELISA. 
Trastuzumab, a human IgG antibody, was diluted to a concentration of 10,000 ng/mL 




Figure 3.5  IgG production from cultures arising from 1or 2 B cells.  (A) The 
amount of IgG secreted by patient-derived B cells diluted to 1 or 2 cells per well after 
10 days in culture was measured by ELISA from cell culture supernatants.  Cultures 
originating from 1 or 2 B cells were created by serial dilution or FACs sorting and 
plated in standard media along with autologous irradiated PBMCs, EBV, and CpG 
ODN and grown for 18 days.  (B) ELISA standard curve from which results from (A) 




Studies of humoral memory responses from ex vivo B cell cultures have been 
performed in the context of infectious diseases (Traggiai, Becker et al. 2004; Pinna, 
Corti et al. 2009), but not in cancer.4  As a first step toward applying this 
methodology in melanoma, B cells derived from individuals with melanoma were 
compared to healthy volunteer B cells to determine whether they were able to 
secrete comparable levels of IgG antibodies.  Since it has been reported that 
memory B cells from individuals with metastatic melanoma cells are 
hyporesponsive to activation signals as well as their reduced numbers in the 
peripheral blood (Carpenter, Mick et al. 2009), it was important to determine 
whether a reduced memory cell compartment in melanoma would impact on the 
presence of switched memory B cells in blood and the ability of B cells to secrete 
IgG antibodies in ex vivo cultures.  These evaluations were imperative for the 
successful application of this approach to the study of humoral memory responses 
to melanoma in patients. 
Similar ranges of antibody production, 1-10 µg per culture, were observed 
between patients (n=300 cultures derived from 5 individuals) and healthy 
volunteers (n=300 cultures derived from 5 individuals) (Figure 3.6).  These results 
illustrate that while antibody production varied among individuals and culture 
wells, overall both volunteer groups contained switched memory B cells capable of 
secreting high amounts of IgG antibodies.  The observed high production of 
antibodies from B cell cultures was essential to the process of the identification of 
antibody specificity and important to subsequent evaluations of reactivity to 
tumor cells.
                                                         
4 With the exception of the work presented within this thesis, which has been published elsewhere 
















































































































































































































































































































































































































































































Taken together, these results demonstrate the successful establishment of IgG 
antibody secreting ex vivo B cell cultures from the peripheral blood of cancer 
patients and healthy volunteers.  The ex vivo expansion of B cells and production of 
IgG by human B cells reported here also support the premise that the use of a TLR9 
agonist along with EBV, a method initially reported by Traggiai et al., can be 
utilized as a way to produce high amounts of human IgG antibodies from 




3.3   Methodology to Detect Tumor-specific Antibodies from B Cell 
Cultures 
Having found that mature antibody-secreting B cell cultures can be successfully 
established from patients with melanoma, the next aim of this work was to 
develop a methodology which would allow for the evaluation of the reactivity of 
these human antibodies from ex vivo B cell cultures to melanoma cells.  As stated 
previously, whole cells were chosen due to the lack of recombinant melanoma 
surface antigens commercially available at the time of this study and the benefits 
of using whole cells expressing a multitude of natively-expressed cell surface 
antigens. 
In particular, the experiments described herein were aimed at developing cell-
based methods to: (1) evaluate humoral memory of patients to melanoma and (2) 
identify antibodies with specificity to melanoma cells. 
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3.3.1 Detection of Tumor-specific Antibodies by Immunocytochemistry 
The detection of the specific binding of antibodies to melanoma cells was first 
evaluated using immunocytochemistry methods (described in Chapter 2, Section 
2.5.4).  Using an anti-melanoma monoclonal antibody specific for the tumor-
associated antigen HMW-MAA (HMW-MAA antibody), the binding of this antibody 
targeting HMW-MAA  could be visualized across a range (30 µg/mL to 20 ng/mL) 
of antibody concentrations on cytospins of A-375 melanoma cells, which are 
known to highly express this antigen on the cell surface (Figure 3.7, top).   
Additionally this HMW-MAA antibody at high antibody concentrations (30 µg/mL) 
was not found to bind to melanocytes (Figure 3.7, bottom left), supporting the 
specificity of this methodology to detect the binding of antibodies to TAAs.  Lastly, 
the assay background was evaluated by the addition of high amounts of non-
melanoma specific IgG present in healthy volunteer donor serum and was found to 
be negligible, as seen by the absence of antibody reactivity to A-375 melanoma 
cells (Figure 3.7, bottom right).  This technique has the advantage of demonstrable 
requirement of the need for only low (20 ng/mL) amounts of antibodies for 
specific detection (Figure 3.7, top right).  The application of this methodology in 
this instance yielded a qualitative method to detect tumor-reactive antibodies and 
required minimal assay development.    
While this type of assay afforded some advantages, it also nevertheless required 
the production of copious amounts of slides, and the readouts were qualitative, 
although not easily quantitative and very low throughput.  Additionally, the lack of 
quantitative results from this assay translated into a method which would not 
allow for the clear selection of cell culture wells with higher degrees of binding to 
melanoma cells and permit the rapid selection of B clones from thousands of cell 
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culture wells.  Thus the application of immunocytochemistry followed by light 
microscopy analysis, while useful for a rapid qualitative detection of an antibody, 
does not provide an ideal framework to screen the specificity of antibodies to 
melanoma cells for thousands of patient-derived antibody cultures. 
 
 
Figure 3.7  Immunocytochemical detection of a melanoma-specific antibody. 
Immunocytochemistry of cytospin preparations demonstrate that an antibody against 
the melanoma-associated antigen HMW-MAA, expressed on the surface of A-375 
metastatic melanoma cells, can detect the antigen at 30 µg/mL (top left), 200 ng/mL 
(top middle) and 20 ng/mL (top right), while no binding to melanocytes was seen 
(bottom left).  IgG from 5% human serum (bottom right) was not observed to bind to A-




3.3.2 Detection of Tumor-Specific Antibodies by Flow Cytometry 
The use of flow cytometry to identify novel anti-melanoma antibodies was also 
explored as a potential screening tool.  Unlike the previously described methods of 
immunocytochemistry followed by analysis with light microscopy, the fixation of 
cells is not required in flow cytometry.  Flow cytometry presents the advantage of 
using live cells, negating any batch to batch variability of fixation methods and 
potential alteration or masking of some antigenic epitopes residing on the cell 
surface.  Using flow cytometry, the binding of melanoma specific antibodies to 
melanoma cells and not melanocytes could also be seen using live cells (Figure 
3.8).  The specific binding of antibodies to melanoma cells could also be detected at 
low concentrations of antibodies, 20 ng/mL, making it comparable in sensitivity to 
immunocytochemistry methods using light microscopy (Figure 3.7 & Figure 3.8).   
Flow cytometry, while benefiting from good sensitivity and from the use of live 
cells, suffered from some drawbacks as a screening tool.  The primary 
disadvantage was the need for simultaneous maintenance of several cell lines to 
evaluate antibody specificity across multiple melanoma cell types as well as 
normal cells.  In comparison to the other technique described previously, where 
multiple slides of the same batch of cells could be produced and stored, this would 
be more challenging with live cells.  While more laborious in the sense of length of 
the assay and maintenance of cell lines, this technique could serve as a valuable 
method to verify antibody binding results from other methods, particularly with 
the regards to the effects of fixatives on antigens.  In summary, while this 
technique was not deemed suitable for screening purposes, it could nonetheless 
serve as a useful tool once a melanoma-reactive antibody was identified.  This flow 
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cytometric assay was sensitive, required small amounts of antibody, and was 
demonstrated to allow the identification of melanoma-reactive antibodies. 
 
 
Figure 3.8  Detection of a melanoma-specific antibody by flow cytometry.  Flow 
cytometric analysis demonstrates specific binding of the HMW-MAA antibody to HMW-
MAA antigen presented on A-375 cells (left) at 30 µg/mL (dashed line), 200 ng/mL 
(dotted line) and 20 ng/mL (black line), but not to melanocytes (right, 30 µg/mL HMW-




3.3.3 Development of a Novel Cell-based ELISA to Screen for Melanoma-
specific Antibodies 
An ELISA was next developed and evaluated as a suitable technique to use for the 
screening of melanoma specific antibodies.  Key requirements for this assay were 
that: (1) it should be suitable for use in a medium throughput manner, (2) it should 
permit the identification of antibodies to cell surface antigens, (3) large batches 
cell cultures could be made at one time and frozen, and (4) the results should be 
semi-quantitative.  An assay fulfilling the above parameters would present as an 
ideal methodology to use for screening of melanoma-reactive antibodies from 
thousands of B cell cultures. 
 
3.3.3.1 Assay Principle 
The principle of a cell-based ELISA to detect antibodies that were bound to cell 
surface proteins was initially evaluated using (1) U-937 cells which express FcγRs 
and (2) IgG containing human sera (Anderson and Abraham 1980).  A simple cell-
based ELISA was constructed (Figure 3.9, left) based on a method described to 
measure the binding of anti-CD20 antibodies to a CD20 expressing B cell line 
(Hong, Presta et al. 2004).  The binding of IgG antibodies present in human serum 
to FcγR on U-937 cells was evaluated using a colorimetric detection system.  In this 
ELISA, the Fc-binding of IgG antibodies to cell surface FcγRs expressed on U-937 
cells could be detected when compared to samples treated with buffer (culture 
medium) alone (Figure 3.9, right).  Importantly, the detection of IgG binding 
(absorbance value) was decreased with decreasing amounts of IgG containing sera 
(Figure 3.9, right), demonstrating the potential quantitative nature of this assay.  
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This could later prove useful as a way to identifying cultures with the highest 
amount of melanoma-reactive antibodies.   Results from this assay showed that the 
binding of IgG present in human serum to the U-937 cell line could be semi-
quantitatively detected utilizing a cell-based ELISA.  
 
 
Figure 3.9  Evaluation of the proof of principle of a cell-based ELISA.  The binding 
of IgG in human sera to the FcγRs expressed on U-937 cells was evaluated in a live 
cell-based ELISA.  The experimental design of the assay is shown (left) along with the 
assay results for IgG antibodies in different concentrations of human serum compared 
to buffer (culture medium) only (right). 
 
This pilot assay was performed on live cells which were kept on ice so that the 
results would not be confounded by effects of fixatives on antigens.  But as noted 
previously, with the ultimate aim of developing this assay to screen thousands of 




In designing an assay using fixed cells, the aim was to lightly fix the cells, so that 
the highest cytological preservation of cell surface proteins would be obtained.  
While a cell-based ELISA used to detect melanoma-antibodies had been previously 
reported (Cai and Garen 1995), the use of glutaraldehyde in this assay was not 
likely to meet the objective of this study, which was to measure the binding of 
antibodies to cell surface antigens, and prompted the development of a new assay 
with an alternate fixative.  Glutaraldehyde is a very effective cross-linker and 
fixative, providing excellent preservation of cell morphology, but it may be less 
than ideal for use in a cell-based ELISA.  The use of glutaraldehyde has been shown 
to result in the severe distortion and masking of cell surface molecules, thereby 
causing a high loss of antigenicity, artifacts and false positive recognition of some 
antigens residing on the surface of cells (Walker, Llull et al. 1992).  With the above 
knowledge, alternative fixatives were explored for use in the cell-based ELISA.  
Two alternate preservatives commonly used for fixing cells used for cell based 
assays were next evaluated: methanol and formaldehyde (Walker, Llull et al. 1992; 
Erdile, Smith et al. 2001).  The detection of antibodies against HMW-MAA 
expressed on melanoma cells was compared using melanoma cells fixed with 
either methanol or formaldehyde solution.  Formaldehyde was observed to yield 
greater detection (absorbance value) of HMW-MAA on A-375 cells compared to 
methanol (Figure 3.10).  The concentration of formaldehyde used in a cell-based 
ELISA, 0.5%,  has been shown elsewhere to result in the best cell antigenicity, cell 
morphology, binding, consistent assay results, and to have no adverse effects on 
antibody-antigen binding after being stored for up to 12 months at -80˚C (Walker, 





Figure 3.10  Comparison of different fixatives for use in the cell-based ELISA.  
During early assay development cell fixatives were evaluated due to high background 
using live cells.  The detection of HMW-MAA expressed on the cell surface of A-375 
melanoma cells was evaluated by a cell-based ELISA for cells treated with either 
methanol or formaldehyde, diluted to 0.5% in HBSS.  Each condition was tested in 
triplicate and error bars represent one standard deviation (SD).   
 
After formaldehyde was chosen as the cell fixative, the effect of plate washing on 
cell adherence was investigated.  Cells were seeded at a density of 3 x 105 cells per 
well on 96 well plates and grown until confluent.  Plates were then washed 18 
times to replicate each step of washing in the ELISA and adherence was monitored 
by light microscopy.  A representative image shows the high adherence of cells 
after multiple plate washing steps (Figure 3.11).  The lack of cell loss is important, 





Figure 3.11  Evaluation of washing steps on cell adherence in the cell-based 
ELISA.  Adherence of A-375 melanoma cells to wells was monitored by light 
microscopy.  A-375 melanoma cells were seeded on 96 well plates and grown until 
confluent.  Cells were then fixed with 0.5% formaldehyde in HBSS, wrapped in 
aluminum foil, and stored at -80ºC until day of assay.  After plates were thawed at 
room temperature for 30 minutes, wells were washed 18 times to replicate washing 
steps in the assay and the adherence of cells was monitored by light microscopy.  
Representative image shown at 80x magnification. 
 
These assessments of fixatives and cell adherence were the initial steps in 
developing a cell-based ELISA, a tool to detect antibodies recognizing melanoma 
antigens.  Using cells highly adherent to 96 well plates and fixed with 0.5% 
formaldehyde, a cell-based ELISA was created and incubation times and reagents 




3.3.3.2 Assay Optimization 
Several parameters were evaluated in the development of a cell-based ELISA for 
the detection of melanoma-reactive antibodies.  This optimization was performed 
using the A-375 melanoma cell line, which highly expresses the HMW-MAA, and an 
antibody targeting this antigen.  Optimal conditions such as incubation time, 
detection time and antibody concentrations were defined as the shortest 
incubation time, or least amount of reagent, or fewest additives, where the quality 
of the results was not decreased. 
One such parameter evaluated was the optimal incubation time of antibody 
containing cell culture supernatants to adherent tumor cells.  Using the HMW-MAA 
antibody diluted in B cell culture media, antibody incubation time was evaluated at 
30 minute intervals: 60, 90 and 120 minutes, along with multiple decreasing 
concentrations of HMW-MAA antibody: 250, 125, 62.5,  and 31 ng/mL.  It was 
found that absorbance values for the 90 and 120 minute incubation periods were 
similar, while the 60 minute incubation had a lower absorbance value (Figure 
3.12A, left).  For these conditions, there was not a large reduction in the assay 
background (buffer only condition) among the three incubation times, suggesting 
that any non-specific binding of bovine proteins present in the culture media was 
not increased over time (Figure 3.12A, right).  Detection of the antibody at 
concentrations as low as 31 ng/mL was observed with an incubation time as low 
as 60 minutes.  However, the incubation time of 90 minutes was selected due to 
increased absorbance values at this time point, while an additional incubation of 
30 minutes (120 minutes total incubation) did not provide significant increases in 





Figure 3.12  Evaluation of selected parameters for the development of a fixed 
cell-based ELISA.  A cell-based ELISA was optimized to detect melanoma-reactive 
antibodies using the A-375 melanoma cell line and a HMW-MAA antibody.  Primary 
incubation time was evaluated for antibodies over a range of concentrations and buffer 
to optimize antibody detection (A, left) and non-specific binding (A, right).  The 
secondary antibody was also evaluated at multiple titrations (B, left) to achieve optimal 
antibody detection and reduced background (B, right).
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Another key parameter evaluated in the development of the cell-based ELISA was 
the concentration of the secondary antibody, a F(ab’)2 antibody fragment specific 
for the IgG Fc region, which was used to detect the binding of melanoma-reactive 
antibodies to tumor cells.  In this optimization step, the criteria were set to select 
the condition with highest antibody detection (absorbance value) accompanied by 
the lowest background.  The detection antibody was tested at three dilutions: 
1:250, 1:500 and 1:1000, with 1:250 being the highest amount of antibody that 
could be used in a reasonably cost-effective manner.  The highest detection of the 
anti-HMW-MAA antibody along with highest background was observed with the 
highest amount of antibody, at a 1:250 dilution (Figure 3.12B).  Since a higher 
amount of background was also observed with the highest amount of detection 
antibody, the antibody diluted 1:500 was selected for the assay since this 
concentration had reduced background while still maintaining adequate detection 
of melanoma-reactive antibodies to melanoma cells. 
 
3.3.3.3 Verification of Assay Sensitivity and Specificity 
After setting up the final parameters of cell-based ELISA, the assay was further 
evaluated for the following two key factors: assay sensitivity and assay specificity.  
First, it was crucial to determine that this assay could specifically detect the 
binding of antibodies to antigens on tumor cells and not just the binding of non-
specific antibodies to 96 well plates or the non-specific binding of antibodies to 
cells.  Secondly, it was important to ensure that the assay was sensitive enough to 
adequately detect antibodies present in patient B cell culture supernatants. 
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Assay sensitivity was assessed by comparing the binding of the melanoma-specific 
HMW-MAA antibody diluted to a range of concentrations to A-375 melanoma cells.  
The binding of the melanoma-specific antibody to antigens expressed on the 
surface of melanoma cells could distinctly be detected and differentiated at 
antibody concentrations as low as 10 ng/mL by the cell-based ELISA (Figure 3.13).  
Based on the concentration of IgG measured from cultures arising from one or two 
B cells 10 days after their establishment (Figure 3.5), an assay with a lower limit of 
sensitivity of 10 ng/mL would likely detect melanoma-reactive antibodies present 
in patient B cell culture supernatants.  Thus, this method could theoretically detect 
melanoma-reactive antibodies secreted from a single B cell clone. 
 
 
Figure 3.13  Detection of melanoma-specific antibodies to melanoma cells and 
not to melanocytes by a cell-based ELISA.  Detection of the HMW-MAA antibody to 
A-375 melanoma cells over a range of antibody concentrations was compared to 
melanocytes.  The HMW-MAA antibody was tested in triplicates for each concentration 
and error bars represent one SD. 
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The ability of the cell-based ELISA to detect antibodies bound to cell surface 
antigens expressed on cancer cells was also verified using a commercially available 
antibody.  The detection of the binding of Trastuzumab, a monoclonal antibody 
against the tumor associated antigen Her2/neu (whose proto-oncogene is 
amplified/overexpressed in 25-30% of primary breast cancers) to breast cancer 
cells was evaluated using the cell-based ELISA (Slamon, Godolphin et al. 1989).  
The assay was performed exactly as previously described (Chapter 2, Section 
2.7.5), with the exception that the breast cancer cell line SK-BR-3 rather than 
melanoma cells or melanocytes was used to coat the 96 well plates.  Performing 
this assay, it was possible to specifically detect Trastuzumab binding to breast 
cancer cells (Figure 3.14), supporting the robustness of this assay to detect tumor-
specific antibodies as well as the potential application of this methodology to study 
host B cell responses to other cancers. 
The specific detection of antigen-antibody binding was also evaluated for 
melanoma cells.  Comparing cell culture media containing no human antibodies, 
non-specific human IgG and an antibody targeting melanoma cells, the specific 
detection of antibodies against melanoma cell surface proteins could be measured 






Figure 3.14  Utilizing the cell-based ELISA to detect the binding of a 
commercially antibody therapeutic to cancer cells.  The binding of Trastuzumab to 
SK-BR-3 breast cells compared to an IgG isotype control or media only (no antibody) 
using the cell-based ELISA.  Conditions were tested in triplicate and error bars 
represent one SD. 
 
Figure 3.15  The specific detection of melanoma antibodies against melanoma 
cell surface antigens by a cell-based ELISA.  Melanoma-specific antibody, HMW-
MAA antibody, binding to A-375 melanoma cells was compared to an IgG isotype 
control in the absence of antibody.  Conditions were tested in triplicate and error bars 
represent one SD. 
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By comparing the binding of either the anti-HMW-MAA antibody or Trastuzumab 
to tumor cells to that of media containing bovine IgG or to the non-specific IgG 
control (which could represent irrelevant IgG antibodies secreted from the human 
B cells), non-tumor antigen-specific antibodies were not observed to become 
immobilized on the plates themselves or seen to become non-specifically bound to 
proteins on tumor cells.  If this were to occur high absorbance values would have 
been detected for the non-specific IgG control or media only.  Rather, the assay 
specifically detected the binding of tumor-specific antibodies to tumor cells 
(Figure 3.14 & Figure 3.15).  Furthermore, upon comparing the addition of HMW-
MAA antibody to plates coated with A-375 melanoma cells to those coated with 
melanocytes, the specific binding of this antibody to melanoma cells, and not to 
normal cells such as melanocytes, was observed (Figure 3.13), verifying the 
specificity of the assay. 
 
3.3.3.4 Selection of Positive and Negative Controls  
Integral to screening for melanoma-reactive antibodies was the choice of 
appropriate controls for the ELISA.  Controls were necessary not only to monitor 
the performance of the assay, but also to compare results across assays, cell lines 
and individuals.  For the negative control, a human (non-specific) IgG antibody was 
selected.   This negative control ensured that assays with high amounts of non-
specific background would be discounted from analyses.  The HMW-MAA antibody, 
used in the previous sections to develop the assay, was next evaluated for use as a 
positive control in the cell-based ELISA.  The binding of this antibody to 5 
melanoma cell lines was evaluated by FACS, and expression of HMW-MAA was 
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detected on the 5 melanoma cell lines evaluated (Figure 3.16, top).  Expression 
(level of fluorescent intensity above isotype control) of HMW-MAA varied among 
melanoma cell lines, with a 9-fold difference between A-375 and WM-115 cells and 
60-fold difference between A-375 and SK-MEL-28 cells (Figure 3.16, top).  The 
variable antigen expression of the HMW-MAA among melanoma cell lines would 
make it challenging to set general cut-off points by which to select positive cultures 
based on the positive control absorbance values.  This is because expression levels 
could be log scale values apart among available panels of cell lines (Figure 3.16, 
top).  Additionally, the lack of expression of this antigen on non-malignant cells 
such as melanocytes (Figure 3.16, top) would require a separate positive control 
antibody for such cells used in the ELISA.  Since screening would not only require 
the comparison of antibody reactivity to melanoma cells but also to melanocytes, it 
was preferable to choose an antigen expressed more uniformly on both melanoma 





Figure 3.16  Expression of two tumor cell surface antigens on melanoma cell 
lines and melanocytes.  Tumor cell surface antigen expression on five melanoma cell 
lines and primary melanocytes was evaluated by flow cytometry.  HMW-MAA (top) was 
detected with the 225.28S chimeric-HMW-MAA IgG antibody and Her2/neu (bottom) 





In summary, a specific and adequately sensitive cell-based ELISA with appropriate 
positive and negative controls was developed for the purpose of identifying novel 
patient derived melanoma-reactive antibodies.  Exploration of other 
methodologies such as immunocytochemistry followed by light microscopy 
evaluations and flow cytometric methods were useful in assessing the specificity of 
an antibody and provide additional tools to examine the effects of fixation on 
antigenicity, but also serve as confirmation of the ELISA results, since similar 
results were seen for the detection of the anti-HMW-MAA antibody across these 
three different methodologies.  Additionally, these assays can be adapted to study 
many different adherent malignant and non-malignant cell lines, as seen by the 
example of the detection of Trastuzumab binding to SK-BR-3 breast cancer cells, in 
order to screen for tumor-reactive antibodies from human B cell cultures 











3.4   Proof of Principle: Reactivity of Antibodies Isolated from 
Individuals to Melanoma Cells 
Having developed an adequate screening assay to detect anti-tumor antibodies 
from human B cell culture supernatants, the next stage was to investigate whether 
any melanoma-reactive human IgG antibodies could be identified from ex vivo 
peripheral blood B cell cultures.  To test whether melanoma-reactive IgG 
antibodies could be readily detected, peripheral blood B cells from a small cohort 
of patients with melanoma were studied and compared to B cells derived from the 
blood of healthy volunteers.  This section details the process by which patient-
derived antibodies produced in primary B cell cultures were screened for 
reactivity to cells. 
 
3.4.1 Process for Screening Human IgG Antibodies 
Once B cell cultures were established from patients, cultures were grown for 18 
days and antibodies secreted in these primary cell culture supernatants were 
screened against melanoma cell lines or non-malignant cells using the cell-based 
ELISA described in the previous section (method detailed in Chapter 2, Section 
2.7.5) in order to identify melanoma-reactive B cell cultures.  The steps in this 




Figure 3.17  Process for identifying melanoma-reactive antibodies from human B 
cells.  Schematic of process used to identify melanoma-reactive antibodies from 
patients with melanoma.  Freshly isolated B cells from peripheral blood were activated 
with CpG ODN and transformed with EBV and cultured along with irradiated 
autologous PBMCs as feeder cells for 18 days.  After 18 days in culture, cell culture 
supernatants were removed and tested using the cell-based ELISA for reactivity to 
melanoma cells (A-375 or WM-115) or to normal cells such as melanocytes.  The cell-
based ELISA results were used to initially select positive melanoma-reactive cultures 
for further expansion and analyses. 
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3.4.2 Criteria for the Assessment of Antibody Reactivity to Tumor Cells 
Utilizing the cell-based ELISA for screening, the next criteria explored were 
concerned with the selection of melanoma-reactive B cell cultures.  While others 
have defined positive reactivity to be the mean absorbance value of the negative 
control antibodies plus 3 times the SD of the mean (Kirkwood and Robinson 1990), 
more stringent criteria were set in this study, which allowed for the selection of 
cultures with the highest reactivity to melanoma cells for further sub-cloning.5  
The use of stringent criteria ensured that results would be less likely to reflect 
false positive values obtained by ELISA and more likely lead to the selection of 
antibody clones with reactivity to melanoma cells.  A cut-off point was used for 
each assay, to select B cell cultures by choosing wells with absorbance values 
measured to be at or above 75% of the absorbance value of the positive control (in 
this instance Trastuzumab) to melanoma cells (Figure 3.18).  In the example 
presented in Figure 3.18 below, two B cell cultures had absorbance values which 
produced optical density values of at least 75% of the positive control; cultures 
would be selected and expanded for further reactivity evaluations. 
                                                         




Figure 3.18  An example of cell-based ELISA results for patient B cell culture 
supernatants along with negative and positive assay controls.  Data from the cell-
based ELISA measuring the reactivity of antibodies in B cell culture supernatants (blue) 
from one patient (M133) B cell culture plate to WM-115 melanoma cells.  Each bar 
represents reactivity of a supernatant removed from a single B cell culture.  Non-
specific human IgG antibody (yellow) was used as the negative control and 
Trastuzumab (pink) served as the positive control.  Both controls were tested in 
triplicates.  The dashed line represents the 75% absorbance value of the positive 
control, a cut-off used to choose clones for further evaluations. 





3.4.3 Initial Assessments of the Detection of Melanoma-reactive 
Antibodies from Human B cell Cultures 
The possibility of the identification of melanoma-reactive antibodies from ex vivo 
human B cell cultures from a patient with melanoma (M120) was explored using 
the newly established cell-based ELISA.  In these experiments, the binding of 
antibodies produced in these cultures was studied against two separate melanoma 
cell lines as well as against melanocytes.  Analysis of the reactivity of these B cell 
cultures (n=120) revealed that antibodies from this patient bound to melanoma 
cells (A-375 metastatic melanoma and WM-115 primary melanoma cells) and 
overall had less reactivity to melanocytes (Figure 3.19).  The patient evaluated in 
this example was arbitrarily selected and at the time of B cell isolation was 
classified as having Stage II melanoma.  These patient cultures along with those 
from another patient (Figure 3.18) served as examples of the feasibility of this 
approach to identify melanoma-reactive antibodies from patients.  While findings 
of melanoma-reactive IgG antibodies from patient B cells have been documented, 
these findings have been restricted to only a few antibodies; furthermore, some 
were of the IgM class from individuals with unusual clinical progressions, such as 
autoimmune responses, such as Vitiligo followed by disease-free survival of over 6 
years (Kirkwood and Robinson 1990).  Such findings may provide insights into 
mechanisms of relapse-free survival, and suggest that humoral responses may 
form a component of these responses in selected patients.  These individual cases 
notwithstanding, the objective here was to assess how widespread a host B cell 
response to melanoma was across individuals, and how applicable this new cell-
based ELISA would be towards identifying monoclonal antibodies recognizing 
melanoma.  These promising findings from the very first two patients studied 
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supported this approach as a potentially useful method to evaluate and discover 
melanoma-specific antibodies from patients. 
A limitation of these initial assessments related to the rigor of evaluation of these 
antibody cultures using a cell-based ELISA, being restricted to the examination of 
up to three or four cell lines (Figure 3.19) at any one time.  Only 3 assays, one for 
each cell line, could reasonably be performed from B cell cultures at a given time 
due to the volume of available cell supernatant from each culture.  This limitation 
restricted the level of reactivity one could examine against different cells, and the 
ability to test each culture supernatant in triplicate.  In the future, such a limitation 
could be overcome by further refinement of the cell-based ELISA such as the use of 
384 well plates, which would require less volume of supernatant, or by increasing 
the level of sensitivity of the assay with the use of a fluorescence detection system 
rather than the present colorimetric one, so that less supernatant would be 
required per assay.  Alternately, other methodologies could be utilized as tools to 
study humoral immune responses and identify novel antibodies and antigens 
beyond the cell-based ELISA, such as the use of protein microarrays.  Protein 
microarrays have been described to have the potential to detect the reactivities of 
antibodies against possibly thousands of proteins and have recently be used to 
evaluate humoral immune responses in ovarian, pancreatic and colorectal cancers 
(Gnjatic, Ritter et al. 2010; Babel, Barderas et al. 2009).  While improvements to 
the cell-based ELISA could allow for further evaluation of additional cell lines or 
the additional use of other tools such as arrays, even one ELISA coated with one 
melanoma cell line could possibly provide sufficient information to select 
melanoma-reactive cultures which could subsequently be further expanded and 




Figure 3.19  Assessing the reactivity of antibodies in patient B cell culture 
supernatants to multiple cell types by ELISA.  The reactivity of antibodies in B cell 
culture supernatants (blue, n=120) from patient M120 was assessed using the cell-
based ELISA.  Antibody reactivity was evaluated against three cell types by ELISA: 
primary melanocytes, the metastatic melanoma cell line A-375, and the primary 
melanoma cell line WM-115.  Absorbance values were normalized across assays 
relative to the positive control, Trastuzumab (pink), which was tested in triplicate.  Non-
specific IgG (yellow) was used as a negative control and also tested in triplicate.  Error 
bars represent one SD. 
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Next, the reactivity of antibodies to melanoma cells was further evaluated from B 
cell cultures established from a cohort of six patients and 6 healthy volunteers.  
Results from the cell-based ELISA show that antibody cultures (n=360) from 
patients (n=6) had overall higher antibody reactivity to both primary and 
metastatic melanoma cells, compared to antibody cultures derived from healthy 
volunteers (n=6 individuals; 360 cultures), which were tested against the same cell 
lines (Figure 3.20).  Healthy volunteer B cell cultures all had absorbance values 
below the 0.75 relative absorbance cut-off point for the cell-based ELISA using A-
375 and WM-115 melanoma cells (Figure 3.20).  Strikingly, it was observed that 
melanoma-reactive antibodies were detected in more than one individual with 
melanoma against each cell line (Figure 3.20).  The observation that anti-tumor 
antibody responses (cultures above the cut-off point) were observed with patient 
B cell cultures, but not with healthy volunteer B cells, further supports the capacity 
of this cell-based ELISA to specifically detect antibody responses to malignancy. 
Upon examination of the reactivity of B cell culture supernatants to the A-375 and 
WM-115 melanoma cell lines, all six patients had at least one culture with 
reactivity to the A-375 cell line, while three patients had at least one culture 
reactive to the WM-115 cell line (Figure 3.21).  In these preliminary investigations, 
it was also observed that a few cultures found in two out of the six patients had 
reactivity to both melanoma cell lines evaluated (Figure 3.21).  This may be due to 
antibodies arising against an antigen expressed on both cell lines in these patients.  
These cultures are of great interest because they bind to two different melanoma 
cell lines, one which was derived from a primary melanoma from one individual 
(WM-115) and the other from a metastatic melanoma lesion from another 
individual (A-375).  Such antibodies may be against commonly expressed antigens 
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Figure 3.20  Initial assessment of the reactivity of antibodies derived from 
melanoma patients and healthy volunteers to melanoma cells.  Antibodies in B cell 
culture supernatants derived from healthy volunteers (n=6) and melanoma patients 
(n=6) were evaluated for reactivity to A-375 metastatic melanoma cells (A) and WM-
115 primary melanoma cells (B).  Culture supernatants from both healthy volunteers 
(n=360 cultures) and patients (n=360 cultures) were evaluated for reactivity to 
melanoma cells using a cell-based ELISA.  Absorbance values across assays were 
normalized based on a positive control antibody assigned a relative absorbance of 1.  






Figure 3.21  Estimation of positive melanoma-reactive antibody cultures from 6 
patients.  The number of positive cultures from 6 patients evaluated against two cell 
lines: A-375 and WM-115 using the cell based ELISA (see Figure 3.20).  Cultures were 
counted as positive if the absorbance value was at least 75% of the control antibody.  
Cultures with wells selected as positive for both cell lines are shown in black bars. 
 
The finding that each of the 6 individuals studied had at least one tumor cell-
reactive antibody culture (Figure 3.21), suggests that a memory B cell response to 
melanoma is present in many individuals with cancer.  Taken together, these 
results suggest that a common host B cell response to melanoma exists among this 








3.5   Conclusions 
This chapter demonstrated that it was possible to establish ex vivo IgG antibody-
secreting B cell cultures from the peripheral blood of individuals with melanoma, 
as well as from healthy volunteers, and presents a cell-based ELISA method to 
rapidly identify novel tumor cell-reactive antibodies from clinical specimens.   
Patient-derived B cell cultures were observed to produce antibodies that recognize 
melanoma cells derived from primary and metastatic tissues.  This reactivity to 
melanoma cells was not observed in healthy volunteers who have not had 
exposure to melanoma, supporting the premise that there are specific mature 
memory B cell responses to cancer.  Further study showed that some B cell 
cultures have antibodies that bind to melanoma cells, but do not recognize normal 
melanocytes.  These results show great promise for the identification of novel 
melanoma antibodies from patient specimens.  Applications of these methods to 
evaluate humoral responses to melanoma are presented in Chapter 4, and efforts 
to discover monoclonal antibodies from patients are presented in Chapter 5. 
The methodology described herein includes the establishment of antibody-
secreting B cell cultures, a screening assay, and a process to identify cultures with 
melanoma-reactive antibodies.  This work potentially has multiple clinical 
applications, including the discovery of new diagnostic and therapeutic antibodies 
which could also reveal novel cell surface antigens.  Melanoma-reactive antibodies 
isolated from patients could be co-immunoprecipitated with antigen, which could 
lead to the identification of novel antigens by mass spectrometry.  Such an 
approach has also been employed using phage display libraries to construct IgG1 
antibodies following antigen identification, and it was shown that some of these 
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antibodies were able to mediate ADCC in vitro (Kurosawa, Akahori et al. 2008).   
The use of human antibodies rather than phage display library-derived clones 
would negate the need to construct IgG antibodies, and affinity-matured antibodies 
could be immediately tested for their ability to mediate ADCC.  Also, these novel 
antigens could be used as imaging agents, biomarkers, or diagnostic tools. 
Furthermore, the detection of melanoma-reactive antibodies from patients but not 
from healthy volunteers using the cell-based ELISA points to the potential 
diagnostic utility of this method.   With further stringent optimization, this ELISA 
could be employed as a non-invasive diagnostic tool to identify the presence of a 
humoral response to melanoma in individuals.  This assay could also benefit from 
technical improvements, including the use of multiple tumor cell lines in one well 
or normal cells in a multiplex assay format, so that reactivity could be assessed 
against multiple cell lines at once.  Additionally, increased assay sensitivity may be 
gained by using fluorescent rather than colorimetric detection of antibody-antigen 
binding.    Moreover, with sufficient correlations with clinical and other diagnostic 
parameters, this cell-based ELISA may potentially be investigated as a tool to 
inform on patient outcomes, responses to therapies, and to guide clinical decisions. 
Strikingly, it was found that melanoma-reactive antibody cultures were observed 
in all six patients studied, and this prevalent response merits further exploration.  
Correlating clinical parameters with degree of antibody response to cancer could 
guide the selection of patients capable of providing the most abundant source of 
anti-melanoma antibodies.  Additionally, monitoring the memory B cell repertoire 
of patients can provide insights into the mature B cell response to cancer, 
supporting the clinical relevance of activating this less-frequently examined arm of 




Chapter 4: Monitoring the Humoral Immune Response to 
Melanoma6 
  
                                                         
6 Section 4.2 and Figures 4.1-4.9 and Table 4.1 are reproduced in part or in full from Gilbert, 
Karagiannis et al. 2011. 
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4.1   Introduction and Aims 
The humoral immune response to melanoma has been evidenced by the presence 
of anti-tumor antibodies in the serum of patients in reports dating back over 40 
years (Lewis, Ikonopisov et al. 1969; Sahin, Türeci et al. 1995; Old and Chen 1998; 
Stockert, Jäger et al. 1998).   These serological studies have provided some insight 
into temporal antibody responses present in the blood at a given time against 
patient autologous tumor cells and recombinant forms of well-defined melanoma 
antigens.  Further interrogation of the anti-tumor antibody compartment of 
patients from memory B cells could complement such serological studies and 
potentially provide additional perspective into the presence and frequency of 
circulating memory B cells in patient peripheral blood.  In principle, these memory 
B cells may be activated to mount an anti-tumor antibody response.  To achieve 
this, the cell-based ELISA (developed in Chapter 3, Section 3.3.3) was utilized to 
assess the reactivity of antibodies from circulating memory B cells derived from 
both patients and healthy volunteers to melanoma cells.   Evaluation of memory B 
cell antibody responses to non-autologous melanoma cells utilizing the cell-based 
ELISA may confer some advantages in evaluating humoral responses to melanoma 
over the examination of such responses against autologous melanoma cells or a 
few pre-defined recombinant melanoma antigens.  By measuring antibody 
reactivity to whole non-autologous cells, overall reactivity to antigens present on 
melanoma cells can be assessed rather than just a few melanoma antigens or rare 
antibodies which only recognize autologous cells.  Monitoring the circulating 
human memory B cell compartment of patients for anti-tumor IgG antibodies can 
permit the characterization of the circulating B cell repertoire of individuals and 
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would allow for further insight into the breadth of mature B cell responses to 
malignancy. 
This chapter will also examine a novel aspect of humoral immune responses in the 
cutaneous tumor microenvironment.  B cells have been found to infiltrate both 
primary and metastatic melanoma tumors and it has been suggested that this 
infiltration may hold some significance in melanoma prognosis (Clemente, Mihm et 
al. 1996; Ladányi, Kiss et al. 2011; Erdag, Schaefer et al. 2012).  These studies have 
primarily identified B cells by pan-B cell markers such as CD19+ or CD20+ cells 
and, most likely, this B cell infiltration is comprised of multiple B cell subsets, and 
each subset may hold distinct roles in the tumor microenvironment (Staquicini, 
Tandle et al. 2008; Schreiber, Old et al. 2011).  Tumor-specific antibodies have 
been detected from B cells in melanoma tumors (Kirkwood and Robinson 1990; 
Yeilding, Gerstner et al. 1992).  However, the direct impact of tumor-specific 
antibodies in providing a significant anti-tumor immune response in the tumor is 
not clear.  The effector mechanisms of such tumor-specific antibodies may be 
weakened in the tumor microenvironment by mechanisms of immune escape such 
as expression of inhibitory FcγRs (FcγRIIB) on melanoma cells which may function 
as a decoy rendering the Fc region of anti-tumor antibodies inert (Cassard, Cohen-
Solal et al. 2008; Schreiber, Old et al. 2011).  Also, it is possible that other 
regulatory factors, such as cytokines, in the tumor microenvironment may 
contribute to the alteration of the anti-tumor antibody response. 
Individuals with metastatic melanoma and some other cancers have been 
hypothesized to exist in a state of enhanced Th2 driven inflammation (Sheu, Lin et 
al. 2001; Agarwal, Verma et al. 2006; Nevala, Vachon et al. 2009).  In melanoma, 
the increase of circulating Th2 cytokines such as IL-4, IL-5, -10 and IL-13 has been 
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associated with tumor burden (Nevala, Vachon et al. 2009) .  The inflammatory 
environment of tumors, such as the presence of Th2 cytokines is thought to be pro-
tumor by the upregulation of VEGF by tumor cells, which contributes to tumor 
angiogenesis (Nevala, Vachon et al. 2009).  These Th2 cytokines are also associated 
with IgE class switching (IL-4) and the production of IgG4 antibodies (IL-10, IL-4) 
(Jeannin, Lecoanet et al. 1998); here it is hypothesized that Th2 cytokines present 
in the tumor microenvironment, such as IL-4 and IL-10, may modulate anti-tumor 
antibody responses in tumors resulting in the increased production of IgG4 
secretion from B cells.  In order to test this hypothesis and examine possible IgG 
subclass polarization in the tumor, the production and proportional distribution of 
the IgG subclasses were measured from B cells residing in metastatic melanoma 
tumors. 
Studying the distribution of IgG subclasses in the tumor microenvironment may 
provide valuable insight into the local antibody response to melanoma from 
memory B cells found in situ.  IgG is comprised of four antibody subclasses, each 
having different molecular structures and effector functions, with IgG1 being 
generally thought to have the most potent immune effector function (Bruggemann, 
Williams et al. 1987).  Changes in the proportions of IgG subclass levels in the 
tumor, such as decreased levels of IgG1 and increased levels of IgG4, may result in 
the dominance of such a subclass reported to be a poor activator of complement 
(van der Zee, van Swieten et al. 1986),  to have low affinity to relevant FcγRs 
involved in effector function (Bruhns, Iannascoli et al. 2009), and to possibly have 
low affinity to antigens due to Fab arm exchange resulting in the inability to 
crosslink antigens (van der Neut Kolfschoten, Schuurman et al. 2007).  Thus, it is 
hypothesized that a modulation of IgG subclass in the tumor by Th2 cytokines 
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towards IgG4 production may weaken the tumoricidal properties of memory B 
cells. 
The main objective of this chapter is to characterize the antibody response to 
melanoma from memory B cells in both the periphery and tumor 
microenvironment.  The specific aims of this chapter are two-fold: 
1. To evaluate the prevalence of the melanoma-reactive B cell compartment in 
circulating B cells from 21 patient cohorts comprised of individuals diagnosed 
with Stage I, II, III and IV melanoma. 
2. To compare the IgG subclass composition from memory B cells in the peripheral 
blood and the tumor microenvironment in order to investigate possible local 
modulation of the humoral immune responses. 
 
 
4.2   Monitoring Peripheral Blood B cells for Melanoma-reactive IgG 
Antibodies 
Prior to evaluating the reactivity of antibodies secreted by B cells among a patient 
cohort, the presence and frequency of the memory B cell compartment was first 
evaluated.  CD27+ was used as a marker of memory B cells (Klein, Rajewsky et al. 
1998) and the circulating memory B cell populations were compared among 
patient groups and healthy volunteers.  Following these characterizations, 
evaluations of memory B cell responses were performed in patients such as those 
evaluating antibody responses to melanoma in relation to disease progression and 
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those estimating of the frequency of memory B cells producing melanoma-reactive 
antibodies. 
 
4.2.1 Analysis of Circulating CD27+ Memory B cell Compartments 
Disruption in memory B cell homeostasis has been documented in autoimmune 
diseases such as Systemic Lupus Erythematosus (SLE) and HIV and more recently 
in cancer (Odendahl, Jacobi et al. 2000; De Milito, Mörch et al. 2001; Carpenter, 
Mick et al. 2009).  Carpenter and colleagues observed that patients with advanced 
melanoma and with other advanced breast, brain, and pancreatic tumors had a 
reduction in the proportion of peripheral blood CD27+ cells compared to healthy 
volunteers, and that these CD27+ memory cells showed a reduced response to B 
cell activation signals and ability to stimulate T cells in ex vivo stimulation assays 
(Carpenter, Mick et al. 2009).  These results suggest a weakened humoral immune 
response in patients with Stage IV melanoma. 
To evaluate if there was a reduction of circulating memory cells as a function of 
disease progression, the CD27+ memory B cell compartment was compared among 
healthy volunteers, non-metastatic (Stage I & II) and metastatic (Stage III & IV) 
melanoma patients by flow cytometric analyses (see Chapter 2, Section 2.6.3.1).  A 
significant (P<0.05) decrease in the percentage of CD27+ B cells from the mature 
(CD22+) B cell pool (mean %CD27+ cells in CD22+cell population  ± SEM) was 
observed for both non-metastatic (16.5 ± 1.8) and metastatic melanoma (16.2 
±1.5) patients compared to healthy volunteers (45.8 ± 9.4) (Figure 4.1).   The 
results described here for the healthy volunteer and metastatic melanoma 
patients’ memory B cell populations were similar to the more exhaustive study 
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performed by Carpenter and colleagues (Carpenter, Mick et al. 2009).  These 
results also provided additional information on alterations of the B cell phenotype 
in early points of malignancy by the examination of the memory B cell 
compartment of individuals with non-metastatic disease.  
 
Figure 4.1  Estimations of the peripheral blood CD27+ memory B cell 
compartment in patients diagnosed with non-metastatic and metastatic 
melanoma compared to healthy volunteers.  The percentage of memory (CD27+) B 
cells in total mature (CD22+) B cell populations was compared among healthy 
volunteers (n=5) and melanoma patients diagnosed with non-metastatic (n=4) and 
metastatic melanoma (n=5).  Error bars represent standard error of the mean (SEM).  
Melanoma patients with metastatic and non-metastatic disease were compared to 
healthy volunteers using a Mann Whitney U Test.  *=P<0.05. 
 
Interestingly, no significant difference in the percentage of CD27+ memory B cell 
populations was detected between metastatic and non-metastatic melanoma 
patient groups, despite both groups having significantly lower circulating memory 
B cell compartments than healthy volunteers (Figure 4.1).  These results point to a 
reduction in the memory B compartment in the periphery at earlier stages of 
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malignancy.  This loss of memory B cells in the peripheral blood of cancer patients 
is not well understood.  One possibility would be the sequestering of memory B 
cells from circulation, which may include the infiltration of memory B cells into 
tumors.  Interestingly, Carpenter and colleagues observed a significant difference 
among the proportion of CD27+ populations among healthy volunteers, patients 
with active Stage IV melanoma and those with Stage IV melanoma who had no 
evidence of disease.  In this study, patients with active disease were found to have 
the most reduced CD27+ populations, followed by those with no evidence of 
disease and then healthy volunteers (Carpenter, Mick et al. 2009).  These findings 
do not largely support the hypothesis that B cells are primarily being sequestered 
in the tumors.  This is because even though patients with higher tumor burden had 
the smallest CD27+ circulating B cell compartment, a reduction in memory B cell 
populations was also seen in those diagnosed with Stage IV melanoma and 
currently having no evidence of disease and therefore with a tumor burden similar 
to healthy volunteers.  Alternatively, the decrease in memory B cell populations in 
patients may represent an overall reduction or dysregulation of memory B cells in 
individuals with melanoma.  Here, the loss of circulating memory B cell phenotype 
has been observed in both patient groups and does not appear to solely be a 
function of increasing tumor burden.   
More importantly in terms of understanding the effects of a reduced memory B cell 
compartment in melanoma patients on the humoral immune response, the 
question whether there is a proportionate loss of B cells with anti-tumor reactivity 
in circulation remains unclear and warrants further evaluation (See Section 4.2.3 
for such evaluations).  Prior to addressing this question, the characterization of the 
reactivity of antibodies from circulating memory B cells from both patients and 
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healthy volunteer will first be examined in order to assess the presence and 
prevalence of the humoral immune response to melanoma in peripheral blood B 
cells. 
 
4.2.2 Prevalence of Melanoma-reactive Antibodies from Patient and 
Healthy Volunteers  
The presence and prevalence of circulating B cells containing melanoma-reactive 
IgG antibodies were evaluated for both patients and healthy volunteers from 
peripheral blood B cell ex vivo cultures.  This was achieved by measuring antibody 
reactivity to melanoma cells using a novel cell-based ELISA (Chapter 3).  Antibody 
reactivity was calculated relative to a non-specific human IgG control in order to 
compare the anti-melanoma antibody response to metastatic and primary 
melanoma cells between patients and healthy volunteers, and among patient 
groups.   Absorbance values were normalized using the following formula:   
              
                                       
                                            
 
Fold increase represents antibody responses to melanoma from memory B cells to 
an array of antigens expressed on melanoma cells. 
The prevalence of melanoma-reactive antibodies in patients was compared to 
healthy volunteers employing the cell-based ELISA.  First, the reactivity of 
antibodies secreted in B cell cultures to metastatic melanoma cells was evaluated 
for 600 B cell cultures derived from 10 healthy volunteers (60 cultures per 
individual, individual age ranged from 21-46) and for 600 B cell cultures derived 
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from 10 patients (n=4 stage II, n=4 stage III, and n=2 stage IV, individual age 
ranged from 49-88).  A significant increase (P<0.001) in the mean reactivity (fold 
increase) of antibodies to metastatic melanoma cells was found in patient culture 
supernatants (2.5 fold increase, 95% confidence interval [CI] 2.4 to 2.6) compared 
to healthy volunteer culture supernatants (1.1 fold increase, 95% CI 1.1. to 1.2) 
(Figure 4.2, A).  Only a few cultures derived from healthy volunteer B cells, 
approximately 1% of cultures, were measured to have reactivity greater than a 3-
fold increase above the IgG control (Figure 4.2, B).  This high reactivity of these few 
cultures may reflect reactivity to proteins not exclusively expressed on melanoma 
cells.  Alternatively, these few cultures may represent false positive results from 
the ELISA.  While healthy volunteers and patients were not age matched due to the 
inaccessibility of older healthy volunteers, humoral immunity is thought to be 
enhanced in younger patients (Allman and Miller 2005) and the use of younger 
individuals in the healthy volunteer group could quite possibility provide an even 
more rigorous comparison to the humoral immunity of older patients with 
melanoma.  In comparison to healthy volunteer cultures, patient cultures such as 
those derived from patient M111 were seen to have many cultures with high 
antibody reactivity to metastatic melanoma cells (Figure 4.2, C).  One of these 
cultures from patient M111 was selected for further expansion and subcloning to 
produce a monoclonal culture, and subsequently the antibody specificity and 
functions of one of these patient antibodies was further characterized as detailed 
in Chapter 5, Section 5.2.2.  Overall, a significantly higher reactivity to metastatic 
melanoma cells was observed from patient cultures compared to those derived 




Figure 4.2  Reactivity of antibodies derived from patient and healthy volunteer B 
cells to metastatic melanoma cells.  (A) Mean reactivity of B culture supernatants 
(n=600) from 10 melanoma patients was compared to the mean reactivity of B cell 
culture supernatants from 10 healthy volunteers (n=600).  Antibody reactivity for each 
B cell culture was evaluated from individual healthy volunteers (B) and patients (C) and 
was determined using the cell-based ELISA.  Fold increase values represent the 
absorbance value of each B cell culture relative to the mean absorbance value of a 
negative control antibody.  Error bars in (A) represent 95% CI.  A two-sided Student’s t 
test was used to compare healthy volunteers and patients (A).  *** = P<0.001.  
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Next, the reactivity of antibodies from patient and healthy volunteer B cell cultures 
was evaluated against WM-115 human primary melanoma cells.  A significant 
(P<0.001) increase was observed in the mean antibody reactivity of cultures 
(n=600) derived from 10 patients (2.3 fold increase, 95% CI 2.2 to 2.4) to primary 
melanoma cells compared to cultures (n=600) derived from 10 healthy volunteers 
(1.0 fold increase, 95% CI 1.0 to 1.1) (Figure 4.3A).  Similar to the results obtained 
for the reactivity of cultures to metastatic melanoma cells, a few cultures (<2%) 
from healthy volunteers had reactivity to primary melanoma cells greater than 3-
fold increase above the non-specific human IgG control (Figure 4.3B).  
Interestingly, patient B cell cultures overall displayed higher reactivity to 
metastatic melanoma cells (A-375) than those melanoma cells derived from a 
primary lesion (WM-115).  The patient with the highest number of cultures 
containing antibodies reactive to primary melanoma cells was patient M273 
(Figure 4.3C) who was also seen to have little reactivity to metastatic melanoma 
cells (Figure 4.2C).  The differential binding of antibody cultures to primary and 
metastatic melanoma cells may reflect the difference of antigen expression on cells 
during disease progression (Barrow, Browning et al. 2006) although it could 
equally be due to individual patient responses to specific antigens expressed by 
different tumor cells.   In support of the first possibility, the expression of 
differentiation antigens has been found to decrease with advancing disease, and 
antibodies against such antigens may not bind to metastatic cells that lack the 
expression of these antigens (Trefzer, Hofmann et al. 2006).  Overall, in addition to 
the metastatic melanoma cell line, melanoma patients but not healthy volunteers 




Figure 4.3  Reactivity of antibodies derived from patient and healthy volunteer B 
cells to primary melanoma cells.  (A) Mean reactivity of B culture supernatants 
(n=600) from 10 melanoma patients was compared to the mean reactivity of B cell 
culture supernatants from 10 healthy volunteers (n=600).  Antibody reactivity for each 
B cell culture was evaluated from individual healthy volunteers (B) and patients (C) and 
was determined by the cell-based ELISA.  Fold increase values represent the 
absorbance value of each B cell culture relative to the mean absorbance value of a 
negative control antibody.  Error bars in (A) represent 95% CI.  A two-sided Student’s t 
test was used to compare healthy volunteers and patients (A).  *** = P<0.001. 
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Examining the reactivity of antibodies secreted from patient B cells against 
primary and metastatic melanoma cells (Figure 4.2 & Figure 4.3) demonstrated the 
presence of a circulating B cell compartment in this patient cohort containing 
antibodies reactive to melanoma cells.  While a reduction of the CD27+ memory B 
cell phenotype has been observed in individuals with melanoma (Figure 4.1), B 
cells activated ex vivo from patients were found to secrete antibodies in similar 
ranges compared to B cells from healthy volunteers (Figure 3.6).  The presence of a 
circulating mature B cell compartment in patients that recognizes melanoma 
antigens in this patient cohort supports the presence of humoral immune 
responses against melanoma cells which can be detected following the ex vivo 
activation of patient B cells.  The antibody repertoire from this compartment 
merits further analyses in order to elucidate possible clinical correlations with 
antibody responses and important prognostic factors.  These findings, especially 
when conducted using larger patient cohorts, will provide valuable insights into 





4.2.3 Antibody Response from Memory B cells in Relation to Disease 
Progression 
In order to examine if antibody response measured from ex vivo activated memory 
B cells changed in relation to disease progression, a 21 patient cohort was studied 
(Table 4.1).  The reactivity of antibody cultures (n=1,800) from these patients to A-
375 melanoma cells was evaluated using the cell-based ELISA.  Patients diagnosed 
with non-metastatic melanoma were observed to have significantly higher 
antibody reactivity (measured as fold increase above the negative control 
antibody) compared to those with metastatic disease (Figure 4.4).  While reduced, 
the presence of melanoma-reactive cultures from patients with metastatic disease 
was still significantly (P<0.001) higher than that of healthy volunteers (Figure 4.4).  
These results demonstrate the presence of an anti-tumor B cell compartment 
among circulating patient B cells that is reduced in metastatic disease.  Since 
antigen composition may change with evolving malignancies (Trefzer, Hofmann et 
al. 2006), measuring overall antibody reactivity to whole cells rather than just one 





Table 4.1  Reactivity of Patient-derived Antibody-secreting B cell Cultures to 
Metastatic Melanoma Cells 
Stage 
Patient 
ID* Age Sex Ethnicity 
Mean fold 
increase† 








I M119 51 F Caucasian 1.1 1.0 to 1.2 2.8 2 
II M133 75 M Caucasian 2.7 2.6 to 2.8 4.2 38 
II M88 70 M Caucasian 6.1 5.4 to 6.9 17 63 
II M144 69 M Caucasian 1.6 1.4 to 1.8 4.8 3 
II M256 49 F Caucasian 2.6 2.5 to 2.8 6.2 22 
II M120 66 F Caucasian 1.5 1.4 to 1.7 6.8 5 
II M274 63 F Caucasian 1.6 1.5 to 1.5 3.5 82 
II M271 38 M Caucasian 1.3 1.1 to 2.2 7.7 2 
II M285 81 M Caucasian 2.0 1.9 to 1.5 3.7 50 
    
Mean 2.4 2.2 to 2.7 6.7 33 
III M111 67 M Caucasian 3.2 3.0 to 3.3 5.8 14 
III M80 54 M Caucasian 1.8 1.6 to 1.9 3.6 13 
III M92 77 M Caucasian 1.8 1.6 to  1.9 3.8 97 
III M272 88 M Caucasian 1.8 1.7 to 1.9 2.8 40 
III M273 68 M Caucasian 1.3 1.2 to  1.4 2.8 6 
III M164 23 M Asian 1.0 0.8 to 1.1 2.9 8 
    
Mean 1.8 1.7 to 1.9 3.6 30 
IV M72 77 F Caucasian 1.7 1.5 to 1.9 3.3 92 
IV M74 72 F Caucasian 1.0 0.8 to 1.1 3.5 10 
IV M130 66 M Caucasian 1.8 1.7 to 1.9 3.1 19 
IV M139 55 F Caucasian 1.5 1.4 to 1.6 2.6 2 
IV M132 51 M Caucasian 1.8 1.7 to 1.8 2.7 8 
IV M187 31 F Caucasian 0.7 0.6 to 0.8 1.3 12 
        Mean 1.4 1.3 to 1.5 2.8 24 
*Patient ID corresponds to patient number in all figures and text. 
†Fold increase values were calculated by dividing the absorbance value of B cell culture 
supernatants by the absorbance value of a non-specific IgG negative control using a cell-
based ELISA.    
†† Percent of cultures with absorbance values greater than 75% of a positive control 






Figure 4.4  The reactivity of IgG antibodies to melanoma cells from metastatic 
and non-metastatic melanoma patient and healthy volunteer B cell cultures.   
Antibodies derived from peripheral blood B cell cultures established from healthy 
volunteers (n=10), non-metastatic (n=9), and metastatic melanoma patients (n=12) 
were evaluated for reactivity to A-375 melanoma cells.  Antibody reactivity was 
measured as fold increase above a non-specific IgG antibody using a cell-based 
ELISA.  Error bars represent 95% CI.  Groups were compared using a one-way 





When antibody responses were assessed in relation to disease stages, it was found 
that antibody reactivity to metastatic melanoma cells diminished as a function of 
disease stage (Figure 4.5).  A significant reduction in antibody response was 
observed in Stage IV patients compared to those diagnosed with Stage II and III 
melanoma (Figure 4.5).  These results support the hypothesis that the anti-tumor 
humoral immune response is present in patient circulation, but it is hindered or 
modulated with advancing disease, quite possibly due to mechanisms of immune 
tolerance induced in these patients by tumor cells.  The reduced reactivity of 
antibodies with disease progression may demonstrate weakened immune 
responses against a set group of antigens on the surface of melanoma cells.  
Weakened humoral responses with disease progression have also been previously 
observed in melanoma by serologic studies (Lewis, Ikonopisov et al. 1969), and 
levels of auto-antibodies to specific antigens in the sera of patients with melanoma 
and other cancers have been shown to be higher than serum auto-antibody titers 
from healthy volunteers or those with benign neoplasms (Shimbo, Tanemura et al. 
2010; Blixt, Bueti et al. 2011).   
The degree by which these tumor-reactive IgG antibodies have undergone 
extensive somatic hypermutation and have high affinity for their corresponding 
TAAs remains unclear in this study.  Following the future identification of antigens 
for some patient-derived tumor-specific antibodies, this could be addressed 
through the measurement of antigen-antibody affinity.  Or prior to antigen 
identification, this could also be assessed through the evaluation of mutations in 
multiple tumor-specific antibodies from a patient compared to germline IgG4, such 
as the analysis performed for clone M80_1F2 (Appendix B), to evaluate if patient-
derived antibodies are clonally related as evidence of somatic hypermutation.  
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Such evaluations could inform on the degree by which these patients could 
generate a potent mature humoral immune response against melanoma cells.  
 
 
Figure 4.5  The reactivity of patient-derived IgG antibodies to melanoma cells in 
relation to disease progression.  Antibody reactivity to A-375 melanoma cells was 
measured from patient B cell cultures derived from patients with Stage II (n=8), Stage 
III (n=6), and Stage IV (n=6) melanoma by the cell-based ELISA.  Fold increase values 
represent absorbance values relative to a negative control antibody (fold increase).  
Error bars represent 95% CI.  A one-way ANOVA was used to compare groups.  ** = 
P<0.01; *** = P<0.001. 
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From this 21 patient cohort, a relationship between antibody response and disease 
stage was observed.  Previous serological studies have shown some evidence that 
serum-resident antibodies are diminished with advancing disease (Lewis, 
Ikonopisov et al. 1969); the findings described herein suggest that there is a 
reduction in the humoral immunity to melanoma with advancing disease.  This 
would imply that there may be either a decreased total frequency in memory B 
cells producing melanoma-reactive antibodies, or a limited capacity of these B cells 
to secrete antibodies once activated, or a combination of both of these factors.  
Since this study examines the circulating memory B cell compartment and not 
serum-resident antibodies, one can exclude the possibility that the loss of tumor-
reactive antibodies from the circulation with advancing disease is due to the direct 
adsorption of antibodies by tumors.  It is possible that the observed reduction of 
antibody responses in patients with advanced disease could be function of the lack 
of CD4+ T cell help.  The presence of CD4+ T cells with specificity to TAAs has been 
described in melanoma and other cancers and furthermore has been described to 
correlate with antibody responses (Disis, Calenoff et al. 1994; Gnjatic, Atanackovic 
et al. 2003; Vence, Paluka et al. 2007).  It could be possible that the lack of sufficent 
CD4+ T cell responses to tumor antigens could result in the ablation of memory B 
cells in the presence of some tumor antigens (Savelyeva, King et al. 2005) leading 
to a reduction of antibody responses such as those observed herein for patients 
with advancing disease.  These results described herein support the premise that 
the anti-tumor humoral immune response is present in patient circulation but 
perhaps hindered or modulated with advancing disease, possibly due to 
mechanisms of immune tolerance. 
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Peripheral blood was only available for one Stage I patient who had a mean 
antibody response of 1.1 fold increase (Table 4.1), which was comparable to those 
results obtained for healthy volunteers (Figure 4.2).  Patients in the very early 
stages of melanoma, such as Stage I, could be speculated to have low antibody 
responses due to localized disease and limited exposure to tumor antigens.  
However, here no conclusions on tumor reactivity of patient B cells in very early 
disease setting could be drawn due to sampling limitations. 
Additional parameters such as treatment, age, sex, and rate of disease progressions 
(in a short term 6 months to 2 year follow up) were explored for this patient 
cohort.  No correlations between antibody response and these parameters were 
found.  Whether or not antibody responses can be used as prognostic factors 
remains unclear.  One patient of interest in this study, M120, was diagnosed with 
Stage II melanoma and remained in remission for 5 years, clear of active disease.  
While this patient had similar overall mean reactivity to melanoma cells compared 
to patients such as M130 and M132 who died in the course of this study, this 
patient was observed to have the second highest maximum antibody response 
from one B cell culture (Table 4.1).  This high antibody response observed in one B 
cell culture could possibly represent the presence of a melanoma-specific clone 
with high reactivity to melanoma cells in this patient.  Also of note was a patient 
(M72) with Stage IV melanoma who is a long term survivor (8 years) with stable 
disease who was found to have the highest percentage of tumor reactive cultures 
(92%) among the patient cohort (Table 4.1).  While no clear prognostic factors of 
antibody responses emerged from this patient cohort, retrospective analysis 
aimed at evaluating prognostic factors may provide further insights into the 
clinical significance of host humoral immune responses to melanoma. 
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Autoantibodies to some tumor antigens have been shown to correlate with lower 
incidence of metastases or relapse, with follow-up of > 10 years in other cancers 
such as lymphoma and breast carcinoma (Ait-Tahar, Damm-Welk et al. 2010; Blixt, 
Bueti et al. 2011).  Additionally, the evaluation of antibodies to TAAs may lead to 
the early detection of some cancers such as lung, colon and breast cancers (Ran, Hu 
et al. 2008; Zhong, Coe et al. 2006; Zhong, Ge et al. 2008).  Thus, a longer term 
monitoring of this patient cohort or an extended study incorporating a larger 
cohort of patients may provide insights into components of the humoral immune 
system that could hold clinical relevance in melanoma, such as diagnosis or 
prognostic factors for patients with high or low antibody responses.  Also the 
degree to which a patient can mount an antibody response may provide insights 
into the selection of therapy, or in the prediction of responses to therapies.  For 
example, it has been reported that treatment with the anti-CTLA-4 antibody, 
Ipilimumab, led to the serological enhancement of antibodies against the cancer 
testis antigen NY-ESO-1 (Yuan, Gnjatic et al. 2008); thus, patients with broad 
antibody responses/repertoires may make good candidates for 
immunotherapeutic strategies such as those at enhancing T cell responses which 
in turn could enhance the humoral immune response against TAAs on cancer cells. 
 
4.2.4 Frequency Estimations of Patient B cells Producing Melanoma-
reactive Antibodies 
The prevalence of antibody cultures containing melanoma-reactive antibodies was 
approximated for a 21 patient cohort by estimating the percentage of melanoma-
reactive cultures.  Melanoma cultures were defined as reactive if the absorbance 
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value of the culture was greater than 75% of the positive control antibody when 
tested in the cell-based ELISA (criteria detailed in Chapter 3, Section 3.4.2).  Using 
these criteria, it was estimated that 28% of the patient B cell cultures, each 
originating from 500 cells, contained memory B cells with reactivity to metastatic 
melanoma cells (Figure 4.6).  A similar frequency of melanoma-reactive antibodies 
was not seen from a cohort of 10 healthy volunteers (Figure 4.6).  These results 
point to the low to moderate numbers of circulating memory B cells in the 
peripheral blood of patients that are capable of producing anti-melanoma 
antibodies, although the presence of such tumor-reactive antibodies in patient B 
cells does not necessarily translate to potent anti-tumor antibody responses in the 
melanoma cutaneous tumor microenvironment.   
 














Figure 4.6  Estimation of the frequency of B cell cultures containing antibodies 
that bind to melanoma cells.  The percentage of positive cultures was estimated for 
healthy volunteers (n=10) and melanoma patients (n=21) using the cell-based ELISA 
using A-375 melanoma cells.  Positive cultures were calculated from the number of 
cultures originating from 500 B cells which had absorbance values above 75% of the 
positive control antibody. 
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Next, the frequency of memory B cells producing antibodies that react with 
melanoma cells was estimated from a Stage II melanoma patient by performing 
LDAs using a similar approach to those previously performed by others (Pinna, 
Corti et al. 2009).   The frequency of B cells with melanoma-reactive antibodies 
was calculated from patients by plating B cells from the same individual at varying 
densities, culturing cells for 18 days, and then calculating the percentage of culture 
supernatants with no reactivity to cells/non-reactive cultures (defined as cultures 
<75% positive control absorbance) using the cell-based ELISA.   Following the 
calculation of the percentage of non-reactive cultures from each density of plated B 
cells (ranging from 125-10,000 B cells) and performing linear regression analysis 
on these results, from the Poisson distribution one can estimate that when 37% of 
the wells have no reactivity to melanoma cells, each well on average had one B cell 
with melanoma-reactive antibodies.  Thus the frequency of melanoma-reactive 
antibody producing B cells was estimated from the density at which 37% of the 
wells have no reactivity to melanoma cells under the assumption that a reactive 
culture represented one B cell clone (see Chapter 2, Section 2.7.5 for further detail 
of the method).  Patients with Stage II melanoma were selected for these analyses 
since they were predicted to have the highest frequency of melanoma-reactive B 
cells (Figure 4.5).  Individuals with Stage II melanoma would thus require the least 
total number of B cells and least amount of patient blood; therefore frequency 
studies were conducted with samples from this cohort.  LDAs provided a tool to 
estimate the frequency of B cells from Stage II patients that were capable of 
producing antibodies reactive to cells of interest, such as melanoma cells or 
normal skin cells such as melanocytes. 
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The frequency of B cells producing antibodies that react to a metastatic melanoma 
cell line (A-375) were estimated for patient M256 (Figure 4.7).  For this patient, 
the frequency of B cells that produce antibodies that react to A-375 cells was 
estimated to be 1 in 1790 B cells.  Reactivity of antibodies from the same 
supernatant was also evaluated against melanocytes but the same frequency of 
reactive antibodies to A-375 cells was not seen (Figure 4.7).  In fact, B cells plated 
at the same densities had almost no reactivity to melanocytes compared to A-375 
cells.  These results suggest that a much lower frequency of antibodies exist in 





Figure 4.7  Estimations of the frequency of B cells producing antibodies that 
bind to metastatic melanoma cells compared to melanocytes from a Stage II 
patient.  The frequency of ex vivo cultured B cells that produced reactive antibodies to 
cells of interest was estimated using limiting dilution assays for one patient (M256).  
The percentage of non-reactive cultures was calculated from the number of B cell 
culture wells in the cell-based ELISA with absorbance values >75% of the positive 
control antibody.  Reactivity to both the A-375 metastatic melanoma cells and 




Next, the frequency of melanoma-reactive antibodies from B cells was compared 
across multiple cell lines originating from metastatic and primary melanoma 
tumors.  Utilizing three metastatic melanoma cell lines (A-2058, A-375 and SK-
MEL-28) and one primary melanoma cell line (WM-115), the estimation of the 
frequency of patient B cells that produce antibodies that react with different tumor 
cells was made for patient M256.  Interestingly, similar frequencies among the 
metastatic melanoma cell lines (A-2058, 1 out of 1,170 B cells; A-375, 1 out of 1790 
B cells; and SK-MEL-28, 1 out of 1,650 B cells) were observed (Figure 4.8).  
However, frequency of reactive B cells to the WM-115 primary melanoma cell line 
could not be estimated based on the density of B cells chosen and would likely be 
less frequent than the rates measured for metastatic melanoma cells for this 
individual (Figure 4.8).  This may be a result of the antibodies being against 
proteins expressed in metastatic disease and not in earlier stages of malignancy.  
Alternatively, the results may be related to a lack of reactivity to the particular 
melanoma cell line and not informative of disease stage. 
Lastly, to evaluate if there was a difference in the frequencies of B cells producing 
melanoma-reactive antibodies between patients, the frequency of B cell cultures 
capable of producing melanoma-reactive antibodies from 2 patients diagnosed 
with Stage II melanoma were compared (M256 and M271, Table 4.1).  In 
comparing the B cells from these two patients, similar frequencies of cells 
producing anti-melanoma antibodies were estimated against the A-375 metastatic 
melanoma cell line (Figure 4.9) for patient M256 (1 in 1,790 B cells) and patient 
M271 (1 in 2,430 B cells) by LDA.  These frequency estimations corresponded to 
previous descriptions of antibody responses, where it was found that patient 
M256 had higher mean antibody reactivity values and a more frequent B cell 
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mediated antibody response to melanoma than B cell cultures from patient M271, 
who was also diagnosed with Stage II disease (Table 4.1 & Figure 4.9). 
 
 
Figure 4.8  Estimations of the frequency of B cells producing melanoma-reactive 
antibodies to three metastatic and one primary melanoma cell line from a Stage II 
patient.  Using LDAs, the frequency of B cells that produced melanoma-reactive 
antibodies in culture was estimated for one patient (M256) against three metastatic 
melanoma cell lines (A-2058, A-375, and SK-MEL-28) and one primary melanoma cell 
line (WM-115).  The percentage of non-reactive cultures was calculated from the 
number of B cell culture wells in the cell-based ELISA with absorbance values >75% of 





Figure 4.9  Frequency of B cells producing melanoma-reactive antibodies from 
two patients with Stage II melanoma.  Using LDAs, the frequency of B cells that 
produced melanoma-reactive antibodies in culture was estimated for two patients 
(M256 and M271) against A-375 metastatic melanoma cells.  The percentage of non-
reactive cultures was calculated from the number of B cell culture wells in the cell-




Considering the array of tumor antigens patients are potentially exposed to and 
the expected variability in humoral immune responses among patients, these 
results support the presence of a moderately frequent anti-melanoma antibody 
compartment in patient peripheral blood memory B cells.  Frequencies were 
estimated to be in the range of 1 in 2000 memory B cells.  By comparison, these 
responses were less frequent than rates described for memory B cell-derived 
antibodies against toxoid, measles virus antigens and Varicella Zoster virus 
antigens, which have been reported to be 1 in 400, 1 in 50, and 1 in 585, 
respectively, for individual donors (Pinna, Corti et al. 2009).  In light of these 
estimations, the frequency of memory B cells with melanoma-reactive antibodies 
is lower than the frequency of reactive antibodies following common vaccinations.  
However, they do represent the presence of long term memory to melanoma in 
patients. 
These studies are the first to report the frequency of tumor-reactive antibody 
secreting memory B cells in patients with cancer.  Knowledge of the frequencies of 
such cells could be important when considering potential therapeutic approaches 
to activate memory B cells.  Since a correlation between serum antibody titers and 
the frequency of memory B cells may not necessarily exist (Leyendeckers, 
Odendahl et al. 1999), the measurement of the frequency of memory B cells 
capable of producing anti-tumor antibodies could guide the selection of patients 
and potency of methods required to active these memory B cells or serve as a 
parameter which would allow the monitoring of patient humoral immune 
responses over time or patient responses to treatments.  The identification and 
selection of patient groups with high frequencies of memory B cells with natural 
antibody responses against melanoma antigens may also allow for the selection of 
-184- 
 
appropriate candidates for immunotherapies aimed at enhancing humoral 
immune responses to cancer such as vaccines.  It is possible that in the future, the 
memory humoral immune response could be evaluated as a biomarker in cancer. 
Thus far, the anti-melanoma IgG antibody response has been characterized from 
peripheral blood memory B cells.  While a humoral immune response to melanoma 
was observed throughout this 21 patient cohort, some degree of dysregulation of 
the humoral immune response to melanoma has also been observed in patients, 
including a reduced CD27+ B cell compartment and less frequent antibody 
responses with increasing tumor burden.   Another potential aspect of 
dysregulated humoral immunity will be examined next, namely the proportion of 
IgG subclasses expressed by B cells in circulation and in tumor lesions, which may 
potentially influence the effectiveness of humoral immunity against tumor cells. 
 
 
4.3  Relative Proportion of the IgG Subclasses Secreted by B cells  
To further explore the humoral immune response to melanoma, the relative 
proportional production of IgG subclasses from memory B cells was investigated in 
patients and compared to healthy volunteers.  Four IgG subclasses have been 
named relative to their abundance in sera: IgG1>IgG2>IgG3>IgG4, with each 
subclass having different affinity to FcγRs on immune cells and distinct effector 
functions (Bruggemann, Williams et al. 1987; Bruhns, Iannascoli et al. 2009).  This 
section will evaluate the relative IgG subclass proportions from B cells isolated 
from patient peripheral blood and tumors in order to study subclass composition 
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in individuals with melanoma.   It is hypothesized here that Th2 cytokines, such as 
IL-4 and IL-10, present in the tumor microenvironment may polarize 
immunoglobulin production favoring the production of IgG subclasses in tumors 
with less potent effector functions, such as antibodies of the IgG4 subclass.  While 
not previously described in melanoma tumors, significant levels of IgG4 positive 
plasma cell infiltration have been very recently described in another cancer, 
extrahepatic cholangiocarcinoma (biliary tract cancer), and this increase in IgG4+ 
cells has been proposed to be mediated by the tumor cell production of IL-10 
(Harada, Shimoda et al. 2012). 
 
4.3.1 Proportional Production of IgG Subclasses from Peripheral Blood B 
cells Isolated from Healthy Volunteers and Patients 
Relative proportions of the IgG subclasses were first evaluated in peripheral blood 
B cells from both patients and healthy volunteers.  Since the composition of IgG 
subclass antibodies secreted by the peripheral memory B cell compartment had 
not been reported, the IgG1-4 subclass composition was determined for healthy 
volunteer peripheral blood B cells following B cell isolation and ex vivo culture 
(described in Chapter 2, Section 2.4.2) and the concentration of IgG1-4 subclasses 
in these cultures was analyzed using an in-house adapted IgG subclass ELISA 
(Chapter 2, Section 2.7.4).  This evaluation was also conducted to investigate any 
potential effects of EBV transformation and TLR9 activation on the proportional 
production of antibodies of different subclasses secreted in ex vivo cultured B cells.  
It should be noted that the ex vivo stimulation techniques were used to culture B 
cells in these examinations because they are particularly key to the survival of B 
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cells isolated from blood and other tissues, including those derived from tumors.  
The IgG subclass composition in healthy volunteer peripheral blood B cells was 
found to be similar to those values reported for IgG subclass composition in sera of 
individual normal donors (Table 4.2).  Thus the addition of EBV and the TLR9 
agonist CpG ODN, used to transformed and activate human B cells, did not appear 
to significantly affect the proportional production of IgG subclasses in peripheral 
blood B cell cultures. 
 
Table 4.2  Proportional Production of IgG Subclasses in Healthy Volunteer 
Serum and Peripheral Blood B cell Cultures 
Source % IgG1  % IgG2 % IgG3 % IgG4 
Serum† 60-70 14-20 4-8 2-6 
Peripheral blood B 
cells†† 
79 ± 8 14 ± 8 4 ± 1  2 ± 1 
†  Values reported from Hamilton et al. 1987   
†† Values represent mean ± one SD and were derived experimentally from healthy 
volunteers (n=4) and tested in triplicate for each individual. 
 
Next, the IgG subclass composition of antibodies secreted from the peripheral 
blood B cells of patients with metastatic melanoma was assessed to evaluate 
whether there was any modulation in IgG subclass proportional expression in 
circulating B cells within the context of cancer.  The IgG subclass composition 
(mean ± SD) in ex vivo metastatic melanoma patient (n=3) peripheral blood B cell 
culture supernatants for IgG1, IgG2, IgG3, and IgG4 was: 69.7.% ± 16.4%, 22.2% ± 
9.3%, 4.2% ±3.8% ,and 4.2% ± 3.3% , respectively (Figure 4.10).  No significant 
statistical difference was found between the IgG subclasses produced by 
peripheral blood B cells from these patients and healthy volunteers when 
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employing a two-sided Student’s t test (Figure 4.10).  The similarity of IgG subclass 
compositions produced from memory B cells between patients and healthy 
volunteers suggests a possible lack of IgG subclass modulation in the peripheral 
blood memory B cell compartment of the patients evaluated, although subtle 




Figure 4.10  Relative proportional production of IgG subclasses from patient and 
healthy volunteer peripheral blood B cells. B cells isolated from healthy volunteers 
(n=4) and Stage III metastatic melanoma patients (n=3) were cultured in the presence 
of irradiated autologous PBMCs, EBV and the TLR9 agonist CpG ODN.  Culture 
supernatants were removed after 10 days and IgG subclass was analyzed by ELISA.  
Each sample condition was tested in triplicate and values represent mean fraction of 




4.3.2 Relative Proportional Production of IgG Subclasses from Tumor-
resident B cells  
Following the culture of tumor-resident B cells from three melanoma tumor 
lesions (described in Chapter 2, Section 2.4.3), the composition of IgG subclasses in 
these cultures was measured by ELISA (See Chapter 2, Section 2.7.4).  An increase 
in the relative proportional production of antibodies of the IgG4 subclass was 
observed in the two skin tumors (M218 and M221), along with a relative decrease 
in the proportional production of IgG1 (Figure 4.11) when compared to IgG 
subclass portions measured from patient peripheral blood (Figure 4.10).  These 
IgG subclass ELISA results from B cells derived from cutaneous tumors from two 
individuals displayed a striking shift in the proportions of antibody subclasses 
secreted by tumor-resident B cells.  Notably, this shift in antibody subclass 
composition has not been described before in the melanoma tumor 
microenvironments and represents a novel finding of this thesis.  Interestingly, 
there has been one report of altered serum IgG4 levels in some melanoma patients, 
with elevated levels of IgG4 in the sera of a portion individuals diagnosed with 
later stage disease (Daveau, Pavie-Fischer et al. 1977).   No similar reports of 
altered IgG4 levels in the sera have been reported for other solid tumors or in the 
microenvironment of the tumor beyond the observation of infiltrating IgG4+ 
plasma cells in extrahepatic cholangiocarcinoma (Harada, Shimoda et al. 2012).  
These novel findings of an increase in IgG4-expressing B cells in cutaneous 
metastases, taken together with the findings of Daveau et al., suggest a potential 
association between IgG4-producing B cells and melanoma, which may have 





Figure 4.11  Relative proportional production of IgG subclasses from B cells 
isolated from metastatic melanoma tumors in the skin and lymph nodes.  Single 
cell suspensions were derived from metastatic melanoma tumors found in the skin 
(n=2) and lymph nodes (n=1) and cultured in the presence of EBV and CpG ODN.  
Culture supernatants were removed after 18 days and IgG subclass concentrations in 
culture supernatants were determined by ELISA.  Patient B cell cultures were pooled 
for each patient and then tested in triplicate with values representing the mean fraction 





Inversely, the decrease in the production of IgG1 antibodies in the cutaneous 
metastases from two individuals also suggests a potential mechanism that may 
modulate the anti-tumor antibody responses in solid tumors.  This would be 
because antibodies of the IgG1 subclass are thought to have the most potent 
effector functions (Bruggemann, Williams et al. 1987), which would be important 
for the host to mount an effective immune response against tumor antigen bearing 
cells.  Indeed, IgG is the primary subclass used for cancer immunotherapy (Weiner, 
Murray et al. 2012).  Thus a reduction in IgG1-producing B cells in the tumor could 
result in a weakened humoral immune response if these antibodies recognized 
tumor cells.  However, the specificity of these IgG1-4 antibodies to melanoma cells 
remains unknown.  Efforts to explore the melanoma cell reactivity of in situ tumor 
resident B cells were attempted, however these were not successful to-date due to 
irregular availability of tumor samples and also due to technical issues relating to 
the sensitivity of IgG subclass reagents.  
In addition to 2 skin metastases, IgG subclass composition was also evaluated for B 
cells residing in a non-sentinel lymph node metastasis.  The percentage (mean ± 
SD) of each IgG subclass produced from B cells isolated from a lymph node 
metastasis was: IgG1=83.2 ± 3.6; IgG2=6.5 ±0.5; IgG3=3.2 ± 1.0; IgG4= 7.0 ± 2.0.  
Interestingly, the IgG subclass composition was different for B cells derived from a 
lymph node metastasis compared to those measured from the two cutaneous 
metastases (Figure 4.11).  This may be because only a small fraction of the total B 
cell population in the lymph metastasis measured for IgG subclass composition 
was comprised of infiltrating B cells which had already undergone class switching.  
Unlike the lymph nodes, B cells are not normally found in skin, and the B cells 
derived from these cutaneous metastases may represent only those B cells 
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infiltrating the tumor.  Additionally, while unexplored, it could be possible that the 
tumor microenvironment, such as the cytokine levels, of this lesion differed from 
the skin lesions, resulting in differential proportional productions of IgG 
subclasses. 
Unfortunately, these results represent a very small sample set due to the lack of 
availability of patient tumors for research purposes, which posed a limitation to 
this work.  To further support these findings, it would be worthwhile to evaluate B 
cells from more cutaneous and lymph node tumors from other individuals.  
Notably, while only two cutaneous tumors were available for study during the 
course of thesis, similar IgG subclass composition between these two patients, 
M218 (IgG1=43.1 ± 1.7; IgG2=2.8 ± 0.5; IgG3=22.3 ± 2.2; IgG4= 31.6 ± 1.5) and 
M221 (IgG1=43.3 ± 2.0; IgG2=5.4 ± 0.0; IgG3=27.2 ± 2.6; IgG4= 23.3 ± 3.9), was 
measured.  These findings support the idea that the skewing of relative IgG 
subclass proportions in the cutaneous metastases is not a one-off finding from rare 
patient, since it was observed in 2 out of the 2 patients evaluated. 
In summary, an increase in the mean relative proportional production of 
antibodies of the IgG4 subclass was found between B cells isolated from metastatic 
patient peripheral blood (4.2%, n=4) and from metastatic cutaneous tumors 
(27.5%, n=2).   While matched samples obtained at the same time from individuals 
were not available for an evaluation between tumors and peripheral blood, levels 
of IgG4 production was still found to be increased in cutaneous tumors compared 
to those values reported to be normal in serum and patient blood from those with 
metastatic disease.  The differences in antibody subclasses in blood versus the 
tumor could possibly be attributed to the increased presence of melanoma cells in 
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cutaneous tumors compared to peripheral blood, resulting in a different cytokine 
environment, which will next be explored.   
 
4.3.3 Th2-associated Cytokines and Polarization of IgG Subclasses in the 
Presence of Melanoma Cells 
To elucidate if melanoma cells contributed to the polarization of IgG subclass 
expression in cutaneous tumors, B cells were co-cultured in the presence or 
absence of metastatic melanoma cells, and IgG subclass composition from each 
condition was then evaluated in these ex vivo co-cultures (experiments preformed 
in collaboration with Dr. Panagiotis Karagiannis, KCL).  Patient B cells along with 
irradiated autologous PBMCs were co-cultured in the presence or absence of A-
375 melanoma cells at a ratio of 1:5:10 for B cells, PBMCs, and melanoma cells, 
respectively.  After 5 days in culture the proportional production of antibody 
subclasses was measured by ELISA along with Th2 cytokines IL-4 and IL-10 which 
were measured using a Luminex multiplex cytokine assay (Millipore).  In these co-
culture experiments, a proportional decrease in IgG1 secretion was seen along 
with an increase in IgG4 secretion upon the addition of metastatic melanoma cells 
together with irradiated PBMCs (Figure 4.12A), which was in concordance with 
the results obtained for IgG subclass composition in skin metastases.  The 
production of total IgG levels in these co-culture experiments were similar (Figure 
4.12).  A polarization of IgG subclass production towards IgG4  was not seen in co-
cultures without melanoma cells, such as those with just B cells and PBMCs, 
suggesting that tumor cells may have provided a key factor that influenced 
subclass expression in these experiments (Figure 4.12A).    
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Further examination of the Th2 cytokine profiles from these co-culture 
experiments revealed increased levels of IL-10 and IL-4 in cultures where 
melanoma cells were included (Figure 4.12C).  This finding holds significance 
because IL-10 is known to be secreted by regulatory cells such as Tregs and 
alternately activated macrophages in the tumor microenvironments, but it is also 
secreted by melanoma cells (Dummer, Bastian et al. 1996; Couper, Blount et al. 
2008; Itakura, Huang et al. 2011).  The secretion of IL-10 by melanoma cells in 
addition to other immune cells such as T cells may result in the concentration of 
IL-10 in the tumor microenvironment, which would favor IgG4 production.  The IL-
10 cytokine has been associated with increased production of IgG4 and decreased 
IgG1 production in culture (Satoguina, Weyand et al. 2005), and it is thought to 
augment IL-4 induced IgG4 class switching by B cells (Jeannin, Lecoanet et al. 
1998).  It is therefore conceivable that elevated levels of the Th2 cytokines, IL-4 
and IL-10, may modulate antibody subclass production in B cells residing in 
cutaneous tumors, potentially favoring an increased production of IgG4 in the 




Figure 4.12  Co-culture assays evaluating IgG subclasses and cytokine 
composition in the presence of melanoma cells.  (A) The fraction of each IgG 
subclass in patient peripheral blood B cell cultures with and without PBMC and 
melanoma cells was evaluated by ELISA.  (B) Comparison of the total amount of IgG 
secreted in cultures.  Values represent mean ± SD of 3 independent experiments 
preformed in triplicates. (C) Concentrations of selected Th2 cytokines, IL-10 and IL-4, 
secreted in cultures measured using Luminex multiplex cytokine assays (Millipore).  
Box plots represent minimum, maximum, and mean values.  Results of two assay 
conditions were analyzed using the Mann Whitney U test (IL-4: * P<0.01; IL-10: ** 
P<0.01, n=9 replicates per co-culture condition).   Experiments were performed in 
collaboration with Dr. Panagiotis Karagiannis, KCL. 
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Elevated levels of IgG4 in the tumor microenvironment may present a mechanism 
by which the tumor and other IL-10 producing immune cells can polarize the 
humoral response and reduce the potency of antibody functions.  First, the 
polarization towards IgG4 antibody production, can result in elevated levels of an 
antibody class thought to have the weakest effector functions, manifested by  
inhibition of complement activation (van der Zee, van Swieten et al. 1986), low 
affinity to key Fc receptors involved in cell mediated cytotoxicity (Bruhns, 
Iannascoli et al. 2009) and inability to crosslink identical antigens due to Fab arm 
exchange properties (van der Neut Kolfschoten, Schuurman et al. 2007).  If these 
IgG4 antibodies are melanoma-reactive, it is possible they may also compete with 
melanoma-reactive antibodies of the IgG1 class, and once bound to tumor cells 
they may contribute to a less potent anti-tumor response compared to IgG1.  
Conversely, these IgG4 antibodies could occupy FcγRs on immune cells present in 
the tumor preventing the engagement of these cells by other antibodies of more 
potent antibody subclasses to mediate cytotoxic effects against the tumor. 
 Taken together, the functional properties of IgG4 could contribute to weakened 
humoral immune response in the cutaneous tumor microenvironment and may 
represent a mechanism of tumor escape from the host humoral immune response.  
These findings have been subsequently explored in mouse models of melanoma 
which were employed to compare the efficacy of antibodies of the IgG1 and IgG4 
classes targeting the HMW-MAA antigen, and the impact of the presence of IgG4 
antibodies on otherwise potent IgG1-mediated anti-tumor responses in vitro and 




4.4   Conclusions 
A prevalent memory B cell antibody response to melanoma was observed in this 
study, despite the reduction in the CD27+ memory B cell compartment in patients.  
These observations provide evidence that long-term humoral memory responses 
to melanoma are present in patients, even in those with non-metastatic disease.  
These early host humoral immune responses to cancer could quite possibly have 
significant anti-tumor effects in patients; indeed lymphocyte infiltration into the 
primary melanoma tumors has been associated with better prognosis (Clark, Elder 
et al. 1989; Clemente, Mihm et al. 1996).  Patients in early stages of malignancy 
were found to have antibody responses to melanoma from memory B cells at a 
frequency of approximately 1 in 2,000 B cells.  The finding suggests that the 
memory B cell compartment is mounted in early stages of disease, but the later 
reduction of anti-melanoma antibody responses detected from this compartment 
could suggest a weakening of the circulating memory B cell anti-tumor response to 
melanoma with progressing malignancy.  This work complements previous work 
examining temporal antibody responses in the serum, by contributing to the 
characterization of antibody responses to melanoma and providing assessments of 
the reactivity and frequency of long term memory responses to melanoma.   
The study of humoral immune responses in the local tumor environments led to 
the novel finding of elevated levels of IgG4 in the cutaneous metastatic lesions 
presented in this thesis.  This finding may represent a new mechanism by which 
tumors can evade anti-tumor memory B cell responses.  By dissecting antibody 
subclass composition in the tumor, the possible modulation of humoral immune 
responses in the cutaneous Th2 microenvironment has been hypothesized.  It 
could be speculated that the presence of elevated levels of IgG4, favored by the 
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local expression of Th2 cytokines such as IL-4 and IL-10, may result in a weakened 
anti-tumor humoral immune response by exerting less potent effector functions 
than the other IgG subclasses or by directly competing with other tumoricidal 
antibodies in binding to melanoma cells or FcγRs, thereby blocking the effector 
functions of these antibodies.  Such potential immunomodulatory mechanisms of 
action of IgG4 antibodies are presently being explored by engineering IgG1 and 
IgG4 antibodies against a melanoma antigen and performing in vitro assays 
evaluating the ability of such antibodies to mediate ADCC and ADCP in different 
proportions for each subclass, and by evaluating the efficacy of such antibodies in 
animal models of melanoma using engrafted human effector cells. 
In summary, while a long term humoral memory response to melanoma has been 
described here, the effectiveness and anti-tumor properties of this response may 
be impaired with disease progression along with changes of IgG subclass 




Chapter 5: Novel Antibodies Targeting Melanoma Cells7 
  
                                                         




5.1   Introduction and Aims 
The discovery of monoclonal antibodies targeting TAAs has generated 
considerable interest over the last 30 years.  Antibodies against TAAs expressed in 
solid tumors, such Her2/neu and EGFR, have shown considerable clinical and 
commercial success in the treatment of breast and colorectal cancers (Campoli, 
Ferris et al. 2010).  The mechanisms of action of such antibodies were principally 
developed to be Fab-mediated resulting in the inhibition of tumor antigen 
functions.  However, the important contributions of Fc-mediated immunological 
mechanisms of actions of these antibodies in patients are emerging, primarily 
through the observation of correlations between patient FcγR polymorphisms and 
clinical responses (Hudis 2007; Strome, Sausville et al. 2007; Musolino, Naldi et al. 
2008).  The contribution of the Fc portion of therapeutic antibodies towards 
immune-mediated tumor cell death has also been clearly demonstrated in mouse 
tumor xenograft models where administration of a fully functional antibody, with a 
Fab region specific to Her2/neu, was shown to result in a significantly higher 
reduction in tumor growth compared to a Fc mutated antibody with the same 
antigen specificity but with impaired FcγR binding (Clynes, Towers et al. 2000).  
Thus, it has become increasingly clear that the Fc-mediated functions of antibodies 
can constitute key components of their efficacy (Clynes, Takechi et al. 1998; 
Clynes, Towers et al. 2000; Nimmerjahn and Ravetch 2008).  These findings 
illustrate the important potential of monoclonal antibodies with specificity to 
overexpressed antigens on the surface of tumor cells to mediate cellular 




Antibodies directed at TAAs, even those that do not directly inhibit antigen 
function, may additionally provide important vehicles for the specific delivery of 
other cytotoxic molecules, such as chemotherapeutic agents, radionuclides, and 
enzymes to tumor cells.  Furthermore, such antibodies may serve as important 
diagnostic tools for disease staging and imaging (Chester, Pedley et al. 2004; 
Mayer, Francis et al. 2006; Lewis Phillips 2008; Scott, Wolchok et al. 2012).  Thus, 
the discovery of monoclonal antibodies against over expressed TAAs has 
important and widespread clinical utility. 
The results presented in Chapter 4 highlight the presence of an anti-melanoma 
antibody compartment in patient memory B cells, supporting the claim that tumor 
cells are recognized by the humoral immune system in individuals with melanoma.  
While the ability of such cells to mount a significant anti-tumor antibody response 
in the host is unclear, the striking presence of melanoma-reactive mature B cells in 
patients and the antibodies these B cells produce may represent a source of 
reagents whose clinical utility, including evaluations of their therapeutic potential, 
merits further attention.  If identified, characterized, expressed in recombinant 
form, and administered in sufficient quantities, these patient-derived antibodies 
may be assessed for their cytotoxic activity against cancer cells as passive 
immunotherapies.  This could be achieved by examining possible mechanisms of 
action of these antibodies to inhibit antigen function along with evaluations of 
their potency in activating immune effector cells to mount an anti-tumor response.  
Therefore, functional assessments of the cytotoxic capacity against tumors of such 
patient-derived melanoma-specific antibodies warrant further investigation to 




Marketed antibodies for cancer are all of the IgG class, the most dominant antibody 
class in plasma and non-mucosal tissues.  Antibodies of the IgG class possess long 
half-lives in blood regulated through the neonatal Fc receptor (Reichert and Valge-
Archer 2007; Roopenian and Akilesh 2007).   Additionally, antibodies of the IgG 
class, and especially those of the IgG1 subclass, are widely thought to mediate Fc 
effector functions through the engagement of cellular and non-cellular components 
of the innate immune system such as the binding to FcγRs on immune cells 
including neutrophils, macrophages and NK cells (Bruggemann, Williams et al. 
1987).  Many studies of IgG-mediated ADCC have centered around the IgG Fc 
binding to FcγRIIIA on NK cells because once these cells become activated 
following Fc-FcR binding, it is thought they can mediate potent cytotoxic effects 
against tumor cells.  However, NK cells have been found to poorly infiltrate solid 
tumors (Albertsson, Basse et al. 2003; Bowles, Wang et al. 2006), and in melanoma 
NK cells have been reported to be at densities significantly lower than those 
required in vitro to mediate efficient killing of melanoma cells (Balsamo, Vermi et 
al. 2012).  Thus, antibodies of the IgG class could potentially have less potent Fc-
mediated anti-tumor responses in solid tumors compared to hematological 
malignancies due to the distribution of immune cells.   
Much recent effort has centered on engineering therapeutic antibodies to improve 
Fc-mediated effector functions.  These strategies have included increasing the 
affinities of IgG antibodies to FcγRs (Kubota, Niwa et al. 2009) and engineering 
different antibody glycoforms (Jefferis 2012).  And a few have begun to explore the 
therapeutic use of other immunoglobulin classes, mainly IgE and IgA, for 
immunotherapy (Dechant, Beyer et al. 2007; Desjarlais, Lazar et al. 2007; 
Karagiannis, Singer et al. 2009).  Exploitation of antibody classes such as IgE for 
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cancer immunotherapy may allow for the engagement of alternate FcRs, such as 
FcεRI and CD23 (FcεRI), expressed on different immune cell populations, and the 
activation of these receptors in the tumor could potentially result in a potent Fc-
mediated anti-tumor response.  Thus, alternate classes of antibodies such as IgE 
targeting TAAs may have potent anti-tumor Fc-mediated effects in solid tumors 
and this hypothesis, proposed by Karagiannis and others, has been supported in 
both in vitro and in vivo models of ovarian and breast cancers (Gould, Mackay et al. 
1999; Karagiannis, Wang et al. 2003; Karagiannis, Singer et al. 2009; Daniels, 
Leuchter et al. 2012). 
An antibody of the IgE class targeting a melanoma antigen may represent a novel 
therapeutic modality for the treatment of melanoma.  Numerous studies suggest 
that antibodies of the IgE class may be of interest since they have the potential to 
elicit Th2 immune responses in solid tumors and their use may confer some 
advantages over those displayed by antibodies of the IgG class.  Such attributes 
include the lack of inhibitory receptors, higher affinity to their cognate Fc 
receptors, and the ability to engage many tissue resident immune cells expressing 
FcεRs which may be associated with tumors (Karagiannis, Josephs et al. 2012).  
Recent effort has focused on developing antibodies of the IgE class for the 
treatment of solid tumors in ovarian and breast cancer (Karagiannis, Josephs et al. 
2012), but to-date this antibody class has not been evaluated for the treatment of  
melanoma.   Thus, the discovery of novel anti-melanoma antibodies may also be 
achieved by developing antibodies of the IgE class targeting a known tumor 
antigen. 
The HMW-MAA is a cell surface proteoglycan highly expressed in melanoma with 
low expression in normal cells, attributes that make it an attractive target for 
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immunotherapy (Campoli, Chang et al. 2004).  HMW-MAA has been implicated in 
the spreading, invasion and migration of melanoma cells and murine IgG 
antibodies, such as the 225.28S clone, targeting this antigen have been shown to 
restrict tumor growth in mouse models of melanoma (Chang, Campoli et al. 2004; 
Hafner, Breiteneder et al. 2005).  In the clinical setting, passive immunotherapeutic 
approaches employing murine anti-idiotypic antibodies to generate host antibody 
responses to HMW-MAA have been met with some response in patients 
(Mittelman, Chen et al. 1990; Mittelman, Chen et al. 1992).  Immunotherapeutic 
strategies targeting the HMW-MAA have focused on the use of these anti-idiotype 
murine antibodies (Mittelman, Chen et al. 1990; Mittelman, Chen et al. 1992), 
antigenic mimitopes (Wagner, Hafner et al. 2005; Luo, Ko et al. 2006), full length 
murine antibodies (Hafner, Breiteneder et al. 2005), and human scFv antibody 
(Wang, Katayama et al. 2011) recognizing this antigen.   The clinical utility of 
recombinant antibodies with a human Fc region such as chimeric/humanized 
monoclonal antibodies targeting HMW-MAA has not yet been demonstrated in 
melanoma.  It is expected that these antibodies may have direct effects on the 
function of this antigen, but the efficacy of such antibodies in the clinic may also 
originate from immunological mechanisms of action, which could include their 
ability to engage immune cells to specifically target melanoma cells.  In light of the 
importance of Fc-mediated mechanisms of action in therapeutic anti-tumor 
responses and the emerging evidence that antibodies of different classes may 
activate immune responses against cancer, the mechanisms of action of IgG and 
IgE antibodies recognizing HMW-MAA merit further dissection in the appraisal of 
these molecules as passive immunotherapies for the treatment of melanoma. 
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The aim of this chapter is to evaluate novel monoclonal antibodies recognizing 
melanoma cell surface antigens and specifically to: 
1. Identify and characterize a melanoma-reactive monoclonal antibody derived 
from a patient. 
2. Evaluate the in vitro function of  human Fc bearing IgG and IgE antibodies 
targeting the HMW-MAA to mediate both Fab and Fc effector mechanisms. 
 
 
5.2  Patient-derived Monoclonal Antibodies 
The successful establishment of antibody-secreting B cell cultures from individuals 
with melanoma and development of screening methods (Chapter 3) in conjunction 
with the findings of a prevalent antibody response to melanoma cells among 
patients with melanoma (Chapter 4) supported the feasibility of the approach 
described herein to identify melanoma-specific antibodies from patients.   
 
5.2.1 Strategies for Discovering Anti-melanoma Antibodies from Clinical 
Specimens 
A strategy leading to the possible discovery of melanoma-specific antibodies from 
peripheral blood B cells (Figure 5.1) was devised based on the findings presented 
Chapter 3.  Following the isolation of B cells, ex vivo antibody-secreting B cell 
cultures were established from individuals and cell culture supernatants were 
evaluated for reactivity to melanoma cells using the cell based-ELISA (Chapter 2, 
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Section 2.7.5).   The reactivity of antibodies in these cultures to melanoma cells 
was measured relative to the reactivity of a non-specific human IgG antibody (fold 
increase) which allowed for the comparison of the reactivity of cultures across 
multiple cell lines (detailed in Chapter 2, Section 2.8.1).  Depending on the amount 
of available supernatant for a given culture, the reactivity of antibodies in cultures 
was evaluated across multiple melanoma cell lines and primary human 
melanocytes (Figure 5.2).  Cultures with high reactivity to one or more melanoma 
cell lines relative to melanocytes would then be selected for expansion.  A limited 
number of cultures were selected for further subcloning and the derivation of 
monoclonal cultures.  For example, following the screening of B cell cultures 
(n=60) derived from one patient (M120) against three melanoma cells lines and 
melanocytes, culture wells such as B6, F10 and G11 would be selected based on 
reactivity to melanoma cell lines relative to melanocytes and would be further 
maintained in culture for subcloning (Figure 5.2).  Cultures which displayed 
similar reactivity among melanoma cells and melanocytes, such as culture G9 




Figure 5.1  Schematic of the process for discovering melanoma-reactive 
antibodies from patients.  Diagram highlighting the process devised to identify novel 
monoclonal antibodies from patients’ B cells for the production of recombinant 




Figure 5.2  Example of cell-based ELISA screening results for B cell cultures 
derived from one patient showing reactivity against human melanoma cells and 
melanocytes.  (A) Supernatant from a 96 well plate containing 60 B cell culture wells 
was screened against melanocytes and three melanoma cell lines using the cell-based 
ELISA.  (B) Selected clones from one individual (from A) illustrate the different degrees 
of binding of supernatants to melanoma cells and melanocytes.  Fold change values 
represent absorbance values of each well divided by the absorbance value of a non-





B cell cultures from multiple patients were selected based on their high reactivity 
to melanoma cells relative to their reactivity to normal cells such as melanocytes.  
Promising cultures from multiple individuals were evaluated for reactivity using 
the cell-based ELISA against multiple cell lines.  For example, the reactivity of 
antibody cultures from multiple patients was assessed against four melanoma cell 
lines and melanocytes, and these results illustrate the variation of the reactivity of 
cultures to different melanoma cell lines relative to melanocytes (Figure 5.3).  Of 
these antibody-producing cultures, some displayed less overall reactivity across 
melanoma cell lines than others, such as culture M130_1E5 where reactivity was 
only higher for one (A-375) of the four melanoma cell lines tested relative to 
melanocytes (Figure 5.3).  Other cultures, such as M133_1D4, displayed high 
reactivity to three out of the four melanoma cell lines evaluated relative to 
melanocytes (Figure 5.3), and represented the most promising antibody 
candidates.  Antibodies reactive to multiple cell lines, with each cell line derived 
from a separate individual, signified promising candidates, since these antibodies 
bound to antigens expressed across individuals rather than just autologous cells.  
Antibodies with reactivity to multiple melanoma cell lines could potentially 
represent reactivity against novel antigens highly expressed across individuals 
with melanoma, thus making the particular clone an attractive candidate to be 
tested as a possible immunotherapeutic with potentially widespread future use. 
Antibodies with lower reactivity to melanoma cells, such as those that were found 
to bind to only one of the melanoma cell lines examined, could also represent 
promising novel monoclonal antibodies with therapeutic potential.  While this low 
reactivity could reflect restricted expression of the antigen in the population, these 
antibodies may still hold some promise in the treatment of aggressive sub-types of 
-209- 
 
cancer for which there are no or limited available treatments.  An example of such 
an antibody is Trastuzumab, which is effective in prolonging survival in the context 
of breast cancer.  Trastuzumab, while targeting Her2/neu, an antigen expressed 
only in a relatively small proportion (20-30%) of breast cancers, still constitutes 
an effective therapeutic option for the subset of patients expressing the Her2/neu 
antigen (Slamon, Godolphin et al. 1989; Vogel, Cobleigh et al. 2002).  Thus, patient-



































































































































































































































































































































































































































After selecting promising antibody cultures using the criteria above, monoclonal B 
cell cultures were then derived by serial dilution (detailed in Chapter 2, Section 
2.8.2).  Antibodies from these monoclonal cultures were then further evaluated for 
reactivity to multiple melanoma cell lines and melanocytes either by the cell-based 
ELISA or by flow cytometric analyses.  Further evaluations of reactivity were 
conducted: (1) to confirm the reactivity of the clone after serial dilution and (2) to 
expand on initial evaluations of specificity.  One monoclonal antibody, M111_2G3, 
was selected from a panel of antibodies (Figure 5.3) and was then evaluated for 
specificity to additional melanoma cells along with other normal cells, such as 
dermal fibroblasts, using flow cytometry.  This M111_2G3 antibody clone showed 
reactivity to two melanoma metastatic cell lines, A-375 and SK-MEL-28, but not to 
primary human skin cells, such as dermal fibroblasts or melanocytes derived from 
healthy volunteers (Figure 5.4).  These flow cytometric analyses of the monoclonal 
culture showed concordance with the initial screening results obtained from the 
originating cultures utilizing the cell-based ELISA, where reactivity was also 
measured against the A-375 and SK-MEL-28 cell lines but not melanocytes (Figure 
5.3).  In summary, these results demonstrate the presence of an antibody clone 
with reactivity to melanoma cells and not melanocytes following the creation of 














































































































































































































































































































Insufficient amounts of antibodies posed a major limitation of this method for 
many of the clones derived.  After 2 to 3 months in culture, B cell division ceased 
and frequent contaminations in the laboratory proved particularly challenging in 
establishing monoclonal cultures.  This meant that some of the most promising 
clones, such as M132_2D4 and M133_1D4 (Figure 5.4), were lost due to 
contamination following the establishment of monoclonal cultures.  This limitation 
was overcome in some cases by extracting ribonucleic acid (RNA) from cells prior 
to their contamination or decrease in proliferation.  RNA from these B cells could 
be sequenced to obtain variable region sequences and then used to engineer 
recombinant forms of the antibodies.  An alternative way to circumvent these 
limitations of cell proliferation and contamination in the future would be to 
identify single B cells with reactivity to melanoma cells by tetramers or other 
fluorescent detection technologies in order to select single tumor-reactive B cells 
and produce antibodies of interest in recombinant form (Tiller, Meffre et al. 2008).  
Such solutions may yield additional melanoma-reactive monoclonal antibodies but 
would require the time consuming work of identifying antibody reactivity from a 
single B cell, cloning, expression, and production of ample amounts of antibodies 
for further characterization. 
In summary, a process for discovering novel antibodies by harnessing the natural 
antibody response to cancer has been described.  This method yielded the 
monoclonal antibody M111_2G3 which demonstrated specificity to melanoma cells 
and not melanocytes.  Next, the potential functional properties of this anti-tumor 




5.2.2 Characterization of Patient-derived Monoclonal Antibodies  
While the presence of B cells producing tumor-reactive antibodies has been 
described in the serum and tumor lesions from patients (Kirkwood and Robinson 
1990; Punt, Barbuto et al. 1994), the capacity of such antibodies to elicit an anti-
tumor response has not yet been characterized.  Using a melanoma-specific 
monoclonal antibody derived from a patient diagnosed with Stage III melanoma, 
M111_2G3, the ability of this patient-derived antibody to mediate cytotoxicity was 
evaluated in vitro using A-375 melanoma cells and human monocytic effector cells.  
The addition of immune effector cells in this assay allowed for assessments of 
ADCC using the limited amount of antibody available.  These evaluations were 
performed alongside another antibody clone, M111_2D10.  Clone M111_2D_10 was 
a monoclonal antibody produced from the same individual and manner as 
M111_2G3, but was found to have no significant reactivity to A-375 cells compared 
to melanocytes (Figure 5.5).  This antibody therefore served as a negative control 
for the functional assays that followed, which evaluated the cytotoxic potential of 




Figure 5.5  Reactivity of two monoclonal antibodies derived from patient M111 to 
melanocytes and melanoma cells.  Two monoclonal antibodies, M111_2G3 and 
M111_2D10, were evaluated for reactivity to A-375 melanoma using the cell-based 
ELISA.  Fold increase values represent absorbance values above the mean 
absorbance of the non-specific IgG control antibody.  These antibodies were evaluated 
for their potential cytotoxicity in vitro against A-375 melanoma cells. 
 
The ability of patient-derived antibodies to mediate cytotoxicity against melanoma 
cells was assessed using a real-time live-dead cell cytotoxicity assay (described in 
detail in Chapter 2, Section 2.10.3).  These assays required low amounts of 
antibodies and were therefore selected to perform functional characterizations 
using limited amount of antibody available.  In these experiments, U-937 human 
monocytic cells were used as effector cells since they are known to express FcγRs 
(Anderson and Abraham 1980) and have been shown by others to have effector 
function that correlates with in vivo efficacy against tumors using primary human 




The potential of the patient-derived melanoma-specific antibody M111_2G3 to 
mediate cytotoxic activity against A-375 tumor cells was then assessed and 
compared to the activities of the non-specific control monoclonal antibody 
M111_2D10.  Employing the live-dead cell cytotoxicity imaging assays, antibody 
mediated cellular cytotoxicity could be visualized for live melanoma cells (green) 
incubated with monocytic cells (blue) when combined with the patient derived 
melanoma-specific monoclonal antibody (M111_2G3) over a period of two hours 
(Figure 5.6, top panel).  In these assays, the loss of viability of live tumor cells 
incubated with effector cells and the antibody clone M111_2G3 could be seen by 
the loss of green fluorescence in tumor cells while the loss of membrane integrity 
was confirmed by the incorporation of red dye (ethidium homodimer-1) into the 
DNA of dead cells over a two hour period at 37˚C.  Increased amounts of tumor cell 
death were evident after 2 hours of incubation with melanoma specific antibody 
M111_2G3 (Figure 5.6, top panel), compared to the non-melanoma specific 
antibody control M111_2D10 (Figure 5.6, bottom panel).  Monocyte cell viability 
was maintained throughout the assay and was similar between cultures treated 
with either the M111_2G3 antibody or the M111_2D10 non-specific control (Figure 























































































































































































































































































































































































































































































































































































































































The cytotoxic effects of antibodies against melanoma cells were quantitated by 
measuring the fluorescence intensity of melanoma cells in these assays.  Live 
melanoma cell fluorescence intensity was reduced to 18% of the original intensity 
values when cells were incubated with the tumor specific antibody M111_2G3, 
whereas cells incubated with the non-specific control M111_2D10 antibody 
demonstrated reduced fluorescence to only 64% of the original intensity values 
relative to the start of the assay (Figure 5.7, top).  Loss of fluorescence observed in 
the control sample may be attributed to a combination of background loss of 
viability in culture conditions, non-specific cytotoxicity triggered by human 
effector cells armed with Fc receptor-bound antibodies, and also photo bleaching 
effects brought about from frequent capturing of images during assay setup.   
When tumor cell viability was assessed by measuring the incorporation of 
ethidium homodimer-1 by tumor cells for each assay condition, a statistically 
significant decrease (P<0.001) in tumor cell viability was observed when 
melanoma cells and effector cells were incubated with a patient-derived 
melanoma-specific antibody (18%, SD=9.5%) compared to the non-specific 
antibody M111_2D10 (95%, SD=5.8%) (Figure 5.7).  The loss of fluorescence of 
live melanoma cells in combination with the uptake of ethidium homodimer-1 
demonstrate that an antibody derived from a patient in the presence of immune 







Figure 5.7  Quantitative analysis of antibody-mediated cellular cytotoxicity 
against tumor cells by patient-derived monoclonal antibodies.  Antibody-mediated 
cellular cytotoxicity of a patient-derived melanoma-reactive antibody, Clone 
M111_2G3, was compared to an antibody clone with no reactivity to the same 
melanoma cells, Clone M111_2D10, when cultured in the presence of tumor cells and 
monocytic effector cells.  A-375 cells were stained with calcium AM (green) and cell 
death was measured by loss of green fluorescence (top) and the incorporation of 
ethidium homodimer-1 (red) into tumor cells (bottom).  Mean and SD (bottom figure) 
were calculated for four separate regions within the frame, while total green 
fluorescence was measured for the entire frame.  *** P<0.001.  P values were 




To further evaluate if melanoma cell death was potentially mediated by the 
engagement and activation of FcγRs on immune effector cells, the movement of 
these effector cells in relation to melanoma cells was tracked in these experiments.  
For cells incubated with the melanoma-specific antibody M111_2G3, there was a 
significant (P=0.002) reduction in the movement of effector cells once in contact 
with melanoma cells (13 µm, 95% CI=10 to 17 µm) compared to effector cells not 
in contact with melanoma cells (25 µm, 95% CI= 18 to 31 µm) (Figure 5.8, left).  
Further analysis showed that for melanoma cells incubated with the non-specific 
M111_2D10 clone, no difference was seen in the movement of effector cells in 
contact with tumor cells compared to effector cells not in contact with tumor cells 
(Figure 5.8, right).  Thus a significant reduction in the movement of effector cells 
was only seen once effector cells were in contact with tumor-specific antibody 
coated tumor cells.  These observations provide further evidence that antibody-
mediated engagement of effector cells may be necessary for cell death, suggesting 
that ADCC may be a mechanism by which this patient-derived antibody could 












Figure 5.8  Movement of effector cells incubated with patient-derived melanoma 
reactive and non-reactive antibodies and melanoma tumor cells.  (A) Movement of 
monocytic effector cells, U-937, was tracked and measured over two hours and 
compared between cells in contact with tumor cells and cells not in contact with tumor 
cells.  This was done for the M111_2G3 melanoma-reactive clone (left) and non-
reactive clone M111_2D10 (right).  (B) Images of U-937 cell movement in tumor cell 
cultures treated with M111_2G3, tracked for cells in contact (left) and cells not in 
contact with tumor cells (right). Movement is indicated by tracking lines (red to yellow) 
from the original position of U-937 cells at t = 0 to t = 2 hours (magnification 20x, Scale 
bar: 50 µm).  *** P<0.001.  P values were calculated using the two-sided Students t 
test.  Data courtesy of Dr. Panagiotis Karagiannis, KCL. 
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Further functional assessments of this M111_2G3 antibody clone, along with 
identification of the antigen it recognizes, were limited by the amount of 
antibodies produced from B cell cultures.  To overcome this limitation, the 
extraction of RNA from these cells was attempted in order to obtain variable 
region sequences to be used to engineer a recombinant form of this antibody clone.  
Unfortunately, this was not achieved for clone M111_2G3 because RNA quality was 
poor from the very small number of cells (103) remaining in the culture which 
were subsequently frozen and possibly suffered a loss of cell integrity and viability 
through the freezing process.  However, this limitation was later overcome for 
other B cell clones by directly placing live cells in RNAlater® Tissue Collection: 
RNA Stabilization Solution (Invitrogen).  Although it was not possible to obtain the 
sequence of clone M111_2G3 variable regions within the timeframe of this project, 
the sequence of another clone, M80_1F2, derived using the same methodology 
from another patient (M80, Table 4.1) and displaying reactivity to melanoma cells, 
was obtained (Figure 5.9).  These heavy and light chain variable regions could then 
be inserted into vectors containing the sequences for human IgG1 Fc regions.  
Transfection of competent cells with these vectors would then result in the 
recombinant production of antibodies in sufficient quantities to perform broader 
characterization including further functional assays such as those evaluating Fab 




Figure 5.9  Variable region nucleic acid sequences and nested PCR for a patient-
derived melanoma-reactive antibody clone.  (A) Nested PCR amplification of heavy 
and light chain variable regions for antibody clone M80_1F2 derived from a patient.  
VH= variable region heavy chain; VK= variable region kappa chain; VL= variable region 
lambda chain.  1 kilobase DNA ladder was used (New England Biolabs) on 1.5% 
agarose gel stained with ethidium bromide.  (B) Heavy chain variable region sequence 
for M80_1F2.  (C) Kappa light chain variable region sequence for M80_1F2.  Data 
courtesy of Mr. Tihomir Dodev, KCL. 
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In summary, a translational approach to discovering novel antibodies from 
melanoma patient memory B cells has been described.  This approach yielded a 
melanoma-specific monoclonal antibody, M111_2G3, which has shown some 
potential in vitro to mediate tumor cell killing.   While further characterization of 
this antibody was limited by the amount of antibody available, limitations to this 
approach could be overcome in the future by RNA extraction from B cells and 
recombinant expression of such antibodies, as demonstrated here for a different 
patient-derived clone.  Thus, harnessing the cancer-specific antibody repertoire of 
melanoma patients offers an alternate strategy for the discovery of novel 
monoclonal antibodies with potential cytotoxic activity.  Next, further assessments 
of antibody function will be explored using engineered antibodies against a known 
melanoma antigen. Such assessments could also prove useful in the future to 
elucidate possible mechanisms of action of new patient-derived antibody clones.  
 
 
5.3  Evaluations of IgG1 and IgE Antibodies Targeting a Melanoma 
Antigen 
The HMW-MAA is a large molecule comprised of a 450 kDa chondroitin sulfate 
proteoglycan and a 250 kDa core glycoprotein, and several antibodies have been 
generated against different regions of this molecule (Ziai, Imberti et al. 1987).  The 
225.28S antibody clone recognizes an epitope of HMW-MAA residing on the 
plasma membrane (Wilson, Imai et al. 1981) and from linear peptide mapping 
studies it is has been suggested that the epitope resides in the 250 kDa core 
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glycoprotein in a region free of internal/flanking glycosylation sites and low 
proteolytic sites (Mittelman, Tiwari et al. 2004).  Since heavy glycosylation or 
proteolysis could prevent antibody recognition of its epitope, protein regions 
lacking these features make ideal antibody targets.  The 225.28S antibody was 
selected for further study because of its epitope location on the cell surface along 
with favorable preclinical efficacy data from the murine version of the antibody in 
animal models (Ghose, Ferrone et al. 1991; Hafner, Breiteneder et al. 2005).  The 
antibody clone was also selected based on promising clinical results from a study 
involving 19 patients using active immunotherapy targeting its epitope, where one 
patient was observed to have a complete remission and 3 patients had partial 
responses (Mittelman, Chen et al. 1990).   
More specifically, the 225.28S anti-HMW-MAA antibody clone (referred to as 
HMW-MAA antibodies hereafter) poses an attractive immunotherapeutic option 
for the treatment of melanoma since it has previously demonstrated some 
preclinical promise.  Preclinical studies with murine HMW-MAA antibodies have 
highlighted the potential of these antibodies to inhibit the growth and migration of 
melanoma cells both in vitro and in a SCID mouse xenotransplantation model of 
melanoma (Hafner, Breiteneder et al. 2005).  Because these studies employed a 
murine antibody, any potential Fc-mediated immunological mechanisms of action 
in either in vitro or in vivo models could not be evaluated in the context of the 
capacity of such antibodies to engage human immune cells.  Previously, the murine 
HMW-MAA antibody had been reported to be a poor mediator of CDC and ADCC in 
mice (Imai, Pellegrino et al. 1982); however, these results, dating back 30 years, 
may not necessarily correlate to human Fc-mediated effector function.  Further 
study of the ability of these antibodies to engage human immune effector cells is 
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warranted through the use of sophisticated methodologies available at the present 
time, such as those used to evaluate ADCC and ADCP (Bracher, Gould et al. 2007), 
to possibly provide insights into the Fc effector functions of these molecules.  
Clinical development of HMW-MAA antibodies has been hindered by their lack of 
human forms, and the generation of HMW-MAA antibodies with human Fc regions 
for further preclinical evaluation may provide insights into the potential clinical 
utility of this antibody clone for passive immunotherapy.   
 
5.3.1 Characterization of Engineered HMW-MAA Antibodies of the IgG1 
and IgE Class 
HMW-MAA antibodies were designed with human Fc regions of the IgG1 and IgE 
classes using previously published variable region sequences (Neri, Natali et al. 
1996).  Using these amino acid sequences, cDNA encoding for the variable regions 
of the antibody was synthesized (Gene Art AG) and cloned into a vector containing 
the cDNA encoding for either the epsilon heavy chain of IgE or the gamma heavy 
chain of IgG1, along with another vector containing the cDNA encoding for the 
human kappa light chain constant region.  All of these constant regions were 
synthesized from the cDNA of human B cells.  DNA from the vectors was produced 
using HiSpeed Plasmid Maxi Kit® (Qiagen®), transfected into human embryonic 
kidney 293 cells which were harvested after 2-4 weeks in culture, and antibodies 
were purified from cell culture supernatant using affinity chromatography as 
described previously (Gould, Mackay et al. 1999; Karagiannis, Singer et al. 2009).  
The construction, production, and biochemical characterization of HMW-MAA 
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antibodies of the IgG and IgE class were performed by Mr. Tihomir Dodev, KCL, 
who kindly provided antibodies for the functional studies described below. 
HMW-MAA antibodies were characterized following antibody cloning, expression 
and purification to confirm the identity and purity of these IgG and IgE antibodies.  
By us sing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), 
the molecular size of these antibodies could be assessed relative to the molecular 
markers (protein ladder) of a known molecular size and compared to IgG and IgE 
isotype control antibodies.  By SDS-PAGE, under reducing conditions, the expected 
molecular masses of the heavy and light chains for HMW-MAA IgG and IgE were 
observed to be similar to the anti-FRα MOv18 IgG1 and IgE chimeric antibody 
isotype controls (Figure 5.10A).  Similarly, the molecular masses for whole Ig 
molecules under non-reducing conditions evaluated by SDS-PAGE for both HMW-
MAA IgG and IgE antibodies were of expected size and similar to their 
corresponding isotype control antibodies (Figure 5.10A).  These results confirm 
the production of proteins which are the same size as IgG and IgE molecules.  Next 
the presence of any impurities, degradation products, or aggregates in the 
antibody preparations was evaluated by size exclusion chromatography.   The 
absence of significant aggregation or degradation of antibodies along with the 
absence of impurities in antibody preparations were confirmed by size exclusion 
chromatography evaluations, since the elution of antibodies was seen at the same 
time as their respective isotype control antibodies without any additional products 
(or peaks) detected (Figure 5.10B).  No additional products before or after the 
elution of the antibody were detected, which, if found, would have indicated 





Figure 5.10  Characterization of engineered antibodies of the IgG and IgE classes 
targeting HMW-MAA.  (A) SDS-PAGE analysis of purified HMW-MAA IgG1 (l) and 
control MOv18IgG1 (2) (left) under non-reducing and reducing conditions and their 
isotype HMW-MAA IgE (3) and control MOv18IgE (4) versions (right), along with (M) 
Spectra™ Multicolor High Range Protein Ladder (Fermentas) visualized by Coomassie 
staining. (B) Size exclusion chromatography analysis of HMW-MAA antibodies and 








Next, the Fab and Fc specificities of engineered HMW-MAA antibodies were 
evaluated.  Had recombinant forms of the antigen been available, antigen binding 
and estimations of affinity could have been assessed by surface plasma resonance 
or ELISA.  However, due to the lack of recombinant antigen, the binding of 
antibody to antigen was assessed using cells known to express the HMW-MAA 
antigen (A-375) and also cells known to lack expression of HMW-MAA 
(melanocytes).  The binding of HMW-MAA antibodies of the IgG and IgE classes to 
A-375 cells but not to melanocytes was observed by flow cytometry (Figure 5.11).  
Additionally, the binding of the 225.28S  HMW-MAA IgG antibody to A-375 cells by 
flow cytometry was similar to the binding of another murine HMW-MAA 
monoclonal antibody clone (Clone LHM2, Invitrogen) generated following the 
immunization of mice with a crude cell extract of A-375 cells (see Chapter 3, Figure 
3.8), which was consistent with the specificity of HMW-MAA antibodies to 
melanoma cells.  Both IgG and IgE HMW-MAA antibodies were also found to bind 
to monocyte cells isolated from a healthy volunteer (Figure 5.12), known to 
express FcγRs and FcεRs, by flow cytometry.  These results display the production 
of antibodies of the IgG and IgE classes with specificity to the HMW-MAA antigen 
expressed on melanoma cells with the ability to bind to Fc receptor bearing 





Figure 5.11  Binding of HMW-MAA IgG and IgE to A-375 melanoma cells and 
melanocytes.  The binding of 225.28S HMW-MA chimeric antibodies, depicted with a 
black line, to A-375 melanoma cells (top) and melanocytes (bottom) was evaluated by 
flow cytometry.  Non-specific isotype controls, MOv18 IgG and IgE, are shown in 





Figure 5.12  Binding of HMW-MAA IgG and IgE to human monocytes.  The binding 
of chimeric 225.28S HMW-MAA antibodies, depicted with a black line, to human 
monocytes isolated from a healthy volunteer was evaluated by flow cytometry.  Non-
specific isotype controls, MOv18 IgG and IgE, are shown in shaded grey.  Data 
courtesy of Dr. Panagiotis Karagiannis, KCL. 
 
 
5.3.2 Cell Adhesion and Invasion Assays 
Antibodies recognizing HMW-MAA have been described to have non-
immunological function against cancer cells through the blockade of interactions 
between HMW-MAA and ECM components, resulting in the interference of  
metastatic processes (Chang, Campoli et al. 2004).  HMW-MAA has also been 
associated with the modulation of cell adhesion and spreading by acting as a co-
receptor for α4β1 integrin, promoting melanoma cell adhesion to fibronectin (Iida, 
Skubitz et al. 1992) and enhancing growth factor-regulated pathways such as FAK 
and ERK, which are important for tumor cell functions of cell adhesion, motility 
and invasion (Eisenmann, McCarthy et al. 1999; Yang, Price et al. 2004).  HMW-
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MAA has additionally been found to interact with matrix metalloproteinase on 
melanoma cells to facilitate melanoma cell invasion and promote proteolysis of 
ECM components such as collagen, resulting in increased tumor cell motility (Iida, 
Pei et al. 2001).  To test if the engineered HMW-MAA antibodies of the IgG and IgE 
class exhibit non-immunological mechanism of action against melanoma cells in 
vitro, the ability of these engineered antibodies to restrict melanoma cell adhesion 
and invasion mediated by this antigen was next evaluated. 
HMW-MAA has been shown to be an important contributor to melanoma adhesion 
and spreading to ECM components such as fibronectin (Iida, Skubitz et al. 1992) .  
The ability of HMW-MAA IgG and IgE antibodies to inhibit melanoma cell adhesion 
was evaluated in vitro using adhesion assays detailed in Chapter 2, Section 2.9.3.  
Melanoma cells coated with HMW-MAA IgG antibodies were found to significantly 
(P<0.01) reduce the adhesion of melanoma cells (21.7%, SD=0.6%) to fibronectin, 
compared to those cells incubated with the non-specific MOv18 IgG isotype control 
(0.4%, SD=2.2%) (Figure 5.13).  A statistically significant (P<0.001) inhibition of 
melanoma cell adhesion was also observed for HMW-MAA antibodies of the IgE 
isotype (19.9%, SD=3%) compared to the MOv18 IgE non-specific control (2.2%, 
SD = 2.1%) (Figure 5.13).  As expected, no significant difference in the inhibition of 
cell adhesion was seen between the HMW-MAA antibodies of IgG and IgE classes, 
which have identical Fab regions (Figure 5.13).  Thus, engineered antibodies of the 
IgG1 and IgE were demonstrated in vitro to directly inhibit the adhesion of 





Figure 5.13  Inhibition of melanoma cell adhesion by HMW-MAA IgG and IgE 
antibodies.  The adhesion of A-375 melanoma cells to fibronectin was evaluated 
following the addition of IgG and IgE antibodies targeting HMW-MAA and non-specific 
isotype controls, MOv18 IgG and IgE.  Percent inhibition of adhesion mediated by all 
antibodies was calculated relative to cells treated with PBS as a 100% reference.  Error 
bars represent one SD.  The experiment was performed each time in triplicate on 3 
separate days. ** P<0.01 and *** P<0.001.  P values were calculated using a two-sided 





Next, the ability of HMW-MAA IgG and IgE antibodies to inhibit melanoma cell 
migration across a collagen layer, representing an evaluation of invasion, was 
analyzed using the in vitro assay detailed in Chapter 2, Section 2.9.4.  Collagen, a 
basement membrane protein, represents a key barrier to the migration of tumor 
cells and is widely used in in vitro assays to evaluate for tumor cell invasion 
potential (Terranova, Hujanen et al. 1986).  In these assays, the restriction of 
tumor cell migration of HMW-MAA expressing cells across a collagen layer with 
the addition of HMW-MAA IgG or IgE antibodies was evaluated to assess the 
potential of these newly engineered antibodies to restrict tumor cell invasion.  A-
375 melanoma cells incubated with HMW-MAA IgG antibodies were found to have 
a significantly reduced migratory capacity (P<0.001) across a collagen layer 
(46.7%, SD=6.9%) compared to those incubated with the non-specific MOv18 IgG 
isotype control (7.7%, SD=5.4%) (Figure 5.14).  Similarly, cell migration was 
inhibited for melanoma cells incubated with the HMW-MAA IgE antibodies (46.1%, 
SD 7.2%) when compared to cells incubated the IgE isotype control (1.2%, 
SD=4.5%) (Figure 5.14).  Similar to the findings of the adhesion assays examining 
the ability of HMW-MAA antibodies to block antigen function, no significant 
difference was seen in the inhibition of melanoma cell migration across a collagen 
layer between samples incubated with HMW-MAA antibodies of the IgG and IgE 





Figure 5.14  Inhibition of melanoma cell invasion by HMW-MAA IgG and IgE 
antibodies.  The migration of A-375 melanoma cells across a collagen layer was 
evaluated following the addition of HMW-MAA IgG and IgE antibodies and non-specific 
isotype controls, MOv18 IgG and IgE.  Percent inhibition of cell migration mediated by 
all antibodies was calculated relative to cells treated with PBS as a 100% reference.  
Error bars represent one SD.  The experiment was performed in triplicate and repeated 







Thus far the non-immunological functions of engineered HMW-MAA antibodies of 
the IgG and IgE classes have been explored in vitro and both antibodies 
demonstrated comparable impairment of melanoma cell adhesion and invasion to 
ECM components.  The results were similar to those reported for murine versions 
of the antibodies evaluated in triple negative breast cancer models, which reported 
a 44.8% inhibition of breast cancer cell adhesion along with a 56.8% inhibition of 
breast cancer cell migration by co-incubation with the murine 225.28S antibody 
clone (Wang, Osada et al. 2010).   The data presented here consequently support 
the ability of these engineered antibodies to inhibit the function of HMW-MAA on 
melanoma expressing cells. 
 
5.3.3 Antibody-dependent Cellular Cytotoxicity and Phagocytosis Assays 
Using Human Primary Monocytes 
While HMW-MAA antibodies have demonstrated inhibition of antigen function in 
relation to melanoma cell adhesion and invasion, they additionally may possess 
effector functions through the engagement of FcRs expressed on immune effector 
cells to elicit a immune cell mediated anti-tumor response.  These mechanisms 
have to-date not been explored in the context of human immunity since only 
murine versions of the 225.28S antibody clone have been evaluated for Fc effector 
function.  Therefore, engineering antibodies with human Fc regions permitted 
production of antibodies with the same antigen specificity but with Fc domains of 
different human classes, allowing for translational assessments of more clinically 
relevant antibodies with potentially improved effector functions. 
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The ability of IgG and IgE antibodies targeting HMW-MAA to engage human 
immune effector cells resulting in the specific killing of melanoma cells was 
evaluated using in vitro functional flow cytometry assays (described in Chapter 2, 
Section 2.10.4) which were designed to simultaneously measure ADCC and ADCP 
(Bracher, Gould et al. 2007).  For these assays, primary human monocytes were 
freshly isolated from both patients with melanoma and healthy volunteers and 
used as effector cells.  The use of primary immune cells allowed for the assessment 
of the ability of anti-melanoma antibodies to activate an individual’s immune 
effector cells to specifically kill tumor cells.  Also, by testing antibodies using both 
patient and healthy volunteer immune cells, any dysregulation of monocytes in 
disease, which many then in turn potentially limit the effector function of these 
antibodies, could be evaluated.  
First, primary monocytes were freshly isolated from healthy volunteers (Chapter 
2, Section 2.3.4), and the ability of HMW-MAA IgG antibodies to engage these cells 
to kill melanoma cells by ADCC/ADCP was evaluated.  Melanoma cells incubated 
with monocytes isolated from healthy volunteers and HMW-MAA IgG were found 
to have a significantly (P<0.001) higher percentage of tumor cell death by ADCP 
(44.5, SD=13.4) when compared to cells incubated with MOv18 IgG isotype control 
(13.0, SD=4.3), or when compared to cells treated with no antibody (8.9, SD=1.5) 
(Figure 5.15).  However, no significant increase in the percentage of ADCC was 
measured for cells incubated with HMW-MAA IgG antibodies (12.6, SD =2.7) 
compared to cells incubated with MOv18 IgG (9.4, SD=1.5), or those treated with 
no antibody (11.2, SD=1.7) (Figure 5.15).  In summary, HMW-MAA IgG antibodies 
were seen to engage monocytes isolated from healthy volunteers to mediate the 
phagocytosis of melanoma cells in this in vitro assay.  These results demonstrate 
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that HMW-MAA IgG antibodies can mediate significant Fc-mediated immune 
effector functions by ADCP. 
Next, the ability of HMW-MAA IgG to engage FcγRs on patient monocytes to 
mediate ADCC and ADCP was measured.  Patient monocytes were freshly isolated 
from three individuals with Stage II melanoma and were evaluated in these in vitro 
efficacy assays to see if cells had any restricted function.  The reason for these 
evaluations lies in the reports of immune cell dysregulation for some immune cell 
populations in melanoma, such as B cells, monocytes and macrophages, which may 
impact on their ability to engage in tumor cell killing (Unger, Bernhard et al. 1983; 
Carpenter, Mick et al. 2009).  No significant difference was seen in the percentage 
of ADCC for cells treated with HMW-MAA IgG antibodies (6.7, SD=4.8) and MOv18 
IgG control antibodies (5.3, SD=4.6), or those cells treated with no antibodies (4.8, 
SD=4.6) (Figure 5.16).  However, a significant difference (P <0.001) in the 
percentage of ADCP was observed between cells treated with HMW-MAA IgG 
antibodies (13.9, SD=2.0) and those treated with MOv18 IgG control antibodies 
(0.9, SD=0.2), and also for cells not incubated with any antibodies (0.9, SD=0.2) 
(Figure 5.16).  Overall, results were similar between patient and healthy volunteer 
monocytes in that HMW-MAA IgG was found to significantly induce ADCP and not 
ADCC (Figure 5.15 & Figure 5.16). 
Monocytes from both healthy volunteers and those with Stage II melanoma were 
both found to mediate ADCP when incubated with HMW-MAA IgG and melanoma 
cells.  These findings suggest that this antibody may effectively activate patient 
effector cells against tumor cells, and therefore may harbor some potential as a 
therapeutic in the context of patient immunity.  These results also point to the 
potential of HMW-MAA IgG antibodies to mediate ADCP in patients; such results 
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have been previously described for Trastuzumab in vitro when incubated with 
breast cancer cells and with monocytes or PBMCs (Lazar, Dang et al. 2006; 
Karagiannis, Singer et al. 2009).  While the direct comparison of ADCP between 
patient and healthy volunteers may be limited by factors such as assay variability, 
still an increased amount of ADCP was seen from monocytes isolated from healthy 
volunteers.   This interesting observation could potentially be explored further by 
performing assays using monocytes isolated from individuals with Stage III and IV 
melanoma which could inform of the ability of HMW-MAA antibodies to induce 





Figure 5.15  Evaluation of HMW-MAA IgG to mediate ADCC and/or ADCP against 
melanoma cells when incubated with primary monocytes derived from healthy 
volunteers.  Primary monocytes isolated from healthy volunteers (n=3) were tested in 
vitro using a 3 color flow cytometric assay to simultaneously measure ADCC and 
ADCP of melanoma cells.  Monocytes were incubated with A-375 melanoma cells and 
ADCC and ADCP mediated by HMW-MAA IgG were compared relative to a non-
specific isotype control (MOv18 IgG) and cells treated with no antibody.  Error bars 
represent one SD.  Each condition was tested in triplicate for each of the three 
volunteers evaluated.  NS= not significant and *** P<0.001.  P values were calculated 
using a two-sided Student’s t test comparing HMW-MAA IgG to either MOv18 IgG or 








Figure 5.16  Evaluation of HMW-MAA IgG to mediate ADCC and/or ADCP against 
melanoma cells when incubated with primary monocytes derived from 
melanoma patients.  Primary monocytes isolated from patients (n=3) with Stage II 
melanoma were tested in vitro using a 3 color flow cytometric assay to measure ADCC 
and ADCP of melanoma cells.  Patient monocytes were incubated with A-375 
melanoma cells and ADCC and ADCP mediated by HMW-MAA IgG were compared 
relative to a non-specific isotype control (MOv18 IgG) and cells treated with no 
antibody.  Error bars represent one SD.  Each condition was tested in triplicate for each 
of three patients evaluated.  NS= not significant and *** P<0.001.  P values were 
calculated using a two-sided Student’s t test comparing HMW-MAA IgG to either 
MOv18 IgG or no antibody. 
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The effector functions of HMW-MAA antibodies of the IgE class were also 
evaluated using the same flow cytometric ADCC/ ADCP assays.  Using monocytes 
isolated from healthy volunteers, no significant differences were observed in the 
percentage of ADCP between cells treated with HMW-MAA IgE (3.9, SD=2.1) and 
the MOv18 IgE isotype control (3.7, SD=2.2), and also between HMW-MAA IgE and  
the no antibody control (1.9, SD=0.8)(Figure 5.17).   However, significantly higher 
percentages (P <0.01) of tumor cells were killed by ADCC when cells were 
incubated with HMW-MAA IgE (22.14, SD=8.6) compared to those incubated with 
the MOv18 IgE isotype control (7.2, SD=3.3), or those cells incubated with no 
antibody (5.1, SD=1.6) (Figure 5.17).    
The ability of HMW-MAA IgE to engage patient monocytes to mediate the ADCC/ 
ADCP against melanoma cells was next evaluated in these ADCC/ADCP assays.  No 
significant differences in the percentage of measured ADCP were seen when 
comparing cells incubated with the HMW-MAA IgE antibody (3.9, SD=1.6) to cells 
incubated with MOv18 IgE antibody (3.0, SD= 0.5), or to cells incubated with no 
antibody (3.8, SD=0.7) (Figure 5.18).  However, a significant increase (P < 0.001) 
was measured in the percentage of ADCC for cells incubated with HMW-MAA IgE 
antibodies (33.1, SD=9.7) compared to those incubated with the MOv18 IgE 
control antibodies (10.4, SD=5.3) (Figure 5.18), or those incubated with no 




Figure 5.17  Evaluation of HMW-MAA IgE to mediate ADCC and/or ADCP against 
melanoma cells when incubated with primary monocytes derived from healthy 
volunteers.  Primary monocytes isolated from 3 healthy volunteers were tested in vitro 
using a 3 color flow cytometric assay to simultaneously measure ADCC and ADCP of 
melanoma cells.  Patient monocytes were incubated with A-375 melanoma cells and 
ADCC and ADCP mediated by HMW-MAA IgE were compared relative to a non-
specific isotype control (MOv18 IgE) and cells treated with no antibody.  Each condition 
was tested in triplicate for the individual evaluated.  Error bars represent one SD. NS= 
not significant, ** P<0.01.  *** P<0.001.  P values were calculated using a two-sided 






Figure 5.18  Evaluation of HMW-MAA IgE to mediate ADCC and/or ADCP against 
melanoma cells when incubated with primary monocytes derived from 
melanoma patients.  Primary monocytes isolated from patients (n=3) with Stage II 
melanoma were tested in vitro using a 3 color flow cytometric assay to simultaneously 
measure ADCC and ADCP of melanoma cells.  Patient monocytes were incubated with 
A-375 melanoma cells and ADCC and ADCP mediated by HMW-MAA IgE were 
compared relative to a non-specific isotype control (MOv18 IgE) and cells treated with 
no antibody.  Each condition was tested in triplicate for each of the three patients 
evaluated.  Error bars represent standard mean error. NS= not significant, ** P<0.01 
and *** P<0.001.  P values were calculated using a two-sided Students t test 





HMW-MAA antibodies of the IgG and IgE classes were shown to have effector 
functions in vitro through different mechanisms of action.  IgG antibodies exhibited 
significant amounts of ADCP, while IgE mediated significant amounts of ADCC in 
these assays.  The disparate mechanism of effector functions of these antibody 
classes has been described for antibodies targeting the Her2/neu antigen in breast 
cancer (Karagiannis, Singer et al. 2009), but these mechanisms are now shown for 
antibodies against melanoma herein using patient monocytes as effector cells.  
These results support the merit of further preclinical development of these IgG and 
IgE antibodies for the treatment of melanoma as single agents or potentially in 
combination to maximize antibody-mediated Fc effector functions in the 
recruitment of immune cells such as monocytes, which may elicit a more effective 
anti-melanoma immune response.  Future studies employing these ADCC/ADCP 
assays could be directed at evaluating if the combination HMW-MAA IgG and IgE 
antibodies could enhance the effector function of a single immune cell population 
bearing both Fcε and Fcγ receptors, including macrophages, monocytes, and 
eosinophils or trigger enhanced ADCC/ADCP in mixed populations of immune cells 
present in solid tumors. 
Monoclonal antibodies of the IgE class may hold particular potential in the 
treatment of melanoma due to the presence of potent immune cells in cutaneous 
metastases expressing FcεRs, such as mast cells and macrophages (Duncan, 
Richards et al. 1998; Erdag, Schaefer et al. 2012).  The administration of HMW-
MAA IgE antibodies in melanoma has the potential to exploit the Th2 responses 
previously characterized to exist in melanoma patients (Nevala, Vachon et al. 
2009).  Additionally, the use of an IgE monoclonal antibody targeting a tumor 
antigen may result in the infiltration of such immune cells normally involved in 
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allergic immune responses and those responses triggered in the presence of 
parasites.  These responses have been previously observed following the 
treatment of tumor-antigen specific IgE antibodies in tumor-bearing animal 
models, and were consistent with prolonged survival and reduced tumor growth in 
the IgE-treated animals (Karagiannis, Wang et al. 2003).  IgE cancer 
immunotherapy could possibly yield promising anti-tumor responses in solid 
tumors as suggested by in vivo solid tumor models (Karagiannis, Bracher et al. 
2007; Teo, Utz et al. 2012), with low potential risks of systemic hypersensitivity, 
even in the presence of soluble forms of the targeted antigen in circulation as 
observed in ex vivo safety models evaluating a tumor-specific IgE antibody 
(Rudman, Josephs et al. 2011). 
  
 
5.4  Conclusions 
This chapter described the discovery, characterization and in vitro functions of 
novel anti-melanoma monoclonal antibodies.  First, the antibody repertoire of 
melanoma patients was harnessed to discover novel tumor-specific antibodies.  
One such patient-derived melanoma-specific monoclonal antibody, M111_2G3, 
mediated ADCC of tumor cells in vitro, suggesting the merit of this approach to 
discover anti-melanoma antibodies with therapeutic potential.  While the amounts 
of available M111_2G3 antibody were limited, further in vitro functional assays 
were employed using in-house engineered monoclonal antibodies recognizing a 
melanoma associated antigen.  These in vitro assays could be applied in future 
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evaluations of the possible mechanisms of action of patient-derived tumor specific 
antibodies to specifically kill or restrict the adhesion or invasion of tumor cells. 
Engineered monoclonal antibodies of the IgG and IgE classes were found in vitro to 
partially restrict tumor cell adhesion and invasion.   Furthermore, these IgE and 
IgG antibodies were capable of activating patient peripheral blood monocytes to 
kill melanoma cells in vitro by disparate mechanisms, one by ADCC and the other 
by ADCP, respectively.  Developing therapeutic anti-melanoma antibodies of the 
IgE class may offer a novel strategy to increase ADCC against melanoma cells.   
Patient-derived melanoma-specific antibodies and those targeting the HMW-MAA 
bearing human Fc regions all collectively offer new immunotherapeutic 
approaches for the treatment of melanoma and warrant further preclinical 
assessments in disease-relevant in vitro and in vivo models.  Such in vitro models 
would permit the examination of the HMW-MAA antibody’s potential to inhibit cell 
proliferation and colony formation along with its ability to engage human patient-
derived effector cells to perform Fc-mediated functions such as CDC and 
ADCC/ADCP, including the assessment of additional immune cell types as effector 
cells.  Analyses of these antibodies with human Fc regions in vivo are also essential 
for future preclinical evaluations of efficacy and should include the use of disease-
relevant animal models of melanoma such as those described by Chu and 
colleagues, which use human tumors transplanted into mice engrafted with human 










6.1   Introduction 
The recent clinical success of the monoclonal antibody Ipilimumab has generated 
renewed interest in the use of antibody therapeutics in melanoma.  Not only does 
Ipilimumab signify the approval of the first monoclonal antibody for the treatment 
of melanoma but, notably, it is the first antibody therapeutic that functions by 
modulating regulatory mechanisms to overcome tolerance and heighten the host 
adaptive immune response against cancer.  These attributes highlight the 
importance of antibodies as a class of drugs to treat melanoma and the merits of 
dissecting immunomodulatory pathways in cancer with the aim of harnessing host 
anti-tumor immune responses.  Key to the success of Ipilimumab were the 
understanding of the nature of T cell responses to melanoma and the devising of a 
drug that would lead to the activation and proliferation of T cells to enhance the 
host anti-tumor cellular immune response.   Further understanding of the nature 
of other immune cell populations and their response to cancer could pave the way 
for additional therapeutic approaches to treat melanoma and other cancers. 
The purpose of this thesis was to investigate the humoral immune response to 
melanoma from a patient cohort and explore the possible anti-tumor functions of 
patient-derived and engineered antibodies against melanoma cell surface antigens.  
The findings presented in this thesis highlight the prevalent humoral immune 
response to melanoma across a 21 patient cohort, provide novel insights into the 
modulation of antibody subclasses in the cutaneous metastatic melanoma 
microenvironment, and describe approaches to discover and characterize novel 
anti-melanoma antibodies, all of which are highly applicable to future 
immunotherapeutic strategies for the treatment of melanoma. 
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6.2   Humoral Immune Response to Melanoma 
Two key contributions of this thesis provide further understanding of the humoral 
immune responses to melanoma.  Firstly, the ex vivo culture of patient and healthy 
volunteer B cells along with the development of the cell-based ELISA (Chapter 3, 
Section 3.3.3) allowed for the broad analysis of host antibody responses to 
antigens displayed on the surface of melanoma cells (Chapter 4, Section 4.1).  
Secondly, the study of IgG subclass composition resulted in the observation of 
increased proportional production of antibodies of the IgG4 subclass in the 
cutaneous metastatic melanoma microenvironment compared to the periphery 
(Chapter 4, Section 4.2), which has not been previously described.  Each of these 
findings contributes to the further understanding of humoral immune response to 
melanoma and provides a fresh perspective on an arm of the adaptive immune 
response which has received little focus until now.   
 
6.2.1 Monitoring the Melanoma-reactive IgG Compartment from Patient 
Memory B cells 
The development of a cell-based ELISA herein has allowed for a broad analysis of 
the humoral immune response to antigens displayed on the surface of melanoma 
cells.  This approach has expanded the scope of characterization of the humoral 
immune response to cancer in several ways.  Firstly, the use of whole cells allowed 
for the assessment of antibody reactivity to a multitude of antigens residing on the 
cell surface.  These are of particular interest in the study of humoral immunity 
against melanoma because these antibodies recognize cell surface antigens and 
may harbor the potential to mediate CDC, ADCC and ADCP against tumor cells 
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upon recognition of their targeted antigen.  Secondly, this work presents an assay 
that could potentially be used as a standardized technique to study anti-tumor 
antibody responses in melanoma and other cancers, something that is currently 
lacking (Reuschenbach, von Knebel Doeberitz et al. 2009).  This readout is not 
limited by the availability of commercially available recombinant antigens or their 
recombinant production because it makes use of readily available cells.  Thirdly, 
assessments of total immunological memory can be made with this approach 
through the examination of antibodies produced from memory B cells rather than 
the evaluation of antibodies resident in the sera at the time point of sampling 
(Lanzavecchia, Bernasconi et al. 2006).  Prior to this work, serological studies have 
provided valuable insight into humoral immune responses to melanoma by 
examining antibody responses to autologous cells (Lewis, Ikonopisov et al. 1969) 
along with antibody responses to several selected recombinant antigens (Stockert, 
Jäger et al. 1998; Trefzer, Hofmann et al. 2006).  However, these more extensive 
serological studies examined melanoma antigens that are predominantly 
cytoplasmic or expressed in the nucleus, and the selection of such antigens has 
been variable across studies.  The approach described herein has general 
applicability and could be used to identify the presence of a memory B cell 
compartment containing tumor-reactive antibodies against cell surface antigens of 
any adherent cell type in different cancers and patient groups.  The approach  
could even be employed to monitor humoral immune responses  prior to and 
following therapeutic treatments, such as vaccines aimed at enhancing humoral 
immunity, or therapeutic antibodies aimed at overcoming immune tolerance, or 
even following the administration of small molecule drugs, such as BRAF kinase 
inhibitors, to evaluate possible effects on tumor-specific antibody responses in a 
similar manner to those studies evaluating T cell function and tumor-specific T cell 
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responses following administration (Boni, Cogdill et al. 2010; Hong, Vence et al. 
2012).  Thus, the development of a cell-based ELISA to measure antibody reactivity 
from ex vivo B cell cultures not only complemented previous serological studies 
but has also allowed for the more general evaluation of the reactivity of antibodies 
to melanoma cells expressing a multitude of antigens along with the assessment of 
the immunologic history of the patient humoral immune response to antigens 
residing on the surface of melanoma cells. 
A melanoma-reactive antibody compartment was found when examining patient 
memory B cells among a cohort of patients diagnosed with Stage I, II, III and IV 
melanoma (Chapter 4).  The specificity of the host antibody response to melanoma 
was supported by the finding that antibodies derived from a cohort of healthy 
volunteers had significantly lower responses to melanoma cells compared to the 
patient cohort (Figure 4.2 & Figure 4.3).  Such a broad humoral immune response 
to melanoma has not been previously described among patients with non-
metastatic and metastatic disease.  This could be because past serological 
evaluations have focused on selected antigens and only provided insight into 
antibody responses against these specific antigens (Stockert, Jäger et al. 1998; 
Trefzer, Hofmann et al. 2006), many of which are lost or acquired during disease 
progression (Barrow, Browning et al. 2006).  The use of whole melanoma cells in 
the cell-based ELISA allowed for the evaluation of antibody reactivity against a 
wide spectrum of antigens, possibly some as of yet unidentified, lending a broader 
characterization of humoral immune responses.  Additionally, the use of non-
autologous cells in the cell-based ELISA demonstrated that these melanoma-
reactive antibodies were not just specific to autologous cancer cells, but rather the 
antibodies recognize cell surface antigens common to other individuals, which 
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could be a particularly meaningful approach to discovering novel antibodies from 
patients to be used as a passive immunotherapy.   This work identified the 
presence of a circulating memory B cell compartment in the blood of most 
patients, capable of producing melanoma-reactive antibodies, thus illustrating the 
overall widespread immunologic B cell memory to melanoma among patients with 
varying stages of disease.   
Monitoring the circulating memory B cell compartment from a 21 patient cohort 
revealed that antibody reactivity to melanoma cells was decreased in relation to 
disease progression (Chapter 4, Section 4.2.3).  In this thesis, it was first evaluated 
whether the decrease in antibody responses in patients with progressing disease 
was solely a function of a decrease in circulating CD27+ memory B cell 
populations.  Interestingly, no significant difference was observed between the 
proportion of the peripheral blood CD27+ memory B cell compartments in the 
blood of non-metastatic compared to that of metastatic melanoma patients (Figure 
4.1), suggesting that the decrease in melanoma-reactive antibodies was not 
entirely a function of the reduced peripheral blood memory B cell compartment 
with progressing malignancy.  It could be hypothesized, following the 
immunoediting paradigm (Dunn, Bruce et al. 2002; Schreiber, Old et al. 2011), that 
such findings may in part be a result of changes in the phenotype of the tumor.  
These may arise from the selective pressure of the immune system on cancer cells, 
allowing the survival of non-immunogenic cancer cells with decreased antigenicity 
and with progressing malignancy.  A decrease in the clonal expansion of these 
melanoma-reactive B cells may follow in the absence of antigen.  Thus, the 
reduction of melanoma-reactive antibodies with disease progression may 
represent weakened host humoral immune responses due to the decreased 
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antigenicity of tumor cells with progressing disease.  This is supported by studies 
demonstrating the loss of some melanoma antigens, such as differentiation 
antigens, with progressing disease (Trefzer, Hofmann et al. 2006), along with 
serological studies examining antibody reactivity to autologous cells, which were 
shown to decrease in patients with advanced malignancy (Lewis, Ikonopisov et al. 
1969).  Other mechanisms may also be at play such as the exhaustion of antigen-
reactive B cells, or immunomodulatory responses triggering less potent humoral 
responses.  In summary, the findings herein have expanded upon the 
characterization of memory B cell homeostasis in melanoma by demonstrating a 
decreased reactivity of antibodies produced from ex vivo activated patient memory 
B cells to melanoma cells.  The use of allogeneic melanoma cells in these 
evaluations, which display a multitude of cell surface antigens that are likely 
commonly expressed across individuals, adds a more general evaluation of the 
decreasing reactivity of antibodies to a larger set of antigens than those previously 
described for autologous cells or even single antigens. 
Further examination of the memory B cell compartment in patients was performed 
to estimate the frequency of melanoma-reactive antibody responses in patients.  
The frequency of B cells producing melanoma-reactive antibodies to multiple 
metastatic melanoma cell lines, with each cell line derived from a different 
individual, was estimated to be similar to B cell cultures derived from one 
individual (Figure 4.7).  These findings suggest the possibility that these metastatic 
cell lines share similar or common cell surface antigens.  Additionally, B cells 
tested from different individuals diagnosed with Stage II melanoma were 
estimated to have comparable frequencies of B cells producing melanoma-reactive 
antibodies, approximately 1 in 2000 B cells (Figure 4.8).  These estimations 
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revealed the low to moderate frequencies of B cells capable of producing 
melanoma-reactive antibodies residing in patients diagnosed with Stage II disease, 
compared to the much higher frequencies of antigen-specific B cells present 
following vaccination for measles virus, tetanus toxin and varicella zoster virus 
antigens, which were reported for one individual to be 1 in 50, 1 in 400, and 1 in 
585 B cells, respectively (Pinna, Corti et al. 2009).  While the frequency of B cells 
producing antibodies to TAAs has not been previously described in patients, the 
frequency of T cells reactive to TAAs such as tyrosinase has been reported to be as 
high as 2.2% of total CD8+ T cells in one of six individuals studied with metastatic 
disease, which roughly translates to 1 in 50 CD8+ T cells (although this finding was 
variable among individuals since 4 patients did not have tyrosinase reactive CD8+ 
T cells and one patient had reactivity of 0.19%, roughly 1 in 500 CD8+ T cells) (Lee, 
Yee et al. 1999).  While it has been demonstrated that patient memory B cells 
capable of producing anti-tumor humoral immune responses exist in the periphery 
in somewhat low to moderate frequencies, it is not known whether these B cells 
are capable of mounting significant anti-tumor responses in patients, although 
strategies to enhance these host responses could be of interest as a potential 
therapeutic approach.   
The presence of B cells producing melanoma-reactive antibodies across patients 
was demonstrated in this thesis and the activation of this arm of adaptive 
immunity in patients could be of therapeutic value.  This claim is also supported by 
a recent study analyzing immune cell infiltration into metastatic melanoma tumors 
and patient survival, which found that the group of patients (8%) with diffuse 
immune cell infiltrates in the tumor contained B cells (25%) and plasma cells (8%) 
among other immune cells.  It was found that the presence of these B linage cells 
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correlated with increased rates of survival of 130 months compared to groups 
with no immune cell infiltrates or perivascular infiltrates, who had survival rates 
of 15 and 23 months, respectively (Erdag, Schaefer et al. 2012).   Taken together, 
these findings hint at the possible anti-tumor role of B cells and lend support for 
the exploration of therapeutic attempts to enhance the frequency of specific sets of 
B cells and perhaps trigger the production of anti-melanoma antibodies.  It could 
be speculated that such attempts may have already been made to enhance host 
humoral immunity to melanoma, although the role of B cells in these attempts has 
not been fully dissected.  For example, in adoptive cell therapies ex vivo activation 
of TILs through the use of IL-2 is primarily thought to expand anti-tumor 
responses mediated by CD8+ T cells, but these mixed lymphocyte populations also 
contain B cells, which can also proliferate in the presence of IL-2 (Mingari, Gerosa 
et al. 1984; Dudley, Yang et al. 2008; Besser, Shapira-Frommer et al. 2010).  
Therefore, it is conceivable that antibodies from these TILs also contribute to the 
anti-tumor response.  It is possible that further targeted activation of specific B cell 
subsets by a TLR9 agonist could enhance B cell mediated anti-tumor responses.   
In the 21 patients studied, no clear relationship between the antibody reactivity of 
ex vivo activated B cells to melanoma cells and clinical outcome was found, though 
the follow-up was limited to between 6 and 24 months.  Longer follow-up of a 
larger patient cohort may help identify any correlations between melanoma-
reactive mature memory B cell responses and disease progression.  In this study, 
of note was one Stage IV patient with the highest % of tumor-reactive cultures 
(92%, Patient 72) in the patient cohort, who is a long-term survivor (8 years) with 
stable disease.  However, in order to draw any meaningful conclusions from this 
observation it would be important to observe similar findings in other long-term 
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survivors with metastatic disease.  It could be speculated that host immunity has 
profound anti-tumor effects in some  patients and could be the mechanism behind 
some reports of “spontaneous” remissions or long term stable disease; indeed, one 
such case reported the infiltration of plasma cells and lymphocytes into the areas 
of tumor necrosis prior to long term remission  (Bulkley, Cohen et al. 1975).   
While correlations between lymphocyte infiltration in primary melanomas and 
improved prognosis have been made (Clark, Elder et al. 1989; Clemente, Mihm et 
al. 1996) along with B and plasma cell infiltration in metastatic tumors (Erdag, 
Schaefer et al. 2012), the effects of these cells and their production of anti-
melanoma antibodies in sufficient quantities to mount a meaningful anti-tumor 
response in patients still remains unclear.  These published observations together 
with data provided in this thesis highlight the importance of further dissecting the 
nature, tumor specificity and potency of humoral responses in patient circulation 
as well as in the tumor microenvironment, and the critical need to assess how the 
presence of different B cell subsets impact on the clinical course of melanoma. 
The widespread presence of memory B cells producing melanoma-reactive 
antibodies in this patient cohort, which included patients with advanced disease, 
suggests that humoral immune responses of sufficient potency may not be present 
to mount significant anti-tumor responses, and that these responses may be 
weakened with progressing disease.  There is also some evidence that the 
activation or functions of such memory B cells and the antibodies they produce 
may be impaired in melanoma, as seen by the hyporesponsiveness of metastatic 
melanoma patient memory B cells to stimuli such as CD40 and TLR9 (Carpenter, 
Mick et al. 2009).  Immunoregulatory elements in the tumor microenvironment 
may also modulate and reduce the potency of any melanoma-reactive antibodies 
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produced.  These may include the expression of Fc-decoy receptors on melanoma 
cells (Cassard, Cohen-Solal et al. 2008), the impairment of cell functions of  
immune cell populations, such as NK or macrophages, rendering them incapable of 
mediating cytotoxic killing such as ADCC/ADCP in solid tumors (Gordon and 
Freedman 2006; Pietra, Manzini et al. 2012), or even the possible suppression of 
antibody production by modulatory factors in the tumor microenvironment.  
Understanding and altering these modulatory mechanisms may hold promise for 
the design of novel immunotherapies for cancer. 
 
 
6.3   IgG4 in the Cutaneous Metastatic Tumor Microenvironment 
The finding of a polarization of IgG subclass production towards IgG4 in the 
metastatic melanoma cutaneous tumor microenvironment represents a novel 
discovery of this thesis.  The role of IgG4 in disease pathogenesis is newly 
emerging with the identification of IgG4-related inflammatory diseases such as 
autoimmune pancreatitis (Stone, Zen et al. 2012).   In cancer, altered levels of IgG4 
in the sera of some metastatic melanoma patients have been previously described 
(Daveau, Pavie-Fischer et al. 1977), along with the recent evidence of the 
infiltration of IgG4+ plasma cells in cholangiocarcinomas, malignancies of the 
biliary duct system (Harada, Shimoda et al. 2012).  Beyond these two reports, the 
relationship between IgG4 and cancer has largely been unexplored. 
Following the observation of IgG4 polarization in the tumor, the influence of Th2 
cytokines on humoral immunity were explored.  Alterations of humoral immune 
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responses, such as antibody class and subclass proportions by Th2 cytokines, have 
been previously described including the effects of IL-4 on IgE and IgG4 class 
switching along with the enhancement of IgG4 production by IL-10 (Jeannin, 
Lecoanet et al. 1998; Satoguina, Weyand et al. 2005).  Increased levels of Th2 
cytokines have been described in melanoma and other cancers with increases in 
the levels of Th2 cytokines, such as IL-4 and IL-10, in patients (Sheu, Lin et al. 
2001; Agarwal, Verma et al. 2006; Nevala, Vachon et al. 2009).   To explore if Th2 
cytokines in the tumor microenvironment can alter IgG subclass production, 
experiments were performed in which metastatic melanoma patient B cells, 
autologous PBMCs, and A-375 metastatic melanoma cells were co-cultured ex vivo.   
Results from these co-culture experiments revealed that increased levels of IgG4 
production were only observed in culture conditions which contained both A-375 
melanoma cells and PBMCs that were measured to have increased levels of IL-4 
and IL-10, and not in culture conditions with B cells cultured with only PBMCs or 
A-375 cells (Figure 4.12).  Interestingly, the skewing of antibody subclasses was 
not seen in these co-culture assays in the absence of melanoma cells, which have 
been shown to secrete IL-10, including the A-375 cell line (Chen, Daniel et al. 1994; 
Sumimoto, Imabayashi et al. 2006), suggesting these cells could be an important 
source of this regulatory cytokine, resulting in the favored production of IgG4 in 
the tumor microenvironment.   
The findings of an increased proportional production of antibodies of the IgG4 
subclass and relative decrease in the proportion of the IgG1 subclass may 
represent a mechanism by which humoral immunity is impaired in melanoma.  
This would be because of the reduction in the production of IgG1 antibodies in the 
tumor, the antibody class thought to have the most potent immune effector 
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functions,  accompanied by the increase in IgG4, which is generally thought to have 
the least potent Fc effector functions among the four IgG subclasses (van der Zee, 
van Swieten et al. 1986; Bruggemann, Williams et al. 1987; Aalberse, Stapel et al. 
2009).  If such ratios were to apply to melanoma-reactive antibodies, the reduced 
capacity of tumor-specific antibodies to mediate CDC, ADCC and ADCP could result 
in a weakened anti-tumor antibody response in the metastatic cutaneous tumor 
microenvironment.  The changes in antibody subclass proportions suggest another 
mechanism of immunomodulation in melanoma and possibly other cancers.  
Further studies are required to dissect these immunomodulatory mechanisms 
affecting antibody functions in cancer.  Strategies aimed at “re-polarizing” the 
tumor microenvironment towards IgG1 production, such as blocking IL-10, could 
possibly have merit in increasing the potency of any tumor-specific humoral 




6.4   Characterization and Functional Studies of Antibodies Targeting 
Melanoma Antigens 
The work presented in this thesis concentrated on two novel approaches that 
warrant further development and consideration as tools to discover future 
therapeutics for melanoma and other solid tumors.  The first approach is the 
potential use of patient-derived melanoma-reactive IgG antibodies for passive 
immunotherapy.   The second approach focuses on comparing the efficacy of 
chimeric antibodies of the IgG1 and IgE classes with human Fc regions and 
variable regions recognizing the characterized melanoma antigen HMW-MAA as 
potential therapeutic agents. 
 
6.4.1 Engineered Antibodies of the IgE and IgG1 Classes Targeting HMW-
MAA 
The HMW-MAA represents an ideal target for a monoclonal antibody therapeutic 
because of its restricted distribution on normal tissue and high expression on 
melanoma and other cancer cells (Campoli, Chang et al. 2004).  Blockade of this 
antigen with monoclonal antibodies has revealed several non-immunological roles 
of HMW-MAA (Chapter 2, Section 1.2.3.1) which may aide the enhancement of the 
metastatic potential of cells expressing this antigen (Price, Colvin Wanshura et al. 
2011).  Antibodies recognizing HMW-MAA, such as the 225.28S murine antibody 
clone, have been shown to restrict tumor growth in murine models of cancer 
(Hafner, Breiteneder et al. 2005).  The work herein has evaluated a chimeric 
version of the 225.28S HMW-MAA antibody engineered in-house and its direct 
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Fab-mediated functions to block melanoma cell adhesion and migration, along 
with its human Fc-mediated effector function to recruit innate immune effector 
cells resulting in the targeted destruction of melanoma cells.  In addition to an IgG1 
antibody, an engineered chimeric antibody with human Fc regions of the IgE class 
targeting the HMW-MAA was also evaluated.  Naturally occurring IgE responses 
are normally targeted against allergens but also protect against parasitic infections 
and perform effector functions against pathogens such as ADCC and ADCP.  It has 
been proposed that therapeutic antibodies of the IgE class hold promise for the 
treatment of solid tumors, such as breast and ovarian cancers, by re-directing high-
affinity IgE receptor-expressing effector cells against tumor cells to harness 
allergic reactions in tumors (Karagiannis, Josephs et al. 2012).  To-date the concept 
of IgE immunotherapy for solid tumors has not been tested in melanoma.  
Melanoma may serve as an ideal tumor type for IgE immunotherapy due to the 
high infiltration of FcεR bearing immune cells in tumors such as mast cells and 
macrophages (Duncan, Richards et al. 1998; Tth, Tth-Jakatics et al. 2000; Erdag, 
Schaefer et al. 2012). 
Functional evaluations of HMW-MAA IgG and IgE antibodies with human Fc 
regions were conducted as a part of this work to assess the non-immunological 
functions of these engineered antibodies to restrict tumor cell adhesion and 
migratory capacity (Chapter 5, Section 5.3.2).  The 225.28S antibody clone binds to 
an epitope of the core glycoprotein of HMW-MAA, a region that has been described 
to contain integrin and collagen binding sites (Wilson, Imai et al. 1981; Kantor, 
Albino et al. 1986; Price, Colvin Wanshura et al. 2011).  The in vitro experiments 
performed herein demonstrate that both the 225.28S IgG and IgE antibodies 
partially block the interactions between melanoma cells and ECM components 
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such as fibronectin and collagen, thus restricting cell adhesion and migration in 
vitro (Figure 5.13 & Figure 5.14).  These experiments using newly engineered 
chimeric 225.28S  antibodies were similar to those performed by Wang and 
colleagues using the original murine 225.28S antibody clone in triple negative 
breast cancer models (Wang, Osada et al. 2010). 
Furthermore, the immunological function of HMW-MAA IgG and IgE antibodies 
was examined through the use of engineered antibodies with human Fc regions 
and effector cells isolated from both healthy volunteers and patients.  These Fc-FcR 
mediated functions of the 225.28 clone have not been previously examined, since 
the original clone bears murine Fc regions which are not expected to effectively 
activate human immune effector cells to provide meaningful evaluations of effector 
function in humans (Bergman, Basse et al. 2000).  These in vitro studies revealed 
that HMW-MAA IgG and IgE antibodies mediated ADCP or ADCC against tumor 
cells through the engagement of FcRs on human monocytes, which are known to 
express FcγRs and FcεRs (Maurer, Fiebiger et al. 1994; Karagiannis, Wang et al. 
2003).  These IgG1 and IgE antibodies were observed to mediate disparate 
mechanisms of action, ADCP and ADCC, respectively.  These findings are in 
concordance with equivalent data reported in relation to effector functions of IgG 
and IgE antibodies recognizing the Her2/neu antigen expressed on breast cancer 
cells (Karagiannis, Singer et al. 2009).  Along with the engineered anti-Her2/neu 
IgE homologue of Trastuzumab, another tumor specific antibody of the IgE class, 
MOv18 IgE, has demonstrated Fcε-mediated ADCC using in vitro and in vivo models 
of ovarian cancer.  This agent is currently undergoing preclinical development 
leading to a Phase I study (Karagiannis, Wang et al. 2003; Karagiannis, Josephs et 
al. 2012).  In addition to the well-described ability of tumor-specific antibodies of 
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the IgG class to mediate ADCC (Reichert 2012; Scott, Wolchok et al. 2012), tumor-
specific antibodies of the IgE class may hold promise for the treatment of 
melanoma and other solid tumors through the engagement of FcεR bearing 
immune effector cells present in the tumor, such as monocytes/macrophages 
resulting in ADCC and ADCP.  These findings highlight the potential of antibodies of 
the IgG and IgE class targeting HMW-MAA to engage cells of the innate immune 
system in patients to mount an anti-tumor response, albeit through different 
mechanisms of action.    
Both the non-immunological and immunological studies presented in this thesis 
provide early evaluations of these chimeric HMW-MAA antibodies and are 
expected to further support the preclinical development of IgG antibodies bearing 
human Fc regions targeting HMW-MAA along with the development of antibodies 
engineered with Fc regions of the IgE class. 
 
6.4.2 Patient-derived Antibodies 
There has been renewed interest in the study of human antibody repertoires as a 
potential source of novel antibodies, particularly in light of the more recent reports 
describing techniques to activate human B cells in ex vivo cell cultures (Traggiai, 
Becker et al. 2004; Kwakkenbos, Diehl et al. 2010).  The focus of such an approach 
has primarily been in the field of infectious diseases with the aim of discovering 
neutralizing antibodies to viruses.  The study of antibody responses in infectious 
diseases provides an ideal model system, considering the availability of virus 
antigens for use in the screening for reactive antibodies and the feasibility of 
studying antibody responses following routine vaccinations.  More challenging is 
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the application of this approach to cancers such as melanoma, even with described 
immunogenicity and documented humoral immune responses.  The reasons 
include disease heterogeneity, particularly with regard to antigen expression 
(Stockert, Jäger et al. 1998; Barrow, Browning et al. 2006; Trefzer, Hofmann et al. 
2006); possible effects of disease on B cell homeostasis, such as collapse of 
memory B cell compartments in metastatic patients (Carpenter, Mick et al. 2009); 
immunomodulatory mechanisms in cancer potentially altering the effectiveness of 
humoral immune responses; and lack of commercially available cell surface 
antigens. 
Through the application of more recent methods for the ex vivo culturing of human 
B cells (Traggiai, Becker et al. 2004), this thesis widely examined humoral memory 
to melanoma in a patient cohort by devising a medium-throughput screening tool 
using cancer cells (Chapter 3).  This approach led to the isolation of monoclonal 
antibodies from patients with melanoma, some of which were characterized to 
have specificity to non-autologous melanoma cell lines but not to normal cells such 
as melanocytes.  These findings support the approach outlined in this thesis 
(Chapter 5, Section 5.2.1) to discover, characterize, and evaluate potential 
cytotoxicity of anti-melanoma antibodies from patient memory B cells.  One such 
melanoma-reactive antibody clone, M111_2G3, was found to mediate cytotoxicity 
in the presence of melanoma cells and human monocytic effector cells (Chapter 5, 
Section 5.2.2), highlighting the cytotoxic potential of such antibodies and their 
possible role in engaging innate immune cells to mount an anti-tumor response.  
The identification of melanoma-reactive antibodies, particularly those that appear 
to specifically bind to melanoma cells such as the M111_2G3, supports the merit of 
this approach to discover monoclonal antibodies from patients with cancer.  
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Furthermore, the finding described herein that memory B cells producing 
melanoma-reactive antibodies were observed across many individuals in the 
cohort studied and not restricted to particular clinical scenarios, or to just a few 
select individuals, or those undergoing specific immunological or other treatments, 
further supports the value of this approach to discovering novel antibodies by 
harnessing the B cell memory responses of patients with cancer. 
The antibody discovery methodology described herein could also be applied to 
identifying antibodies from other immunogenic cancers with reported humoral 
immune responses against tumor associated antigens such as breast, lung, and 
ovarian cancers (Lu, Goodell et al. 2008; Reuschenbach, von Knebel Doeberitz et al. 
2009).  This approach also may lead to the identification of novel tumor-associated 
antigens in melanoma and in other cancers, and the study of such antigens could 
then in turn reveal novel pathways associated with these antigens which 





6.5   Future Work  
6.5.1 Discovery and Preclinical Development of Patient-derived 
Antibodies for Immunotherapy 
Patient-derived melanoma-reactive antibodies were observed to have the capacity 
to mediate cytotoxic effects against melanoma cells in vitro, and these findings 
support the merit of the approach presented in this thesis to discovering novel 
antibodies.  While this methodology resulted in the production of antibodies in 
sufficient amounts for initial characterization and preliminary functional assays, 
the combination of this approach with the engineering of recombinant antibodies 
would be needed to permit the greater characterization of melanoma-reactive 
antibodies.  Further characterization of the antibody clone identified in this thesis 
and others discovered using this approach would include antigen identification by 
mass spectrometry, antibody-antigen affinity measurements, evaluation of 
antibody specificity to tumors using an array of melanoma lesions from different 
individuals, and evaluations of reactivity to other tumors types using tissue arrays, 
as well as reactivity to normal tissues.  Additionally, and depending upon the 
functions of the particular antigenic target on tumor cells, a more comprehensive 
study of possible non-immunological functions should be conducted, including 
studies evaluating the blocking of receptor-ligand interactions and the hindering of 
downstream signaling events that could block tumor cell activation.  Other 
evaluations may include the direct inhibition of cell proliferation, colony 
formation, adhesion and invasion, among others.  In the future, selected antibodies 
could be evaluated for their potential efficacy as passive immunotherapeutic 
agents by using animal models of different cancers that express the particular 
antigens.  In the context of melanoma,  animal models of melanoma, such as those 
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described by Chu and colleagues, should be engrafted with human effector cells so 
that direct and Fc-FcR mediated functions of antibodies can be evaluated in 
relation to efficacy (Chu, Ali et al. 2012).   All of these evaluations would 
collectively serve as steps to evaluate the potential of novel antibodies derived 
from patients as possible immunotherapeutic agents.   
 
6.5.2 Role of IgG4 in Cancer 
The work presented in this thesis constitutes the third report of alterations in IgG4 
production or IgG4+ plasma cell infiltration in cancer, and the first report to have 
described altered production of IgG4 in the cutaneous melanoma 
microenvironment.  While these reports are intriguing findings, the association 
between IgG4 and cancer is not clear and warrants further exploration.  A first step 
would be to evaluate if there is an association between IgG4 and multiple cancer 
types, which could be achieved by analyzing tissues from different tumor types for 
IgG4+ B cell infiltration by immunohistochemistry.  Additionally, similar studies to 
those performed in this thesis could be conducted to evaluate the specificity of the 
different IgG subclasses to tumor cells expressed by B cells residing in excised 
tumors, including the IgG4 antibodies.  Furthermore, it is important to further 
elucidate the exact mechanisms that trigger IgG4 polarization in the tumor 
microenvironment and whether these responses could be re-directed using novel 
therapeutic approaches. 
The possible biological significance of IgG4 in cancer has been largely unexplored.  
The alteration of the proportion of IgG subclasses resulting in increased IgG4 and 
decreased IgG1 proportional production in cutaneous metastatic melanoma 
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tumors as described in this thesis could represent an impairment of humoral 
immunity in the tumor microenvironment.  This hypothesis has been tested by 
colleagues by engineering antibodies of the IgG1 and IgG4 subclasses against a 
melanoma cell surface antigen (HMW-MAA) to compare the ability of these 
subclasses to engage immune effector cells to mediate ADCC and ADCP using in 
vitro flow cytometric assays (Bracher, Gould et al. 2007), and also in animal 
models of melanoma that are engrafted with human immune effector cells (Chu, 
Ali et al. 2012).  These experiments have illustrated the weak Fc effector function 
of IgG4 compared to IgG1 to mediate ADCC/ADCP in vitro and in vivo, along with 
the reduction in the efficacy of IgG1 antibodies in the presence of IgG4 
(Karagiannis, Gilbert et al. manuscript under review).  Further studies are 
currently underway evaluating the mechanisms by which IgG4 antibodies impair 
humoral immunity, and these will shed fresh perspective on the roles of redirected 
humoral responses in melanoma. 
 
6.5.3 Preclinical Development of HMW-MAA IgE and IgG Antibodies 
To further evaluate the potential clinical application of HMW-MAA IgG and IgE 
antibodies, additional assessments of the efficacy of these antibodies bearing Fc 
regions are required.  While these antibodies were observed to engage human 
immune cells in vitro to mediate ADCC and ADCP, such evaluations should also be 
carried out using in vivo models of melanoma.  Using human immune effector cells, 
the Fc-mediated contribution of these antibodies to restrict tumor growth could be 
more fully ascertained in animal models of melanoma, and such work is presently 
being carried out by colleagues.  It would also be of interest to evaluate the efficacy 
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of IgG and IgE classes administered in combination, to test if these antibody classes 
could simultaneously engage different immune cells or even act in concert to 
increase the activation of immune cells bearing both FcεRs and FcγRs resulting in 
an increased restriction of tumor growth compared to the administration of 
individual antibody agents. 
Thus far therapeutic antibodies of the IgE class have yet to be administered in 
humans and the preclinical development of an IgE antibody targeting HMW-MAA 
would require additional safety studies.  It is proposed that tumor-specific 
antibodies of the IgE class may exploit potent immune responses, normally known 
to operate in allergic inflammation and in immune protection against parasitic 
infections, within the tumor, such as the activation of FcεRs on tumor-resident 
immune cells leading to ADCC and ADCP of tumor cells (Karagiannis, Josephs et al. 
2012).  However, if the antigen is shed in the circulation at high enough levels and 
in a multivalent form, the occurrence of such mechanisms in the blood could 
trigger type 1 hypersensitivity, which could lead to anaphylaxis.  Although the 
exact requirements for an antigen to trigger anaphylaxis is not fully understood, it 
is hypothesized that such crosslinking of therapeutic IgE antibodies on tumor 
antigens and FcεR expressing immune cells would be rare events in patient blood, 
but should nevertheless be examined for each antibody candidate in the context of 
individual therapeutic indications.  This concept has so far been examined as part 
of the preclinical development of the anti-FRα IgE antibody MOv18 (Rudman, 
Josephs et al. 2011).   
Following the experiments outlined by Rudman et al., who evaluated the potential 
of the FRα-specific monoclonal antibody MOv18 to mediate type 1 hypersensitivity 
in the blood of patients with ovarian cancer, it would be imperative to evaluate any 
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IgE crosslinking in the presence of soluble multivalent HMW-MAA shed in human 
sera or attached to circulating tumor cells or tumor cell fragments in patient blood 
(Rudman, Josephs et al. 2011).  HMW-MAA is a large antigen which has been 
previously reported to be present in patient blood (Vergilis, Szarek et al. 2005), 
and if it circulates in a multivalent form crosslinking may be a special concern 
because of lack of precise information on the 225.28S antibody epitope (Wilson, 
Imai et al. 1981; Kantor, Albino et al. 1986; Mittelman, Tiwari et al. 2004), which 
could be present on the circulating form of the antigen and/or possibly be a 
repeating determinant.  These safety studies would include monitoring early signs 
of basophil activation from patient blood, along with evaluations of ex vivo mast 
cell degranulation in patient sera together with HMW-MAA IgE to assess the 
overall safety of this molecule in patients with melanoma.  These safety studies, 
along with those evaluating efficacy, toxicity, pharmacokinetics, and bio-
distribution, combined with the evaluations presented in this thesis, would permit 






6.6   Concluding Remarks 
The humoral immune response plays a vital role in maintaining health, particularly 
with respect to bacterial and parasitic infections.  The prevalence, role and potency 
of humoral immune responses are not well understood in relation to malignancy.  
The work herein has shown that there is an antibody response to melanoma 
present in patient memory B cells.  Examination of the reactivity of antibodies 
derived from patient memory B cells to melanoma cell lines that originated from 
different individuals, rather than from autologous tumor cells, using a novel cell-
based ELISA revealed that these responses are present among the patient cohort 
examined, although are decreased with increased disease staging.  While the 
potency of such antibody responses in patients to mount an effective anti-tumor 
response is unclear, one patient-derived monoclonal antibody was characterized 
and found to bind to melanoma cells but not to dermal fibroblasts and 
melanocytes, and was able to mediate cytotoxicity against melanoma cells in vitro.  
This work displays the potential of patient-derived melanoma antibodies to have 
cytotoxic effects against tumor cells, and points to this previously unexplored arm 
of adaptive immunity as a potential source of antibodies to be evaluated for 
passive immunotherapy, or as a source of anti-tumor immunity to be activated 
against melanoma through future novel therapeutic strategies. 
Additionally, evaluations of engineered IgE antibodies targeting the tumor 
associated antigen HMW-MAA may provide another strategy to harness the 
immune system against cancer by exploiting the responses normally mediated by 
antibodies of the IgE class against innocuous allergens and parasites.  The 
exploration of strategies to harness patient immune responses merits further 
attention in the design of effective immunotherapies, whether they are focused on 
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activating natural humoral immune responses in the host, using the antibody 
repertoire of patients as a means to discovering novel monoclonal antibodies, or 
exploiting the effector functions of a class of antibodies, other than the 
conventionally used IgG, against solid tumors. 
Finally, this thesis has presented a highly translational approach to the discovery 
and development of monoclonal antibodies for the treatment of cancer through the 
study of patient specimens and human immune cells.  These approaches have 
included the characterization of humoral immunity in melanoma patients which 
led to pathways to identify novel tumor-specific antibodies with potential 
cytotoxic activity against tumor cells, and also the evaluation of antibodies of the 
IgG and IgE classes targeting a melanoma antigen to recruit human immune cells 
to mediate ADCP and ADCC against tumor cells.  All of these findings are aimed at 
characterizing and harnessing the host immune response against cancer with the 
hope of contributing knowledge that translates into new directions in cancer 





































































































































































































































































































































































































































































































































































































































Alignment of the patient-derived antibody clone M80F2 variable regions to 
germline human immunoglobulin.  Sequence alignment and identification mutation 
sites were performed for variable heavy chains (A) and light chains (B) using the 
IMGT/V-QUEST software (Brochet, Lefranc et al. 2008). 
A 
M80F2 VH 










Productive IGH rearranged sequence (no stop codon and in-
frame junction) 





identity = 94,10% (271/288 
nt) 





identity = 89,58% (43/48 nt) 




D-REGION is in reading frame 1 
FR-IMGT lengths, CDR-IMGT lengths 
and AA JUNCTION 
[25.17.38.11] [8.8.14] CAKDRRVGATFVFDSW 
 
(a) Other possibilities: Homsap_IGHJ5*02 (highest number of consecutive identical nucleotides) 
 
1. Alignment for V-GENE and allele identification 
Closest V-REGIONs (evaluated from the V-REGION first nucleotide to the 2nd-CYS codon) 
 
                                    Score       Identity 
AJ879486 Homsap IGHV3-23*04 F       1282        94,10% (271/288 nt) 
M99660 Homsap IGHV3-23*01 F         1273        93,75% (270/288 nt) 
M35415 Homsap IGHV3-23*02 F         1255        93,06% (268/288 nt) 
AY757302 Homsap IGHV3-23*05 F       1237        92,36% (266/288 nt) 
U29481 Homsap IGHV3-23*03 F         1219        91,67% (264/288 nt) 
 
Alignment with FR-IMGT and CDR-IMGT delimitations 
 
                                    <---------------------------------- FR1-
IMGT --------------- 
M80F2H                              
gaggtgcagctggtggagtctggggga...ggcctggtacagcctggggggtccctgaga 




M99660 Homsap IGHV3-23*01 F         ------------t--------------...---t--------
------------------ 
M35415 Homsap IGHV3-23*02 F         ------------t--------------...---t--------
------------------ 
AY757302 Homsap IGHV3-23*05 F       ------------t--------------...---t--------
------------------ 
U29481 Homsap IGHV3-23*03 F         ------------t--------------...---t--------
------------------ 
 
                                    ----------------->______________ CDR1-IMGT 
___________<----- 
M80F2H                              
ctctcctgtgcagcctctggattcaccttt............aggcactatgccatcagt 
AJ879486 Homsap IGHV3-23*04 F       ------------------------------
............--cag---------g--c 
M99660 Homsap IGHV3-23*01 F         ------------------------------
............--cag---------g--c 
M35415 Homsap IGHV3-23*02 F         ------------------------------
............--cag---------g--c 
AY757302 Homsap IGHV3-23*05 F       ------------------------------
............--cag---------g--c 
U29481 Homsap IGHV3-23*03 F         ------------------------------
............--cag---------g--c 
 
                                    --------------- FR2-IMGT -----------------
-->___________ CDR 
M80F2H                              
tgggtccgccaggctccagggaaggggctggagtgggtctcaggtctgagtggtagt... 
AJ879486 Homsap IGHV3-23*04 F       ------------------------------------------
-c-a-t---------... 
M99660 Homsap IGHV3-23*01 F         ------------------------------------------
-c-a-t---------... 
M35415 Homsap IGHV3-23*02 F         ------------------------------------------
-c-a-t---------... 
AY757302 Homsap IGHV3-23*05 F       ------------------------------------------
-c-a-tta-a-c---... 
U29481 Homsap IGHV3-23*03 F         ------------------------------------------
-t-a-tta-a-cg--... 
 
                                    2-IMGT ________<--------------------------
------------------ 
M80F2H                              
...ggaaataggacatactacgcagactccgtgaag...ggccggttcaccatctccaga 
AJ879486 Homsap IGHV3-23*04 F       ...--tgg---c------------------------...---
------------------ 
M99660 Homsap IGHV3-23*01 F         ...--tgg---c------------------------...---
------------------ 
M35415 Homsap IGHV3-23*02 F         ...--tgg---c----------g-------------...---
--------------a--- 
AY757302 Homsap IGHV3-23*05 F       ...--t-g---c--------t---------------...---
------------------ 
U29481 Homsap IGHV3-23*03 F         ...--t-g---c--------t---------------...---
------------------ 
 
                                    --------- FR3-IMGT -----------------------
------------------ 
M80F2H                              
gacaattccgagaacacgctgtttttgcaaatgaacagcctgagagccgaggacacggcc 
AJ879486 Homsap IGHV3-23*04 F       ---------a------------a-c-----------------
------------------ 
M99660 Homsap IGHV3-23*01 F         ---------a------------a-c-----------------
------------------ 
M35415 Homsap IGHV3-23*02 F         ---------a------------a-c-----------------
------------------ 
AY757302 Homsap IGHV3-23*05 F       ---------a------------a-c-----------------
------------------ 





                                    ----------->_________________ CDR3-IMGT 
______________ 
M80F2H                              
gtgtattactgtgcgaaagatcgccgagtgggagctaccttcgtctttgactcctggggc 
AJ879486 Homsap IGHV3-23*04 F       --a----------------- 
M99660 Homsap IGHV3-23*01 F         --a----------------- 
M35415 Homsap IGHV3-23*02 F         --a----------------- 
AY757302 Homsap IGHV3-23*05 F       --a--------------- 
U29481 Homsap IGHV3-23*03 F         --a--------------- 
 
                                     
M80F2H                              cagggaaccctggtcaccgtctccccag 
AJ879486 Homsap IGHV3-23*04 F        
M99660 Homsap IGHV3-23*01 F          
M35415 Homsap IGHV3-23*02 F          
AY757302 Homsap IGHV3-23*05 F        




3. Alignment for J-GENE and allele identification 
Closest J-REGIONs 
 
                                    Score       Identity 
X86355 Homsap IGHJ4*02 F            195         89,58% (43/48 nt) 
J00256 Homsap IGHJ4*01 F            186         87,50% (42/48 nt) 
M25625 Homsap IGHJ4*03 F            177         85,42% (41/48 nt) 
J00256 Homsap IGHJ5*01 F            174         82,35% (42/51 nt) 
X86355 Homsap IGHJ5*02 F            174         82,35% (42/51 nt) 
 
Note that the highest number of consecutive identical nucleotides has been found in the alignment with 
Homsap_IGHJ5*02 
Alignment 
M80F2H                              
tcgccgagtgggagctaccttcgtctttgactcctggggccagggaaccctggtcaccgt 
X86355 Homsap IGHJ4*02 F            ....................a-ta--------a---------
------------------ 
J00256 Homsap IGHJ4*01 F            ....................a-ta--------a---------
a----------------- 
M25625 Homsap IGHJ4*03 F            ....................g-ta--------a---------
a--g-------------- 
J00256 Homsap IGHJ5*01 F            .................a-aa-tgg--c--------------
a----------------- 
X86355 Homsap IGHJ5*02 F            .................a-aa-tgg--c---c----------
------------------ 
 
M80F2H                              ctccccag 
X86355 Homsap IGHJ4*02 F            ----t--- 
J00256 Homsap IGHJ4*01 F            ----t--- 
M25625 Homsap IGHJ4*03 F            ----t--- 
J00256 Homsap IGHJ5*01 F            ----t--- 








4. Results of IMGT/JunctionAnalysis 
Maximum number of accepted mutations in: 3'V-REGION = 2, D-REGION = 4, 5'J-REGION = 2 
Maximum number of accepted D-GENE = 1 
Analysis of the JUNCTION 
 
 
D-REGION is in reading frame 1. 


























































































Translation of the JUNCTION 
 
 






































































C A K D R R V G A T F V F D S W 



























































Be aware that some allele reference sequences may be incomplete or from cDNAs. In those cases, 









104   105   106   107   108   109   110   111   112.1 112   113   114   115   
116   117   118    
 C     A     K     D     R     R     V     G     A     T     F     V     F     
D     S     W     
tgt   gcg   aaa   gat   cgc   cga   gtg   gga   gct   acc   ttc   gtc   ttt   










6. V-REGION alignment according to the IMGT 
unique numbering 
                                    <-----------------------------------------
----  FR1 - IMGT   
                                    1               5                   10                  
15   
M80F2H                              gag gtg cag ctg gtg gag tct ggg gga ... 
ggc ctg gta cag cct  
AJ879486 Homsap IGHV3-23*04 F       --- --- --- --- --- --- --- --- --- ... --
- t-- --- --- ---  
M99660 Homsap IGHV3-23*01 F         --- --- --- --- t-- --- --- --- --- ... --
- t-- --- --- ---  
M35415 Homsap IGHV3-23*02 F         --- --- --- --- t-- --- --- --- --- ... --
- t-- --- --- ---  
AY757302 Homsap IGHV3-23*05 F       --- --- --- --- t-- --- --- --- --- ... --
- t-- --- --- ---  
U29481 Homsap IGHV3-23*03 F         --- --- --- --- t-- --- --- --- --- ... --
- t-- --- --- ---  
 
                                    ------------------------------------------
> ________________ 
                                                    20                  25                  
30   
M80F2H                              ggg ggg tcc ctg aga ctc tcc tgt gca gcc 
tct gga ttc acc ttt  
AJ879486 Homsap IGHV3-23*04 F       --- --- --- --- --- --- --- --- --- --- --
- --- --- --- ---  
M99660 Homsap IGHV3-23*01 F         --- --- --- --- --- --- --- --- --- --- --
- --- --- --- ---  
M35415 Homsap IGHV3-23*02 F         --- --- --- --- --- --- --- --- --- --- --
- --- --- --- ---  
AY757302 Homsap IGHV3-23*05 F       --- --- --- --- --- --- --- --- --- --- --
- --- --- --- ---  
U29481 Homsap IGHV3-23*03 F         --- --- --- --- --- --- --- --- --- --- --
- --- --- --- ---  
 
                                    __  CDR1 - IMGT  ______________ <---------
-----------------  
                                                    35                  40                  
45   
M80F2H                              ... ... ... ... agg cac tat gcc atc agt 
tgg gtc cgc cag gct  
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AJ879486 Homsap IGHV3-23*04 F       ... ... ... ... --c ag- --- --- --g --c --
- --- --- --- ---  
M99660 Homsap IGHV3-23*01 F         ... ... ... ... --c ag- --- --- --g --c --
- --- --- --- ---  
M35415 Homsap IGHV3-23*02 F         ... ... ... ... --c ag- --- --- --g --c --
- --- --- --- ---  
AY757302 Homsap IGHV3-23*05 F       ... ... ... ... --c ag- --- --- --g --c --
- --- --- --- ---  
U29481 Homsap IGHV3-23*03 F         ... ... ... ... --c ag- --- --- --g --c --
- --- --- --- ---  
 
                                     FR2 - IMGT  -------------------------> 
______________  CDR2 
                                                    50                  55                  
60   
M80F2H                              cca ggg aag ggg ctg gag tgg gtc tca ggt 
ctg agt ggt agt ...  
AJ879486 Homsap IGHV3-23*04 F       --- --- --- --- --- --- --- --- --- -c- a-
t --- --- --- ...  
M99660 Homsap IGHV3-23*01 F         --- --- --- --- --- --- --- --- --- -c- a-
t --- --- --- ...  
M35415 Homsap IGHV3-23*02 F         --- --- --- --- --- --- --- --- --- -c- a-
t --- --- --- ...  
AY757302 Homsap IGHV3-23*05 F       --- --- --- --- --- --- --- --- --- -c- a-
t ta- a-c --- ...  
U29481 Homsap IGHV3-23*03 F         --- --- --- --- --- --- --- --- --- -t- a-
t ta- a-c g-- ...  
 
                                     - IMGT  __________ <---------------------
------------------ 
                                                    65                  70                  
75   
M80F2H                              ... gga aat agg aca tac tac gca gac tcc 
gtg aag ... ggc cgg  
AJ879486 Homsap IGHV3-23*04 F       ... --t gg- --c --- --- --- --- --- --- --
- --- ... --- ---  
M99660 Homsap IGHV3-23*01 F         ... --t gg- --c --- --- --- --- --- --- --
- --- ... --- ---  
M35415 Homsap IGHV3-23*02 F         ... --t gg- --c --- --- --- -g- --- --- --
- --- ... --- ---  
AY757302 Homsap IGHV3-23*05 F       ... --t -g- --c --- --- --t --- --- --- --
- --- ... --- ---  
U29481 Homsap IGHV3-23*03 F         ... --t -g- --c --- --- --t --- --- --- --
- --- ... --- ---  
 
                                    -------------------------------  FR3 - 
IMGT  --------------- 
                                                    80                  85                  
90   
M80F2H                              ttc acc atc tcc aga gac aat tcc gag aac 
acg ctg ttt ttg caa  
AJ879486 Homsap IGHV3-23*04 F       --- --- --- --- --- --- --- --- a-- --- --
- --- -a- c-- ---  
M99660 Homsap IGHV3-23*01 F         --- --- --- --- --- --- --- --- a-- --- --
- --- -a- c-- ---  
M35415 Homsap IGHV3-23*02 F         --- --- --- --a --- --- --- --- a-- --- --
- --- -a- c-- ---  
AY757302 Homsap IGHV3-23*05 F       --- --- --- --- --- --- --- --- a-- --- --
- --- -a- c-- ---  
U29481 Homsap IGHV3-23*03 F         --- --- --- --- --- --t --- --- a-- --- --
- --- -a- c-- ---  
 
                                    ------------------------------------------
------------> ____ 
                                                    95                  100             
104  
M80F2H                              atg aac agc ctg aga gcc gag gac acg gcc 
gtg tat tac tgt gcg  
AJ879486 Homsap IGHV3-23*04 F       --- --- --- --- --- --- --- --- --- --- --
a --- --- --- ---  
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M99660 Homsap IGHV3-23*01 F         --- --- --- --- --- --- --- --- --- --- --
a --- --- --- ---  
M35415 Homsap IGHV3-23*02 F         --- --- --- --- --- --- --- --- --- --- --
a --- --- --- ---  
AY757302 Homsap IGHV3-23*05 F       --- --- --- --- --- --- --- --- --- --- --
a --- --- --- ---  
U29481 Homsap IGHV3-23*03 F         --- --- --- --- --- --- --- --- --- --- --
a --- --- --- ---  
 
                                    __________________  CDR3 - IMGT  
__________________ 
                                     
M80F2H                              aaa gat cgc cga gtg gga gct acc ttc gtc 
ttt gac tcc tgg ggc  
AJ879486 Homsap IGHV3-23*04 F       --- -- 
M99660 Homsap IGHV3-23*01 F         --- -- 
M35415 Homsap IGHV3-23*02 F         --- -- 
AY757302 Homsap IGHV3-23*05 F       --- 
U29481 Homsap IGHV3-23*03 F         --- 
 
                                     
                                     
M80F2H                              cag gga acc ctg gtc acc gtc tcc cca g 
AJ879486 Homsap IGHV3-23*04 F        
M99660 Homsap IGHV3-23*01 F          
M35415 Homsap IGHV3-23*02 F          
AY757302 Homsap IGHV3-23*05 F        




7. V-REGION translation 
                                    <-----------------------------------------
----  FR1 - IMGT   
                                    1               5                   10                  
15   
                                     E   V   Q   L   V   E   S   G   G       G   
L   V   Q   P   
M80F2H                              gag gtg cag ctg gtg gag tct ggg gga ... 
ggc ctg gta cag cct  
                                                                                                 
AJ879486 Homsap IGHV3-23*04 F       --- --- --- --- --- --- --- --- --- ... --
- t-- --- --- ---  
 
                                    ------------------------------------------
> ________________ 
                                                    20                  25                  
30   
                                     G   G   S   L   R   L   S   C   A   A   S   
G   F   T   F   
M80F2H                              ggg ggg tcc ctg aga ctc tcc tgt gca gcc 
tct gga ttc acc ttt  
                                                                                                 
AJ879486 Homsap IGHV3-23*04 F       --- --- --- --- --- --- --- --- --- --- --
- --- --- --- ---  
 
                                    __  CDR1 - IMGT  ______________ <---------
-----------------  
                                                    35                  40                  
45   
                                                     R   H   Y   A   I   S   W   
V   R   Q   A   
M80F2H                              ... ... ... ... agg cac tat gcc atc agt 
tgg gtc cgc cag gct  
                                                     S   S           M                           
-282- 
 
AJ879486 Homsap IGHV3-23*04 F       ... ... ... ... --c ag- --- --- --g --c --
- --- --- --- ---  
 
                                     FR2 - IMGT  -------------------------> 
______________  CDR2 
                                                    50                  55                  
60   
                                     P   G   K   G   L   E   W   V   S   G   L   
S   G   S       
M80F2H                              cca ggg aag ggg ctg gag tgg gtc tca ggt 
ctg agt ggt agt ...  
                                                                         A   I                   
AJ879486 Homsap IGHV3-23*04 F       --- --- --- --- --- --- --- --- --- -c- a-
t --- --- --- ...  
 
                                     - IMGT  __________ <---------------------
------------------ 
                                                    65                  70                  
75   
                                         G   N   R   T   Y   Y   A   D   S   V   
K       G   R   
M80F2H                              ... gga aat agg aca tac tac gca gac tcc 
gtg aag ... ggc cgg  
                                             G   S                                               
AJ879486 Homsap IGHV3-23*04 F       ... --t gg- --c --- --- --- --- --- --- --
- --- ... --- ---  
 
                                    -------------------------------  FR3 - 
IMGT  --------------- 
                                                    80                  85                  
90   
                                     F   T   I   S   R   D   N   S   E   N   T   
L   F   L   Q   
M80F2H                              ttc acc atc tcc aga gac aat tcc gag aac 
acg ctg ttt ttg caa  
                                                                     K               
Y           
AJ879486 Homsap IGHV3-23*04 F       --- --- --- --- --- --- --- --- a-- --- --
- --- -a- c-- ---  
 
                                    ------------------------------------------
------------> ____ 
                                                    95                  100             
104  
                                     M   N   S   L   R   A   E   D   T   A   V   
Y   Y   C   A   
M80F2H                              atg aac agc ctg aga gcc gag gac acg gcc 
gtg tat tac tgt gcg  
                                                                                                 
AJ879486 Homsap IGHV3-23*04 F       --- --- --- --- --- --- --- --- --- --- --
a --- --- --- ---  
 
                                    __________________  CDR3 - IMGT  
__________________ 
                                     
                                     K   D   R   R   V   G   A   T   F   V   F   
D   S   W   G   
M80F2H                              aaa gat cgc cga gtg gga gct acc ttc gtc 
ttt gac tcc tgg ggc  
                                        
AJ879486 Homsap IGHV3-23*04 F       --- -- 
 
                                     
                                     
                                     Q   G   T   L   V   T   V   S   P  
M80F2H                              cag gga acc ctg gtc acc gtc tcc cca g 
                                     






8. V-REGION protein display 
                                              FR1-IMGT          CDR1-IMGT       
FR2-IMGT     CD 
                                               (1-26)            (27-38)        
(39-55)       ( 
                                   __________________________ ____________ 
_________________ __ 
                                   1       10        20         30         40        
50         
                                   .........|.........|...... ...|........ 
.|.........|..... .. 
M80F2H                             EVQLVESGG.GLVQPGGSLRLSCAAS GFTF....RHYA 
ISWVRQAPGKGLEWVSG LS 
AJ879486 Homsap IGHV3-23*04 F      EVQLVESGG.GLVQPGGSLRLSCAAS GFTF....SSYA 
MSWVRQAPGKGLEWVSA IS 
                                                                      RH   I               
G L  
 
                                   R2-IMGT                 FR3-IMGT                 
                                   56-65)                  (66-104)                 
                                   ________ 
_______________________________________ 
                                    60         70        80        90        
100      
                                   ..|..... 
....|.........|.........|.........|....  
M80F2H                             GS..GNRT 
YYADSVK.GRFTISRDNSENTLFLQMNSLRAEDTAVYYC AK 
AJ879486 Homsap IGHV3-23*04 F      GS..GGST 
YYADSVK.GRFTISRDNSKNTLYLQMNSLRAEDTAVYYC AK 
                                        NR                    E   F                    
 
 
9. V-REGION mutation and AA change table 
FR1-
IMGT 






S35>R (- - -) 
a106>c, 
S36>H (+ - -) 
g107>a, 
S36>H (+ - -) 
 
g117>c, 
M39>I (+ + -) 
c120>t 
c164>g, 
A55>G (- + -) 
 
a166>c, 
I56>L (+ + +) 
t168>g, I56>L 
(+ + +) 
t186>a 
g187>a, 
G63>N (- - -) 
g188>a, 
G63>N (- - -) 
c192>g, 
S64>R (- - -) 
 
a250>g, 
K84>E (+ - -) 
a263>t, 






10. V-REGION mutation and AA change statistics 
-284- 
 
















Nb of positions  
including IMGT gaps (nt) 
320 78 36 51 30 117 8 
Nb of nucleotides 296 75 24 51 24 114 8 
Nb of identical 
nucleotides 
279 74 21 48 18 110 8 
Nb of mutations 17 1 3 3 6 4 0 
Mutations 
Silent 5 1 0 1 1 2 0 
Nonsilent 12 0 3 2 5 2 0 
Transitions 
a>g 2 0 0 0 0 2 0 
g>a 3 0 1 0 2 0 0 
c>t 2 0 0 1 0 1 0 
t>c 1 1 0 0 0 0 0 
Transversions 
a>c 2 0 1 0 1 0 0 
c>a 0 0 0 0 0 0 0 
a>t 1 0 0 0 0 1 0 
t>a 1 0 0 0 1 0 0 
g>c 1 0 0 1 0 0 0 
c>g 3 0 1 1 1 0 0 
g>t 0 0 0 0 0 0 0 
t>g 1 0 0 0 1 0 0 
















Nb of positions including 
IMGT 
gaps (AA) 
106 26 12 17 10 39 2 
Nb of AA 98 25 8 17 8 38 2 
Nb of identical AA 89 25 6 15 5 36 2 



























2 0 0 1 0 1 0 
(- - 
+) 




















Productive IGK rearranged sequence (no stop codon and in-frame 
junction) 
V-GENE and allele 





= 94,07% (254/270 nt) 
J-GENE and allele Homsap IGKJ1*01 F 
score = 
181 
identity = 97,37% 
(37/38 nt) 
FR-IMGT lengths, CDR-IMGT 
lengths and AA JUNCTION 
[23.17.36.10] [6.3.5] CQQRGTF 
 
1. Alignment for V-GENE and allele identification 
Closest V-REGIONs (evaluated from the V-REGION first nucleotide to the 2nd-CYS codon plus 
15 nt of the CDR3-IMGT) 
 
                                    Score       Identity 
X59315 Homsap IGKV1-39*01 F         1210        94,07% (254/270 nt) 
X59312 Homsap IGKV1D-39*01 F        1210        94,07% (254/270 nt) 
X59318 Homsap IGKV1-39*02 P         1147        91,48% (247/270 nt) 
Z00013 Homsap IGKV1-9*01 F          1066        88,15% (238/270 nt) 
V01577 Homsap IGKV1-12*01 F         1057        87,78% (237/270 nt) 
 




                                    <---------------------------------- FR1-
IMGT --------------- 
M80F2K                              
.........atgacccagactccatccaccctgtctgcatctgtgggagacagagtcacc 
X59315 Homsap IGKV1-39*01 F         gacatccag---------t--------t--------------
--a--------------- 
X59312 Homsap IGKV1D-39*01 F        gacatccag---------t--------t--------------
--a--------------- 
X59318 Homsap IGKV1-39*02 P         gacatccag---------t--------tt-------------
--a--------------- 
Z00013 Homsap IGKV1-9*01 F          gacatccagt--------t--------tt-------------
--a--------------- 
V01577 Homsap IGKV1-12*01 F         gacatccag---------t-------tt--g-----------
--a--------------- 
 
                                    ----------------->______________ CDR1-IMGT 
___________<----- 
M80F2K                              
atcacttgccgggcaagtcagaacatt..................accacctatttcaat 
X59315 Homsap IGKV1-39*01 F         ----------------------g----
..................-g--g------a--- 
X59312 Homsap IGKV1D-39*01 F        ----------------------g----
..................-g--g------a--- 
X59318 Homsap IGKV1-39*02 P         ----------------------g----
..................-g--g------a--- 
Z00013 Homsap IGKV1-9*01 F          --------------c------gg----
..................-g--gt-----agcc 
V01577 Homsap IGKV1-12*01 F         --------t-----g------ggt---
..................-g--g--gg--agcc 
 
                                    --------------- FR2-IMGT -----------------
-->___________ CDR 
M80F2K                              
tggtatcagcaaaaaccagggaaagcccctaaactcctgatctatgctgca......... 
X59315 Homsap IGKV1-39*01 F         -----------g--------------------g---------
---------......... 
X59312 Homsap IGKV1D-39*01 F        -----------g--------------------g---------
---------......... 
X59318 Homsap IGKV1-39*02 P         -----------g--------------------g---------
---------......... 
Z00013 Homsap IGKV1-9*01 F          --------------------------------g---------
---------......... 
V01577 Homsap IGKV1-12*01 F         -----------g--------------------g---------
---------......... 
 
                                    2-IMGT ________<--------------------------
------------------ 
M80F2K                              
............tccagtttgcaaagtggggtccca...tcaaggttcagtggcagtgga 
X59315 Homsap IGKV1-39*01 F         ............------------------------...---
------------------ 
X59312 Homsap IGKV1D-39*01 F        ............------------------------...---
------------------ 
X59318 Homsap IGKV1-39*02 P         ............------------------------...---
------------------ 
Z00013 Homsap IGKV1-9*01 F          ............----c-------------------...---
--------c--------- 
V01577 Homsap IGKV1-12*01 F         ............------------------------...---
--------c--------- 
 
                                    --------- FR3-IMGT -----------------------
------------------ 
M80F2K                              
......tctgggacagatttcactctcaccatcaccagtctgcaacctgaagattttgca 
X59315 Homsap IGKV1-39*01 F         ......----------------------------g-------
------------------ 
X59312 Homsap IGKV1D-39*01 F        ......----------------------------g-------
------------------ 




Z00013 Homsap IGKV1-9*01 F          ......-----------a-----------a----g---c---
--g--------------- 
V01577 Homsap IGKV1-12*01 F         ......----------------------------g---c---
--g--------------- 
 
                                    ----------->___ CDR3-IMGT _ 
M80F2K                              
acttactactgtcaacagagggggacgttcggccaagggaccaaggtggaaatcaaacga 
X59315 Homsap IGKV1-39*01 F         --------------------ttac-gtac-cct-c 
X59312 Homsap IGKV1D-39*01 F        --------------------ttac-gtac-cct-c 
X59318 Homsap IGKV1-39*02 P         -----t--------gtgtg-ttac-gtacacct-c 
Z00013 Homsap IGKV1-9*01 F          -----t------------cttaat-gt-a-cct-c 




3. Alignment for J-GENE and allele identification 
Closest J-REGIONs 
 
                                    Score       Identity 
J00242 Homsap IGKJ1*01 F            181         97,37% (37/38 nt) 
AF103571 Homsap IGKJ4*02 F          136         84,21% (32/38 nt) 
Z70260 Homsap IGKJ2*02 F            127         81,58% (31/38 nt) 
J00242 Homsap IGKJ4*01 F            127         81,58% (31/38 nt) 




M80F2K                              ggggacgttcggccaagggaccaaggtggaaatcaaacga 
J00242 Homsap IGKJ1*01 F            -t------------------------------------ 
AF103571 Homsap IGKJ4*02 F          -ctc---------gg---------------g------- 
Z70260 Homsap IGKJ2*02 F            -t-c--t--t-----g---------c----g------- 
J00242 Homsap IGKJ4*01 F            -ctc--t------gg---------------g------- 




4. Results of IMGT/JunctionAnalysis 
Maximum number of accepted mutations in: 3'V-REGION = 7, 5'J-REGION = 7 
Maximum number of accepted D-GENE = 0 
Analysis of the JUNCTION 
 
 







































Translation of the JUNCTION 
 
 












C Q Q R G T F 
    
  M80F2K tgt caa cag agg ggg acg ttc + 5 838.94 8.25 
Be aware that some allele reference sequences may be incomplete or from cDNAs. In those cases, 
IMGT/JunctionAnalysis uses automatically the allele *01 for the analysis of the JUNCTION. 
 
 




104 105 106 107 116 117 118  
 C   Q   Q   R   G   T   F   










6. V-REGION alignment according to the IMGT 
unique numbering 
                                    <-----------------------------------------
----  FR1 - IMGT   
                                    1               5                   10                  
15   
M80F2K                              ... ... ... atg acc cag act cca tcc acc 
ctg tct gca tct gtg  
X59315 Homsap IGKV1-39*01 F         gac atc cag --- --- --- t-- --- --- t-- --
- --- --- --- --a  
X59312 Homsap IGKV1D-39*01 F        gac atc cag --- --- --- t-- --- --- t-- --
- --- --- --- --a  
X59318 Homsap IGKV1-39*02 P         gac atc cag --- --- --- t-- --- --- tt- --
- --- --- --- --a  
Z00013 Homsap IGKV1-9*01 F          gac atc cag t-- --- --- t-- --- --- tt- --
- --- --- --- --a  
V01577 Homsap IGKV1-12*01 F         gac atc cag --- --- --- t-- --- --t t-- g-




                                    ------------------------------------------
> ________________ 
                                                    20                  25                  
30   
M80F2K                              gga gac aga gtc acc atc act tgc cgg gca 
agt cag aac att ...  
X59315 Homsap IGKV1-39*01 F         --- --- --- --- --- --- --- --- --- --- --
- --- -g- --- ...  
X59312 Homsap IGKV1D-39*01 F        --- --- --- --- --- --- --- --- --- --- --
- --- -g- --- ...  
X59318 Homsap IGKV1-39*02 P         --- --- --- --- --- --- --- --- --- --- --
- --- -g- --- ...  
Z00013 Homsap IGKV1-9*01 F          --- --- --- --- --- --- --- --- --- --c --
- --- gg- --- ...  
V01577 Homsap IGKV1-12*01 F         --- --- --- --- --- --- --- --t --- --g --
- --- ggt --- ...  
 
                                    __  CDR1 - IMGT  ______________ <---------
-----------------  
                                                    35                  40                  
45   
M80F2K                              ... ... ... ... ... acc acc tat ttc aat 
tgg tat cag caa aaa  
X59315 Homsap IGKV1-39*01 F         ... ... ... ... ... -g- -g- --- --a --- --
- --- --- --g ---  
X59312 Homsap IGKV1D-39*01 F        ... ... ... ... ... -g- -g- --- --a --- --
- --- --- --g ---  
X59318 Homsap IGKV1-39*02 P         ... ... ... ... ... -g- -g- --- --a --- --
- --- --- --g ---  
Z00013 Homsap IGKV1-9*01 F          ... ... ... ... ... -g- -gt --- --a gcc --
- --- --- --- ---  
V01577 Homsap IGKV1-12*01 F         ... ... ... ... ... -g- -g- -gg --a gcc --
- --- --- --g ---  
 
                                     FR2 - IMGT  -------------------------> 
______________  CDR2 
                                                    50                  55                  
60   
M80F2K                              cca ggg aaa gcc cct aaa ctc ctg atc tat 
gct gca ... ... ...  
X59315 Homsap IGKV1-39*01 F         --- --- --- --- --- --g --- --- --- --- --
- --- ... ... ...  
X59312 Homsap IGKV1D-39*01 F        --- --- --- --- --- --g --- --- --- --- --
- --- ... ... ...  
X59318 Homsap IGKV1-39*02 P         --- --- --- --- --- --g --- --- --- --- --
- --- ... ... ...  
Z00013 Homsap IGKV1-9*01 F          --- --- --- --- --- --g --- --- --- --- --
- --- ... ... ...  
V01577 Homsap IGKV1-12*01 F         --- --- --- --- --- --g --- --- --- --- --
- --- ... ... ...  
 
                                     - IMGT  __________ <---------------------
------------------ 
                                                    65                  70                  
75   
M80F2K                              ... ... ... ... tcc agt ttg caa agt ggg 
gtc cca ... tca agg  
X59315 Homsap IGKV1-39*01 F         ... ... ... ... --- --- --- --- --- --- --
- --- ... --- ---  
X59312 Homsap IGKV1D-39*01 F        ... ... ... ... --- --- --- --- --- --- --
- --- ... --- ---  
X59318 Homsap IGKV1-39*02 P         ... ... ... ... --- --- --- --- --- --- --
- --- ... --- ---  
Z00013 Homsap IGKV1-9*01 F          ... ... ... ... --- -c- --- --- --- --- --
- --- ... --- ---  
V01577 Homsap IGKV1-12*01 F         ... ... ... ... --- --- --- --- --- --- --




                                    -------------------------------  FR3 - 
IMGT  --------------- 
                                                    80                  85                  
90   
M80F2K                              ttc agt ggc agt gga ... ... tct ggg aca 
gat ttc act ctc acc  
X59315 Homsap IGKV1-39*01 F         --- --- --- --- --- ... ... --- --- --- --
- --- --- --- ---  
X59312 Homsap IGKV1D-39*01 F        --- --- --- --- --- ... ... --- --- --- --
- --- --- --- ---  
X59318 Homsap IGKV1-39*02 P         --- --- --- --- --- ... ... --- --- --- --
- --- --- --- ---  
Z00013 Homsap IGKV1-9*01 F          --- --c --- --- --- ... ... --- --- --- --
a --- --- --- --a  
V01577 Homsap IGKV1-12*01 F         --- --c --- --- --- ... ... --- --- --- --
- --- --- --- ---  
 
                                    ------------------------------------------
------------> ___  
                                                    95                  100             
104  
M80F2K                              atc acc agt ctg caa cct gaa gat ttt gca 
act tac tac tgt caa  
X59315 Homsap IGKV1-39*01 F         --- -g- --- --- --- --- --- --- --- --- --
- --- --- --- ---  
X59312 Homsap IGKV1D-39*01 F        --- -g- --- --- --- --- --- --- --- --- --
- --- --- --- ---  
X59318 Homsap IGKV1-39*02 P         --- -g- --- --- --- --- --- --- --- --- --
- --t --- --- --g  
Z00013 Homsap IGKV1-9*01 F          --- -g- --c --- --g --- --- --- --- --- --
- --t --- --- ---  
V01577 Homsap IGKV1-12*01 F         --- -g- --c --- --g --- --- --- --- --- --
- --- --t --- ---  
 
                                     CDR3 -  IMGT _ 
                                     
M80F2K                              cag agg ggg acg ttc ggc caa ggg acc aag 
gtg gaa atc aaa cga 
X59315 Homsap IGKV1-39*01 F         --- --t tac -gt ac- cct -c 
X59312 Homsap IGKV1D-39*01 F        --- --t tac -gt ac- cct -c 
X59318 Homsap IGKV1-39*02 P         tgt g-t tac -gt aca cct -c 
Z00013 Homsap IGKV1-9*01 F          --- ctt aat -gt -a- cct -c 




7. V-REGION translation 
                                    <-----------------------------------------
----  FR1 - IMGT   
                                    1               5                   10                  
15   
                                                 M   T   Q   T   P   S   T   L   
S   A   S   V   
M80F2K                              ... ... ... atg acc cag act cca tcc acc 
ctg tct gca tct gtg  
                                     D   I   Q               S           S                       
X59315 Homsap IGKV1-39*01 F         gac atc cag --- --- --- t-- --- --- t-- --
- --- --- --- --a  
 
                                    ------------------------------------------
> ________________ 
                                                    20                  25                  
30   
                                     G   D   R   V   T   I   T   C   R   A   S   
Q   N   I       
-291- 
 
M80F2K                              gga gac aga gtc acc atc act tgc cgg gca 
agt cag aac att ...  
                                                                                     
S           
X59315 Homsap IGKV1-39*01 F         --- --- --- --- --- --- --- --- --- --- --
- --- -g- --- ...  
 
                                    __  CDR1 - IMGT  ______________ <---------
-----------------  
                                                    35                  40                  
45   
                                                         T   T   Y   F   N   W   
Y   Q   Q   K   
M80F2K                              ... ... ... ... ... acc acc tat ttc aat 
tgg tat cag caa aaa  
                                                         S   S       L                           
X59315 Homsap IGKV1-39*01 F         ... ... ... ... ... -g- -g- --- --a --- --
- --- --- --g ---  
 
                                     FR2 - IMGT  -------------------------> 
______________  CDR2 
                                                    50                  55                  
60   
                                     P   G   K   A   P   K   L   L   I   Y   A   
A               
M80F2K                              cca ggg aaa gcc cct aaa ctc ctg atc tat 
gct gca ... ... ...  
                                                                                                 
X59315 Homsap IGKV1-39*01 F         --- --- --- --- --- --g --- --- --- --- --
- --- ... ... ...  
 
                                     - IMGT  __________ <---------------------
------------------ 
                                                    65                  70                  
75   
                                                     S   S   L   Q   S   G   V   
P       S   R   
M80F2K                              ... ... ... ... tcc agt ttg caa agt ggg 
gtc cca ... tca agg  
                                                                                                 
X59315 Homsap IGKV1-39*01 F         ... ... ... ... --- --- --- --- --- --- --
- --- ... --- ---  
 
                                    -------------------------------  FR3 - 
IMGT  --------------- 
                                                    80                  85                  
90   
                                     F   S   G   S   G           S   G   T   D   
F   T   L   T   
M80F2K                              ttc agt ggc agt gga ... ... tct ggg aca 
gat ttc act ctc acc  
                                                                                                 
X59315 Homsap IGKV1-39*01 F         --- --- --- --- --- ... ... --- --- --- --
- --- --- --- ---  
 
                                    ------------------------------------------
------------> ___  
                                                    95                  100             
104  
                                     I   T   S   L   Q   P   E   D   F   A   T   
Y   Y   C   Q   
M80F2K                              atc acc agt ctg caa cct gaa gat ttt gca 
act tac tac tgt caa  
                                         S                                                       
X59315 Homsap IGKV1-39*01 F         --- -g- --- --- --- --- --- --- --- --- --
- --- --- --- ---  
 
                                     CDR3 -  IMGT _ 
                                     
-292- 
 
                                     Q   R   G   T   F   G   Q   G   T   K   V   
E   I   K   R  
M80F2K                              cag agg ggg acg ttc ggc caa ggg acc aag 
gtg gaa atc aaa cga 
                                         S   Y   S   T   P  




8. V-REGION protein display 
                                              FR1-IMGT          CDR1-IMGT       
FR2-IMGT     CD 
                                               (1-26)            (27-38)        
(39-55)       ( 
                                   __________________________ ____________ 
_________________ __ 
                                   1       10        20         30         40        
50         
                                   .........|.........|...... ...|........ 
.|.........|..... .. 
M80F2K                             ...MTQTPSTLSASVGDRVTITCRAS QNI......TTY 
FNWYQQKPGKAPKLLIY AA 
X59315 Homsap IGKV1-39*01 F        DIQMTQSPSSLSASVGDRVTITCRAS QSI......SSY 
LNWYQQKPGKAPKLLIY AA 
                                         T  T                  N       TT  F                    
 
                                   R2-IMGT                 FR3-IMGT                 
                                   56-65)                  (66-104)                 
                                   ________ 
_______________________________________ 
                                    60         70        80        90        
100      
                                   ..|..... 
....|.........|.........|.........|....  
M80F2K                             .......S 
SLQSGVP.SRFSGSG..SGTDFTLTITSLQPEDFATYYC QQ 
X59315 Homsap IGKV1-39*01 F        .......S 
SLQSGVP.SRFSGSG..SGTDFTLTISSLQPEDFATYYC QQSYSTP 
                                                                      T                
 
 
9. V-REGION mutation and AA change table 





S7>T (+ - 
+) 
t28>a, 





S28>N (- - -) 
g107>c, 
S36>T (+ - 
+) 
g110>c, 














S107>R (- - -
) 
t322>g, 
Y108>G (+ - 
-) 
a323>g, 
Y108>G (+ - 
-) 
c324>g, 





S109>T (+ - 
+) 
t327>g, 




10. V-REGION mutation and AA change statistics 
















Nb of positions  
including IMGT gaps (nt) 
320 (327) 78 36 51 30 117 8 (15) 
Nb of nucleotides 263 (270) 69 18 51 9 108 8 (15) 
Nb of identical 
nucleotides 
253 (254) 66 15 48 9 107 8 (9) 
Nb of mutations 10 (16) 3 3 3 0 1 0 (6) 
Mutations 
Silent 3 1 0 2 0 0 0 
Nonsilent 7 (13) 2 3 1 0 1 0 (6) 
Transitions 
a>g 1 (2) 1 0 0 0 0 0 (1) 
g>a 3 0 1 2 0 0 0 
c>t 0 0 0 0 0 0 0 
t>c 0 0 0 0 0 0 0 
Transversions 
a>c 1 0 0 1 0 0 0 
c>a 0 0 0 0 0 0 0 
a>t 0 0 0 0 0 0 0 
t>a 2 2 0 0 0 0 0 
g>c 3 (4) 0 2 0 0 1 0 (1) 
c>g 0 (1) 0 0 0 0 0 0 (1) 
g>t 0 0 0 0 0 0 0 
t>g 0 (3) 0 0 0 0 0 0 (3) 


















Nb of positions including 
IMGT 
gaps (AA) 
106 (109) 26 12 17 10 39 2 (5) 
Nb of AA 87 (90) 23 6 17 3 36 2 (5) 
Nb of identical AA 80 21 3 16 3 35 2 
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(- - 
+) 












Aalberse, R. C., S. O. Stapel, J. Schuurman and T. Rispens (2009). "Immunoglobulin 
G4: an odd antibody." Clinical & Experimental Allergy 39(4): 469-477. 
ACS (2012). "Cancer Facts & Figures 2012." American Cancer Society  retrieved 19 
September 2012, from http://www.cancer.org/acs/groups/content/ 
@epidemiologysurveilance/documents/document/acspc-031941.pdf. 
Agarwal, A., S. Verma, U. Burra, N. Murthy, N. Mohanty and S. Saxena (2006). "Flow 
Cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of 
immunological dysfunction in patients of Superficial Transitional cell 
carcinoma of bladder." Cancer Immunology, Immunotherapy 55(6): 734-
743. 
Agematsu, K., H. Nagumo, Y. Oguchi, T. Nakazawa, K. Fukushima, K. Yasui, S. Ito, T. 
Kobata, C. Morimoto and A. Komiyama (1998). "Generation of Plasma Cells 
From Peripheral Blood Memory B Cells: Synergistic Effect of Interleukin-10 
and CD27/CD70 Interaction." Blood 91(1): 173-180. 
Ahmadzadeh, M., L. A. Johnson, B. Heemskerk, J. R. Wunderlich, M. E. Dudley, D. E. 
White and S. A. Rosenberg (2009). "Tumor antigen–specific CD8 T cells 
infiltrating the tumor express high levels of PD-1 and are functionally 
impaired." Blood 114(8): 1537-1544. 
Ait-Tahar, K., C. Damm-Welk, B. Burkhardt, M. Zimmermann, W. Klapper, A. Reiter, 
K. Pulford and W. Woessmann (2010). "Correlation of the autoantibody 
response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase–
positive anaplastic large cell lymphoma with tumor dissemination and 
relapse risk." Blood 115(16): 3314-3319. 
Albertsson, P. A., P. H. Basse, M. Hokland, R. H. Goldfarb, J. F. Nagelkerke, U. 
Nannmark and P. J. K. Kuppen (2003). "NK cells and the tumour 
microenvironment: implications for NK-cell function and anti-tumour 
activity." Trends in Immunology 24(11): 603-609. 
Allman, D. and J. P. Miller (2005). "B cell development and receptor diversity 
during aging." Current Opinion in Immunology 17(5): 463-467. 
Anderson, C. L. and G. N. Abraham (1980). "Characterization of the Fc receptor for 
IgG on a human macrophage cell line, U937." Journal of Immunology 
125(6): 2735-2741. 
Andreu, P., M. Johansson, N. I. Affara, F. Pucci, T. Tan, S. Junankar, L. Korets, J. Lam, 
D. Tawfik, D. G. DeNardo, L. Naldini, K. E. de Visser, M. De Palma and L. M. 
Coussens (2010). "FcR[gamma] Activation Regulates Inflammation-
Associated Squamous Carcinogenesis." Cancer Cell 17(2): 121-134. 
Atkins, M. B., M. T. Lotze, J. P. Dutcher, R. I. Fisher, G. Weiss, K. Margolin, J. Abrams, 
M. Sznol, D. Parkinson, M. Hawkins, C. Paradise, L. Kunkel and S. A. 
Rosenberg (1999). "High-Dose Recombinant Interleukin 2 Therapy for 
Patients With Metastatic Melanoma: Analysis of 270 Patients Treated 
Between 1985 and 1993." Journal of Clinical Oncology 17(7): 2105-2116. 
Babel, I., R. Barderas, R. Díaz-Uriarte, J. L. Martínez-Torrecuadrada, M. Sánchez-
Carbayo and J. I. Casal (2009). "Identification of Tumor-associated Autoantigens 
for the Diagnosis of Colorectal Cancer in Serum Using High Density Protein 
Microarrays." Molecular & Cellular Proteomics 8(10): 2382-2395. 
-296- 
 
Balch, C. M., J. E. Gershenwald, S.-j. Soong, J. F. Thompson, M. B. Atkins, D. R. Byrd, 
A. C. Buzaid, A. J. Cochran, D. G. Coit, S. Ding, A. M. Eggermont, K. T. Flaherty, 
P. A. Gimotty, J. M. Kirkwood, K. M. McMasters, M. C. Mihm, Jr, D. L. Morton, 
M. I. Ross, A. J. Sober and V. K. Sondak (2009). "Final Version of 2009 AJCC 
Melanoma Staging and Classification." Journal of Clinical Oncology 27(36): 
6199-6206. 
Balsamo, M., W. Vermi, M. Parodi, G. Pietra, C. Manzini, P. Queirolo, S. Lonardi, R. 
Augugliaro, A. Moretta, F. Facchetti, L. Moretta, M. C. Mingari and M. Vitale 
(2012). "Melanoma cells become resistant to NK-cell-mediated killing when 
exposed to NK-cell numbers compatible with NK-cell infiltration in the 
tumor." European Journal of Immunology 42(7): 1833-1842. 
Barbas, C. F. (1995). "Synthetic human antibodies." Nature Medicine 1(8): 837-
839. 
Barrow, C., J. Browning, D. MacGregor, I. D. Davis, S. Sturrock, A. A. Jungbluth and J. 
Cebon (2006). "Tumor Antigen Expression in Melanoma Varies According 
to Antigen and Stage." Clinical Cancer Research 12(3): 764-771. 
Bergman, I., P. H. Basse, M. A. Barmada, J. A. Griffin and N.-K. V. Cheung (2000). 
"Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and 
human effectors." Cancer Immunology, Immunotherapy 49(4): 259-266. 
Bernasconi, N. L., N. Onai and A. Lanzavecchia (2003). "A role for Toll-like 
receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in 
naive B cells and constitutive expression in memory B cells." Blood 
101(11): 4500-4504. 
Bernasconi, N. L., E. Traggiai and A. Lanzavecchia (2002). "Maintenance of 
Serological Memory by Polyclonal Activation of Human Memory B Cells." 
Science 298(5601): 2199-2202. 
Besser, M. J., R. Shapira-Frommer, A. J. Treves, D. Zippel, O. Itzhaki, L. Hershkovitz, 
D. Levy, A. Kubi, E. Hovav, N. Chermoshniuk, B. Shalmon, I. Hardan, R. 
Catane, G. Markel, S. Apter, A. Ben-Nun, I. Kuchuk, A. Shimoni, A. Nagler and 
J. Schachter (2010). "Clinical Responses in a Phase II Study Using Adoptive 
Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in 
Metastatic Melanoma Patients." Clinical Cancer Research 16(9): 2646-2655. 
Blixt, O., D. Bueti, B. Burford, D. Allen, S. Julien, M. Hollingsworth, A. Gammerman, I. 
Fentiman, J. Taylor-Papadimitriou and J. M. Burchell (2011). 
"Autoantibodies to aberrantly glycosylated MUC1 in early stage breast 
cancer are associated with a better prognosis." Breast Cancer Research 
13(2): R25. 
Boni, A., A. P. Cogdill, P. Dang, D. Udayakumar, C.-N. J. Njauw, C. M. Sloss, C. R. 
Ferrone, K. T. Flaherty, D. P. Lawrence, D. E. Fisher, H. Tsao and J. A. Wargo 
(2010). "Selective BRAFV600E Inhibition Enhances T-Cell Recognition of 
Melanoma without Affecting Lymphocyte Function." Cancer Research 
70(13): 5213-5219. 
Bowers, P. M., R. A. Horlick, T. Y. Neben, R. M. Toobian, G. L. Tomlinson, J. L. Dalton, 
H. A. Jones, A. Chen, L. Altobell, X. Zhang, J. L. Macomber, I. P. Krapf, B. F. Wu, 
A. McConnell, B. Chau, T. Holland, A. D. Berkebile, S. S. Neben, W. J. Boyle 
and D. J. King (2011). "Coupling mammalian cell surface display with 
somatic hypermutation for the discovery and maturation of human 





Bowles, J. A., S.-Y. Wang, B. K. Link, B. Allan, G. Beuerlein, M.-A. Campbell, D. 
Marquis, B. Ondek, J. E. Wooldridge, B. J. Smith, J. B. Breitmeyer and G. J. 
Weiner (2006). "Anti-CD20 monoclonal antibody with enhanced affinity for 
CD16 activates NK cells at lower concentrations and more effectively than 
rituximab." Blood 108(8): 2648-2654. 
 Bracher, M., H. J. Gould, B. J. Sutton, D. Dombrowicz and S. N. Karagiannis (2007). 
"Three-colour flow cytometric method to measure antibody-dependent 
tumour cell killing by cytotoxicity and phagocytosis." Journal of 
Immunological Methods 323(2): 160-171. 
Brahmer, J. R., C. G. Drake, I. Wollner, J. D. Powderly, J. Picus, W. H. Sharfman, E. 
Stankevich, A. Pons, T. M. Salay, T. L. McMiller, M. M. Gilson, C. Wang, M. 
Selby, J. M. Taube, R. Anders, L. Chen, A. J. Korman, D. M. Pardoll, I. Lowy and 
S. L. Topalian (2010). "Phase I Study of Single-Agent Anti–Programmed 
Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, 
Pharmacodynamics, and Immunologic Correlates." Journal of Clinical 
Oncology 28(19): 3167-3175. 
Brochet, X., M.-P. Lefranc and V. Giudicelli (2008). "IMGT/V-QUEST: the highly 
customized and integrated system for IG and TR standardized V-J and V-D-J 
sequence analysis." Nucleic Acids Research 36(suppl 2): W503-W508. 
Bruggemann, M., G. Williams, C. Bindon, M. Clark, M. Walker, R. Jefferis, H. 
Waldmann and M. Neuberger (1987). "Comparison of the effector functions 
of human immunoglobulins using a matched set of chimeric antibodies." 
Journal of Experimental Medicine. 166(5): 1351-1361. 
Bruhns, P., B. Iannascoli, P. England, D. A. Mancardi, N. Fernandez, S. Jorieux and M. 
Daëron (2009). "Specificity and affinity of human Fcγ receptors and their 
polymorphic variants for human IgG subclasses." Blood 113(16): 3716-
3725. 
Bulkley, G. B., M. H. Cohen, P. M. Banks, D. H. Char and A. S. Ketcham (1975). "Long-
term spontaneous regression of malignant melanoma with visceral 
metastases Report of a case with immunologic profile." Cancer 36(2): 485-
494. 
Caballero, O. L. and Y.-T. Chen (2009). "Cancer/testis (CT) antigens: Potential 
targets for immunotherapy." Cancer Science 100(11): 2014-2021. 
Cai, X. and A. Garen (1995). "Anti-melanoma antibodies from melanoma patients 
immunized with genetically modified autologous tumor cells: selection of 
specific antibodies from single-chain Fv fusion phage libraries." 
Proceedings of the National Academy of Sciences 92(14): 6537-6541. 
Campoli, M., R. Ferris, S. Ferrone and X. Wang (2010). "Immunotherapy of 
Malignant Disease with Tumor Antigen–Specific Monoclonal Antibodies." 
Clinical Cancer Research 16(1): 11-20. 
Campoli, M. R., C.-C. Chang, T. Kageshita, X. Wang, J. B. McCarthy and S. Ferrone 
(2004). "Human High Molecular Weight-Melanoma-Associated Antigen 
(HMW-MAA): A Melanoma Cell Surface Chondroitin Sulfate Proteoglycan 
(MSCP) with Biological and Clinical Significance." Critical Reviews in 
Immunology 24(4): 267-296. 
Carey, T. E., T. Takahashi, L. A. Resnick, H. F. Oettgen and L. J. Old (1976). "Cell 
surface antigens of human malignant melanoma: mixed hemadsorption 
assays for humoral immunity to cultured autologous melanoma cells." 




Carpenter, E. L., R. Mick, A. J. Rech, G. L. Beatty, T. A. Colligon, M. R. Rosenfeld, D. E. 
Kaplan, K.-M. Chang, S. M. Domchek, P. A. Kanetsky, L. A. Fecher, K. T. 
Flaherty, L. M. Schuchter and R. H. Vonderheide (2009). "Collapse of the 
CD27+ B-Cell Compartment Associated with Systemic Plasmacytosis in 
Patients with Advanced Melanoma and Other Cancers." Clinical Cancer 
Research 15(13): 4277-4287.  
Carpenter, E. L., R. Mick, A. J. Rech, G. L. Beatty, T. A. Colligon, M. R. Rosenfeld, D. E. 
Kaplan, K. M. Chang, S. M. Domchek, P. A. Kanetsky, L. A. Fecher, K. T. 
Flaherty, L. M. Schuchter and R. H. Vonderheide (2009). "Collapse of the 
CD27+ B-cell compartment associated with systemic plasmacytosis in 
patients with advanced melanoma and other cancers." Clinical Cancer 
Research 15(13): 4277-4287. 
Carter, P., L. Presta, C. M. Gorman, J. B. Ridgway, D. Henner, W. L. Wong, A. M. 
Rowland, C. Kotts, M. E. Carver and H. M. Shepard (1992). "Humanization of 
an anti-p185HER2 antibody for human cancer therapy." Proceedings of the 
National Academy of Sciences 89(10): 4285-4289. 
Carter, P., L. Smith and M. Ryan (2004). "Identification and validation of cell 
surface antigens for antibody targeting in oncology." Endocrine Related 
Cancer 11(4): 659-687. 
Carter, P. J. (2006). "Potent antibody therapeutics by design." Nature Reviews 
Immunology 6(5): 343-357. 
Cartron, G., L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat and H. 
Watier (2002). "Therapeutic activity of humanized anti-CD20 monoclonal 
antibody and polymorphism in IgG Fc receptor Fcgamma RIIIa gene." Blood 
99(3): 754-758. 
Cassard, L., J. F. G. Cohen-Solal, E. M. Fournier, S. Camilleri-Broët, A. Spatz, S. 
Chouaïb, C. Badoual, A. Varin, S. Fisson, P. Duvillard, C. Boix, S. M. Loncar, X. 
Sastre-Garau, A. N. Houghton, M.-F. Avril, I. Gresser, W. H. Fridman and C. 
Sautès-Fridman (2008). "Selective expression of inhibitory Fcgamma 
receptor by metastatic melanoma impairs tumor susceptibility to IgG-
dependent cellular response." International Journal of Cancer 123(12): 
2832-2839. 
Chames, P. and D. Baty (2009). "Bispecific antibodies for cancer therapy: The light 
at the end of the tunnel?" mAbs 1(6): 539-547. 
Chames, P., M. Van Regenmortel, E. Weiss and D. Baty (2009). "Therapeutic 
antibodies: successes, limitations and hopes for the future." British Journal 
of Pharmacology 157(2): 220-233. 
Chang, C.-C., M. Campoli, W. E. I. Luo, W. Zhao, K. S. Zaenker and S. Ferrone (2004). 
"Immunotherapy of Melanoma Targeting Human High Molecular Weight 
Melanoma-Associated Antigen: Potential Role of Nonimmunological 
Mechanisms." Annals of the New York Academy of Sciences 1028(1): 340-
350. 
Chapman, P. B., A. Hauschild, C. Robert, J. B. Haanen, P. Ascierto, J. Larkin, R. 
Dummer, C. Garbe, A. Testori, M. Maio, D. Hogg, P. Lorigan, C. Lebbe, T. 
Jouary, D. Schadendorf, A. Ribas, S. J. O'Day, J. A. Sosman, J. M. Kirkwood, A. 
M. M. Eggermont, B. Dreno, K. Nolop, J. Li, B. Nelson, J. Hou, R. J. Lee, K. T. 
Flaherty and G. A. McArthur (2011). "Improved Survival with Vemurafenib 
in Melanoma with BRAF V600E Mutation." New England Journal of 
Medicine 364(26): 2507-2516. 
-299- 
 
Cheever, M. A. and C. S. Higano (2011). "PROVENGE (Sipuleucel-T) in Prostate 
Cancer: The First FDA-Approved Therapeutic Cancer Vaccine." Clinical 
Cancer Research 17(11): 3520-3526. 
Chen, K., W. Xu, M. Wilson, B. He, N. W. Miller, E. Bengten, E.-S. Edholm, P. A. 
Santini, P. Rath, A. Chiu, M. Cattalini, J. Litzman, J. B Bussel, B. Huang, A. 
Meini, K. Riesbeck, C. Cunningham-Rundles, A. Plebani and A. Cerutti 
(2009). "Immunoglobulin D enhances immune surveillance by activating 
antimicrobial, proinflammatory and B cell-stimulating programs in 
basophils." Nature Immunology 10(8): 889-898. 
Chen, Q., V. Daniel, D. W. Maher and P. Hersey (1994). "Production of IL-10 by 
melanoma cells: Examination of its role in immunosuppression mediated by 
melanoma." International Journal of Cancer 56(5): 755-760. 
Chen, Y.-T., A. O. Güre, S. Tsang, E. Stockert, E. Jäger, A. Knuth and L. J. Old (1998). 
"Identification of multiple cancer/testis antigens by allogeneic antibody 
screening of a melanoma cell line library." Proceedings of the National 
Academy of Sciences 95(12): 6919-6923. 
Chester, K., B. Pedley, B. Tolner, J. Violet, A. Mayer, S. Sharma, G. Boxer, A. Green, S. 
Nagl and R. Begent (2004). "Engineering Antibodies for Clinical 
Applications in Cancer." Tumor Biology 25(1-2): 91-98. 
Chester, K. A., R. H. J. Begent, L. Robson, P. A. Keep, R. B. Pedley, J. A. Boden Libiol, G. 
Boxer, A. Green, G. Winter, O. Cochet and R. E. Hawkins (1994). "Phage 
libraries for generation of clinically useful antibodies." The Lancet 
343(8895): 455-456. 
Chu, C.-C., N. Ali, P. Karagiannis, P. Di Meglio, A. Skowera, L. Napolitano, G. 
Barinaga, K. Grys, E. Sharif-Paghaleh, S. N. Karagiannis, M. Peakman, G. 
Lombardi and F. O. Nestle (2012). "Resident CD141 (BDCA3)+ dendritic 
cells in human skin produce IL-10 and induce regulatory T cells that 
suppress skin inflammation." Journal of Experimental Medicine 209(5): 
935-945. 
Claffey, K. P., L. F. Brown, L. F. del Aguila, K. Tognazzi, K.-T. Yeo, E. J. Manseau and 
H. F. Dvorak (1996). "Expression of Vascular Permeability Factor/Vascular 
Endothelial Growth Factor by Melanoma Cells Increases Tumor Growth, 
Angiogenesis, and Experimental Metastasis." Cancer Research 56(1): 172-
181. 
Clark, W. H., D. E. Elder, D. Guerry, L. E. Braitman, B. J. Trock, D. Schultz, M. 
Synnestvedt and A. C. Halpern (1989). "Model Predicting Survival in Stage I 
Melanoma Based on Tumor Progression." Journal of the National Cancer 
Institute 81(24): 1893-1904. 
Clemente, C. G., M. C. Mihm, R. Bufalino, S. Zurrida, P. Collini and N. Cascinelli 
(1996). "Prognostic value of tumor infiltrating lymphocytes in the vertical 
growth phase of primary cutaneous melanoma." Cancer 77(7): 1303-1310. 
Clynes, R., Y. Takechi, Y. Moroi, A. Houghton and J. V. Ravetch (1998). "Fc receptors 
are required in passive and active immunity to melanoma." Proceedings of 
the National Academy of Sciences 95(2): 652-656. 
Clynes, R., T. Towers, L. Presta and J. Ravetch (2000). "Inhibitory Fc receptors 
modulate in vivo cytoxicity against tumor targets." Nature Medicine 6(4): 
443-446. 
Coronella-Wood, J. and E. Hersh (2003). "Naturally occurring B-cell responses to 
breast cancer." Cancer Immunology, Immunotherapy 52(12): 715-738. 
Couper, K. N., D. G. Blount and E. M. Riley (2008). "IL-10: The Master Regulator of 
Immunity to Infection." Journal of Immunology 180(9): 5771-5777. 
-300- 
 
CRUK (2012). "Skin cancer incidence statistics." Cancer Research United Kingdom  
retrieved 15 September 2012, from http://www.cancerresearchuk.org/ 
cancer-info/cancerstats/incidence. 
Cummins, D. L., J. M. Cummins, H. Pantle, M. A. Silverman, A. L. Leonard and A. 
Chanmugam (2006). "Cutaneous Malignant Melanoma." Mayo Clinic 
Proceedings 81(4): 500-507. 
Daniels, T., R. Leuchter, R. Quintero, G. Helguera, J. Rodríguez, O. Martínez-Maza, B. 
Schultes, C. Nicodemus and M. Penichet (2012). "Targeting HER2/neu with 
a fully human IgE to harness the allergic reaction against cancer cells." 
Cancer Immunology, Immunotherapy 61(7): 991-1003. 
Daveau, M., J. Pavie-Fischer, L. Rivat, C. Rivat, C. Ropartz, H. H. Peter, J. P. Cesarini 
and F. M. Kourilsky (1977). "IgG4 subclass in malignant melanoma." Journal 
of the National Cancer Institute 58(2):189-192. 
Davies, H., G. R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. 
Woffendin, M. J. Garnett, W. Bottomley, N. Davis, E. Dicks, R. Ewing, Y. Floyd, 
K. Gray, S. Hall, R. Hawes, J. Hughes, V. Kosmidou, A. Menzies, C. Mould, A. 
Parker, C. Stevens, S. Watt, S. Hooper, R. Wilson, H. Jayatilake, B. A. 
Gusterson, C. Cooper, J. Shipley, D. Hargrave, K. Pritchard-Jones, N. Maitland, 
G. Chenevix-Trench, G. J. Riggins, D. D. Bigner, G. Palmieri, A. Cossu, A. 
Flanagan, A. Nicholson, J. W. C. Ho, S. Y. Leung, S. T. Yuen, B. L. Weber, H. F. 
Seigler, T. L. Darrow, H. Paterson, R. Marais, C. J. Marshall, R. Wooster, M. R. 
Stratton and P. A. Futreal (2002). "Mutations of the BRAF gene in human 
cancer." Nature 417(6892): 949-954. 
De Milito, A., C. Mörch, A. Sönnerborg and F. Chiodi (2001). "Loss of memory 
(CD27) B lymphocytes in HIV-1 infection." AIDS 15(8): 957-964. 
De Plaen, E., C. Traversari, J. J. Gaforio, J.-P. Szikora, C. De Smet, F. Brasseur, P. van 
der Bruggen, B. Lethé, C. Lurquin, P. Chomez, O. De Backer, T. Boon, K. 
Arden, W. Cavenee and R. Brasseur (1994). "Structure, chromosomal 
localization, and expression of 12 genes of the MAGE family." 
Immunogenetics 40(5): 360-369. 
de Vries, J. E., G. D. Keizer, A. A. Te Velde, A. Voordouw, D. Ruiter, P. Rümke, H. Spits 
and C. G. Figdor (1986). "Characterization of melanoma-associated surface 
antigens involved in the adhesion and motility of human melanoma cells." 
International Journal of Cancer 38(4): 465-473. 
Dechant, M., T. Beyer, T. Schneider-Merck, W. Weisner, M. Peipp, J. G. J. van de 
Winkel and T. Valerius (2007). "Effector Mechanisms of Recombinant IgA 
Antibodies against Epidermal Growth Factor Receptor." Journal of 
Immunology 179(5): 2936-2943. 
Degiovanni, G., P. Hainaut, T. Lahaye, P. Weynants and T. Boon (1990). "Antigens 
recognized on a melanoma cell line by autologous cytolytic T lymphocytes 
are also expressed on freshly collected tumor cells." European Journal of 
Immunology 20(8): 1865-1868. 
Desai, S. A., X. Wang, E. J. Noronha, T. Kageshita and S. Ferrone (1998). 
"Characterization of Human Anti-High Molecular Weight-Melanoma-
associated Antigen Single-Chain Fv Fragments Isolated from a Phage 
Display Antibody Library." Cancer Research 58(11): 2417-2425. 
Desjarlais, J. R., G. A. Lazar, E. A. Zhukovsky and S. Y. Chu (2007). "Optimizing 
engagement of the immune system by anti-tumor antibodies: an engineer's 




Diamond, M. S., M. Kinder, H. Matsushita, M. Mashayekhi, G. P. Dunn, J. M. 
Archambault, H. Lee, C. D. Arthur, J. M. White, U. Kalinke, K. M. Murphy and 
R. D. Schreiber (2011). "Type I interferon is selectively required by 
dendritic cells for immune rejection of tumors." Journal of Experimental 
Medicine 208(10): 1989-2003. 
Disis, M. L., E. Calenoff, G. McLaughlin, A. E. Murphy, W. Chen, B. Groner, M. Jeschke, 
N. Lydon, E. McGlynn, R. B. Livingston, R. Moe and M. A. Cheever (1994). 
"Existent T-Cell and Antibody Immunity to HER-2/neu Protein in Patients 
with Breast Cancer." Cancer Research 54(1): 16-20. 
Dong, H., S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, P. C. Roche, J. 
Lu, G. Zhu, K. Tamada, V. A. Lennon, E. Celis and L. Chen (2002). "Tumor-
associated B7-H1 promotes T-cell apoptosis: A potential mechanism of 
immune evasion." Nature Medicine 8(8): 793-800. 
Dudley, M. E., J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. 
E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, L. J. Rogers, G. J. Gracia, 
S. A. Jones, D. P. Mangiameli, M. M. Pelletier, J. Gea-Banacloche, M. R. 
Robinson, D. M. Berman, A. C. Filie, A. Abati and S. A. Rosenberg (2005). 
"Adoptive Cell Transfer Therapy Following Non-Myeloablative but 
Lymphodepleting Chemotherapy for the Treatment of Patients With 
Refractory Metastatic Melanoma." Journal of Clinical Oncology 23(10): 
2346-2357. 
Dudley, M. E., J. C. Yang, R. Sherry, M. S. Hughes, R. Royal, U. Kammula, P. F. 
Robbins, J. Huang, D. E. Citrin, S. F. Leitman, J. Wunderlich, N. P. Restifo, A. 
Thomasian, S. G. Downey, F. O. Smith, J. Klapper, K. Morton, C. Laurencot, D. 
E. White and S. A. Rosenberg (2008). "Adoptive Cell Therapy for Patients 
With Metastatic Melanoma: Evaluation of Intensive Myeloablative 
Chemoradiation Preparative Regimens." Journal of Clinical Oncology 
26(32): 5233-5239. 
Dummer, W., B. C. Bastian, N. Ernst, C. Schänzle, A. Schwaaf and E. B. Bröcker 
(1996). "Interleukin-10 production in malignant melanoma: preferential 
detection of IL-10-secreting tumor cells in metastatic lesions." International 
Journal of Cancer 66(5): 607-610. 
Duncan, L. M., L. A. Richards and M. C. M. Jr. (1998). "Increased mast cell density in 
invasive melanoma." Journal of Cutaneous Pathology 25(1): 11-15. 
Dunn, G. P., A. T. Bruce, H. Ikeda, L. J. Old and R. D. Schreiber (2002). "Cancer 
immunoediting: from immunosurveillance to tumor escape." Nature 
Immunology 3(11): 991-998. 
Edwards, J. C. and G. Cambridge (2006). "B-cell targeting in rheumatoid arthritis 
and other autoimmune diseases." Nature Reviews Immunology 6(5): 394-
403. 
Emmerich, J., J. B. Mumm, I. H. Chan, D. LaFace, H. Truong, T. McClanahan, D. M. 
Gorman and M. Oft (2012). "IL-10 directly activates and expands tumor 
resident CD8+ T cells without de novo infiltration from secondary lymphoid 
organs." Cancer Research72(14): 3570-3581. 
Erdag, G., J. T. Schaefer, M. E. Smolkin, D. H. Deacon, S. M. Shea, L. T. Dengel, J. W. 
Patterson and C. L. Slingluff (2012). "Immunotype and Immunohistologic 
Characteristics of Tumor-Infiltrating Immune Cells Are Associated with 




Erdile, L. F., D. Smith and D. Berd (2001). "Whole cell ELISA for detection of tumor 
antigen expression in tumor samples." Journal of Immunological Methods 
258(1-2): 47-53. 
Findlay, J. and R. Dillard (2007). "Appropriate calibration curve fitting in ligand 
binding assays." The AAPS Journal 9(2): E260-E267. 
FitzGerald, D. J., A. S. Wayne, R. J. Kreitman and I. Pastan (2011). "Treatment of 
Hematologic Malignancies with Immunotoxins and Antibody-Drug 
Conjugates." Cancer Research 71(20): 6300-6309. 
Flaherty, K. T., I. Puzanov, K. B. Kim, A. Ribas, G. A. McArthur, J. A. Sosman, P. J. 
O'Dwyer, R. J. Lee, J. F. Grippo, K. Nolop and P. B. Chapman (2010). 
"Inhibition of Mutated, Activated BRAF in Metastatic Melanoma." New 
England Journal of Medicine 363(9): 809-819. 
Funaro, A., G. Gribaudo, A. Luganini, E. Ortolan, N. Lo Buono, E. Vicenzi, L. Cassetta, 
S. Landolfo, R. Buick, L. Falciola, M. Murphy, G. Garotta and F. Malavasi 
(2008). Generation of potent neutralizing human monoclonal antibodies 
against cytomegalovirus infection from immune B cells, BMC Biotechnology 
8:85.  
Gascan, H., J. F. Gauchat, M. G. Roncarolo, H. Yssel, H. Spits and J. E. de Vries (1991). 
"Human B cell clones can be induced to proliferate and to switch to IgE and 
IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T 
cell clones." Journal of Experimental Medicine 173(3): 747-750. 
Gerlini, G., A. Tun-Kyi, C. Dudli, G. Burg, N. Pimpinelli and F. O. Nestle (2004). 
"Metastatic Melanoma Secreted IL-10 Down-Regulates CD1 Molecules on 
Dendritic Cells in Metastatic Tumor Lesions." The American Journal of 
Pathology 165(6): 1853-1863. 
Geuijen, C. A. W., N. Bijl, R. C. M. Smit, F. Cox, M. Throsby, T. J. Visser, M. A. C. 
Jongeneelen, A. B. H. Bakker, A. M. Kruisbeek, J. Goudsmit and J. de Kruif 
(2005). "A proteomic approach to tumour target identification using phage 
display, affinity purification and mass spectrometry." European Journal of 
Cancer 41(1): 178-187. 
Ghose, T., S. Ferrone, A. H. Blair, Y. Kralovec, M. Temponi, M. Singh and M. Mammen 
(1991). "Regression of human melanoma xenografts in nude mice injected 
with methotrexate linked to monoclonal antibody 225.28 to human high 
molecular weight-melanoma associated antigen." Cancer Immunology, 
Immunotherapy 34(2): 90-96. 
Gilbert, A. E., P. Karagiannis, T. Dodev, A. Koers, K. Lacy, D. H. Josephs, P. Takhar, J. 
L. Geh, C. Healy, M. Harries, K. M. Acland, S. M. Rudman, R. L. Beavil, P. J. 
Blower, A. J. Beavil, H. J. Gould, J. Spicer, F. O. Nestle and S. N. Karagiannis 
(2011). "Monitoring the systemic human memory B cell compartment of 
melanoma patients for anti-tumor IgG antibodies." PLoS One 6(4): e19330. 
Gnjatic, S., D. Atanackovic, E. Jäger, M. Matsuo, A. Selvakumar, N. K. Altorki, R. G. 
Maki, B. Dupont, G. Ritter, Y.-T. Chen, A. Knuth and L. J. Old (2003). "Survey 
of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer 
patients: Correlation with antibody responses." Proceedings of the National 
Academy of Sciences 100(15): 8862-8867. 
Gnjatic, S., E. Ritter, M. W. Büchler, N. A. Giese, B. Brors, C. Frei, A. Murray, N. 
Halama, I. Zörnig, Y. T. Chen, C. Andrews, G. Ritter, L. J. Old, K. Odunsi and D. 
Jäger (2010). "Seromic profiling of ovarian and pancreatic cancer." 
Proceedings of the National Academy of Sciences of the United States of 
America 107(11): 5088-5093.  
-303- 
 
Gordon, I. O. and R. S. Freedman (2006). "Defective Antitumor Function of 
Monocyte-Derived Macrophages from Epithelial Ovarian Cancer Patients." 
Clinical Cancer Research 12(5): 1515-1524. 
Goto, Y., S. Ferrone, T. Arigami, M. Kitago, A. Tanemura, E. Sunami, S. L. Nguyen, R. 
R. Turner, D. L. Morton and D. S. B. Hoon (2008). "Human High Molecular 
Weight Melanoma-Associated Antigen: Utility for Detection of Metastatic 
Melanoma in Sentinel Lymph Nodes." Clinical Cancer Research 14(11): 
3401-3407. 
Gould, H. J., G. A. Mackay, S. N. Karagiannis, C. M. O'Toole, P. J. Marsh, B. E. Daniel, L. 
R. Coney, V. R. Zurawski, M. Joseph, M. Capron, M. Gilbert, G. F. Murphy and 
R. Korngold (1999). "Comparison of IgE and IgG antibody-dependent 
cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian 
carcinoma." European Journal of Immunology 29(11): 3527-3537. 
Gould, H. J. and B. J. Sutton (2008). "IgE in allergy and asthma today." Nature 
Reviews Immunology 8(3): 205-217. 
Gould, H. J., B. J. Sutton, A. J. Beavil, R. L. Beavil, N. McCloskey, H. A. Coker, D. Fear 
and L. Smurthwaite (2003). "The biology of IgE and the basis of allergic 
disease." Annual Review of Immunology 21: 579-628. 
Green, L. L., M. C. Hardy, C. E. Maynard-Currie, H. Tsuda, D. M. Louie, M. J. Mendez, 
H. Abderrahim, M. Noguchi, D. H. Smith, Y. Zeng, N. E. David, H. Sasai, D. 
Garza, D. G. Brenner, J. F. Hales, R. P. McGuinness, D. J. Capon, S. Klapholz 
and A. Jakobovits (1994). "Antigen-specific human monoclonal antibodies 
from mice engineered with human Ig heavy and light chain YACs." Nature 
Genetics 7(1): 13-21. 
Hafner, C., H. Breiteneder, S. Ferrone, C. Thallinger, S. Wagner, W. M. Schmidt, J. 
Jasinska, M. Kundi, K. Wolff, C. C. Zielinski, O. Scheiner, U. Wiedermann and 
H. Pehamberger (2005). "Suppression of human melanoma tumor growth 
in SCID mice by a human high molecular weight-melanoma associated 
antigen (HMW-MAA) specific monoclonal antibody." International Journal 
of Cancer 114(3): 426-432. 
Harada, K., S. Shimoda, Y. Kimura, Y. Sato, H. Ikeda, S. Igarashi, X.-S. Ren, H. Sato 
and Y. Nakanuma (2012). "Significance of immunoglobulin G4 (IgG4)-
positive cells in extrahepatic cholangiocarcinoma: Molecular mechanism of 
IgG4 reaction in cancer tissue." Hepatology 56(1): 157-164. 
Harper, J. R. and R. A. Reisfeld (1983). "Inhibition of Anchorage-Independent 
Growth of Human Melanoma Cells by a Monoclonal Antibody to a 
Chondroitin Sulfate Proteoglycan." Journal of the National Cancer Institute 
71(2): 225. 
Herlyn, M., Z. Steplewski, D. Herlyn, W. H. Clark, A. H. Ross, M. Blaszczyk, K. Y. Pak 
and H. Koprowski (1983). "Production and Characterization of Monoclonal 
Antibodies against Human Malignant Melanoma." Cancer Investigation 
1(3): 215-224. 
Hicklin, D. J. and L. M. Ellis (2005). "Role of the Vascular Endothelial Growth Factor 
Pathway in Tumor Growth and Angiogenesis." Journal of Clinical Oncology 
23(5): 1011-1027. 
Hill, G. J., E. T. Krementz and H. Z. Hill (1984). "Dimethyl triazeno imidazole 
carboxamide and combination therapy for melanoma IV. Late results after 
complete response to chemotherapy (central oncology group protocols 
7130, 7131, and 7131A)." Cancer 53(6): 1299-1305. 
-304- 
 
Hino, R., K. Kabashima, Y. Kato, H. Yagi, M. Nakamura, T. Honjo, T. Okazaki and Y. 
Tokura (2010). "Tumor cell expression of programmed cell death-1 ligand 1 
is a prognostic factor for malignant melanoma." Cancer 116(7): 1757-1766. 
Hodi, F. S., S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. 
Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, W. Akerley, A. J. M. van den 
Eertwegh, J. Lutzky, P. Lorigan, J. M. Vaubel, G. P. Linette, D. Hogg, C. H. 
Ottensmeier, C. Lebbé, C. Peschel, I. Quirt, J. I. Clark, J. D. Wolchok, J. S. 
Weber, J. Tian, M. J. Yellin, G. M. Nichol, A. Hoos and W. J. Urba (2010). 
"Improved Survival with Ipilimumab in Patients with Metastatic 
Melanoma." New England Journal of Medicine 363(8): 711-723. 
Hoet, R. M., E. H. Cohen, R. B. Kent, K. Rookey, S. Schoonbroodt, S. Hogan, L. Rem, N. 
Frans, M. Daukandt, H. Pieters, R. van Hegelsom, N. C. Neer, H. G. Nastri, I. J. 
Rondon, J. A. Leeds, S. E. Hufton, L. Huang, I. Kashin, M. Devlin, G. Kuang, M. 
Steukers, M. Viswanathan, A. E. Nixon, D. J. Sexton, H. R. Hoogenboom and R. 
C. Ladner (2005). "Generation of high-affinity human antibodies by 
combining donor-derived and synthetic complementarity-determining-
region diversity." Nature Biotechnology 23(3): 344-348. 
Hong, D. S., L. Vence, G. Falchook, L. G. Radvanyi, C. Liu, V. Goodman, J. J. Legos, S. 
Blackman, A. Scarmadio, R. Kurzrock, G. Lizee and P. Hwu (2012). 
"BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in 
Cancer Patients Does Not Impair Overall Immune Competency." Clinical 
Cancer Research 18(8): 2326-2335. 
Hong, K., L. G. Presta, Y. Lu, A. Penn, C. Adams, A. Chuntharapai, J. Yang, W. L. Wong 
and Y. G. Meng (2004). "Simple quantitative live cell and anti-idiotypic 
antibody based ELISA for humanized antibody directed to cell surface 
protein CD20." Journal of Immunological Methods 294(1-2): 189-197. 
Hudis, C. A. (2007). "Trastuzumab -- Mechanism of Action and Use in Clinical 
Practice." New England Journal of Medicine 357(1): 39-51. 
Hynes, R. O. (1992). "Integrins: versatility, modulation, and signaling in cell 
adhesion." Cell 69(1): 11-25. 
Iida, J., A. M. L. Meijne, R. C. Spiro, E. Roos, L. T. Furcht and J. B. McCarthy (1995). 
"Spreading and Focal Contact Formation of Human Melanoma Cells in 
Response to the Stimulation of Both Melanoma-associated Proteoglycan 
(NG2) and α4β1 Integrin." Cancer Research 55(10): 2177-2185. 
Iida, J., D. Pei, T. Kang, M. A. Simpson, M. Herlyn, L. T. Furcht and J. B. McCarthy 
(2001). "Melanoma chondroitin sulfate proteoglycan regulates matrix 
metalloproteinase-dependent human melanoma invasion into type I 
collagen." Journal of Biological Chemistry 276(22): 18786-18794. 
Iida, J., A. P. Skubitz, L. T. Furcht, E. A. Wayner and J. B. McCarthy (1992). 
"Coordinate role for cell surface chondroitin sulfate proteoglycan and alpha 
4 beta 1 integrin in mediating melanoma cell adhesion to fibronectin."  
Journal of Cell Biology 118(2): 431-444. 
Imai, K., T. Nakanishi, T. Noguchi, A. Yachi and S. Ferrone (1983). "Selective in vitro 
toxicity of purothionin conjugated to the monoclonal antibody 225.28S to a 
human high-molecular-weight melanoma-associated antigen." Cancer 
Immunology, Immunotherapy 15(3): 206-209. 
Itakura, E., R.-R. Huang, D.-R. Wen, E. Paul, P. H. Wunsch and A. J. Cochran (2011). 
"IL-10 expression by primary tumor cells correlates with melanoma 
progression from radial to vertical growth phase and development of 
metastatic competence." Modern Pathology 24(6): 801-809. 
-305- 
 
Iwai, Y., M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo and N. Minato (2002). 
"Involvement of PD-L1 on tumor cells in the escape from host immune 
system and tumor immunotherapy by PD-L1 blockade." Proceedings of the 
National Academy of Sciences 99(19): 12293-12297. 
Jager, D., E. Stockert, E. Jager, A. O. Gure, M. J. Scanlan, A. Knuth, L. J. Old and Y.-T. 
Chen (2000). "Serological Cloning of a Melanocyte rab Guanosine 5'-
Triphosphate-binding Protein and a Chromosome Condensation Protein 
from a Melanoma Complementary DNA Library." Cancer Research 60(13): 
3584-3591. 
Jakobovits, A., R. G. Amado, X. Yang, L. Roskos and G. Schwab (2007). "From 
XenoMouse technology to panitumumab, the first fully human antibody 
product from transgenic mice." Nature Biotechnology 25(10): 1134-1143. 
Janeway, C., P. Travers, M. Walport and M. Shlomchik (2005). "Immunobiology: the 
immune system in health and disease."  6th Edition. 
Jeannin, P., S. Lecoanet, Y. Delneste, J.-F. Gauchat and J.-Y. Bonnefoy (1998). "IgE 
Versus IgG4 Production Can Be Differentially Regulated by IL-10." The 
Journal of Immunology 160(7): 3555-3561. 
Jefferis, R. (2009). "Glycosylation as a strategy to improve antibody-based 
therapeutics." Nature reviews. Drug discovery 8(3): 226-234. 
Jefferis, R. (2012). "Isotype and glycoform selection for antibody therapeutics." 
Archives of Biochemistry and Biophysics 526(2): 159-166. 
Jensen-Jarolim, E., G. Achatz, M. C. Turner, S. Karagiannis, F. Legrand, M. Capron, M. 
L. Penichet, J. A. Rodríguez, A. G. Siccardi, L. Vangelista, A. B. Riemer and H. 
Gould (2008). "AllergoOncology: the role of IgE-mediated allergy in cancer." 
Allergy 63(10): 1255-1266. 
Jonker, D. J., C. J. O'Callaghan, C. S. Karapetis, J. R. Zalcberg, D. Tu, H.-J. Au, S. R. 
Berry, M. Krahn, T. Price, R. J. Simes, N. C. Tebbutt, G. van Hazel, R. 
Wierzbicki, C. Langer and M. J. Moore (2007). "Cetuximab for the Treatment 
of Colorectal Cancer." New England Journal of Medicine 357(20): 2040-
2048. 
Junutula, J. R., K. M. Flagella, R. A. Graham, K. L. Parsons, E. Ha, H. Raab, S. Bhakta, T. 
Nguyen, D. L. Dugger, G. Li, E. Mai, G. D. Lewis Phillips, H. Hiraragi, R. N. Fuji, 
J. Tibbitts, R. Vandlen, S. D. Spencer, R. H. Scheller, P. Polakis and M. X. 
Sliwkowski (2010). "Engineered Thio-Trastuzumab-DM1 Conjugate with an 
Improved Therapeutic Index to Target Human Epidermal Growth Factor 
Receptor 2–Positive Breast Cancer." Clinical Cancer Research 16(19): 4769-
4778. 
Kalialis, L. V., K. T. Drzewiecki and H. Klyver (2009). "Spontaneous regression of 
metastases from melanoma: review of the literature." Melanoma Research 
October 19(5): 275-282. 
Kantor, R. R. S., A. P. Albino, A. K. Ng and S. Ferrone (1986). "Biosynthesis and 
Intracellular Processing of Four Human Melanoma Associated Antigens." 
Cancer Research 46(10): 5223-5228. 
Karagiannis, P., A. E. Gilbert, D. H. Josephs, N. Ali, T. Dodev, L. Saul, L. Roberts, E. 
Beddowes, A. Koers, S. Ferreira, J. L. C. Geh, C. Healy, M. Harries, K. M. 
Acland, Philip J. Blower, Tracey Mitchell, David Fear, J. F. Spicer, K. E. Lacy, 
F. O. Nestle and S. N. Karagiannis (manuscript under revision). "IgG4 





Karagiannis, P., J. Singer, J. Hunt, S. Gan, S. Rudman, D. Mechtcheriakova, R. 
Knittelfelder, T. Daniels, P. Hobson, A. Beavil, J. Spicer, F. Nestle, M. Penichet, 
H. Gould, E. Jensen-Jarolim and S. Karagiannis (2009). "Characterisation of 
an engineered trastuzumab IgE antibody and effector cell mechanisms 
targeting HER2/ neu -positive tumour cells." Cancer Immunology, 
Immunotherapy 58(6): 915-930. 
Karagiannis, S., M. Bracher, R. Beavil, A. Beavil, J. Hunt, N. McCloskey, R. Thompson, 
N. East, F. Burke, B. Sutton, D. Dombrowicz, F. Balkwill and H. Gould (2008). 
"Role of IgE receptors in IgE antibody-dependent cytotoxicity and 
phagocytosis of ovarian tumor cells by human monocytic cells." Cancer 
Immunology, Immunotherapy 57(2): 247-263. 
Karagiannis, S., D. Josephs, P. Karagiannis, A. Gilbert, L. Saul, S. Rudman, T. Dodev, 
A. Koers, P. Blower, C. Corrigan, A. Beavil, J. Spicer, F. Nestle and H. Gould 
(2012). "Recombinant IgE antibodies for passive immunotherapy of solid 
tumours: from concept towards clinical application." Cancer Immunology, 
Immunotherapy 61(9): 1547-1564. 
Karagiannis, S. N., M. G. Bracher, J. Hunt, N. McCloskey, R. L. Beavil, A. J. Beavil, D. J. 
Fear, R. G. Thompson, N. East, F. Burke, R. J. Moore, D. D. Dombrowicz, F. R. 
Balkwill and H. J. Gould (2007). "IgE-Antibody-Dependent Immunotherapy 
of Solid Tumors: Cytotoxic and Phagocytic Mechanisms of Eradication of 
Ovarian Cancer Cells." Journal of Immunology 179(5): 2832-2843. 
Karagiannis, S. N., M. G. Bracher, J. Hunt, N. McCloskey, R. L. Beavil, A. J. Beavil, D. J. 
Fear, R. G. Thompson, N. East, F. Burke, R. J. Moore, D. D. Dombrowicz, F. R. 
Balkwill and H. J. Gould (2007). "IgE-Antibody-Dependent Immunotherapy 
of Solid Tumors: Cytotoxic and Phagocytic Mechanisms of Eradication of 
Ovarian Cancer Cells." Journal of Immunology 179(5): 2832-2843. 
Karagiannis, Sophia N., Q. Wang, N. East, F. Burke, S. Riffard, Marguerite G. Bracher, 
Richard G. Thompson, Stephen R. Durham, Lawrence B. Schwartz, 
Frances R. Balkwill and Hannah J. Gould (2003). "Activity of human 
monocytes in IgE antibody-dependent surveillance and killing of ovarian 
tumor cells." European Journal of Immunology 33(4): 1030-1040. 
Kerkar, S. P. and N. P. Restifo (2012). "Cellular Constituents of Immune Escape 
within the Tumor Microenvironment." Cancer Research 72(13); 1–6. 
King, M. A. (2000). "Detection of dead cells and measurement of cell killing by flow 
cytometry." Journal of Immunological Methods 243(1–2): 155-166. 
Kirkwood, J. M. and J. E. Robinson (1990). "Human IgG and IgM monoclonal 
antibodies against autologous melanoma produced by Epstein-Barr-virus-
transformed B lymphocytes." Cancer Immunology, Immunotherapy 32(4): 
228-234. 
Kirkwood, J. M., A. A. Tarhini, M. C. Panelli, S. J. Moschos, H. M. Zarour, L. H. 
Butterfield and H. J. Gogas (2008). "Next Generation of Immunotherapy for 
Melanoma." Journal of Clinical Oncology 26(20): 3445-3455. 
Klein, U., K. Rajewsky and R. Küppers (1998). "Human Immunoglobulin 
(Ig)M+IgD+ Peripheral Blood B Cells Expressing the CD27 Cell Surface 
Antigen Carry Somatically Mutated Variable Region Genes: CD27 as a 
General Marker for Somatically Mutated (Memory) B Cells." The Journal of 
Experimental Medicine 188(9): 1679-1689. 
Kohler, G. and C. Milstein (1975). "Continuous cultures of fused cells secreting 




Kotlan, B., P. Simsa, J.-L. Teillaud, W. H. Fridman, J. Toth, M. McKnight and M. C. 
Glassy (2005). "Novel Ganglioside Antigen Identified by B Cells in Human 
Medullary Breast Carcinomas: The Proof of Principle Concerning the 
Tumor-Infiltrating B Lymphocytes." Journal of Immunology 175(4): 2278-
2285. 
Kraft, S. and J.-P. Kinet (2007). "New developments in Fc[epsi]RI regulation, 
function and inhibition." Nature Reviews Immunology 7(5): 365-378. 
Kubota, T., R. Niwa, M. Satoh, S. Akinaga, K. Shitara and N. Hanai (2009). 
"Engineered therapeutic antibodies with improved effector functions." 
Cancer Science 100(9): 1566-1572. 
Kuppers, R. (2003). "B cells under influence: transformation of B cells by Epstein-
Barr virus." Nature Reviews Immunology 3(10): 801-812. 
Kurosawa, G., Y. Akahori, M. Morita, M. Sumitomo, N. Sato, C. Muramatsu, K. Eguchi, 
K. Matsuda, A. Takasaki, M. Tanaka, Y. Iba, S. Hamada-Tsutsumi, Y. Ukai, M. 
Shiraishi, K. Suzuki, M. Kurosawa, S. Fujiyama, N. Takahashi, R. Kato, Y. 
Mizoguchi, M. Shamoto, H. Tsuda, M. Sugiura, Y. Hattori, S. Miyakawa, R. 
Shiroki, K. Hoshinaga, N. Hayashi, A. Sugioka and Y. Kurosawa (2008). 
"Comprehensive screening for antigens overexpressed on carcinomas via 
isolation of human mAbs that may be therapeutic." Proceedings of the 
National Academy of Sciences 105(20): 7287-7292. 
Kwakkenbos, M. J., S. A. Diehl, E. Yasuda, A. Q. Bakker, C. M. M. van Geelen, M. V. 
Lukens, G. M. van Bleek, M. N. Widjojoatmodjo, W. M. J. M. Bogers, H. Mei, A. 
Radbruch, F. A. Scheeren, H. Spits and T. Beaumont (2010). "Generation of 
stable monoclonal antibody-producing B cell receptor-positive human 
memory B cells by genetic programming." Nat Med 16(1): 123-128. 
Lacy, K. E., S. N. Karagiannis and F. O. Nestle (2012). "Immunotherapy for 
melanoma." Expert Review of Dermatology 7(1): 51-68. 
Ladányi, A., J. Kiss, A. Mohos, B. Somlai, G. Liszkay, K. Gilde, Z. Fejős, I. Gaudi, J. 
Dobos and J. Tímár (2011). "Prognostic impact of B-cell density in 
cutaneous melanoma." Cancer Immunology, Immunotherapy 60(12): 1729-
1738. 
Lanzavecchia, A., N. Bernasconi, E. Traggiai, C. R. Ruprecht, D. Corti and F. Sallusto 
(2006). "Understanding and making use of human memory B cells." 
Immunological Reviews 211(1): 303-309. 
Latzka, J., S. Gaier, G. Hofstetter, N. Balazs, U. Smole, S. Ferrone, O. Scheiner, H. 
Breiteneder, H. Pehamberger and S. Wagner (2011). "Specificity of 
Mimotope-Induced Anti-High Molecular Weight-Melanoma Associated 
Antigen (HMW-MAA) Antibodies Does Not Ensure Biological Activity." PLoS 
One 6(5): e19383. 
Lazar, G. A., W. Dang, S. Karki, O. Vafa, J. S. Peng, L. Hyun, C. Chan, H. S. Chung, A. 
Eivazi, S. C. Yoder, J. Vielmetter, D. F. Carmichael, R. J. Hayes and B. I. Dahiyat 
(2006). "Engineered antibody Fc variants with enhanced effector function." 
Proceedings of the National Academy of Sciences 103(11): 4005-4010. 
Lee, P. P., C. Yee, P. A. Savage, L. Fong, D. Brockstedt, J. S. Weber, D. Johnson, S. 
Swetter, J. Thompson, P. D. Greenberg, M. Roederer and M. M. Davis (1999). 
"Characterization of circulating T cells specific for tumor-associated 
antigens in melanoma patients." Nature Medicine 5(6): 677-685. 
Lens, M. B. and M. Dawes (2004). "Global perspectives of contemporary 
epidemiological trends of cutaneous malignant melanoma." British Journal 




Lewis, M. G., R. L. Ikonopisov, R. C. Nairn, T. M. Phillips, G. H. Fairley, D. C. 
Bodenham and P. Alexander (1969). "Tumour-specific Antibodies in Human 
Malignant Melanoma and their Relationship to the Extent of the Disease." 
British Medical Journal 3(5670): 547-552. 
Lewis Phillips, G. D. (2008). "Targeting HER2-positive breast cancer with 
trastuzumab–DM1, an antibody–cytotoxic drug conjugate." Cancer 
Research. 68: 9280-9290. 
Leyendeckers, H., M. Odendahl, A. Löhndorf, J. Irsch, M. Spangfort, S. Miltenyi, N. 
Hunzelmann, M. Assenmacher, A. Radbruch and J. Schmitz (1999). 
"Correlation analysis between frequencies of circulating antigen-specific 
IgG-bearing memory B cells and serum titers of antigen-specific IgG." 
European Journal of Immunology 29(4): 1406-1417. 
Li, G.-M., C. Chiu, J. Wrammert, M. McCausland, S. F. Andrews, N.-Y. Zheng, J.-H. Lee, 
M. Huang, X. Qu, S. Edupuganti, M. Mulligan, S. R. Das, J. W. Yewdell, A. K. 
Mehta, P. C. Wilson and R. Ahmed (2012). "Pandemic H1N1 influenza 
vaccine induces a recall response in humans that favors broadly cross-
reactive memory B cells." Proceedings of the National Academy of Sciences 
109(23): 9047-9052. 
Lichtenfels, R., W. E. Biddison, H. Schulz, A. B. Vogt and R. Martin (1994). "CARE-
LASS (calcein-release-assay), an improved fluorescence-based test system 
to measure cytotoxic T lymphocyte activity." Journal of Immunological 
Methods 172(2): 227-239. 
Liewendahl, K. and S. Pyrhönen (1993). "Radioimmunodetection and 
Radioimmunotherapy of Malignant Melanoma: A Review." Acta Oncologica 
32(7-8): 717-721. 
Lim, H. W., P. Hillsamer, A. H. Banham and C. H. Kim (2005). "Cutting Edge: Direct 
Suppression of B Cells by CD4+CD25+ Regulatory T Cells." Journal of 
Immunology 175(7): 4180-4183. 
Lipson, E. J. and C. G. Drake (2011). "Ipilimumab: An Anti-CTLA-4 Antibody for 
Metastatic Melanoma." Clinical Cancer Research 17(22): 6958-6962. 
Lonberg, N. (2008). "Fully human antibodies from transgenic mouse and phage 
display platforms." Current Opinion in Immunology 20(4): 450-459. 
Lonberg, N., L. D. Taylor, F. A. Harding, M. Trounstine, K. M. Higgins, S. R. Schramm, 
C. C. Kuo, R. Mashayekh, K. Wymore and J. G. McCabe (1994). "Antigen-
specific human antibodies from mice comprising four distinct genetic 
modifications." Nature 368(6474): 856-859. 
Lu, H., V. Goodell and M. L. Disis (2008). "Humoral Immunity Directed against 
Tumor-Associated Antigens As Potential Biomarkers for the Early Diagnosis 
of Cancer." Journal of Proteome Research 7(4): 1388-1394. 
Lund, F. E. and T. D. Randall (2010). "Effector and regulatory B cells: modulators of 
CD4(+) T cell immunity." Nature Reviews Immunology 10(4): 236-247. 
Luo, W., E. Ko, J. C.-f. Hsu, X. Wang and S. Ferrone (2006). "Targeting Melanoma 
Cells with Human High Molecular Weight-Melanoma Associated Antigen-
Specific Antibodies Elicited by a Peptide Mimotope: Functional Effects."  
Journal of Immunology 176(10): 6046-6054. 
Manjarrez-Orduno, N., T. D. Quach and I. Sanz (2009). "B Cells and Immunological 
Tolerance." Journal of Investigative Dermatology 129(2): 278-288. 
Mantovani, A., S. Sozzani, M. Locati, P. Allavena and A. Sica (2002). "Macrophage 
polarization: tumor-associated macrophages as a paradigm for polarized 
M2 mononuclear phagocytes." Trends in Immunology 23(11): 549-555. 
-309- 
 
Mao, S., C. Gao, C.-H. L. Lo, P. Wirsching, C.-H. Wong and K. D. Janda (1999). "Phage-
display library selection of high-affinity human single-chain antibodies to 
tumor-associated carbohydrate antigens sialyl Lewisx and Lewisx." 
Proceedings of the National Academy of Sciences 96(12): 6953-6958. 
Maurer, D., E. Fiebiger, B. Reininger, B. Wolff-Winiski, M. H. Jouvin, O. Kilgus, J. P. 
Kinet and G. Stingl (1994). "Expression of functional high affinity 
immunoglobulin E receptors (Fc epsilon RI) on monocytes of atopic 
individuals." Journal of Experimental Medicine 179(2): 745-750. 
Mayer, A., R. J. Francis, S. K. Sharma, B. Tolner, C. J. Springer, J. Martin, G. M. Boxer, J. 
Bell, A. J. Green, J. A. Hartley, C. Cruickshank, J. Wren, K. A. Chester and R. H. 
J. Begent (2006). "A Phase I Study of Single Administration of Antibody-
Directed Enzyme Prodrug Therapy with the Recombinant Anti–
Carcinoembryonic Antigen Antibody-Enzyme Fusion Protein MFECP1 and a 
Bis-Iodo Phenol Mustard Prodrug." Clinical Cancer Research 12(21): 6509-
6516. 
McCafferty, J., A. D. Griffiths, G. Winter and D. J. Chiswell (1990). "Phage antibodies: 
filamentous phage displaying antibody variable domains." Nature 
348(6301): 552-554. 
Miller, G. and M. Lipman (1973). "Release of Infectious Epstein-Barr Virus by 
Transformed Marmoset Leukocytes." Proceedings of the National Academy 
of Sciences 70(1): 190-194. 
Mingari, M. C., F. Gerosa, G. Carra, R. S. Accolla, A. Moretta, R. H. Zubler, T. A. 
Waldmann and L. Moretta (1984). "Human interleukin-2 promotes 
proliferation of activated B cells via surface receptors similar to those of 
activated T cells." Nature 312(5995): 641-643. 
Miraglia, S., E. E. Swartzman, J. Mellentin-Michelotti, L. Evangelista, C. Smith, I. 
Gunawan, K. Lohman, E. M. Goldberg, B. Manian and P.-M. Yuan (1999). 
"Homogeneous Cell- and Bead-Based Assays for High Throughput Screening 
Using Fluorometric Microvolume Assay Technology." Journal of 
Biomolecular Screening 4(4): 193-204. 
Mittelman, A., Z. J. Chen, T. Kageshita, H. Yang, M. Yamada, P. Baskind, N. Goldberg, 
C. Puccio, T. Ahmed and Z. Arlin (1990). "Active specific immunotherapy in 
patients with melanoma. A clinical trial with mouse antiidiotypic 
monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-
melanoma-associated antigen monoclonal antibodies." Journal of Clinical 
Investigation 86(6): 2136-2144. 
Mittelman, A., Z. J. Chen, H. Yang, G. Y. Wong and S. Ferrone (1992). "Human high 
molecular weight melanoma-associated antigen (HMW-MAA) mimicry by 
mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral 
anti-HMW-MAA immunity and prolongation of survival in patients with 
stage IV melanoma." Proceedings of the National Academy of Sciences 
89(2): 466-470. 
Mittelman, A., R. Tiwari, G. Lucchese, J. Willers, R. Dummer and D. Kanduc (2004). 
"Identification of Monoclonal Anti-HMW-MAA Antibody Linear Peptide 
Epitope by Proteomic Database Mining." Journal of Investigative 
Dermatology 123(4): 670-675. 
Mizukami, M., T. Hanagiri, T. Baba, T. Fukuyama, Y. Nagata, T. So, Y. Ichiki, M. 
Sugaya, M. Yasuda, M. Takenoyama, K. Sugio and K. Yasumoto (2005). 
"Identification of tumor associated antigens recognized by IgG from tumor-
infiltrating B cells of lung cancer: Correlation between Ab titer of the 
patient's sera and the clinical course." Cancer Science 96(12): 882-888. 
-310- 
 
Muna, N. M., S. Marcus and C. Smart (1969). "Detection by immunofluorescenge of 
antibodies specific for human malignant melanoma cells." Cancer 23(1): 88-
93. 
Musolino, A., N. Naldi, B. Bortesi, D. Pezzuolo, M. Capelletti, G. Missale, D. Laccabue, 
A. Zerbini, R. Camisa, G. Bisagni, T. M. Neri and A. Ardizzoni (2008). 
"Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical 
Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu-
Positive Metastatic Breast Cancer." Journal of Clinical Oncology 26(11): 
1789-1796. 
Neri, D., P. G. Natali, H. Petrul, P. Soldani, M. R. Nicotra, R. Vola, A. Rivella, A. M. 
Creighton, P. Neri and M. Mariani (1996). "Recombinant Anti-Human 
Melanoma Antibodies Are Versatile Molecules." Journal of Investigative 
Dermatology 107(2): 164-170. 
Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg and D. 
Schadendorf (1998). "Vaccination of melanoma patients with peptide- or 
tumor lysate-pulsed dendritic cells." Nature Medicine 4(3): 328-332. 
Nevala, W. K., C. M. Vachon, A. A. Leontovich, C. G. Scott, M. A. Thompson, S. N. 
Markovic and f. t. M. S. G. o. t. M. C. C. Center (2009). "Evidence of Systemic 
Th2-Driven Chronic Inflammation in Patients with Metastatic Melanoma." 
Clinical Cancer Research 15(6): 1931-1939. 
Nicholaou, T., W. Chen, I. Davis, H. Jackson, N. Dimopoulos, C. Barrow, J. Browning, 
D. MacGregor, D. Williams, W. Hopkins, E. Maraskovsky, R. Venhaus, L. Pan, 
E. Hoffman, L. Old and J. Cebon (2011). "Immunoediting and persistence of 
antigen-specific immunity in patients who have previously been vaccinated 
with NY-ESO-1 protein formulated in ISCOMATRIX™." Cancer Immunology, 
Immunotherapy 60(11): 1625-1637. 
Nicholaou, T., L. M. Ebert, I. D. Davis, G. A. McArthur, H. Jackson, N. Dimopoulos, B. 
Tan, E. Maraskovsky, L. Miloradovic, W. Hopkins, L. Pan, R. Venhaus, E. W. 
Hoffman, W. Chen and J. Cebon (2009). "Regulatory T-Cell–Mediated 
Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in 
Patients with Advanced Malignant Melanoma." Clinical Cancer Research 
15(6): 2166-2173. 
Nimmerjahn, F. and J. V. Ravetch (2007). "Antibodies, Fc receptors and cancer." 
Current Opinion in Immunology 19(2): 239-245. 
Nimmerjahn, F. and J. V. Ravetch (2008). "Fc[gamma] receptors as regulators of 
immune responses." Nature Reviews Immunology 8(1): 34-47. 
O'Day, S. J., O. Hamid and W. J. Urba (2007). "Targeting cytotoxic T-lymphocyte 
antigen-4 (CTLA-4)." Cancer 110(12): 2614-2627. 
Ober, R. J., C. G. Radu, V. Ghetie and E. S. Ward (2001). "Differences in promiscuity 
for antibody–FcRn interactions across species: implications for therapeutic 
antibodies." International Immunology 13(12): 1551-1559. 
Odendahl, M., A. Jacobi, A. Hansen, E. Feist, F. Hiepe, G. R. Burmester, P. E. Lipsky, A. 
Radbruch and T. Dörner (2000). "Disturbed Peripheral B Lymphocyte 
Homeostasis in Systemic Lupus Erythematosus." Journal of Immunology 
165(10): 5970-5979. 
Old, L. J. and Y.-T. Chen (1998). "New Paths in Human Cancer Serology." Journal of 
Experimental Medicine 187(8): 1163-1167. 
Pardoll, D. M. (2012). "The blockade of immune checkpoints in cancer 




Patel, D., P. Balderes, A. Lahiji, M. Melchior, S. Ng, R. Bassi, Y. Wu, H. Griffith, X. 
Jimenez, D. L. Ludwig, D. J. Hicklin and X. Kang (2007). "Generation and 
characterization of a therapeutic human antibody to melanoma antigen 
TYRP1." Human Antibodies 16(3): 127-136. 
Pietra, G., C. Manzini, S. Rivara, M. Vitale, C. Cantoni, A. Petretto, M. Balsamo, R. 
Conte, R. Benelli, S. Minghelli, N. Solari, M. Gualco, P. Queirolo, L. Moretta 
and M. C. Mingari (2012). "Melanoma Cells Inhibit Natural Killer Cell 
Function by Modulating the Expression of Activating Receptors and 
Cytolytic Activity." Cancer Research 72(6); 1407–1415. 
Pillay, V., H. K. Gan and A. M. Scott (2011). "Antibodies in oncology." Nature 
Biotechnology. 28: 518-529. 
Pinna, D., D. C. Corti, D. B. Jarrossay, F. Sallusto and A. Lanzavecchia (2009). "Clonal 
dissection of the human memory B-cell repertoire following infection and 
vaccination." European Journal of Immunology 39(5): 1260-1270. 
Platts-Mills, T., J. Vaughan, S. Squillace, J. Woodfolk and R. Sporik (2001). 
"Sensitisation, asthma, and a modified Th2 response in children exposed to 
cat allergen: a population-based cross-sectional study." The Lancet 
357(9258): 752-756. 
Poschke, I., D. Mougiakakos and R. Kiessling (2011). "Camouflage and sabotage: 
tumor escape from the immune system." Cancer Immunology, 
Immunotherapy 60(8): 1161-1171. 
Price, M. A., L. E. Colvin Wanshura, J. Yang, J. Carlson, B. Xiang, G. Li, S. Ferrone, A. Z. 
Dudek, E. A. Turley and J. B. McCarthy (2011). "CSPG4, a potential 
therapeutic target, facilitates malignant progression of melanoma." Pigment 
Cell & Melanoma Research 24(6): 1148-1157. 
Prieto, P. A., J. C. Yang, R. M. Sherry, M. S. Hughes, U. S. Kammula, D. E. White, C. L. 
Levy, S. A. Rosenberg and G. Q. Phan (2012). "CTLA-4 Blockade with 
Ipilimumab: Long-Term Follow-up of 177 Patients with Metastatic 
Melanoma." Clinical Cancer Research 18(7): 2039-2047. 
Punnonen, J., G. Aversa, B. G. Cocks, A. N. McKenzie, S. Menon, G. Zurawski, R. de 
Waal Malefyt and J. E. de Vries (1993). "Interleukin 13 induces interleukin 
4-independent IgG4 and IgE synthesis and CD23 expression by human B 
cells." Proceedings of the National Academy of Sciences 90(8): 3730-3734. 
Punt, C. J. A., J. A. M. Barbuto, H. Zhang, W. J. Grimes, K. D. Hatch and E. M. Hersh 
(1994). "Anti-tumor antibody produced by human tumor-infiltrating and 
peripheral blood B lymphocytes." Cancer Immunology, Immunotherapy 
38(4): 225-232. 
Rabinovich, G. A., D. Gabrilovich and E. M. Sotomayor (2007). "Immunosuppressive 
Strategies that are Mediated by Tumor Cells." Annual Review of 
Immunology 25(1): 267-296. 
Rajewsky, K. (1996). "Clonal selection and learning in the antibody system." Nature 
381(6585): 751-758. 
Ran, Y., H. Hu, Z. Zhou, L. Yu, L. Sun, J. Pan, J. Liu and Z. Yang (2008). "Profiling 
Tumor-Associated Autoantibodies for the Detection of Colon Cancer." 
Clinical Cancer Research 14(9): 2696-2700. 
Reichert, J. M. (2011). "Antibody-based therapeutics to watch in 2011." mAbs 3(1): 
76-99. 




Reichert, J. M. and V. E. Valge-Archer (2007). "Development trends for monoclonal 
antibody cancer therapeutics." Nature Reviews Drug Discovover 6(5): 349-
356. 
Reischl, I. G., N. Corvaia, F. Effenberger, B. Woeff-Winiski, E. Krömer and G. C. 
Mudde (1996). "Function and regulation of FcεRI expression on monocytes 
from non-atopic donors." Clinical & Experimental Allergy 26(6): 630-641. 
Reuschenbach, M., M. von Knebel Doeberitz and N. Wentzensen (2009). "A 
systematic review of humoral immune responses against tumor antigens." 
Cancer Immunology, Immunotherapy 58(10): 1535-1544. 
Rice, J., C. H. Ottensmeier and F. K. Stevenson (2008). "DNA vaccines: precision 
tools for activating effective immunity against cancer." Nature Reviews 
Cancer 8(2): 108-120. 
Riemer, A. B., B. Hantusch, B. Sponer, G. Kraml, C. Hafner, C. C. Zielinski, O. Scheiner, 
H. Pehamberger and E. Jensen-Jarolim (2005). "High-molecular-weight 
melanoma-associated antigen mimotope immunizations induce antibodies 
recognizing melanoma cells." Cancer Immunology, Immunotherapy 54(7): 
677-684. 
Riemer, A. B. and E. Jensen-Jarolim (2007). "Mimotope vaccines: Epitope mimics 
induce anti-cancer antibodies." Immunology Letters 113(1): 1-5. 
Rivera, Z., S. Ferrone, X. Wang, S. Jube, H. Yang, H. I. Pass, S. Kanodia, G. Gaudino 
and M. Carbone (2012). "CSPG4 As a Target of Antibody-Based 
Immunotherapy For Malignant Mesothelioma." Clinical Cancer Research 
18(19); 5352-63. 
Romond, E. H., E. A. Perez, J. Bryant, V. J. Suman, C. E. Geyer, Jr., N. E. Davidson, E. 
Tan-Chiu, S. Martino, S. Paik, P. A. Kaufman, S. M. Swain, T. M. Pisansky, L. 
Fehrenbacher, L. A. Kutteh, V. G. Vogel, D. W. Visscher, G. Yothers, R. B. 
Jenkins, A. M. Brown, S. R. Dakhil, E. P. Mamounas, W. L. Lingle, P. M. Klein, J. 
N. Ingle and N. Wolmark (2005). "Trastuzumab plus Adjuvant 
Chemotherapy for Operable HER2-Positive Breast Cancer." New England 
Journal of Medicine 353(16): 1673-1684. 
Roopenian, D. C. and S. Akilesh (2007). "FcRn: the neonatal Fc receptor comes of 
age." Nature Reviews Immunology 7(9): 715-725. 
Rosenberg, S. A., J. C. Yang and N. P. Restifo (2004). "Cancer immunotherapy: 
moving beyond current vaccines." Nature Medicine 10(9): 909-915. 
Rothberg, B. E. G., M. B. Bracken and D. L. Rimm (2009). "Tissue Biomarkers for 
Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-
analysis." Journal of the National Cancer Institute. 101(7): 452-474. 
Rudman, S. M., D. H. Josephs, H. Cambrook, P. Karagiannis, A. E. Gilbert, T. Dodev, J. 
Hunt, A. Koers, A. Montes, L. Taams, S. Canevari, M. Figini, P. J. Blower, A. J. 
Beavil, C. F. Nicodemus, C. Corrigan, S. B. Kaye, F. O. Nestle, H. J. Gould, J. F. 
Spicer and S. N. Karagiannis (2011). "Harnessing engineered antibodies of 
the IgE class to combat malignancy: initial assessment of FcɛRI-mediated 
basophil activation by a tumour-specific IgE antibody to evaluate the risk of 
type I hypersensitivity." Clinical & Experimental Allergy 41(10): 1400-
1413. 
Sahagan, B. G., H. Dorai, J. Saltzgaber-Muller, F. Toneguzzo, C. A. Guindon, S. P. Lilly, 
K. W. McDonald, D. V. Morrissey, B. A. Stone and G. L. Davis (1986). "A 
genetically engineered murine/human chimeric antibody retains specificity 




Sahin, U., O. Türeci, H. Schmitt, B. Cochlovius, T. Johannes, R. Schmits, F. Stenner, G. 
Luo, I. Schobert and M. Pfreundschuh (1995). "Human neoplasms elicit 
multiple specific immune responses in the autologous host." Proceedings of 
the National Academy of Sciences 92(25): 11810-11813. 
Sanz, I., C. Wei, F. E.-H. Lee and J. Anolik (2008). "Phenotypic and functional 
heterogeneity of human memory B cells." Seminars in Immunology 20(1): 
67-82. 
Sato, S., J. M. Tuscano, M. Inaoki and T. F. Tedder (1998). "CD22 negatively and 
positively regulates signal transduction through the B lymphocyte antigen 
receptor." Seminars in Immunology 10(4): 287-297. 
Satoguina, J. S., E. Weyand, J. Larbi and A. Hoerauf (2005). "T Regulatory-1 Cells 
Induce IgG4 Production by B Cells: Role of IL-10." Journal of Immunology 
174(8): 4718-4726. 
Savelyeva, N., C. A. King, E. S. Vitetta and F. K. Stevenson (2005). "Inhibition of a 
vaccine-induced anti-tumor B cell response by soluble protein antigen in 
the absence of continuing T cell help." Proceedings of the National Academy 
of Sciences of the United States of America 102(31): 10987-10992. 
Schadendorf, D., S. Ugurel, B. Schuler-Thurner, F. O. Nestle, A. Enk, E.-B. Bröcker, S. 
Grabbe, W. Rittgen, L. Edler, A. Sucker, C. Zimpfer-Rechner, T. Berger, J. 
Kamarashev, G. Burg, H. Jonuleit, A. Tüttenberg, J. C. Becker, P. Keikavoussi, 
E. Kämpgen and G. Schuler (2006). "Dacarbazine (DTIC) versus vaccination 
with autologous peptide-pulsed dendritic cells (DC) in first-line treatment 
of patients with metastatic melanoma: a randomized phase III trial of the 
DC study group of the DeCOG." Annals of Oncology 17(4): 563-570. 
Schauer, U., F. Stemberg, C. H. L. Rieger, M. Borte, S. Schubert, F. Riedel, U. Herz, H. 
Renz, M. Wick, H. D. Carr-Smith, A. R. Bradwell and W. Herzog (2003). "IgG 
Subclass Concentrations in Certified Reference Material 470 and Reference 
Values for Children and Adults Determined with The Binding Site 
Reagents." Clinical Chemistry 49(11): 1924-1929. 
Scheid, J. F., H. Mouquet, N. Feldhahn, M. S. Seaman, K. Velinzon, J. Pietzsch, R. G. 
Ott, R. M. Anthony, H. Zebroski, A. Hurley, A. Phogat, B. Chakrabarti, Y. Li, M. 
Connors, F. Pereyra, B. D. Walker, H. Wardemann, D. Ho, R. T. Wyatt, J. R. 
Mascola, J. V. Ravetch and M. C. Nussenzweig (2009). "Broad diversity of 
neutralizing antibodies isolated from memory B cells in HIV-infected 
individuals." Nature 458(7238): 636-640. 
Schioppa, T., R. Moore, R. G. Thompson, E. C. Rosser, H. Kulbe, S. Nedospasov, C. 
Mauri, L. M. Coussens and F. R. Balkwill (2011). "B regulatory cells and the 
tumor-promoting actions of TNF-α during squamous carcinogenesis." 
Proceedings of the National Academy of Sciences 108(26): 10662-10667. 
Schreiber, R. D., L. J. Old and M. J. Smyth (2011). "Cancer Immunoediting: 
Integrating Immunity’s Roles in Cancer Suppression and Promotion." 
Science 331(6024): 1565-1570. 
Schwartzentruber, D. J., D. H. Lawson, J. M. Richards, R. M. Conry, D. M. Miller, J. 
Treisman, F. Gailani, L. Riley, K. Conlon, B. Pockaj, K. L. Kendra, R. L. White, 
R. Gonzalez, T. M. Kuzel, B. Curti, P. D. Leming, E. D. Whitman, J. Balkissoon, 
D. S. Reintgen, H. Kaufman, F. M. Marincola, M. J. Merino, S. A. Rosenberg, P. 
Choyke, D. Vena and P. Hwu (2011). "gp100 Peptide Vaccine and 
Interleukin-2 in Patients with Advanced Melanoma." New England Journal 
of Medicine 364(22): 2119-2127. 
Scott, A. M., J. D. Wolchok and L. J. Old (2012). "Antibody therapy of cancer." Nature 
Reviews Cancer 12(4): 278-287. 
-314- 
 
Shawler, D. L., R. M. Bartholomew, L. M. Smith and R. O. Dillman (1985). "Human 
immune response to multiple injections of murine monoclonal IgG." Journal 
of Immunology 135(2): 1530-1535. 
Sheu, B.-C., R.-H. Lin, H.-C. Lien, H.-N. Ho, S.-M. Hsu and S.-C. Huang (2001). 
"Predominant Th2/Tc2 Polarity of Tumor-Infiltrating Lymphocytes in 
Human Cervical Cancer." Journal of Immunology 167(5): 2972-2978. 
Shimbo, T., A. Tanemura, T. Yamazaki, K. Tamai, I. Katayama and Y. Kaneda (2010). 
"Serum Anti-BPAG1 Auto-Antibody Is a Novel Marker for Human 
Melanoma." PLoS One 5(5): e10566. 
Sica, A., T. Schioppa, A. Mantovani and P. Allavena (2006). "Tumour-associated 
macrophages are a distinct M2 polarised population promoting tumour 
progression: Potential targets of anti-cancer therapy." European Journal of 
Cancer 42(6): 717-727. 
Slamon, D. J., W. Godolphin, L. A. Jones, J. A. Holt, S. G. Wong, D. E. Keith, W. J. Levin, 
S. G. Stuart, J. Udove and A. Ullrich (1989). "Studies of the HER-2/neu proto-
oncogene in human breast and ovarian cancer." Science 244(4905): 707-
712. 
Slifka, M. K., R. Antia, J. K. Whitmire and R. Ahmed (1998). "Humoral Immunity Due 
to Long-Lived Plasma Cells." Immunity 8(3): 363-372. 
Soengas, M. S. and S. W. Lowe (2003). "Apoptosis and melanoma chemoresistance." 
Oncogene 22(20): 3138-3151. 
Sosman, J. A., K. B. Kim, L. Schuchter, R. Gonzalez, A. C. Pavlick, J. S. Weber, G. A. 
McArthur, T. E. Hutson, S. J. Moschos, K. T. Flaherty, P. Hersey, R. Kefford, D. 
Lawrence, I. Puzanov, K. D. Lewis, R. K. Amaravadi, B. Chmielowski, H. J. 
Lawrence, Y. Shyr, F. Ye, J. Li, K. B. Nolop, R. J. Lee, A. K. Joe and A. Ribas 
(2012). "Survival in BRAF V600–Mutant Advanced Melanoma Treated with 
Vemurafenib." New England Journal of Medicine 366(8): 707-714. 
Spector, N. L. and K. L. Blackwell (2009). "Understanding the Mechanisms Behind 
Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–
Positive Breast Cancer." Journal of Clinical Oncology 27(34): 5838-5847. 
Staquicini, F. I., A. Tandle, S. K. Libutti, J. Sun, M. Zigler, M. Bar-Eli, F. Aliperti, E. C. 
Perez, J. E. Gershenwald, M. Mariano, R. Pasqualini, W. Arap and J. D. Lopes 
(2008). "A Subset of Host B Lymphocytes Controls Melanoma Metastasis 
through a Melanoma Cell Adhesion Molecule/MUC18-Dependent 
Interaction: Evidence from Mice and Humans." Cancer Research 68(20): 
8419-8428. 
Steinitz, M., G. Klein, S. Koskimies and O. Makel (1977). "EB virus-induced B 
lymphocyte cell lines producing specific antibody." Nature 269(5627): 420-
422. 
Stockert, E., E. Jäger, Y.-T. Chen, M. J. Scanlan, I. Gout, J. Karbach, M. Arand, A. Knuth 
and L. J. Old (1998). "A Survey of the Humoral Immune Response of Cancer 
Patients to a Panel of Human Tumor Antigens." Journal of Experimental 
Medicine 187(8): 1349-1354. 
Stone, J. H., Y. Zen and V. Deshpande (2012). "IgG4-Related Disease." New England 
Journal of Medicine 366(6): 539-551. 
Stove, C., V. Stove, L. Derycke, V. Van Marck, M. Mareel and M. Bracke (2003). "The 
Heregulin Human Epidermal Growth Factor Receptor as a New Growth 
Factor System in Melanoma with Multiple Ways of Deregulation."  Journal of 
Investigative Dermatology121(4): 802-812. 
-315- 
 
Strome, S. E., E. A. Sausville and D. Mann (2007). "A Mechanistic Perspective of 
Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects." 
The Oncologist 12(9): 1084-1095. 
Sugden, B. and W. Mark (1977). "Clonal transformation of adult human leukocytes 
by Epstein-Barr virus." Journal of Virology 23(3): 503-508. 
Sumimoto, H., F. Imabayashi, T. Iwata and Y. Kawakami (2006). "The BRAF–MAPK 
signaling pathway is essential for cancer-immune evasion in human 
melanoma cells." Journal of Experimental Medicine 203(7): 1651-1656. 
Tan, T.-T. and L. M. Coussens (2007). "Humoral immunity, inflammation and 
cancer." Current Opinion in Immunology 19(2): 209-216. 
Tarhini, A. A. and J. M. Kirkwood (2009). "Clinical and Immunologic Basis of 
Interferon Therapy in Melanoma." Annals of the New York Academy of 
Sciences 1182(1): 47-57. 
Teo, P., P. Utz and J. Mollick (2012). "Using the allergic immune system to target 
cancer: activity of IgE antibodies specific for human CD20 and MUC1." 
Cancer Immunology, Immunotherapy published online 13 June 2012: 1-15. 
Terranova, V. P., E. S. Hujanen, D. M. Loeb, G. R. Martin, L. Thornburg and V. 
Glushko (1986). "Use of a reconstituted basement membrane to measure 
cell invasiveness and select for highly invasive tumor cells." Proceedings of 
the National Academy of Sciences 83(2): 465-469. 
Tiller, T., E. Meffre, S. Yurasov, M. Tsuiji, M. C. Nussenzweig and H. Wardemann 
(2008). "Efficient generation of monoclonal antibodies from single human B 
cells by single cell RT-PCR and expression vector cloning." Journal of 
Immunological Methods 329(1–2): 112-124. 
Topalian, S. L., F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, 
J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, P. D. Leming, D. R. 
Spigel, S. J. Antonia, L. Horn, C. G. Drake, D. M. Pardoll, L. Chen, W. H. 
Sharfman, R. A. Anders, J. M. Taube, T. L. McMiller, H. Xu, A. J. Korman, M. 
Jure-Kunkel, S. Agrawal, D. McDonald, G. D. Kollia, A. Gupta, J. M. Wigginton 
and M. Sznol (2012). "Safety, Activity, and Immune Correlates of Anti–PD-1 
Antibody in Cancer." New England Journal of Medicine 366(26): 2443-
2454. 
Traggiai, E., S. Becker, K. Subbarao, L. Kolesnikova, Y. Uematsu, M. R. Gismondo, B. 
R. Murphy, R. Rappuoli and A. Lanzavecchia (2004). "An efficient method to 
make human monoclonal antibodies from memory B cells: potent 
neutralization of SARS coronavirus." Nature Medicine 10(8): 871-875. 
Trefzer, U. a., M. a. Hofmann, S. a. Reinke, Y.-J. b. Guo, H. a. Audring, G. c. Spagnoli 
and W. a. Sterry (2006). "Concordant loss of melanoma differentiation 
antigens in synchronous and asynchronous melanoma metastases: 
implications for immunotherapy." Melanoma Research 16(2): 137-145. 
Tth, T., R. Tth-Jakatics, S. Jimi, S. Takebayashi and N. Kawamoto (2000). "Cutaneous 
malignant melanoma: Correlation between neovascularization and 
peritumor accumulation of mast cells overexpressing vascular endothelial 
growth factor." Human Pathology 31(8): 955-960. 
Unger, S. W., M. I. Bernhard, R. C. Pace and H. J. Wanebo (1983). "Monocyte 
dysfunction in human cancer." Cancer 51(4): 669-674. 
van der Neut Kolfschoten, M., J. Schuurman, M. Losen, W. K. Bleeker, P. Martínez-
Martínez, E. Vermeulen, T. H. den Bleker, L. Wiegman, T. Vink, L. A. Aarden, 
M. H. De Baets, J. G. J. van de Winkel, R. C. Aalberse and P. W. H. I. Parren 
(2007). "Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic 
Fab Arm Exchange." Science 317(5844): 1554-1557. 
-316- 
 
van der Zee, J. S., P. van Swieten and R. C. Aalberse (1986). "Inhibition of 
complement activation by IgG4 antibodies." Clinical and Experimental 
Immunology 64(2): 415-422. 
Vaughan, T. J., J. K. Osbourn and P. R. Tempest (1998). "Human antibodies by 
design." Nature Biotechnology 16(6): 535-539. 
Vence, L., A. K. Palucka, J. W. Fay, T. Ito, Y.-J. Liu, J. Banchereau and H. Ueno (2007). 
"Circulating tumor antigen-specific regulatory T cells in patients with 
metastatic melanoma." Proceedings of the National Academy of Sciences 
104(52): 20884-20889. 
Vergilis, I. J., M. Szarek, S. Ferrone and S. R. Reynolds (2005). "Presence and 
Prognostic Significance of Melanoma-Associated Antigens CYT-MAA and 
HMW-MAA in Serum of Patients with Melanoma." Journal of Investigative 
Dermatology 125(3): 526-531. 
Vogel, C. L., M. A. Cobleigh, D. Tripathy, J. C. Gutheil, L. N. Harris, L. Fehrenbacher, D. 
J. Slamon, M. Murphy, W. F. Novotny, M. Burchmore, S. Shak, S. J. Stewart 
and M. Press (2002). "Efficacy and Safety of Trastuzumab as a Single Agent 
in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer." 
Journal of Clinical Oncology 20(3): 719-726. 
Wagner, S., C. Hafner, D. Allwardt, J. Jasinska, S. Ferrone, C. C. Zielinski, O. Scheiner, 
U. Wiedermann, H. Pehamberger and H. Breiteneder (2005). "Vaccination 
with a Human High Molecular Weight Melanoma-Associated Antigen 
Mimotope Induces a Humoral Response Inhibiting Melanoma Cell Growth 
In Vitro." Journal of Immunology 174(2): 976-982. 
Waldmann, T. A. (2006). "The biology of interleukin-2 and interleukin-15: 
implications for cancer therapy and vaccine design." Nat Rev Immunol 6(8): 
595-601. 
Walker, K. W., R. Llull, G. K. Balkian, H. S. Ko, K. M. Flores, R. Ramsamooj, K. S. Black, 
C. W. Hewitt and D. C. Martin (1992). "A rapid and sensitive cellular 
enzyme-linked immunoabsorbent assay (CELISA) for the detection and 
quantitation of antibodies against cell surface determinants : I. A 
comparison of cell fixation and storage techniques." Journal of 
Immunological Methods 154(1): 121-130. 
Wang, X., A. Katayama, Y. Wang, L. Yu, E. Favoino, K. Sakakura, A. Favole, T. 
Tsuchikawa, S. Silver, S. C. Watkins, T. Kageshita and S. Ferrone (2011). 
"Functional Characterization of an scFv-Fc Antibody that 
Immunotherapeutically Targets the Common Cancer Cell Surface 
Proteoglycan CSPG4." Cancer Research 71(24): 7410-7422. 
Wang, X., T. Osada, Y. Wang, L. Yu, K. Sakakura, A. Katayama, J. B. McCarthy, A. 
Brufsky, M. Chivukula, T. Khoury, D. S. Hsu, W. T. Barry, H. K. Lyerly, T. M. 
Clay and S. Ferrone (2010). "CSPG4 Protein as a New Target for the 
Antibody-Based Immunotherapy of Triple-Negative Breast Cancer." Journal 
of the National Cancer Institute 102(19): 1496-1512. 
Wang, Y., Y. Ma, Y. Fang, S. Wu, L. Liu, D. Fu and X. Shen (2012). "Regulatory T cell: a 
protection for tumour cells." Journal of Cellular and Molecular Medicine 
16(3): 425-436. 
Watson, D., G. Burns and I. Mackay (1983). "In vitro growth of B lymphocytes 
infiltrating human melanoma tissue by transformation with EBV: evidence 
for secretion of anti-melanoma antibodies by some transformed cells." 
Journal of Immunology 130(5): 2442-2447. 
-317- 
 
Weiner, L. M. and H. Borghaei (2006). "Targeted therapies in solid tumors: 
Monoclonal antibodies and small molecules." Human Antibodies 15(3): 
103-111. 
Weiner, Louis M., Joseph C. Murray and Casey W. Shuptrine (2012). "Antibody-
Based Immunotherapy of Cancer." Cell 148(6): 1081-1084. 
Weiner, L. M., R. Surana and S. Wang (2010). "Monoclonal antibodies: versatile 
platforms for cancer immunotherapy." Nature Reviews Immunol 10(5): 
317-327. 
Wheatley, K., N. Ives, B. Hancock, M. Gore, A. Eggermont and S. Suciu (2003). "Does 
adjuvant interferon-α for high-risk melanoma provide a worthwhile 
benefit? A meta-analysis of the randomised trials." Cancer Treatment 
Reviews 29(4): 241-252. 
Wilson, B. S., K. Imai, P. G. Natali and S. Ferrone (1981). "Distribution and 
molecular characterization of a cell-surface and a cytoplasmic antigen 
detectable in human melanoma cells with monoclonal antibodies." 
International Journal of Cancer 28(3): 293-300. 
Wistuba, I. I., David Bryant, C. Behrens, S. Milchgrub, A. K. Virmani, R. Ashfaq, J. D. 
Minna and A. F. Gazdar (1999). "Comparison of Features of Human Lung 
Cancer Cell Lines and Their Corresponding Tumors." Clinical Cancer 
Research 5: 991–1000. 
Woof, J. M. (2012). "Insights from Fc receptor biology: A route to improved 
antibody reagents." mAbs 4(3): 291-293. 
Wrammert, J., K. Smith, J. Miller, W. A. Langley, K. Kokko, C. Larsen, N.-Y. Zheng, I. 
Mays, L. Garman, C. Helms, J. James, G. M. Air, J. D. Capra, R. Ahmed and P. C. 
Wilson (2008). "Rapid cloning of high-affinity human monoclonal 
antibodies against influenza virus." Nature 453(7195): 667-671. 
Yamaguchi, H., K. Furukawa, S. R. Fortunato, P. O. Livingston, K. O. Lloyd, H. F. 
Oettgen and L. J. Old (1987). "Cell-surface antigens of melanoma recognized 
by human monoclonal antibodies." Proceedings of the National Academy of 
Sciences 84(8): 2416-2420. 
Yang, J., M. A. Price, C. L. Neudauer, C. Wilson, S. Ferrone, H. Xia, J. Iida, M. A. 
Simpson and J. B. McCarthy (2004). "Melanoma chondroitin sulfate 
proteoglycan enhances FAK and ERK activation by distinct mechanisms." 
Journal of Cell Biology 165(6): 881-891. 
Yeilding, N. M., C. Gerstner and J. M. Kirkwood (1992). "Analysis of two human 
monoclonal antibodies against melanoma." International Journal of Cancer 
52(6): 967-973. 
Yuan, J., S. Gnjatic, H. Li, S. Powel, H. F. Gallardo, E. Ritter, G. Y. Ku, A. A. Jungbluth, 
N. H. Segal, T. S. Rasalan, G. Manukian, Y. Xu, R.-A. Roman, S. L. Terzulli, M. 
Heywood, E. Pogoriler, G. Ritter, L. J. Old, J. P. Allison and J. D. Wolchok 
(2008). "CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell 
responses in metastatic melanoma patients with clinical benefit." 
Proceedings of the National Academy of Sciences 105(51): 20410-20415. 
Zhang, H., D. F. Lake, J. A. M. Barbuto, R. M. Bernstein, W. J. Grimes and E. M. Hersh 
(1995). "A Human Monoclonal Antimelanoma Single-Chain Fv Antibody 
Derived from Tumor-infiltrating Lymphocytes." Cancer Research 55(16): 
3584-3591. 
Zhang, J.-Y., C. A. Casiano, X.-X. Peng, J. A. Koziol, E. K. L. Chan and E. M. Tan (2003). 
"Enhancement of Antibody Detection in Cancer Using Panel of Recombinant 
Tumor-associated Antigens." Cancer Epidemiology Biomarkers & 
Prevention 12(2): 136-143. 
-318- 
 
Zhang, W., M. Gordon, A. M. Schultheis, D. Y. Yang, F. Nagashima, M. Azuma, H.-M. 
Chang, E. Borucka, G. Lurje, A. E. Sherrod, S. Iqbal, S. Groshen and H.-J. Lenz 
(2007). "FCGR2A and FCGR3A Polymorphisms Associated With Clinical 
Outcome of Epidermal Growth Factor Receptor Expressing Metastatic 
Colorectal Cancer Patients Treated With Single-Agent Cetuximab." Journal 
of Clinical Oncology 25(24): 3712-3718. 
Zhong, L., S. P. Coe, A. J. Stromberg, N. H. Khattar, J. R. Jett and E. A. Hirschowitz 
(2006). "Profiling Tumor-Associated Antibodies for Early Detection of Non-
small Cell Lung Cancer." Journal of Thoracic Oncology 1(6). 
Zhong, L., K. Ge, J. C. Zu, L. H. Zhao, W. K. Shen, J. F. Wang, X. G. Zhang, X. Gao, W. Hu, 
Y. Yen and K. H. Kernstine (2008). "Autoantibodies as potential biomarkers 
for breast cancer." Breast cancer research 10(3): R40. 
 Ziai, M. R., L. Imberti, M. R. Nicotra, G. Badaracco, O. Segatto, P. G. Natali and S. 
Ferrone (1987). "Analysis with Monoclonal Antibodies of the Molecular and 
Cellular Heterogeneity of Human High Molecular Weight Melanoma 
Associated Antigen." Cancer Research 47(9): 2474-2480. 
Zippelius, A., A. Gati, T. Bartnick, S. Walton, B. Odermatt, E. Jaeger, R. Dummer, M. 
Urosevic, V. Filonenko, K. Osanai, H. Moch, Y.-T. Chen, L. Old, A. Knuth and D. 
Jaeger (2007). "Melanocyte differentiation antigen RAB38/NY-MEL-1 
induces frequent antibody responses exclusively in melanoma patients." 
Cancer Immunology, Immunotherapy 56(2): 249-258. 
 
 
